Cancer Statistics, 2001

Ca-A Cancer Journal for Clinicians 51, 15-36

DOI: 10.3322/canjclin.51.1.15

Citation Report

#	Article	IF	CITATIONS
1	Diagnosis and management of superficial bladder cancer. Current Problems in Cancer, 2001, 25, 224-278.	1.0	146
2	The Less Harmful Cigarette:  A Controversial Issue. A Tribute to Ernst L. Wynder. Chemical Research in Toxicology, 2001, 14, 767-790.	1.7	626
3	Male Inflammatory Breast Cancer. Clinical Breast Cancer, 2001, 2, 153-155.	1.1	19
4	Systemic Irinotecan or Regional Floxuridine Chemotherapy Prolongs Survival After Hepatic Cryosurgery in Patients with Metastatic Colon Cancer Refractory to 5-Fluorouracil. Clinical Colorectal Cancer, 2001, 1, 36-42.	1.0	11
5	Diffuse Large-Cell Lymphomas: A Review of Therapy. Clinical Lymphoma and Myeloma, 2001, 2, 155-163.	2.1	3
6	Frequency of PSA-mRNA-bearing cells in the peripheral blood of patients after prostate biopsy. British Journal of Cancer, 2001, 85, 557-562.	2.9	25
7	En bloc resection for locally advanced cancer of the pancereas: Is it worthwhile?. Gastroenterology, 2001, 120, A106.	0.6	4
8	Colorectal cancer screening. Primary Care - Clinics in Office Practice, 2001, 28, 661-674.	0.7	11
9	Automated detection of lung nodules in CT scans: Preliminary results. Medical Physics, 2001, 28, 1552-1561.	1.6	217
10	Preventing death of barrett's cancer: does frequent surveillance endoscopy do it?. American Journal of Medicine, 2001, 111, 137-141.	0.6	7
11	Achieving quality in flexible sigmoidoscopy screening for colorectal cancer. American Journal of Medicine, 2001, 111, 643-653.	0.6	18
12	Rectal cancer in hereditary nonpolyposis colorectal cancer. American Journal of Surgery, 2001, 181, 207-210.	0.9	56
13	Is there a role for curative surgery for pelvic recurrence from rectal carcinoma in the presence of hydronephrosis?. American Journal of Surgery, 2001, 182, 274-277.	0.9	23
14	Evaluation of minimally invasive surgical staging for esophageal cancer. American Journal of Surgery, 2001, 182, 702-706.	0.9	22
15	Chemotherapy in stage IV lung cancer (take home messages). Lung Cancer, 2001, 33, S121-S123.	0.9	2
16	Staging of non-small cell lung cancer: consensus, controversies and challenges. Lung Cancer, 2001, 34, S95-S107.	0.9	54
17	Moving to the routine management of pre symptomatic lung cancer. Lung Cancer, 2001, 34, S1-S5.	0.9	1
18	The role of surgery in the treatment of prostate cancer. Seminars in Oncology Nursing, 2001, 17, 85-89.	0.7	2

#	Article	IF	Citations
19	The epidemiology of prostate cancer in the United States. Seminars in Oncology Nursing, 2001, 17, 72-77.	0.7	21
20	Late effects of cancer and its treatment. Seminars in Oncology Nursing, 2001, 17, 241-248.	0.7	131
21	Complete 5-year follow-up of a prospective phase II trial of preoperative chemoradiotherapy for esophageal cancer. Surgery, 2001, 130, 620-628.	1.0	15
22	Predicting the biologic behavior of ductal carcinoma in situ: An analysis of molecular markers. Surgery, 2001, 130, 593-601.	1.0	33
23	A Genome Screen of Families with Multiple Cases of Prostate Cancer: Evidence of Genetic Heterogeneity. American Journal of Human Genetics, 2001, 69, 148-158.	2.6	80
24	Colorectal cancer-screening tests and associated health behaviors. American Journal of Preventive Medicine, 2001, 21, 132-137.	1.6	169
25	The Norwegian decision on screening for prostate cancer: a response. Lancet Oncology, The, 2001, 2, 746-749.	5.1	4
26	A novel gene on human chromosome 2p24 is differentially expressed between androgen-dependent and androgen-independent prostate cancer cells. European Journal of Cancer, 2001, 37, 2129-2134.	1.3	6
27	Prostate cancer: Natural history and surgical treatment of localised disease. European Journal of Cancer, 2001, 37, 127-136.	1.3	7
28	Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Annals of Thoracic Surgery, 2001, 72, 1918-1925.	0.7	189
29	New strategies and treatment modalities for optimizing patient outcomes. Seminars in Hematology, 2001, 38, 1-7.	1.8	5
30	USE of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients. Urology, 2001, 58, 729-734.	0.5	8
31	Rationale for earlier and less frequent prostate cancer screening. Urology, 2001, 58, 639-641.	0.5	19
32	Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology, 2001, 58, 843-848.	0.5	943
34	CLINICAL UNDER STAGING OF HIGH RISK NONMUSCLE INVASIVE UROTHELIAL CARCINOMA TREATED WITH RADICAL CYSTECTOMY. Journal of Urology, 2001, 166, 490-493.	0.2	245
35	Pancreatic Cancer in Hereditary Pancreatitis: Consensus Guidelines for Prevention, Screening and Treatment. Pancreatology, 2001, 1, 416-422.	0.5	84
36	MOLECULAR GENETIC PROFILING OF GLEASON GRADE 4/5 PROSTATE CANCERS COMPARED TO BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 2001, 166, 2171-2177.	0.2	179
37	DIFFICULT EARLY MELANOMAS. Dermatologic Clinics, 2001, 19, 319-325.	1.0	6

#	Article	IF	CITATIONS
38	ROLE OF THE ULTRASONIC SURGICAL ASPIRATOR IN GYNECOLOGY. Obstetrics and Gynecology Clinics of North America, 2001, 28, 775-790.	0.7	7
39	ROLE OF EARLY ADJUVANT HORMONAL THERAPY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Journal of Urology, 2001, 166, 2208-2215.	0.2	79
40	Hereditary Pancreatic Cancer. Pancreatology, 2001, 1, 466-471.	0.5	44
41	Pancreatic cancer: the evolving role of systemic therapy. Expert Opinion on Pharmacotherapy, 2001, 2, 1939-1947.	0.9	6
42	IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opinion on Biological Therapy, 2001, 1, 719-732.	1.4	98
43	Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13790-13795.	3.3	2,270
44	Developing a Rural Colorectal Screening Program. Oncology Issues, 2001, 16, 12-17.	0.0	2
45	Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer. Journal of Clinical Oncology, 2001, 19, 4216-4223.	0.8	251
46	Postmastectomy Breast Reconstruction: Current Techniques. Cancer Control, 2001, 8, 419-426.	0.7	24
47	Editorial comments on †Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study'. Annals of Oncology, 2001, 12, 1339-1340.	0.6	5
48	Phase II Study of Paclitaxel and Valspodar (PSC 833) in Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2001, 19, 2975-2982.	0.8	96
49	Mass Spectroscopy as a Discovery Tool for Identifying Serum Markers for Prostate Cancer. Clinical Chemistry, 2001, 47, 1924-1926.	1.5	17
50	Osteoprotegerin in Serum as a Novel Marker of Bone Metastatic Spread in Prostate Cancer. Clinical Chemistry, 2001, 47, 2061-2063.	1.5	42
51	Symptom Indexes to Assess Outcomes of Treatment for Early Prostate Cancer. Medical Care, 2001, 39, 1118-1130.	1.1	113
52	Elevated COX-2 Expression in Cervical Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 443-446.	0.6	45
53	Biliary tract cancer. Current Opinion in Gastroenterology, 2001, 17, 450-457.	1.0	11
54	Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 496-499.	0.6	142
55	Technologic Advances for Evaluation of Cervical Cytology: Is Newer Better?. Obstetrical and Gynecological Survey, 2001, 56, 765-774.	0.2	44

#	Article	IF	Citations
56	Ovarian cancer screening: are we making any progress?. Current Opinion in Oncology, 2001, 13, 399-402.	1.1	41
57	Sentinel nodes in gynecologic malignancies. Current Opinion in Oncology, 2001, 13, 403-407.	1.1	21
58	Gastric cancer and H. pylori: Host genetics open the way. Gastroenterology, 2001, 121, 1002-1004.	0.6	55
59	New Innovations in Cervical Cancer Screening. Clinical Obstetrics and Gynecology, 2001, 44, 538-549.	0.6	22
60	Selenium in Cancer Prevention: Clinical Issues and Implications. Cancer Investigation, 2001, 19, 540-553.	0.6	40
61	Environmental and Host Factors in Testicular Germ Cell Tumors. Cancer Investigation, 2001, 19, 842-853.	0.6	48
62	Cyclin D1 Polymorphism and Increased Risk of Colorectal Cancer at Young Age. Journal of the National Cancer Institute, 2001, 93, 1106-1108.	3.0	70
63	Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2001, 19, 3477-3482.	0.8	289
64	Mediastinal Staging of Non-Small-Cell Lung Cancer. Cancer Control, 2001, 8, 311-317.	0.7	38
67	Metastatic colorectal cancer. Current Treatment Options in Oncology, 2001, 2, 459-471.	1.3	85
68	Neoplastic meningitis. Current Treatment Options in Oncology, 2001, 2, 517-527.	1.3	35
69	Prevention of non-melanoma skin cancer. Current Oncology Reports, 2001, 3, 295-300.	1.8	23
70	A Prospective Study of 2-[18F] Fluoro-2-Deoxy-D-Glucose/Positron Emission Tomography Scan, 99mTc-Labeled Arcitumomab (CEA-Scan), and Blind Second-Look Laparotomy for Detecting Colon Cancer Recurrence in Patients With Increasing Carcinoembryonic Antigen Levels. Annals of Surgical Oncology, 2001, 8, 779-786.	0.7	81
71	The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer. Breast Cancer, 2001, 8, 321-328.	1.3	5
72	Practice parameters for the identification and testing of patients at risk for dominantly inherited colorectal cancerâ€"supporting documentation. Diseases of the Colon and Rectum, 2001, 44, 1404-1412.	0.7	19
73	Prostate cancer screening practices and beliefs. Journal of General Internal Medicine, 2001, 16, 831-837.	1.3	62
74	Screening for prostate cancer: evidence and perspectives. BJU International, 2001, 88, 811-817.	1.3	43
75	Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer. Psycho-Oncology, 2001, 10, 521-533.	1.0	25

#	Article	IF	Citations
76	Polymorphic repeats in the androgen receptor gene in high-risk sibships. Prostate, 2001, 48, 200-205.	1.2	43
77	Determination of county-level prostate carcinoma incidence and detection rates with medicare claims data. Cancer, 2001, 92, 102-109.	2.0	24
78	A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma. Cancer, 2001, 92, 303-310.	2.0	73
79	Microsatellite analysis?DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma. Cancer, 2001, 92, 768-775.	2.0	82
80	Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma. Cancer, 2001, 92, 1213-1223.	2.0	160
81	Dosimetric analysis of urinary morbidity following prostate brachytherapy (125I vs. 103Pd) combined with external beam radiation therapy. International Journal of Cancer, 2001, 96, 83.	2.3	10
82	Mutagen sensitivity as an indicator of soft tissue sarcoma risk. Environmental and Molecular Mutagenesis, 2001, 38, 223-226.	0.9	11
83	Genotypic and phenotypic progression in endometrial tumorigenesis: Determining when defects in DNA mismatch repair and KRAS2 occur. Genes Chromosomes and Cancer, 2001, 32, 295-301.	1.5	18
84	Identification of Prognostic Factors in Advanced Epithelial Ovarian Carcinoma. Gynecologic Oncology, 2001, 82, 532-537.	0.6	211
85	Complete Surgical Cytoreduction of Advanced Ovarian Carcinoma Using the Argon Beam Coagulator. Gynecologic Oncology, 2001, 83, 39-48.	0.6	49
86	Role of Wide/Radical Hysterectomy and Pelvic Lymph Node Dissection in Endometrial Cancer with Cervical Involvement. Gynecologic Oncology, 2001, 83, 72-80.	0.6	78
87	Improved Therapeutic Index of Lower Dose Topotecan Chemotherapy in Recurrent Ovarian Cancer. Gynecologic Oncology, 2001, 83, 257-262.	0.6	54
88	Preventive Gynecologic Surgery for BRCA1/2 Carriersâ€" Information for Decision-Making. Gynecologic Oncology, 2001, 83, 168-170.	0.6	6
89	Bax-Induced Apoptosis as a Novel Gene Therapy Approach for Carcinoma of the Cervix. Gynecologic Oncology, 2001, 83, 370-377.	0.6	28
90	Expression of Cell-Cycle Mediators in Ovarian Cancer Cells after Transfection with p16INK4a, p21WAF1/Cip-1, and p53. Gynecologic Oncology, 2001, 83, 543-548.	0.6	18
91	Complications of Hepatic Artery Infusion : A Review of 4580 Reported Cases. International Journal of Gastrointestinal Cancer, 2001, 30, 147-160.	0.4	82
92	Identification of a Gene Frequently Mutated in Prostate Tumors. Medical Oncology, 2001, 18, 179-188.	1.2	5
93	Part II. Laparoscopic approach to abdominal malignancies. Current Problems in Cancer, 2001, 25, 311-326.	1.0	0

#	Article	IF	CITATIONS
94	The Future of Colon Cancer Prevention. Annals of the New York Academy of Sciences, 2001, 952, 88-108.	1.8	33
95	Staging of pancreatic cancer before and after neoadjuvant chemoradiation. Journal of Gastrointestinal Surgery, 2001, 5, 626-633.	0.9	83
96	Melanoma of the Head and Neck: Current Concepts in Diagnosis and Management. Laryngoscope, 2001, 111, 1209-1222.	1.1	45
97	Apoptosis induction in prostate cancer cells by a novel gene product, pHyde, involves caspase-3. Oncogene, 2001, 20, 5982-5990.	2.6	33
98	Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression. Oncogene, 2001, 20, 7935-7944.	2.6	39
99	Transcript map and complete genomic sequence for the 310 kb region of minimal allele loss on chromosome segment 11p15.5 in non-small-cell lung cancer. Oncogene, 2001, 20, 8154-8164.	2.6	26
100	Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene, 2001, 20, 8184-8192.	2.6	95
101	Comprehensive Cancer Centres and the war on cancer. Nature Reviews Cancer, 2001, 1, 240-245.	12.8	11
102	High Vegetable and Fruit Diet Intervention in Premenopausal Women with Cervical Intraepithelial Neoplasia. Journal of the American Dietetic Association, 2001, 101, 1167-1174.	1.3	45
103	Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Seminars in Oncology, 2001, 28, 551-559.	0.8	89
104	Breast cancer chemoprevention: Current status and future directions. Seminars in Oncology, 2001, 28, 253-259.	0.8	14
105	Endocrine therapy in the treatment of metastatic breast cancer. Seminars in Oncology, 2001, 28, 291-304.	0.8	86
106	Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Seminars in Oncology, 2001, 28, 3-7.	0.8	144
107	Weekly docetaxel and estramustine in patients with hormonerefractory prostate cancer. Seminars in Oncology, 2001, 28, 16-21.	0.8	51
108	Docetaxel and exisulind in hormone-refractory prostate cancer. Seminars in Oncology, 2001, 28, 56-61.	0.8	15
109	A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Seminars in Oncology, 2001, 28, 62-66.	0.8	113
110	Preliminary phase I results of G3139 (-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Seminars in Oncology, 2001, 28, 67-70.	0.8	69
111	Prostate cancer: Multimodality approaches with docetaxel. Seminars in Oncology, 2001, 28, 77-85.	0.8	7

#	Article	IF	Citations
112	Expression of Prostate Specific Molecules in Bacille Calmette-Guerin: An Immunotherapeutic Approach to Prostate Cancer. Prostate Journal, 2001, 3, 92-97.	0.2	1
113	2001 Highlights From: 2nd International Lung Cancer Congress Kauai, Hawaii July 18–21, 2001. Clinical Lung Cancer, 2001, 3, 93-96.	1.1	0
114	MCM2 - a promising marker for premalignant lesions of the lung: a cohort study. BMC Cancer, 2001, 1 , 6 .	1.1	84
115	Multiple Myeloma: An Old Disease with New Hope for the Future. Ca-A Cancer Journal for Clinicians, 2001, 51, 273-285.	157.7	36
116	Second-Line Chemotherapy for Small-Cell Lung Cancer: A Review. Clinical Lung Cancer, 2001, 3, 118-124.	1.1	1
117	BCL2 Antisense Transcripts Decrease Intracellular Bcl2 Expression and Sensitize LNCaP Prostate Cancer Cells to Apoptosis-Inducing Agents. Cancer Biotherapy and Radiopharmaceuticals, 2001, 16, 421-429.	0.7	6
118	Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing Trends. Journal of the National Cancer Institute, 2001, 93, 824-842.	3.0	659
119	Monoclonal Antibody Therapy in the Treatment of Non-Hodgkin Lymphoma. JAMA - Journal of the American Medical Association, 2001, 286, 1149.	3.8	18
120	Lung Epithelial Proliferation: a Biomarker for Chemoprevention Trials?. Journal of the National Cancer Institute, 2001, 93, 1042-1043.	3.0	13
121	Long-Term Impact of Smoking on Lung Epithelial Proliferation in Current and Former Smokers. Journal of the National Cancer Institute, 2001, 93, 1081-1088.	3.0	87
122	Intratumoral Adenovirus-Mediated Suicide Gene Transfer for Hepatic Metastases from Colorectal Adenocarcinoma: Results of a Phase I Clinical Trial. Molecular Therapy, 2001, 4, 182-191.	3.7	104
123	Renal Cell Carcinoma and Interferon at the Millennium. Cancer Investigation, 2001, 19, 281-291.	0.6	7
124	Demographics and occurrence of oral and pharyngeal cancers. Journal of the American Dental Association, 2001, 132, 7S-11S.	0.7	344
125	Colorectal cancer screening compliance by medicine residents: perceived and actual. American Journal of Gastroenterology, 2001, 96, 3004-3008.	0.2	43
126	Chemotherapy-Induced Menopause: A Literature Review. Cancer Investigation, 2001, 19, 641-648.	0.6	39
127	Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine, 2001, 345, 948-955.	13.9	669
128	Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 15044-15049.	3.3	399
129	Dangers and Unreliability of Mammography: Breast Examination is a Safe, Effective, and Practical Alternative. International Journal of Health Services, 2001, 31, 605-615.	1.2	22

#	ARTICLE	IF	CITATIONS
130	Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2001, 93, 605-618.	3.0	295
131	Review of Recent Advances in Fluorescence Bronchoscopy in Early Localization of Central Airway Lung Cancer. Oncologist, 2001, 6, 257-262.	1.9	83
132	A Review of Residential Radon Case-Control Epidemiologic Studies Performed in the United States. Reviews on Environmental Health, 2001, 16, 151-67.	1.1	33
133	The association of microsomal epoxide hydrolase polymorphisms and lung cancer risk in African-Americans and Mexican-Americans. Carcinogenesis, 2001, 22, 923-928.	1.3	47
134	Ductal Lavage for Detection of Cellular Atypia in Women at High Risk for Breast Cancer. Journal of the National Cancer Institute, 2001, 93, 1624-1632.	3.0	262
135	Antagonist: Should we eradicate Helicobacter pylori before long term antireflux therapy?. Gut, 2001, 49, 616-617.	6.1	10
136	Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond. Oncologist, 2001, 6, 133-146.	1.9	137
137	Future for Ovarian Cancer Screening: Novel Markers From Emerging Technologies of Transcriptional Profiling and Proteomics. Journal of the National Cancer Institute, 2001, 93, 1437-1439.	3.0	63
138	Pancreatic Carcinoma: Developing a Protocol for Multi-Detector Row CT. Radiology, 2001, 220, 3-4.	3.6	36
139	Is Cisplatin Required for the Treatment of Non-Small-Cell Lung Cancer? Experience and Preliminary Results of a Phase I/II Trial with Topotecan and Vinorelbine. Oncology, 2001, 61, 35-41.	0.9	14
140	Percutaneous Biopsy and Sentinel Lymphadenectomy. American Journal of Roentgenology, 2001, 177, 887-891.	1.0	18
141	Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes and Development, 2001, 15, 3249-3262.	2.7	544
142	Fear, Coping, and Information. Health Marketing Quarterly, 2002, 20, 51-73.	0.6	43
143	Screening for Colorectal Cancer. New England Journal of Medicine, 2002, 346, 40-44.	13.9	172
144	p53 and PTEN/MMAC1/TEP1 Gene Therapy of Human Prostate PC-3 Carcinoma Xenograft, Using Transferrin-Facilitated Lipofection Gene Delivery Strategy. Human Gene Therapy, 2002, 13, 761-773.	1.4	40
145	The solitary pulmonary nodule: Aggressive excisional strategy. Seminars in Thoracic and Cardiovascular Surgery, 2002, 14, 292-296.	0.4	4
146	Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients With Previously Untreated Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2002, 20, 1182-1191.	0.8	85
147	Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2002, 20, 3605-3616.	0.8	305

#	ARTICLE	IF	CITATIONS
148	A Randomized Phase IIb Trial of Anethole Dithiolethione in Smokers with Bronchial Dysplasia. Journal of the National Cancer Institute, 2002, 94, 1001-1009.	3.0	132
149	Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4608-4613.	3.3	51
150	Raloxifene Is Associated with Less Side Effects Than Tamoxifen in Women with Early Breast Cancer: A Questionnaire Study from One Physician's Practice. Journal of Women's Health and Gender-Based Medicine, 2002, 11, 291-301.	1.7	11
151	Computer-assisted analysis of oral brush biopsies at an oral cancer screening program. Journal of the American Dental Association, 2002, 133, 357-362.	0.7	57
152	Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297. Journal of Clinical Oncology, 2002, 20, 3270-3275.	0.8	679
153	Gene therpay for prostate cancer. Expert Review of Anticancer Therapy, 2002, 2, 309-321.	1.1	12
154	A One-Day, Hospital-Wide Survey of Dying Inpatients. Journal of Palliative Medicine, 2002, 5, 363-374.	0.6	13
155	Temozolomide in Combination With Docetaxel in Patients With Advanced Melanoma: A Phase II Study of the Hellenic Cooperative Oncology Group. Journal of Clinical Oncology, 2002, 20, 420-425.	0.8	44
156	Chemoprevention of Aerodigestive Tract Cancers. Annual Review of Medicine, 2002, 53, 223-243.	5.0	36
157	Early Management of Prostate Cancer: How to Respond to an Elevated PSA?. Annual Review of Medicine, 2002, 53, 355-368.	5.0	14
158	Procedure-Related Abdominal Discomfort in Patients Undergoing Colorectal Cancer Screening: A Comparison of Colonoscopy and Flexible Sigmoidoscopy. American Journal of Gastroenterology, 2002, 97, 3056-3061.	0.2	53
159	A Prospective, Controlled Assessment of Factors Influencing Acceptance of Screening Colonoscopy. American Journal of Gastroenterology, 2002, 97, 3186-3194.	0.2	272
160	Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. American Journal of Gastroenterology, 2002, 97, 1319-1327.	0.2	70
161	Human kallikrein gene 13 (KLK13) expression by quantitative RT–PCR: an independent indicator of favourable prognosis in breast cancer. British Journal of Cancer, 2002, 86, 1457-1464.	2.9	58
162	Effects of Extracts of Coriolus versicolor (I'm-Yunityâ,,¢) on Cell-Cycle Progression and Expression of Interleukins-1β,-6, and -8 in Promyelocytic HL-60 Leukemic Cells and Mitogenically Stimulated and Nonstimulated Human Lymphocytes. Journal of Alternative and Complementary Medicine, 2002, 8, 591-602.	2.1	48
163	Chemoprevention of colorectal cancer. American Journal of Gastroenterology, 2002, 97, 13-21.	0.2	90
164	TRAIL: A Mechanism of Tumor Surveillance in an Immune Privileged Site. Journal of Immunology, 2002, 169, 4739-4744.	0.4	95
165	Retrospective analysis of missed advanced adenomas on surveillance colonoscopy. American Journal of Gastroenterology, 2002, 97, 1143-1147.	0.2	23

#	Article	IF	CITATIONS
166	A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Annals of Oncology, 2002, 13, 1225-1235.	0.6	34
167	Effects of benzyl isothiocyanate and phenethyl isothiocyanate on DNA adduct formation by a mixture of benzo[a]pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Carcinogenesis, 2002, 23, 1433-1439.	1.3	42
168	Informing Clinical Trial Participants About Study Results. JAMA - Journal of the American Medical Association, 2002, 288, 363.	3.8	140
169	Colorectal Cancer Screening for Persons at Average Risk. Journal of the National Cancer Institute, 2002, 94, 1126-1133.	3.0	71
170	Primary Adult Soft Tissue Sarcoma: Time-Dependent Influence of Prognostic Variables. Journal of Clinical Oncology, 2002, 20, 4344-4352.	0.8	204
171	In vitro assay-assisted treatment selection for women with breast or ovarian cancer Endocrine-Related Cancer, 2002, 9, 171-182.	1.6	44
172	Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2002, 20, 1335-1343.	0.8	261
173	Oncologists' Attitudes and Practices Regarding Banking Sperm Before Cancer Treatment. Journal of Clinical Oncology, 2002, 20, 1890-1897.	0.8	363
174	Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 599-603.	1.8	597
175	Localized Adenocarcinoma of the Pancreas: The Rationale for Preoperative Chemoradiation. Oncologist, 2002, 7, 34-45.	1.9	75
176	One Operation After Percutaneous Diagnosis of Nonpalpable Breast Cancer. American Journal of Roentgenology, 2002, 178, 673-679.	1.0	41
177	Contrast-enhanced US of the Prostate with Sonazoid: Comparison with Whole-Mount Prostatectomy Specimens in 12 Patients. Radiology, 2002, 222, 361-366.	3.6	85
178	Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma. Journal of Clinical Oncology, 2002, 20, 3545-3557.	0.8	104
179	Evaluation of the Epidoxorubicin–Formaldehyde Conjugate, Epidoxoform, in a Mouse Mammary Carcinoma Model. Cancer Investigation, 2002, 20, 713-724.	0.6	8
180	Percutaneous Ethanol Injection for Treatment of Cervical Lymph Node Metastases in Patients with Papillary Thyroid Carcinoma. American Journal of Roentgenology, 2002, 178, 699-704.	1.0	177
181	Breast Cancer Detection: Evaluation of a Mass-Detection Algorithm for Computer-aided Diagnosisâ€"Experience in 263 Patients. Radiology, 2002, 224, 217-224.	3.6	7 5
182	CHOP plus Rituximab â€" Balancing Facts and Opinion. New England Journal of Medicine, 2002, 346, 280-282.	13.9	45
183	High-Frequency Doppler US of the Prostate: Effect of Patient Position. Radiology, 2002, 222, 634-639.	3.6	56

#	Article	IF	CITATIONS
184	Rituximab: clinical development and future directions. Expert Opinion on Biological Therapy, 2002, 2, 97-110.	1.4	36
185	Multiple Myeloma. Hematology American Society of Hematology Education Program, 2002, 2002, 214-240.	0.9	61
186	Molecular Characterization of Canine Prostaglandin G/H Synthase-2 and Regulation in Prostatic Adenocarcinoma Cells in Vitro. Endocrinology, 2002, 143, 1134-1143.	1.4	15
187	Reimbursement for Screening Mammography—The Medicare Disparity: A Policy Perspective. Policy, Politics, and Nursing Practice, 2002, 3, 240-247.	0.8	2
188	Intraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-Up. Journal of Clinical Oncology, 2002, 20, 694-698.	0.8	76
189	Nontraditional Cytotoxic Therapies for Relapsed/Refractory Multiple Myeloma. Oncologist, 2002, 7, 20-29.	1.9	20
190	Decision-Analytic Model and Cost-Effectiveness Evaluation of Postmastectomy Radiation Therapy in High-Risk Premenopausal Breast Cancer Patients. Journal of Clinical Oncology, 2002, 20, 2713-2725.	0.8	48
191	New Techniques and Agents in the Adjuvant Therapy of Pancreatic Cancer. Acta Oncol \tilde{A}^3 gica, 2002, 41, 582-595.	0.8	37
192	Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis, 2002, 23, 1653-1660.	1.3	66
193	Fecal occult blood testing for colorectal cancer: a perspective. Annals of Oncology, 2002, 13, 61-64.	0.6	10
194	Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2002, 20, 125-133.	0.8	118
195	Diet and Oral, Pharyngeal, and Esophageal Cancer. Nutrition and Cancer, 2002, 44, 104-126.	0.9	66
196	Southern Blotting of Genomic DNA from Lung and Its Tumors: Application to Analysis of Allele Loss on Chromosome 11p15.5., 2003, 75, 263-278.		0
197	DNA Repair Gene ERCC1 and ERCC2/XPD Polymorphisms and Risk of Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology, 2002, 128, 1084.	1.5	108
198	Fiber optic probe for polarized reflectance spectroscopy in vivo: Design and performance. Journal of Biomedical Optics, 2002, 7, 388.	1.4	68
199	Blood Transfusions as a Risk Factor for Non-Hodgkin's Lymphoma in the San Francisco Bay Area: A Population-based Study. American Journal of Epidemiology, 2002, 155, 725-731.	1.6	29
200	Role of biomarkers for early detection of lung cancer and chemoprevention. European Respiratory Journal, 2002, 19, 1151-1158.	3.1	55
201	Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-junand c-fosoncogenes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3836-3841.	3.3	45

#	Article	IF	CITATIONS
202	From the Archives of the AFIP. Radiographics, 2002, 22, 189-216.	1.4	317
203	A Randomized Clinical Trial to Assess the Benefit of Offering On-Site Mobile Mammography in Addition to Health Education for Older Women. American Journal of Roentgenology, 2002, 179, 1509-1514.	1.0	48
204	Seeking Calmer Waters in a Sea of Controversy. Oncologist, 2002, 7, 172-173.	1.9	8
205	The role of tumor lymphangiogenesis in metastatic spread. FASEB Journal, 2002, 16, 922-934.	0.2	264
206	Dietary Fat Intake and Ovarian Cancer in a Cohort of US Women. American Journal of Epidemiology, 2002, 156, 22-31.	1.6	78
207	Purpose-in-Life and Breast Health Behavior in Hispanic and Anglo Women. Journal of Holistic Nursing, 2002, 20, 232-249.	0.6	22
208	Grape seed extract induces apoptotic death of human prostate carcinoma DU145 cells via caspases activation accompanied by dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis, 2002, 23, 1869-1876.	1.3	142
209	The growth hormone-deficient Spontaneous Dwarf rat is resistant to chemically induced mammary carcinogenesis. Carcinogenesis, 2002, 23, 977-982.	1.3	68
210	A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Annals of Oncology, 2002, 13, 116-120.	0.6	32
211	Carcinoma of the Anus: Strategies in Management. Oncologist, 2002, 7, 188-199.	1.9	50
212	Quality of Breast Cancer Care: What Do We Know?. Journal of Clinical Oncology, 2002, 20, 4381-4393.	0.8	93
213	Anthropometric Characteristics, Physical Activity, and Risk of Non-Hodgkin's Lymphoma Subtypes and B-Cell Chronic Lymphocytic Leukemia: A Prospective Study. American Journal of Epidemiology, 2002, 156, 527-535.	1.6	100
214	Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut, 2002, 51, 323-328.	6.1	183
215	Chemoprevention of prostate cancer. , 2002, , 331-344.		1
216	A Dominant-negative Mutant of Androgen Receptor Coregulator ARA54 Inhibits Androgen Receptor-mediated Prostate Cancer Growth. Journal of Biological Chemistry, 2002, 277, 4609-4617.	1.6	57
217	Molecular Cloning and Characterization of STAMP1, a Highly Prostate-specific Six Transmembrane Protein that Is Overexpressed in Prostate Cancer. Journal of Biological Chemistry, 2002, 277, 36689-36696.	1.6	80
218	Phase I Trial of Intravesical Gemcitabine in Bacillus Calmette-Guérin–Refractory Transitional-Cell Carcinoma of the Bladder. Journal of Clinical Oncology, 2002, 20, 3193-3198.	0.8	189
219	Progress in breast cancer chemoprevention Endocrine-Related Cancer, 2002, 9, 15-32.	1.6	16

#	Article	IF	CITATIONS
220	Novel therapeutics for head and neck cancer. Current Opinion in Oncology, 2002, 14, 334-342.	1.1	50
221	Breast Health and Disease Over a Lifetime. Clinical Obstetrics and Gynecology, 2002, 45, 1140-1161.	0.6	7
222	Fast Magnetic Resonance Imaging With Contrast for Soft Tissue Sarcoma Viability. Clinical Orthopaedics and Related Research, 2002, 397, 212-227.	0.7	64
223	Lycopene and Tomato Products in Health Promotion. Experimental Biology and Medicine, 2002, 227, 924-927.	1.1	108
224	Tomatoes, Lycopene, and Prostate Cancer: Progress and Promise. Experimental Biology and Medicine, 2002, 227, 869-880.	1.1	135
225	Novel Prostate-Specific Promoter Derived from PSA and PSMA Enhancers. Molecular Therapy, 2002, 6, 415-421.	3.7	85
226	1357. Intraperitoneal Therapy of Ovarian Cancer Using an Engineered Measles Virus. Molecular Therapy, 2002, 5, S444-S445.	3.7	55
227	Multidisciplinary Management of Soft-Tissue Sarcomas. Cancer Investigation, 2002, 20, 818-824.	0.6	5
228	Breast Cancer: Introduction. Clinical Obstetrics and Gynecology, 2002, 45, 738-745.	0.6	6
229	Mouth Cancer. Clinical Obstetrics and Gynecology, 2002, 45, 952-954.	0.6	0
230	Assessing Adults with Leukemia. Nurse Practitioner, 2002, 27, 49-60.	0.2	5
232	Pancreatic Cancer: Evidence-Based Diagnosis and Treatment. Clinical Obstetrics and Gynecology, 2002, 45, 855-865.	0.6	2
233	Carrying On. Nursing Research, 2002, 51, 9-17.	0.8	65
234	Chemoprevention of head and neck cancer: an update. Current Opinion in Oncology, 2002, 14, 318-322.	1.1	7
235	What Outcomes Matter to Patients. Medical Care, 2002, 40, III-11-III-19.	1.1	34
236	Implementation of a Comprehensive Cancer Control Program at the Worksite: Year One Summary Report. Journal of Occupational and Environmental Medicine, 2002, 44, 398-406.	0.9	12
237	Hand-Assisted Laparoscopic Surgery for Cancer. Cancer Journal (Sudbury, Mass), 2002, 8, 144-153.	1.0	7
238	The Majority of Children and Adolescents With Acute Myeloid Leukemia Have Detectable Anti-DT388-GMCSF IgG Concentrations, but at Concentrations That Should Not Preclude In Vivo Activity. Journal of Pediatric Hematology/Oncology, 2002, 24, 521-526.	0.3	3

#	Article	IF	CITATIONS
239	Reducing the Risk of Colorectal Cancer by Intervening in the Process of Carcinogenesis. Cancer Journal (Sudbury, Mass), 2002, 8, 208-221.	1.0	7
240	Fluorescence In Situ Hybridization as an Ancillary Tool in Urine Cytology to Diagnose Urothelial Carcinoma., 2002, 7, 70-74.		4
241	Colonoscopy as a Screening Test for Colorectal Cancer in Average-Risk Individuals. Mayo Clinic Proceedings, 2002, 77, 951-956.	1.4	9
242	Meta-Analysis of Measures of Sexual Activity and Prostate Cancer. Epidemiology, 2002, 13, 72-79.	1.2	225
243	Urinary Bladder Cancer. Clinical Obstetrics and Gynecology, 2002, 45, 844-854.	0.6	9
244	Multiple Myeloma. Clinical Obstetrics and Gynecology, 2002, 45, 928-938.	0.6	7
245	Adjuvant High Dose Rate Vaginal Brachytherapy as Treatment of Stage I and II Endometrial Carcinoma. Obstetrics and Gynecology, 2002, 99, 235-240.	1.2	4
246	Second malignancies in early stage laryngeal carcinoma patients treated with radiotherapy. Journal of Laryngology and Otology, 2002, 116, 190-193.	0.4	48
247	Preoperative Predictors of Survival After Resection of Small Hepatocellular Carcinomas. Annals of Surgery, 2002, 235, 722-731.	2.1	170
248	Genetic susceptibility–molecular epidemiology of head and neck cancer. Current Opinion in Oncology, 2002, 14, 310-317.	1.1	82
249	Current surgical management of breast cancer. Current Opinion in Obstetrics and Gynecology, 2002, 14, 45-52.	0.9	41
250	The Immunotherapy of Patients With Ovarian Cancer. Journal of Immunotherapy, 2002, 25, 189-201.	1.2	34
251	Breast Cancer and Masses in Women 22 Years of Age and Younger. Clinical Obstetrics and Gynecology, 2002, 45, 758-760.	0.6	2
252	Role of the Obstetrician-Gynecologist in Reducing the Incidence of and Death Rate from Colorectal Cancer. Clinical Obstetrics and Gynecology, 2002, 45, 812-819.	0.6	6
253	Biodistribution of a 153Gd-Folate Dendrimer, Generation = 4, in Mice With Folate-Receptor Positive and Negative Ovarian Tumor Xenografts. Investigative Radiology, 2002, 37, 199-204.	3.5	90
254	The Use of Molecular Profiling of Early Colorectal Cancer to Predict Micrometastases. Archives of Surgery, 2002, 137, 1377.	2.3	25
255	Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized Trial. Journal of Clinical Oncology, 2002, 20, 3578-3585.	0.8	241
256	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 2002, 100, 3063-3067.	0.6	759

#	Article	IF	CITATIONS
257	Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. Journal of Clinical Oncology, 2002, 20, 1248-1259.	0.8	1,933
258	Metastatic Melanoma: Chemotherapy to Biochemotherapy. Cancer Control, 2002, 9, 31-38.	0.7	55
259	Histopathological Classification Phenotype and Molecular Pathology of Lung Tumors. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2002, , 105-114.	0.0	1
260	Marketing Medicine to the Public: A Reader's Guide. JAMA - Journal of the American Medical Association, 2002, 287, 774.	3.8	8
261	Population-Based Cancer Screening. Oncology Nursing Forum, 2002, 29, 853-861.	0.5	6
262	Chronic Pancreatitis and Pancreatic Cancer. Digestive Diseases, 2002, 20, 32-37.	0.8	101
263	The Expanding Role of Epirubicin in the Treatment of Breast Cancer. Cancer Control, 2002, 9, 16-27.	0.7	15
264	Colorectal Cancer Screening: A Challenge for Magnetic Resonance Colonography. Topics in Magnetic Resonance Imaging, 2002, 13, 427-434.	0.7	6
265	Cutaneous Malignant Melanoma. Clinical Obstetrics and Gynecology, 2002, 45, 830-843.	0.6	4
266	Ultrasound-Guided Biopsy and Ablation in the Neck. Ultrasound Quarterly, 2002, 18, 3-12.	0.3	12
267	Advances in Ultrasound for the Detection of Prostate Cancer. Ultrasound Quarterly, 2002, 18, 135-142.	0.3	28
268	Treatment Considerations for the Elderly Person With Cancer. AACN Advanced Critical Care, 2002, 13, 43-60.	1.9	4
270	Bone mass and the risk of prostate cancer: The Framingham study. American Journal of Medicine, 2002, 113, 734-739.	0.6	21
271	Discovery of Novel Tumor Markers of Pancreatic Cancer using Global Gene Expression Technology. American Journal of Pathology, 2002, 160, 1239-1249.	1.9	271
272	FEZ1/LZTS1 Is Down-Regulated in High-Grade Bladder Cancer, and Its Restoration Suppresses Tumorigenicity in Transitional Cell Carcinoma Cells. American Journal of Pathology, 2002, 160, 1345-1352.	1.9	38
273	Telomere Shortening Is Nearly Universal in Pancreatic Intraepithelial Neoplasia. American Journal of Pathology, 2002, 161, 1541-1547.	1.9	323
274	Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma. American Journal of Pathology, 2002, 161, 2295-2309.	1.9	129
275	Effect of hypergastrinemia on pancreatic carcinogenesis. American Journal of Surgery, 2002, 183, 441-444.	0.9	7

#	Article	IF	CITATIONS
276	The utility of routine preoperative computed tomography scanning in the management of veterans with colon cancer. American Journal of Surgery, 2002, 183, 499-503.	0.9	47
277	Increased expression of alpha-1-antitrypsin, glutathione S-transferase π and vascular endothelial growth factor in human pancreatic adenocarcinoma. American Journal of Surgery, 2002, 184, 642-647.	0.9	41
278	Breast cancer-treatment for the future based on lessons from the past. American Journal of Surgery, 2002, 184, 477-483.	0.9	5
279	Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues. Journal of the National Cancer Institute, 2002, 94, 252-266.	3.0	1,300
280	Expression of PH-20 in Normal and Neoplastic Breast Tissue. Journal of Surgical Research, 2002, 103, 203-207.	0.8	63
281	Vitamin E Succinate Inhibits Colon Cancer Liver Metastases. Journal of Surgical Research, 2002, 106, 292-298.	0.8	76
282	Bax-Induction Gene Therapy of Pancreatic Cancer. Journal of Surgical Research, 2002, 106, 346-351.	0.8	36
283	How Surgeon Age Affects Surveillance Strategies for Extremity Soft Tissue Sarcoma Patients after Potentially Curative Treatment. Journal of Surgical Research, 2002, 108, 227-234.	0.8	12
284	Serological Cloning of PARIS-1: A New TBC Domain-Containing, Immunogenic Tumor Antigen from a Prostate Cancer Cell Line. Biochemical and Biophysical Research Communications, 2002, 290, 830-838.	1.0	33
285	Are People Being Screened for Colorectal Cancer as Recommended? Results from the National Health Interview Survey. Preventive Medicine, 2002, 35, 199-206.	1.6	97
286	Evaluation of a Community Breast Screening Promotion Program. Preventive Medicine, 2002, 35, 349-361.	1.6	9
287	Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiotherapy and Oncology, 2002, 64, 37-40.	0.3	58
288	Radioactive sources embedded in suture are associated with improved postimplant dosimetry in men treated with prostate brachytherapy. Radiotherapy and Oncology, 2002, 65, 123-127.	0.3	287
289	Lung Cancer â€" Time to Move on from Chemotherapy. New England Journal of Medicine, 2002, 346, 126-128.	13.9	264
290	PERCENT PROSTATE NEEDLE BIOPSY TISSUE WITH CANCER IS MORE PREDICTIVE OF BIOCHEMICAL FAILURE OR ADVERSE PATHOLOGY AFTER RADICAL PROSTATECTOMY THAN PROSTATE SPECIFIC ANTIGEN OR GLEASON SCORE. Journal of Urology, 2002, 167, 516-520.	0.2	132
291	Testicular Lymphoma: A Mysterious Link Between the Testis and the Brain. Clinical Lymphoma and Myeloma, 2002, 3, 173-174.	2.1	1
292	On-site screening sigmoidoscopy promotes long-term utilization but fails as a venue for training primary care endoscopists. Gastroenterology, 2002, 122, 1226-1234.	0.6	9
293	Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology, 2002, 122, 1800-1807.	0.6	214

#	Article	IF	Citations
294	A prospective, blinded assessment of the impact of preoperative staging on the management of rectal cancer. Gastroenterology, 2002, 123, 24-32.	0.6	186
295	Biochemotherapy of melanoma. Seminars in Oncology, 2002, 29, 446-455.	0.8	16
296	Staging, stage migration, and patterns of spread in gastric cancer. Seminars in Radiation Oncology, 2002, 12, 141-149.	1.0	32
297	Procedural success and complications of large-scale screening colonoscopy. Gastrointestinal Endoscopy, 2002, 55, 307-314.	0.5	427
298	Selective Estrogen Receptor Modulators as a New Therapeutic Drug Group: Concept to Reality in a Decade. Clinical Breast Cancer, 2002, 2, 272-281.	1.1	31
299	Preclinical Studies of Gemcitabine and Trastuzumab in Breast and Lung Cancer Cell Lines. Clinical Breast Cancer, 2002, 3, S12-S16.	1.1	19
300	Matrix Metalloproteinases in Colorectal Cancer. Clinical Colorectal Cancer, 2002, 1, 208-219.	1.0	33
301	Liposomal Doxorubicin for the Treatment of Hormone-Refractory Prostate Cancer. Clinical Prostate Cancer, 2002, 1, 37-41.	2.1	26
302	High Gleason Scores and Lower Prostate-Specific Antigen Levels in a Single Institution Over the Past Decade. Clinical Prostate Cancer, 2002, 1, 115-117.	2.1	3
303	Phase I Study of Dose-Dense Alternating Doublets in Advanced Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2002, 3, 265-270.	1.1	2
304	Irinotecan in Non–Small-Cell Lung Cancer: Status of Ongoing Trials. Clinical Lung Cancer, 2002, 4, S15-S20.	1.1	3
305	The role of sigmoidoscopy and colonoscopy in the diagnosis and management of lower gastrointestinal disorders: endoscopic findings, therapy, and complications. Medical Clinics of North America, 2002, 86, 1253-1288.	1.1	72
306	Primary prevention of colorectal cancer: diet and drugs. Gastroenterology Clinics of North America, 2002, 31, 587-623.	1.0	28
307	Replication-Selective Herpes Simplex Virus Type 1 Mutant Therapy of Cervical Cancer Is Enhanced by Low-Dose Radiation. Human Gene Therapy, 2002, 13, 627-639.	1.4	65
308	Impact of Previous Local Treatment for Prostate Cancer on Subsequent Metastatic Disease. Journal of Urology, 2002, 168, 1008-1012.	0.2	99
309	Breast Cancer Prevention. American Journal of Cancer, 2002, 1, 173-178.	0.4	0
310	Hairy Cell Leukemia. American Journal of Cancer, 2002, 1, 189-203.	0.4	0
311	Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: An overview of the Department of Defense Center for Prostate Disease Research national database. Surgery, 2002, 132, 213-219.	1.0	98

#	Article	IF	Citations
312	Preventing lung cancer by stopping smoking. Clinics in Chest Medicine, 2002, 23, 27-36.	0.8	4
313	Liver imaging: A surgeon's perspective. Clinics in Liver Disease, 2002, 6, 271-295.	1.0	6
314	Early Onset Prostate Cancer: Predictors Of Clinical Grade. Journal of Urology, 2002, 167, 1659-1663.	0.2	32
315	Oral health, taste, and olfaction. Clinics in Geriatric Medicine, 2002, 18, 709-717.	1.0	31
316	Efficient triage of the "screen-positive―at-risk patient. Obstetrics and Gynecology Clinics of North America, 2002, 29, 735-750.	0.7	2
317	Breast Cancer Risk Reduction: Strategies for Women at Increased Risk. Annual Review of Medicine, 2002, 53, 519-540.	5.0	31
318	Anastrozole in the management of breast cancer. Expert Opinion on Pharmacotherapy, 2002, 3, 1329-1339.	0.9	4
319	Phase II Study of Docetaxel in Patients with Pancreatic Cancer Previously Untreated with Cytotoxic Chemotherapy. Cancer Investigation, 2002, 20, 464-472.	0.6	39
320	The development of immunotherapies for non-small cell lung cancer. Expert Opinion on Biological Therapy, 2002, 2, 265-278.	1.4	25
321	Tumor Vaccines. American Journal of Clinical Dermatology, 2002, 3, 609-616.	3.3	12
322	PC-SPES for the Treatment of Prostate Cancer?. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2002, 2, 73-89.	0.1	1
323	The use of retinoids in the prevention and treatment of skin cancer. Expert Opinion on Pharmacotherapy, 2002, 3, 299-303.	0.9	19
324	The Role of NSAIDs in the Prevention of Colon Cancer. Cancer Investigation, 2002, 20, 1002-1011.	0.6	31
325	A Case-Control Study of Dietary Phytoestrogens and Testicular Cancer Risk. Nutrition and Cancer, 2002, 44, 44-51.	0.9	41
326	Early Detection and Successful Treatment of Drug-Induced Pneumonitis with Corticosteroids. Cancer Investigation, 2002, 20, 876-879.	0.6	12
327	Parameter optimization of a computer-aided diagnosis scheme for the segmentation of microcalcification clusters in mammograms. Medical Physics, 2002, 29, 475-483.	1.6	28
328	Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology, 2002, 59, 2-8.	0.5	72
329	Percentage of core lengths involved with prostate cancer: does it add to the percentage of positive prostate biopsies in predicting postoperative prostate-specific antigen outcome for men with intermediate-risk prostate cancer?. Urology, 2002, 59, 704-708.	0.5	30

#	Article	IF	CITATIONS
330	Impact of prostate cancer screening on health-related quality of life in at-risk families. Urology, 2002, 59, 901-906.	0.5	27
331	A review of measurement of patient preferences for treatment outcomes after prostate cancer. Urology, 2002, 60, 72-77.	0.5	17
332	Secondary hormonal therapies in the treatment of prostate cancer. Urology, 2002, 60, 87-92.	0.5	61
333	Role of "saturation biopsy―in the detection of prostate cancer among difficult diagnostic cases. Urology, 2002, 60, 93-97.	0.5	115
334	Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology, 2002, 60, 3-11.	0.5	310
335	Integrin $\hat{l}\pm\nu$ and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology, 2002, 60, 531-536.	0.5	109
336	Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer. Urology, 2002, 60, 454-457.	0.5	11
337	Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. Urology, 2002, 60, 1034-1039.	0.5	29
338	Cigarette smoking and risk of breast cancer in women. Lancet, The, 2002, 360, 1033-1034.	6.3	19
339	Surgical resection of multifocal non-Small cell lung cancer is associated with prolonged survival. Annals of Thoracic Surgery, 2002, 74, 988-994.	0.7	121
340	Renal transplantation and prostate cancer: guidelines for screening and treatment. Transplantation Proceedings, 2002, 34, 3196-3199.	0.3	26
341	Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstetrics and Gynecology, 2002, 99, 235-240.	1.2	103
342	Preoperative endoscopic stent placement before pancreaticoduodenectomy: A meta-analysis of the effect on morbidity and mortality. Gastrointestinal Endoscopy, 2002, 56, 529-534.	0.5	117
343	Evaluation of Prognostic Factors and Treatment Modalities in Ovarian Cancer Patients with Brain Metastases. Gynecologic Oncology, 2002, 85, 487-492.	0.6	77
344	Patient Selection for Therapy in Prostate Cancer. European Urology Supplements, 2002, 1, 2-6.	0.1	0
345	Does PSA Testing Influence the Natural History of Prostate Cancer?. European Urology Supplements, 2002, 1, 3-10.	0.1	2
346	New Technical Improvements for TRUS in the Diagnosis of Prostate Cancer. European Urology Supplements, 2002, 1, 8-14.	0.1	10
347	Prevention and Screening. European Urology Supplements, 2002, 1, 3-9.	0.1	5

#	Article	IF	CITATIONS
348	Looking to the Future: Advances in the Management of Hormone-Refractory Prostate Cancer. European Urology Supplements, 2002, 1, 44-53.	0.1	8
349	The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer. Lung Cancer, 2002, 36, 159-165.	0.9	42
350	Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer, 2002, 37, 1-6.	0.9	70
351	The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer, 2002, 37, 303-309.	0.9	42
353	Molecular approaches to lung cancer evaluation. Lung Cancer, 2002, 38, 9-17.	0.9	7
354	Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Human Pathology, 2002, 33, 1182-1187.	1.1	88
355	Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes. Seminars in Hematology, 2002, 39, 57-62.	1.8	21
356	Current therapeutic approaches in the treatment of non-Hodgkin's lymphoma. Seminars in Oncology Nursing, 2002, 18, 3-9.	0.7	0
357	A single-institution case series of patients with cutaneous melanoma and non-Hodgkin's lymphoma. Journal of the American Academy of Dermatology, 2002, 46, 55-61.	0.6	15
358	Long-term surveillance of previously treated breast cancer survivors by primary care physicians. Primary Care Update for Ob/Gyns, 2002, 9, 110-115.	0.1	0
359	Fads and fashions: the price women pay. Primary Care Update for Ob/Gyns, 2002, 9, 138-143.	0.1	5
360	Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2002, 7, 159-166.	0.8	52
361	DD23 Biomarker. Urologic Oncology: Seminars and Original Investigations, 2002, 7, 185-190.	0.8	26
362	Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. Urologic Oncology: Seminars and Original Investigations, 2002, 7, 213-219.	0.8	48
363	Primary radiation therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2002, 7, 239-257.	0.8	8
364	MR imaging of lung cancer. European Journal of Radiology, 2002, 44, 172-181.	1.2	51
365	Reviews of evidence on interventions to prevent dental caries, oral and pharyngeal cancers, and sports-related craniofacial injuries 11The names and affiliations of the Task Force members are listed at the beginning of this supplement, and at www.thecommunityguide.org American Journal of	1.6	144
366	Preventive Medicine, 2002, 23, 21-54. Part I: Chemotherapy for epithelial ovarian cancer–treatment at first diagnosis. Lancet Oncology, The, 2002, 3, 529-536.	5.1	134

#	Article	IF	Citations
367	Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-EGFP fusion protein against prostate cancer in rats. International Immunopharmacology, 2002, 2, 783-796.	1.7	14
368	The role of mitogen-activated protein (MAP) kinase in breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2002, 80, 239-256.	1.2	347
369	Motility is rate-limiting for invasion of bladder carcinoma cell lines. International Journal of Biochemistry and Cell Biology, 2002, 34, 762-775.	1.2	22
370	Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. European Journal of Cancer, 2002, 38, 977-985.	1.3	86
371	Current treatment of follicular non-Hodgkin's lymphoma. European Journal of Cancer, 2002, 38, 1167-1172.	1.3	26
372	Dibenzoylmethane induces cell cycle deregulation in human prostate cancer cells. Cancer Letters, 2002, 178, 161-165.	3.2	53
373	p53 codon 72 polymorphism and its association with bladder cancer. Cancer Letters, 2002, 179, 175-183.	3.2	120
374	Pain and Leukemia: The Stories of Three Children. Journal of Pediatric Oncology Nursing, 2002, 19, 2-11.	1.5	7
375	New Horizons in Oncologic Embolotherapy. Journal of Vascular and Interventional Radiology, 2002, 13, P116-P123.	0.2	2
376	Therapy for stage I and stage II non-small cell lung cancer. Clinics in Chest Medicine, 2002, 23, 173-190.	0.8	2
377	Colon cancer: detection and prevention. Gastroenterology Clinics of North America, 2002, 31, 565-586.	1.0	10
378	Results of the 5 Region Prostate Biopsy Method: The Repeat Biopsy Population. Journal of Urology, 2002, 168, 500-503.	0.2	73
379	Chemotherapy for colorectal cancer. Hematology/Oncology Clinics of North America, 2002, 16, 969-994.	0.9	7
380	Prostate Cancer Stage Shift has Eliminated the Gap in Disease-free Survival in Black and White American Men after Radical Prostatectomy. Journal of Urology, 2002, 168, 479-482.	0.2	33
381	Management of small cell lung cancer. Clinics in Chest Medicine, 2002, 23, 225-239.	0.8	31
382	Standard surgical approaches in the management of esophageal cancer. Surgical Oncology Clinics of North America, 2002, 11, 351-363.	0.6	1
383	ALLELIC LOSS ON CHROMOSOMES 8 AND 9 CORRELATES WITH CLINICAL OUTCOME IN LOCALLY ADVANCED CLEAR CELL CARCINOMA OF THE KIDNEY. Journal of Urology, 2002, 167, 1464-1468.	0.2	53
384	Melanoma incidence trends. Dermatologic Clinics, 2002, 20, 589-595.	1.0	80

#	Article	IF	CITATIONS
385	Pathology of lung cancer. Clinics in Chest Medicine, 2002, 23, 65-81.	0.8	446
386	Screening mammography: proven benefit, continued controversy. Radiologic Clinics of North America, 2002, 40, 395-407.	0.9	79
387	Targeted Screening For Prostate Cancer In High Risk Families: Early Onset Is A Significant Risk Factor For Disease In First Degree Relatives. Journal of Urology, 2002, 168, 483-487.	0.2	41
388	Lung cancer evolution to preinvasive management. Clinics in Chest Medicine, 2002, 23, 37-48.	0.8	21
389	Clinical Significance of Small Polyps Found During Screening with Flexible Sigmoidoscopy. Gastrointestinal Endoscopy Clinics of North America, 2002, 12, 41-51.	0.6	27
390	GUANOSINE PHOSPHATE BINDING PROTEIN COUPLED RECEPTORS IN PROSTATE CANCER: A REVIEW. Journal of Urology, 2002, 167, 1458-1463.	0.2	50
391	The role of sigmoidoscopy and colonoscopy in the diagnosis and management of lower gastrointestinal disorders: technique, indications, and contraindications. Medical Clinics of North America, 2002, 86, 1217-1252.	1.1	29
392	Colonoscopy as a Screening Test for Colorectal Cancer in Average-Risk Individuals. Mayo Clinic Proceedings, 2002, 77, 951-956.	1.4	14
393	Breast cancer: An introduction to the problem. Obstetrics and Gynecology Clinics of North America, 2002, 29, 117-122.	0.7	12
394	Comparison of [18 F]Fluorocholine and [18 F]Fluorodeoxyglucose for Positron Emission Tomography of Androgen Dependent and Androgen Independent Prostate Cancer. Journal of Urology, 2002, 168, 273-280.	0.2	215
395	Differential Expression of Critical Cellular Genes in Human Lung Adenocarcinomas and Squamous Cell Carcinomas in Comparison to Normal Lung Tissues. Neoplasia, 2002, 4, 141-150.	2.3	40
396	SUPERFICIAL BLADDER CARCINOMA TREATED WITH BACILLUS CALMETTE-GUERIN: PROGRESSION-FREE AND DISEASE SPECIFIC SURVIVAL WITH MINIMUM 10-YEAR FOLLOWUP. Journal of Urology, 2002, 167, 494-501.	0.2	85
397	Secondary prevention: screening and surveillance of persons at average and high risk for colorectal cancer. Hematology/Oncology Clinics of North America, 2002, 16, 841-865.	0.9	7
398	The Role Of Caveolin-1 In Androgen Insensitive Prostate Cancer. Journal of Urology, 2002, 168, 1589-1596.	0.2	66
399	Epidemiology, etiology, and prevention of lung cancer. Clinics in Chest Medicine, 2002, 23, 1-25.	0.8	122
400	Surgical approaches to malignant melanoma. Dermatologic Clinics, 2002, 20, 681-699.	1.0	27
401	Gene therapy for pancreatic cancer. Surgical Oncology Clinics of North America, 2002, 11, 537-569.	0.6	12
402	Cancer screening. Primary Care - Clinics in Office Practice, 2002, 29, 697-725.	0.7	1

#	Article	IF	CITATIONS
403	INCREASING INCIDENCE OF ALL STAGES OF KIDNEY CANCER IN THE LAST 2 DECADES IN THE UNITED STATES: AN ANALYSIS OF SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS PROGRAM DATA. Journal of Urology, 2002, 167, 57-60.	0.2	372
404	Colorectal cancer screening. Surgical Clinics of North America, 2002, 82, 943-957.	0.5	23
405	Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients With Previously Untreated Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2002, 20, 1182-1191.	0.8	125
406	Human Kallikrein Gene 5 (KLK5) Expression by Quantitative PCR: An Independent Indicator of Poor Prognosis in Breast Cancer. Clinical Chemistry, 2002, 48, 1241-1250.	1.5	82
407	Measurement of Prostate-specific Antigen by Use of a Novel Blood Collection and Analytical System. Clinical Chemistry, 2002, 48, 1272-1278.	1.5	7
408	The Vermont Colorectal Cancer Project <subtitle>Self-portrait</subtitle> . Archives of Surgery, 2002, 137, 413.	2.3	11
409	Urothelial Neoplasms of the Kidney and Ureter. Pathology Patterns Reviews, 2002, 117, S36-S48.	0.4	21
410	Chemoprevention in Colorectal Neoplasias: What Is Practical and Feasible?. Digestive Diseases, 2002, 20, 70-72.	0.8	5
412	Intraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-Up. Journal of Clinical Oncology, 2002, 20, 694-698.	0.8	96
413	Invited Commentary • Author's Response. Radiographics, 2002, 22, 1536-1539.	1.4	0
414	Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2002, 20, 125-133.	0.8	130
415	Intravesical Therapy for Superficial Cancer: Need for More Options. Journal of Clinical Oncology, 2002, 20, 3185-3186.	0.8	25
416	Temozolomide in Combination With Docetaxel in Patients With Advanced Melanoma: A Phase II Study of the Hellenic Cooperative Oncology Group. Journal of Clinical Oncology, 2002, 20, 420-425.	0.8	58
417	Vive La Difference: Sex and Fluorouracil Toxicity. Journal of Clinical Oncology, 2002, 20, 1439-1441.	0.8	21
418	Age, Sex, and Racial Differences in the Use of Standard Adjuvant Therapy for Colorectal Cancer. Journal of Clinical Oncology, 2002, 20, 1192-1202.	0.8	261
419	Postoperative Nomogram for 12-Year Sarcoma-Specific Death. Journal of Clinical Oncology, 2002, 20, 791-796.	0.8	491
420	Recurrent Ovarian Cancer: Evidence-Based Treatment. Journal of Clinical Oncology, 2002, 20, 1161-1163.	0.8	98
421	Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2002, 20, 1335-1343.	0.8	297

#	Article	IF	Citations
422	Families Facing Cancer: The Forgotten Priority. Clinical Journal of Oncology Nursing, 2002, 6, 69-70.	0.3	4
423	Is Colonoscopic Screening of a Low-Risk (Normal) Population Ethically Justifiable?. Digestive Diseases, 2002, 20, 246-252.	0.8	6
424	p53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World Journal of Gastroenterology, 2002, 8, 459.	1.4	51
425	Chemotherapy-Induced Nausea and Vomiting. Clinical Journal of Oncology Nursing, 2002, 6, 94-102.	0.3	71
426	Patterns of Symptom Distress in Adults Receiving Treatment for Lung Cancer. Journal of Palliative Care, 2002, 18, 150-159.	0.4	45
427	A Retrospective Analysis Comparing Patients 70 Years or Older to Patients Younger than 70 Years with Non—Small-Cell Lung Cancer Treated with Surgery at Indiana University: 1989–1999. Clinical Lung Cancer, 2002, 3, 200-204.	1.1	8
428	Hypersensitivity Pneumonitis in Advanced Non-Small-Cell Lung Cancer Patients Receiving Gemcitabine and Paclitaxel: Report of Two Cases and a Review of the Literature. Clinical Lung Cancer, 2002, 4, 52-56.	1.1	19
429	Small-Cell Lung Cancer: State of the Art. Clinical Lung Cancer, 2002, 4, 87-94.	1.1	33
430	Promising Developments in Targeted Therapies for non–small-Cell Lung Cancer. Clinical Lung Cancer, 2002, 4, 111-123.	1.1	3
431	The Validity and Clinical Utility of Symptom Monitoring in Advanced Lung Cancer: A Literature Review. Clinical Lung Cancer, 2002, 4, 153-160.	1.1	20
432	Irinotecan Combined with Radiation Therapy for Patients with Stage III Nonâ€"Small-Cell Lung Cancer: Current Trials. Clinical Lung Cancer, 2002, 4, S21-S25.	1.1	3
433	Metastatic lung cancer of the neck: Report of 2 cases. Journal of Oral and Maxillofacial Surgery, 2002, 60, 1057-1061.	0.5	4
434	Hirschsprung disease: A component of the familial cancer syndrome multiple endocrine neoplasia type 2a. Newborn and Infant Nursing Reviews, 2002, 2, 221-227.	0.4	0
435	Future directions for gemcitabine in the treatment of genitourinary cancer. Seminars in Oncology, 2002, 29, 40-45.	0.8	22
436	ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non–small cell lung cancer. Seminars in Oncology, 2002, 29, 37-46.	0.8	134
437	HER2/neu expression in malignant lung tumors. Seminars in Oncology, 2002, 29, 51-58.	0.8	92
438	Meaningful survival in lung cancer patients. Seminars in Oncology, 2002, 29, 125-131.	0.8	12
439	Future directions in the treatment of ovarian cancer. Seminars in Oncology, 2002, 29, 32-42.	0.8	50

#	Article	IF	CITATIONS
440	Prostate-specific antigen in prostate cancer: A case study in the development of a tumor marker to monitor recurrence and assess response. Seminars in Oncology, 2002, 29, 264-273.	0.8	37
441	Expression of target molecules in lung cancer: Challenge for a new treatment paradigm. Seminars in Oncology, 2002, 29, 2-8.	0.8	9
442	Gynecologic brachytherapy I: Proper incorporation of brachytherapy into the current multimodality management of carcinoma of the cervix. Seminars in Radiation Oncology, 2002, 12, 40-52.	1.0	19
443	Results of radiation therapy in gastric cancer. Seminars in Radiation Oncology, 2002, 12, 170-175.	1.0	5
444	Chemotherapy options for gastric cancer. Seminars in Radiation Oncology, 2002, 12, 176-186.	1.0	14
445	Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results. Seminars in Radiation Oncology, 2002, 12, 46-49.	1.0	86
446	The potential role of amifostine in the treatment of carcinoma of the uterine cervix: A review. Seminars in Radiation Oncology, 2002, 12, 68-74.	1.0	3
447	Detection of genomic alterations in human endometrial cancer by two-dimensional gel electrophoresis. American Journal of Obstetrics and Gynecology, 2002, 186, 855-857.	0.7	3
448	Estrogen replacement therapy in patients with early breast cancer. American Journal of Obstetrics and Gynecology, 2002, 187, 289-295.	0.7	24
449	Localized prostate cancer. Current Problems in Surgery, 2002, 39, 843-957.	0.6	34
450	Impact of comorbidity on survival after surgical resection in patients with stage I non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2002, 123, 280-287.	0.4	163
451	Molecular biologic substaging of non-small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2002, 123, 409-410.	0.4	15
452	Disparities in surgical resection of early-stage non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2002, 123, 1173-1176.	0.4	46
453	Assessment of cancer risk and environmental levels of arsenic in New Hampshire. International Journal of Hygiene and Environmental Health, 2002, 205, 85-94.	2.1	112
454	Review of gemcitabine in biliary tract carcinoma. Seminars in Oncology, 2002, 29, 40-45.	0.8	27
455	Pemetrexed in pancreatic cancer. Seminars in Oncology, 2002, 29, 49-53.	0.8	4
456	Myeloma and the newly diagnosed patient: A focus on treatment and management. Seminars in Oncology, 2002, 29, 5-10.	0.8	3
457	Epidermal growth factor receptor-targeted therapy in colorectal cancer. Seminars in Oncology, 2002, 29, 10-17.	0.8	26

#	ARTICLE	IF	Citations
458	IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars in Oncology, 2002, 29, 18-30.	0.8	29
459	High-dose chemotherapy in breast cancer: Where are we now?. Seminars in Oncology, 2002, 29, 16-20.	0.8	0
460	Preoperative serum TA90-IC as an adjunct to serum CA 19-9 in the diagnosis of pancreatic malignancy: A pilot study. Journal of Surgical Education, 2002, 59, 194-198.	0.7	3
461	Evaluation of breast and gynecologic cancers by positron emission tomography. Seminars in Roentgenology, 2002, 37, 151-168.	0.2	9
462	The Virtual Colonoscopy Study. Contemporary Clinical Trials, 2002, 23, 570-583.	2.0	16
463	Focus on colon cancer. Cancer Cell, 2002, 1, 233-236.	7.7	127
464	Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. Journal of Experimental Therapeutics and Oncology, 2002, 2, 337-349.	0.5	47
465	Healthcare Professionals' Awareness of Cancer Support Services. Cancer Practice, 2002, 10, 36-44.	0.8	10
466	Neoadjuvant chemotherapy for the management of ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 585-596.	1.4	27
467	Chemotherapy for advanced epithelial ovarian carcinoma. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 553-571.	1.4	16
468	Surgical pathology of colorectal cancer in filipinos: implications for clinical practice 11No competing interests declared Journal of the American College of Surgeons, 2002, 195, 188-195.	0.2	19
469	Value of Immunohistochemistry in Staging T1 Urothelial Bladder Carcinoma. European Urology, 2002, 42, 459-463.	0.9	26
470	Use of Medicare claims data to measure county-level variation in breast carcinoma incidence and mammography rates. Cancer Detection and Prevention, 2002, 26, 197-202.	2.1	24
471	Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis. Cancer Detection and Prevention, 2002, 26, 419-425.	2.1	82
472	Views of oral cancer prevention and early detection: Maryland physicians. Oral Oncology, 2002, 38, 373-377.	0.8	18
473	Oral cavity and pharynx cancer incidence rates in the United States, 1975–1998 â⁻† â⁻†Portions of this manuscript were presented at the meeting of the American Association of Public Health Dentistry in October 1999 Oral Oncology, 2002, 38, 610-617.	0.8	165
474	Inflammation and the development of pancreatic cancer. Surgical Oncology, 2002, 10, 153-169.	0.8	288
475	Risk estimation for breast cancer development; a clinical perspective. Surgical Oncology, 2002, 10, 183-192.	0.8	46

#	Article	IF	CITATIONS
476	The impact of clinical practice guidelines and clinical trials on treatment decisions. Surgical Oncology, 2002, 11, 255-262.	0.8	10
477	Clinical relevance of molecular markers in lung cancer. Surgical Oncology, 2002, 11, 167-179.	0.8	30
478	Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic experience. Journal of Surgical Oncology, 2002, 80, 19-25.	0.8	126
479	Is abdominoperineal resection a good option for stage IV adenocarcinoma of the distal rectum?. Journal of Surgical Oncology, 2002, 81, 3-7.	0.8	9
480	Cyclooxygenase-2: A novel molecular target for the prevention and treatment of head and neck cancer. Head and Neck, 2002, 24, 792-799.	0.9	194
481	Cancer mortality in the European Union, 1988-1997: The fall may approach 80,000 deaths a year. International Journal of Cancer, 2002, 98, 636-637.	2.3	30
482	Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody. International Journal of Cancer, 2002, 98, 923-929.	2.3	61
483	Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. International Journal of Cancer, 2002, 99, 273-278.	2.3	38
484	Metabolism and DNA binding of the environmental pollutant 6-nitrochrysene in primary culture of human breast cells and in cultured MCF-10A, MCF-7 and MDA-MB-435s cell lines. International Journal of Cancer, 2002, 100, 395-400.	2.3	16
485	Steady state levels of transforming growth factor-?1 and -?2 mRNA and protein expression are elevated in colonic tumorsin vivo irrespective of dietary lipids intervention. International Journal of Cancer, 2002, 100, 635-641.	2.3	11
486	Deletion of chromosomal region 6q14-16 in prostate cancer. International Journal of Cancer, 2002, 102, 142-147.	2.3	23
487	Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer, 2002, 94, 104-110.	2.0	79
488	Therapy choices among older patients with lung carcinoma. Cancer, 2002, 94, 181-187.	2.0	144
489	Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer, 2002, 94, 950-963.	2.0	57
490	Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer, 2002, 94, 1457-1465.	2.0	135
491	Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer, 2002, 94, 2836-2843.	2.0	73
492	Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer, 2002, 94, 2914-2922.	2.0	71
493	Comparative immunohistochemical studies ofbcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Cancer, 2002, 94, 2935-2940.	2.0	87

#	ARTICLE	IF	CITATIONS
494	Squamous cell carcinoma of the oropharynx. Cancer, 2002, 94, 2967-2980.	2.0	414
495	Predictors of skin self-examination performance. Cancer, 2002, 95, 135-146.	2.0	96
496	Complications from treatment for prostate carcinoma among men in the Detroit area. Cancer, 2002, 95, 82-89.	2.0	28
497	The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma. Cancer, 2002, 95, 316-321.	2.0	18
498	Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Cancer, 2002, 95, 296-300.	2.0	26
499	The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer, 2002, 95, 928-932.	2.0	27
500	Gemcitabine and platinum combinations in pancreatic cancer. Cancer, 2002, 95, 908-911.	2.0	17
501	Bilateral testicular germ cell tumors. Cancer, 2002, 95, 1228-1233.	2.0	93
502	Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Cancer, 2002, 95, 1239-1246.	2.0	27
503	Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer, 2002, 95, 1265-1273.	2.0	55
504	A Phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma. Cancer, 2002, 95, 1714-1719.	2.0	26
505	A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer, 2002, 95, 1629-1636.	2.0	119
506	Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma. Cancer, 2002, 95, 1520-1527.	2.0	20
507	Prognostic factors for the survival of patients with esophageal carcinoma in the U.S Cancer, 2002, 95, 1434-1443.	2.0	356
508	Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. Cancer, 2002, 95, 2494-2499.	2.0	33
509	Frequency of nonsentinel lymph node metastasis in melanoma. Annals of Surgical Oncology, 2002, 9, 137-141.	0.7	122
510	Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Annals of Surgical Oncology, 2002, 9, 148-155.	0.7	20
511	Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Annals of Surgical Oncology, 2002, 9, 256-265.	0.7	112

#	Article	IF	CITATIONS
512	Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: The effect of undertreatment. Annals of Surgical Oncology, 2002, 9, 278-286.	0.7	216
513	Matrix metalloproteinases and their role in pancreatic cancer: A review of preclinical studies and clinical trials. Annals of Surgical Oncology, 2002, 9, 668-674.	0.7	147
514	Minimally invasive surgery in the diagnosis and treatment of upper gastrointestinal tract malignancy. Annals of Surgical Oncology, 2002, 9, 725-737.	0.7	14
515	FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Annals of Nuclear Medicine, 2002, 16, 409-416.	1.2	47
516	Concurrent paclitaxel-cisplatin and twice-a-day irradiation in stage IIIA and IIIB NSCLC shows improvement in local control and survival with acceptable hematologic toxicity. Pathology and Oncology Research, 2002, 8, 163-169.	0.9	7
517	Early laryngeal cancer. Current Treatment Options in Oncology, 2002, 3, 3-9.	1.3	14
518	Angiogenesis inhibitors in lung cancer. Current Oncology Reports, 2002, 4, 325-333.	1.8	11
519	Recent developments in the treatment of gastric carcinoma. Current Oncology Reports, 2002, 4, 193-201.	1.8	7
520	Current and future strategies for combined-modality therapy in pancreatic cancer. Current Oncology Reports, 2002, 4, 202-212.	1.8	8
521	Adjuvant and preoperative chemotherapy for gastric cancer. Current Oncology Reports, 2002, 4, 222-228.	1.8	9
522	The role of radical hysterectomy and neoadjuvant chemotherapy in carcinoma of the cervix. Current Oncology Reports, 2002, 4, 145-151.	1.8	1
523	Angiogenesis in ovarian cancer: Molecular pathology and therapeutic strategies. Current Oncology Reports, 2002, 4, 165-174.	1.8	14
524	The role of transrectal ultrasound in diagnosing prostate cancer. Current Urology Reports, 2002, 3, 194-200.	1.0	20
525	New Molecular Targets of Breast Cancer Therapy. Strahlentherapie Und Onkologie, 2002, 178, 123-133.	1.0	23
528	Continued Rightward Shift of Colorectal Cancer. Diseases of the Colon and Rectum, 2002, 45, 1035-1040.	0.7	133
529	Impact of Gender and Parent of Origin on the Phenotypic Expression of Hereditary Nonpolyposis Colorectal Cancer in a Large Newfoundland Kindred With a Common MSH2 Mutation. Diseases of the Colon and Rectum, 2002, 45, 1223-1232.	0.7	48
530	The use of gene transfer for the protection and repair of salivary glands. Oral Diseases, 2002, 8, 183-191.	1.5	36
531	Clinical experience with intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of rectal balloon for prostate immobilization. Medical Dosimetry, 2002, 27, 105-113.	0.4	52

#	Article	IF	CITATIONS
532	Chemoprevention of superficial bladder cancer. Critical Reviews in Oncology/Hematology, 2002, 43, 277-286.	2.0	34
533	Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer. Critical Reviews in Oncology/Hematology, 2002, 44, 15-30.	2.0	28
534	Neoadjuvant Chemotherapy with CPT-11 and Cisplatin Downstages Locally Advanced Gastric Cancer. Journal of Gastrointestinal Surgery, 2002, 6, 212-223.	0.9	36
535	En Bloc Resection for Locally Advanced Cancer of the Pancreas Is It Worthwhile?. Journal of Gastrointestinal Surgery, 2002, 6, 147-158.	0.9	151
536	Stage I-II endometrial adenocarcinoma evolution of therapeutic paradigms: the role of surgery and adjuvant radiation. International Journal of Gynecological Cancer, 2002, 12, 237-249.	1.2	20
537	Molecular analysis of inhibin A and activin A subunit gene loci in epithelial ovarian cancer. International Journal of Gynecological Cancer, 2002, 12, 443-447.	1.2	5
538	An Incentive to Start Hormone Replacement: The Effect of Postmenopausal Hormone Replacement Therapy on the Risk of Colorectal Cancer. Journal of the American Geriatrics Society, 2002, 50, 768-770.	1.3	3
539	Adjuvant whole abdominal radiotherapy in epithelial cancer of the ovary. International Journal of Radiation Oncology Biology Physics, 2002, 53, 360-365.	0.4	10
540	Long-term use of combined radiation therapy and hormonal therapy in the management of Stage D1 prostate cancer. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1146-1151.	0.4	26
541	Pediatric Hodgkin's diseaseâ€"up, up, and beyond. International Journal of Radiation Oncology Biology Physics, 2002, 54, 1-8.	0.4	17
542	Is there a difference in outcome between stage lâ€"II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?. International Journal of Radiation Oncology Biology Physics, 2002, 54, 79-85.	0.4	96
543	non-small-cell lung cancer 1 1This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Additional participating institutions included Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Meritcare Hospital CCOP, Fargo, ND; Sioux Community Cancer Consortium, Sioux Falls, SD; Geisinger Clinical Oncology Program, Danville, PA (Suresh Nair.) Ti ETOq 1	0.4 0.784314	95 røBT /Overlo
544	Phase I study of hyperfractionated accelerated radiotherapy and escalating doses of daily cisplatin for patients with locally advanced non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2002, 54, 729-734.	0.4	5
545	Surviving and thriving?. Psycho-Oncology, 2002, 11, 89-92.	1.0	91
546	Treatment regimen, sexual attractiveness concerns and psychological adjustment among African American breast cancer patients. Psycho-Oncology, 2002, 11, 505-517.	1.0	41
547	Regulation of cell-to-cell communication in non-tumorigenic and malignant human prostate epithelial cells. Prostate, 2002, 50, 73-82.	1.2	27
548	In vivo expression and function of the sodium iodide symporter following gene transfer in the MATLyLu rat model of metastatic prostate cancer. Prostate, 2002, 50, 170-178.	1.2	39
549	Role of family history and ethnicity on the mode and age of prostate cancer presentation. Prostate, 2002, 50, 216-221.	1.2	47

#	ARTICLE	IF	CITATIONS
550	Clinical stage T1c prostate cancer: Pathologic outcomes following radical prostatectomy in black and white men. Prostate, 2002, 50, 236-240.	1.2	16
551	Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. Prostate, 2002, 51, 35-41.	1.2	40
552	Relative promoter strengths in four human prostate cancer cell lines evaluated by particle bombardment-mediated gene transfer. Prostate, 2002, 51, 286-292.	1.2	11
553	Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate, 2002, 51, 247-255.	1.2	62
554	Worry and attitude of men in at-risk families for prostate cancer about genetic susceptibility and genetic testing. Prostate, 2002, 51, 276-285.	1.2	25
555	Altered apoptotic gene expression and acquired apoptotic resistance in cadmium-transformed human prostate epithelial cells. Prostate, 2002, 52, 236-244.	1.2	65
556	Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. Prostate, 2002, 53, 211-217.	1.2	75
557	Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Therapy, 2002, 9, 164-172.	2.2	108
558	Transrectal gene therapy of the prostate in the canine model. Cancer Gene Therapy, 2002, 9, 189-196.	2.2	5
559	A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Therapy, 2002, 9, 553-566.	2.2	171
560	The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene, 2002, 21, 2089-2096.	2.6	66
561	CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene, 2002, 21, 4435-4447.	2.6	53
562	Recent advances in the molecular diagnosis of lung cancer. Oncogene, 2002, 21, 6960-6969.	2.6	29
563	Molecular detection approaches for smoking associated tumors. Oncogene, 2002, 21, 7289-7297.	2.6	64
564	Smoking molecular damage in bronchial epithelium. Oncogene, 2002, 21, 7298-7306.	2.6	136
565	Novel candidate tumor marker genes for lung adenocarcinoma. Oncogene, 2002, 21, 7598-7604.	2.6	89
566	Î ³ -Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene, 2002, 21, 7497-7506.	2.6	103
567	Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center. Prostate Cancer and Prostatic Diseases, 2002, 5, 152-158.	2.0	7

#	Article	IF	CITATIONS
568	Adenocarcinoma of the prostate: an expensive way to die. Prostate Cancer and Prostatic Diseases, 2002, 5, 164-166.	2.0	32
569	Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients. Prostate Cancer and Prostatic Diseases, 2002, 5, 212-218.	2.0	31
570	Glut3 Expression in Biopsy Specimens of Laryngeal Carcinoma Is Associated With Poor Survival. Laryngoscope, 2002, 112, 393-396.	1.1	44
571	Prediction of Survival in Stage I Lung Carcinoma Patients by Telomerase Function Evaluation. Laboratory Investigation, 2002, 82, 729-736.	1.7	39
572	Breast cancer activism: past lessons, future directions. Nature Reviews Cancer, 2002, 2, 225-230.	12.8	20
573	A history of prostate cancer treatment. Nature Reviews Cancer, 2002, 2, 389-396.	12.8	498
574	Lymphangiogenesis and cancer metastasis. Nature Reviews Cancer, 2002, 2, 573-583.	12.8	729
575	Gallstones, cholecystectomy, and the risk for developing pancreatic cancer. British Journal of Cancer, 2002, 86, 1081-1084.	2.9	33
576	Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. British Journal of Cancer, 2002, 86, 1449-1456.	2.9	212
577	Cancer Genetics and Women's Health. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2002, 31, 208-216.	0.2	1
578	Cervical Cancer Risk as a Predictor of Pap Smear Use in Rural North Carolina. Journal of Rural Health, 2002, 18, 67-76.	1.6	20
579	Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses. International Journal of Radiation Oncology Biology Physics, 2002, 53, 282-289.	0.4	16
580	Association of Ki-67, p53, and bcl-2 expression of the primary non-small-cell lung cancer lesion with brain metastatic lesion. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1216-1224.	0.4	24
581	High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. International Journal of Radiation Oncology Biology Physics, 2002, 54, 348-356.	0.4	195
582	Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2002, 54, 670-676.	0.4	42
583	Mammography and Computerized Decision Systems. Annals of the New York Academy of Sciences, 2002, 980, 83-94.	1.8	23
584	Identifying Immunotherapeutic Targets for Prostate Carcinoma through the Analysis of Gene Expression Profiles. Annals of the New York Academy of Sciences, 2002, 975, 232-246.	1.8	21
585	Ethnic Differences in Survival among Pacific Island Patients Diagnosed with Cervical Cancer. Gynecologic Oncology, 2002, 84, 303-308.	0.6	10

#	Article	IF	CITATIONS
586	Survival among U.S. Women with Invasive Epithelial Ovarian Cancer. Gynecologic Oncology, 2002, 84, 399-403.	0.6	137
587	Predictors of Lymphatic Failure in Endometrial Cancer. Gynecologic Oncology, 2002, 84, 437-442.	0.6	109
588	Phase II Trial of Topotecan and Cisplatin in Persistent or Recurrent Squamous and Nonsquamous Carcinomas of the Cervix. Gynecologic Oncology, 2002, 85, 89-94.	0.6	59
589	Phase I Study of Alternating Doublets of Topotecan/Carboplatin and Paclitaxel/Carboplatin in Patients with Newly Diagnosed, Advanced Ovarian Cancer. Gynecologic Oncology, 2002, 85, 129-135.	0.6	11
590	Phase II Evaluation of 3-Day Topotecan with Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer. Gynecologic Oncology, 2002, 85, 278-284.	0.6	16
591	Radical Vaginal Trachelectomy after Supracervical Hysterectomy. Gynecologic Oncology, 2002, 85, 545-547.	0.6	1
592	Stage IIIC Endometrioid Corpus Cancer Includes Distinct Subgroups. Gynecologic Oncology, 2002, 87, 112-117.	0.6	85
593	Laparoscopic Photodynamic Diagnosis of Ovarian Cancer Using 5-Aminolevulinic Acid in a Rat Model. Gynecologic Oncology, 2002, 87, 64-70.	0.6	34
594	Outcome of Reproductive Age Women with Stage IA or IC Invasive Epithelial Ovarian Cancer Treated with Fertility-Sparing Therapy. Gynecologic Oncology, 2002, 87, 1-7.	0.6	257
595	Phase I Radioimmunotherapy Trial with Iodine-131â€"Labeled Humanized MN-14 Antiâ€"Carcinoembryonic Antigen Monoclonal Antibody in Patients with Metastatic Gastrointestinal and Colorectal Cancer. Clinical Colorectal Cancer, 2002, 2, 31-42.	1.0	49
596	The impact of a palliative medicine consultation service in medical oncology. Supportive Care in Cancer, 2002, 10, 337-342.	1.0	64
597	Effect of Selective Ablation of Proliferating Mammary Epithelial Cells on MNU Induced Rat Mammary Tumorigenesis. Breast Cancer Research and Treatment, 2002, 73, 75-83.	1.1	17
598	Signaling inhibitors in the treatment of prostate cancer. Investigational New Drugs, 2002, 20, 159-172.	1.2	13
599	Segregation analysis of prostate cancer in 1,719 white, African-American and Asian-American families in the United States and Canada. Cancer Causes and Control, 2002, 13, 471-482.	0.8	53
600	Hormone-induced protection against breast cancer. Journal of Mammary Gland Biology and Neoplasia, 2002, 7, 77-92.	1.0	72
601	Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lunga Kansas Cancer Institute and Thompson Cancer Survival Center Study. Investigational New Drugs, 2002, 20, 339-342.	1.2	11
602	Chemoprevention of prostate cancer. Cancer and Metastasis Reviews, 2002, 21, 111-124.	2.7	52
603	Chemoprevention of lung cancer: current status and future prospects. Cancer and Metastasis Reviews, 2002, 21, 349-362.	2.7	12

#	Article	IF	CITATIONS
604	Chemoprevention of prostate cancer: current status and future directions. Cancer and Metastasis Reviews, 2002, 21, 297-309.	2.7	42
605	Chemoprevention of skin cancer: current status and future prospects. Cancer and Metastasis Reviews, 2002, 21, 363-380.	2.7	55
606	Indications and use of palliative surgery-results of society of surgical oncology survey. Annals of Surgical Oncology, 2002, 9, 104-112.	0.7	104
608	Hodgkin's disease. Blood Reviews, 2002, 16, 111-117.	2.8	26
609	Pancreatic cancer. Current Problems in Cancer, 2002, 26, 176-275.	1.0	268
610	The Specificity of Amylin for the Diagnosis of Pancreatic Adenocarcinoma. International Journal of Gastrointestinal Cancer, 2002, 31, 123-128.	0.4	9
611	The Convergence of Hormone Regulation and Cell Cycle in Prostate Physiology and Prostate Tumorigenesis. Molecular Biotechnology, 2002, 22, 129-138.	1.3	5
612	Effect of Topotecan Infusion Duration on Hematologic Toxicity in Recurrent Ovarian Carcinoma. Medical Oncology, 2002, 19, 25-34.	1.2	5
613	Generalized Lymphadenopathy: A Rare Presentation of Disseminated Prostate Cancer. Medical Oncology, 2002, 19, 177-180.	1.2	14
614	CPT-11 for Bile-Duct and Gallbladder Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Study. International Journal of Gastrointestinal Cancer, 2003, 32, 107-114.	0.4	28
615	Risk-Awareness of Cutaneous Malignancies Among Rural Populations. Medical Oncology, 2003, 20, 369-374.	1.2	9
616	Recombinant glutamate carboxypeptidase II (prostate specific membrane antigen-PSMA)-cellular localization and bioactivity analyses. The Protein Journal, 2003, 22, 317-326.	1.1	6
617	A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study. Investigational New Drugs, 2003, 21, 373-377.	1.2	17
618	Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture. Journal of Neuro-Oncology, 2003, 65, 77-85.	1.4	15
619	Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma. Clinical and Experimental Metastasis, 2003, 20, 599-609.	1.7	25
620	Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort. Cancer Causes and Control, 2003, 14, 847-857.	0.8	113
621	Evaluation of Fluorodeoxyglucose Positron Emission Tomography in the Detection of Axillary Lymph Node Metastases in Patients With Early-Stage Breast Cancer. Annals of Surgical Oncology, 2003, 10, 622-627.	0.7	79
622	The context of adjustment: Qualitative reports from Australian men being treated for non-localised prostate cancer. Clinical Psychologist, 2003, 7, 81-92.	0.5	3

#	Article	IF	CITATIONS
623	Pilot Evaluation of High-Dose Carboplatin and Paclitaxel Followed by High-Dose Melphalan Supported by Peripheral Blood Stem Cells in Previously Untreated Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology, 2003, 88, 3-8.	0.6	33
624	A phase II Trial of Weekly Paclitaxel, 5-Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Breast Cancer. Breast Cancer Research and Treatment, 2003, 77, 115-123.	1.1	3
625	Retrospective Analysis of Breast Cancer Among Young African American Females. Breast Cancer Research and Treatment, 2003, 78, 81-87.	1.1	14
626	Dietary carotenoids, vegetables, and lung cancer risk in women: the Missouri women's health study (United States). Cancer Causes and Control, 2003, 14, 85-96.	0.8	72
627	Establishment of red fluorescent protein-tagged HeLa tumor metastasis models: determination of DsRed2 insertion effects and comparison of metastatic patterns after subcutaneous, intraperitoneal, or intravenous injection. Clinical and Experimental Metastasis, 2003, 20, 121-133.	1.7	13
628	Three-dimensional segmentation and growth-rate estimation of small pulmonary nodules in helical ct images. IEEE Transactions on Medical Imaging, 2003, 22, 1259-1274.	5.4	277
630	Cancer epidemiology in Hungary and the Béla Johan national program for the decade of health. Pathology and Oncology Research, 2003, 9, 126-130.	0.9	9
631	Bone metastases in breast cancer. Current Treatment Options in Oncology, 2003, 4, 151-158.	1.3	29
632	Effect of the vitamin D3 analog ILXÂ23-7553 on apoptosis and sensitivity to fractionated radiation in breast tumor cells and normal human fibroblasts. Cancer Chemotherapy and Pharmacology, 2003, 51, 415-421.	1.1	35
633	Anthrazyklintherapie beim Mammakarzinom. Onkologe, 2003, 9, 1366-1374.	0.7	1
634	Chemotherapy for localized, high-risk prostate cancer. Seminars in Radiation Oncology, 2003, 13, 152-157.	1.0	5
635	Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. Journal of the American College of Surgeons, 2003, 197, 191-197.	0.2	241
636	Targeting the myeloma cell and its microenvironment: identification and validation of novel targeted MM therapies. European Journal of Haematology, 2003, 70, 263-265.	1.1	0
637	Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Seminars in Oncology, 2003, 30, 150-160.	0.8	40
638	Breast Cancer Patient Perception of the Helpfulness of a Prompt Sheet Versus a General Information Sheet During Outpatient Consultation. Journal of Pain and Symptom Management, 2003, 25, 412-419.	0.6	84
639	The Value of Dynamic Contrast Enhanced Power Doppler Ultrasound Imaging in the Localization of Prostate Cancer. European Urology, 2003, 43, 124-131.	0.9	47
640	Androgen receptor CAG repeat polymorphism in prostate cancer from a Brazilian population. Cancer Detection and Prevention, 2003, 27, 321-326.	2.1	32
641	Lung cancer: The oncologist's role in smoking cessation. Seminars in Oncology, 2003, 30, 94-103.	0.8	25

#	Article	IF	CITATIONS
642	Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer, 2003, 3, 19.	1.1	62
643	The role of the surgeon in quality cancer care. Current Problems in Surgery, 2003, 40, 511-590.	0.6	7
644	Asian-Pacific Islander race independently predicts poor outcome in patients with endometrial cancerâ^†â^†The views expressed herein are those of the authors and do not reflect the official opinion of the Department of Defense or the United States Army or Air Force Gynecologic Oncology, 2003, 89, 218-226.	0.6	32
645	Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigationâ [†] . Gynecologic Oncology, 2003, 89, 233-235.	0.6	68
646	Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapya † a † Presented at the 33rd Annual Meeting of Gynecologic Oncologists, Miami, FL, March 2002 Gynecologic Oncology, 2003, 89, 295-300.	0.6	122
647	Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer. Gynecologic Oncology, 2003, 90, 3-9.	0.6	37
648	$\hat{l}\pm V$ - and $\hat{l}^2 1$ -integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecologic Oncology, 2003, 90, 248-257.	0.6	82
649	Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecologic Oncology, 2003, 91, 46-50.	0.6	138
650	Recommendations of follow-up after treatment of germ cell tumors. Seminars in Oncology, 2003, 30, 382-389.	0.8	18
651	Gemcitabine and anthracyclines in breast cancer. Seminars in Oncology, 2003, 30, 11-14.	0.8	0
652	Antisense therapy directed to protein kinase C-alpha (affinitak, LY900003/ISIS 3521): Potential role in breast cancer. Seminars in Oncology, 2003, 30, 30-33.	0.8	16
653	The spectrum of treatment and future diagnosis of early non-small cell lung carcinoma. Journal of Surgical Education, 2003, 60, 199-203.	0.7	O
654	Preparing for the unexpected: encountering gynecological problems when operating for colon cancer. Journal of Surgical Education, 2003, 60, 12-16.	0.7	1
655	Non-small cell lung cancer: an update. Journal of Surgical Education, 2003, 60, 492-498.	0.7	0
656	Fas-associating death domain protein overexpression induces apoptosis in lung cancer cells. Journal of Thoracic and Cardiovascular Surgery, 2003, 125, 1336-1342.	0.4	38
657	Lung cancer screening with low-dose computed tomography. Seminars in Roentgenology, 2003, 38, 34-38.	0.2	6
658	A Phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer, 2003, 97, 537-544.	2.0	11
659	A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer, 2003, 97, 639-643.	2.0	128

#	Article	IF	CITATIONS
660	Moving disease biology from the lab to the clinic. Cancer, 2003, 97, 796-801.	2.0	72
661	Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma. Cancer, 2003, 97, 969-978.	2.0	29
662	Caveolin-1 expression is a predictor of recurrence-free survival in pT2NO prostate carcinoma diagnosed in Japanese patients. Cancer, 2003, 97, 1225-1233.	2.0	81
663	Renal cell carcinoma with retroperitoneal lymph nodes. Cancer, 2003, 97, 2995-3002.	2.0	185
664	Laparoscopic sentinel lymph node procedure using a combination of patent blue and radioisotope in women with cervical carcinoma. Cancer, 2003, 97, 3003-3009.	2.0	97
665	Symptoms and signs of primary melanoma. Cancer, 2003, 98, 344-348.	2.0	47
666	Short-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for Stage I or II breast carcinoma. Cancer, 2003, 98, 690-696.	2.0	90
667	Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer, 2003, 98, 1401-1410.	2.0	42
668	The biology and therapy of adult acute lymphoblastic leukemia. Cancer, 2003, 98, 1337-1354.	2.0	164
669	Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression. Cancer, 2003, 98, 1649-1657.	2.0	36
670	Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma. Cancer, 2003, 98, 1689-1700.	2.0	418
671	Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer, 2003, 98, 1735-1744.	2.0	836
672	Endometriosis-associated ovarian carcinoma. Cancer, 2003, 98, 1658-1663.	2.0	40
673	Papillary thyroid cancer: High inter-(simple sequence repeat) genomic instability in a typically indolent cancer. Head and Neck, 2003, 25, 825-832.	0.9	9
674	Risk of melanoma among radiologic technologists in the United States. International Journal of Cancer, 2003, 103, 556-562.	2.3	65
675	Impact of comorbidity on lung cancer survival. International Journal of Cancer, 2003, 103, 792-802.	2.3	253
676	Oligogenic segregation analysis of hereditary prostate cancer pedigrees: Evidence for multiple loci affecting age at onset. International Journal of Cancer, 2003, 105, 630-635.	2.3	34
677	In vitro andin vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668. International Journal of Cancer, 2003, 106, 446-454.	2.3	47

#	Article	IF	CITATIONS
678	ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. International Journal of Cancer, 2003, 107, 478-485.	2.3	128
679	Near-infrared Raman spectroscopy for optical diagnosis of lung cancer. International Journal of Cancer, 2003, 107, 1047-1052.	2.3	724
680	Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagnostic Cytopathology, 2003, 28, 301-307.	0.5	57
681	Regional chemotherapy is indicated after surgical resection of colorectal metastases to the liver: A debate. Journal of Surgical Oncology, 2003, 82, 65-72.	0.8	5
682	Breast cancer?have we been chasing the wrong target?. Journal of Surgical Oncology, 2003, 83, 57-60.	0.8	0
683	A discourse: The 2002 Wataru W. Sutow lecture Hodgkin disease in children?perspectives and progress. Medical and Pediatric Oncology, 2003, 40, 73-81.	1.0	11
684	Assessing the unmet information, support and care delivery needs of men with prostate cancer. Patient Education and Counseling, 2003, 49, 233-242.	1.0	173
685	Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2003, 55, 312-321.	0.4	389
686	Process and preliminary outcome of a patterns-of-care study of esophageal cancer in Japan: Patients treated with surgery and radiotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 56, 813-822.	0.4	23
687	Renal cell carcinoma: current status and future directions. Critical Reviews in Oncology/Hematology, 2003, 45, 177-190.	2.0	53
688	Malignant melanoma: current state of primary and adjuvant treatment. Critical Reviews in Oncology/Hematology, 2003, 45, 245-264.	2.0	40
689	Current status of thalidomide and its role in the treatment of metastatic prostate cancer. Critical Reviews in Oncology/Hematology, 2003, 46, 49-57.	2.0	25
690	Molecular biology of transitional cell carcinoma. Critical Reviews in Oncology/Hematology, 2003, 47, 181-193.	2.0	40
691	Breast Cancer in Reduction Mammaplasty Specimens: Case Reports and Guidelines. Breast Journal, 2003, 9, 120-125.	0.4	33
692	Sequential High-Dose Alkylating Therapy and Stem Cell Support for High-Risk Stage III Breast Cancer. Breast Journal, 2003, 9, 472-477.	0.4	2
693	The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. International Journal of Gynecological Cancer, 2003, 13, 138-141.	1.2	4
694	Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma, and related proteins. International Journal of Gynecological Cancer, 2003, 13, 598-606.	1.2	18
695	Skin Cancer Prevention Counseling and Clinical Practices of Pediatricians. Pediatric Dermatology, 2003, 20, 16-24.	0.5	37

#	Article	IF	CITATIONS
696	Older Patients with Colon Cancer: Is Adjuvant Chemotherapy Safe and Effective?. Journal of the American Geriatrics Society, 2003, 51, 567-569.	1.3	13
697	CT Colonography: Practical Aspects and Present Status. Imaging Decisions (Berlin, Germany), 2003, 7, 4-9.	0.2	1
698	Metastatic lung cancer in pregnancy. Respirology, 2003, 8, 107-109.	1.3	11
699	Testicular-sparing surgery: a reasonable option in selected patients with testicular lesions. BJU International, 2003, 91, 337-340.	1.3	30
700	The management of stage T1 grade 3 transitional cell carcinoma of the bladder. BJU International, 2003, 92, 345-348.	1.3	7
701	Long-term complications of brachytherapy in local prostate cancer. BJU International, 2003, 92, 869-873.	1.3	5
702	Segregation Analysis of Prostate Cancer in France: Evidence for Autosomal Dominant Inheritance and Residual Brother-brother Dependence. Annals of Human Genetics, 2003, 67, 125-137.	0.3	36
703	Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinic. Psycho-Oncology, 2003, 12, 769-783.	1.0	228
704	Genome-wide scan of brothers: Replication and fine mapping of prostate cancer susceptibility and aggressiveness loci. Prostate, 2003, 57, 298-308.	1.2	53
705	Combined modality therapy in esophageal cancer: The Memorial experience. Journal of Surgical Oncology, 2003, 21, 228-232.	1.4	14
706	Adenovirus-mediated gene transduction of truncated IkappaBalpha enhances radiosensitivity in human colon cancer cells. Cancer Science, 2003, 94, 745-750.	1.7	30
707	Chemotherapy for pancreatic cancer. Alimentary Pharmacology and Therapeutics, 2003, 18, 1049-1069.	1.9	57
708	EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. British Journal of Cancer, 2003, 88, 648-653.	2.9	70
709	Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF- 12 expression. British Journal of Cancer, 2003, 89, 1345-1351.	2.9	43
710	Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplantation, 2003, 31, 163-170.	1.3	62
711	Early recurrence of rheumatoid arthritis after nonmyeloablative allogeneic blood stem cell transplantation in a patient with multiple myeloma. Bone Marrow Transplantation, 2003, 32, 629-631.	1.3	24
712	Inhibitory effect of adenovirus-uteroglobin transduction on the growth of lung cancer cell lines. Cancer Gene Therapy, 2003, 10, 287-293.	2,2	11
713	ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells. Oncogene, 2003, 22, 781-796.	2.6	55

#	Article	IF	CITATIONS
714	MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene, 2003, 22, 1381-1389.	2.6	176
715	Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis. Oncogene, 2003, 22, 1302-1316.	2.6	135
716	Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene, 2003, 22, 3243-3251.	2.6	467
717	Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene, 2003, 22, 3806-3812.	2.6	168
718	Axis of evil: molecular mechanisms of cancer metastasis. Oncogene, 2003, 22, 6524-6536.	2.6	551
719	Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene, 2003, 22, 6704-6716.	2.6	69
720	PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene, 2003, 22, 5427-5435.	2.6	86
721	pRB2/p130 target genes in non-small lung cancer cells identified by microarray analysis. Oncogene, 2003, 22, 6959-6969.	2.6	21
722	Bcl-2 and Bcl-xL differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene, 2003, 22, 8758-8773.	2.6	125
723	Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73 \hat{l}^2 . Oncogene, 2003, 22, 8394-8402.	2.6	30
724	Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene, 2003, 22, 7414-7430.	2.6	253
725	Assessment of Utility of Ductal Lavage and Ductoscopy in Breast Cancer—A Retrospective Analysis of Mastectomy Specimens. Modern Pathology, 2003, 16, 206-209.	2.9	34
726	Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic Intraepithelial Neoplasia Tissue Microarray. Modern Pathology, 2003, 16, 902-912.	2.9	363
727	Validation of Tissue Microarrays Using P53 Immunohistochemical Studies of Squamous Cell Carcinoma of the Larynx. Modern Pathology, 2003, 16, 1181-1188.	2.9	38
728	Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Medicine, 2003, 9, 279-286.	15.2	586
729	Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature Reviews Cancer, 2003, 3, 502-516.	12.8	1,005
730	Metastasis suppressors alter the signal transduction of cancer cells. Nature Reviews Cancer, 2003, 3, 55-63.	12.8	466
731	Aberrant DNA Methylation in Ovarian Cancer. Annals of the New York Academy of Sciences, 2003, 983, 243-250.	1.8	36

#	Article	IF	CITATIONS
732	Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2003, 56, 355-359.	0.4	58
733	Intraoperative electron radiotherapy as a component of salvage therapy for patients with colorectal cancer and advanced nodal metastases. International Journal of Radiation Oncology Biology Physics, 2003, 56, 966-973.	0.4	26
734	Modulators of Ceramide Metabolism Sensitize Colorectal Cancer Cells to Chemotherapy, A Novel Treatment Strategy. Journal of Gastrointestinal Surgery, 2003, 7, 140-148.	0.9	31
735	Gene Expression in Lung Adenocarcinomas of Smokers and Nonsmokers. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 157-162.	1.4	112
736	Lung cancer in elderly patients. Clinics in Geriatric Medicine, 2003, 19, 139-155.	1.0	7
737	Predictors of advanced proximal neoplasia in persons with abnormal screening flexible sigmoidoscopy. Clinical Gastroenterology and Hepatology, 2003, 1, 103-110.	2.4	37
738	Comprehensive Evaluation of the Older Woman. Mayo Clinic Proceedings, 2003, 78, 1157-1185.	1.4	25
739	Chemoprevention of prostate cancer. Urologic Clinics of North America, 2003, 30, 227-237.	0.8	11
740	An Interval Longer than 12 Weeks Between the Diagnosis of Muscle Invasion and Cystectomy is Associated with Worse Outcome in Bladder Carcinoma. Journal of Urology, 2003, 169, 110-115.	0.2	228
741	Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: an update. Surgical Oncology Clinics of North America, 2003, 12, 193-210.	0.6	6
742	Update on diagnostic imaging for melanoma. Facial Plastic Surgery Clinics of North America, 2003, 11, 49-60.	0.9	1
743	Screening for prostate cancer. Urologic Clinics of North America, 2003, 30, 239-251.	0.8	25
744	Can Prostate Specific Antigen Derivatives and Pathological Parameters Predict Significant Change in Expectant Management Criteria for Prostate Cancer?. Journal of Urology, 2003, 170, 2274-2278.	0.2	71
746	Grade Progression and Regression in Recurrent Urothelial Cancer. Journal of Urology, 2003, 169, 2106-2109.	0.2	22
747	Screening Behavior in Brothers And Sons of Men with Prostate Cancer. Journal of Urology, 2003, 169, 1715-1719.	0.2	32
748	Glycosylation of human pancreatic ribonuclease: differences between normal and tumor states. Glycobiology, 2003, 13, 227-244.	1.3	64
749	Quantitative Gstp1 Methylation Clearly Distinguishes Benign Prostatic Tissue And Limited Prostate Adenocarcinoma. Journal of Urology, 2003, 169, 1138-1142.	0.2	135
750	The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urologic Clinics of North America, 2003, 30, 423-436.	0.8	19

#	Article	IF	CITATIONS
751	Primary prevention of colorectal cancer: diet and drugs. Hematology/Oncology Clinics of North America, 2003, 17, 575-610.	0.9	2
752	The physical burden of prostate cancer. Urologic Clinics of North America, 2003, 30, 305-313.	0.8	34
753	Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis. Clinics in Laboratory Medicine, 2003, 23, 729-754.	0.7	49
7 54	Melanoma from the dermatologist's perspective. Facial Plastic Surgery Clinics of North America, 2003, 11, 277-286.	0.9	2
755	Colon cancer: detection and prevention. Hematology/Oncology Clinics of North America, 2003, 17, 553-574.	0.9	0
7 56	Hepsin and Maspin are Inversely Expressed in Laser Capture Microdissectioned Prostate Cancer. Journal of Urology, 2003, 169, 1316-1319.	0.2	78
757	Population Screening for Prostate Cancer and Early Detection in High-risk African American Men**The opinion and assertions contained herein are the private views of the author and are not to be considered as reflecting the views of the US Army or the Department of Defense, 2003,, 3-10.		0
758	Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer. New England Journal of Medicine, 2003, 348, 2491-2499.	13.9	2,168
759	Transdermal Estradiol Therapy for Advanced Prostate Cancerâ€"Forward to the Past?. Journal of Urology, 2003, 169, 1735-1737.	0.2	88
760	Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. Journal of Translational Medicine, 2003, 1, 13.	1.8	10
761	Rituximab. Drugs, 2003, 63, 803-843.	4.9	412
762	Prostate Cancer on the Internet: Impact on Patients and How Technology Helps Physicians and Researchers. Clinical Prostate Cancer, 2003, 1, 227-234.	2.1	0
763	Salvage Cryosurgery for Recurrent Prostate Cancer After Radiation Therapy: A Seven-Year Follow-up. Clinical Prostate Cancer, 2003, 2, 111-114.	2.1	121
764	Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointestinal Endoscopy, 2003, 57, 23-29.	0.5	127
765	Metabolism of Benzo[c]chrysene and Comparative Mammary Gland Tumorigenesis of Benzo[c]chrysene Bay and Fjord Region Diol Epoxides in Female CD Rats. Chemical Research in Toxicology, 2003, 16, 227-231.	1.7	12
766	Evaluation of the Human Melanoma Targeting Properties of Radiolabeled α-Melanocyte Stimulating Hormone Peptide Analogues. Bioconjugate Chemistry, 2003, 14, 1177-1184.	1.8	73
767	Diphtheria Toxinâ^'Epidermal Growth Factor Fusion Protein and Pseudomonas Exotoxinâ^'Interleukin 13 Fusion Protein Exert Synergistic Toxicity against Human Glioblastoma Multiforme Cells. Bioconjugate Chemistry, 2003, 14, 1107-1114.	1.8	28
768	Stereotactic Core Biopsy. , 2003, , 87-118.		5

#	ARTICLE	IF	Citations
769	Uveal metastasis from breast cancer in 264 patients. American Journal of Ophthalmology, 2003, 136, 264-271.	1.7	213
770	Up-Regulation of ALG-2 in Hepatomas and Lung Cancer Tissue. American Journal of Pathology, 2003, 163, 81-89.	1.9	72
771	Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression Technology. American Journal of Pathology, 2003, 163, 217-229.	1.9	117
772	International prospective evaluation of scintimammography with 99mTechnetium sestamibi. American Journal of Surgery, 2003, 185, 544-549.	0.9	39
773	A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines. Biochemical and Biophysical Research Communications, 2003, 309, 578-583.	1.0	82
774	Sex Hormone Metabolism in Prostate Cancer Cells during Transition to an Androgen-Independent State. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 705-712.	1.8	57
775	Endoscopic ultrasound evaluation in the diagnosis and staging of lung cancer. Lung Cancer, 2003, 41, 259-267.	0.9	50
776	Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer, 2003, 42, 81-91.	0.9	89
777	Progress in ovarian cancer. European Journal of Cancer, Supplement, 2003, 1, 43-55.	2.2	7
778	Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Human Pathology, 2003, 34, 597-604.	1.1	152
779	Informed consent for prostate-specific antigen screening. Urology, 2003, 61, 2-4.	0.5	6
780	Outcomes after radical retropubic prostatectomy. Urology, 2003, 61, 412-416.	0.5	25
781	Informed consent for prostate-specific antigen-based screeningâ€"European view. Urology, 2003, 61, 20-22.	0.5	6
782	Hormonal therapy: historical perspective to future directions. Urology, 2003, 61, 3-7.	0.5	141
783	Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells. Urology, 2003, 61, 1047-1052.	0.5	62
784	Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination. Urology, 2003, 61, 754-759.	0.5	28
785	Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy for prostate cancer. Urology, 2003, 62, 116-120.	0.5	42
786	Rare case of metastatic prostate adenocarcinoma to the pituitary. Urology, 2003, 62, 352.	0.5	12

#	Article	IF	Citations
787	Expectant management of localized prostate cancer. Urology, 2003, 62, 793-799.	0.5	11
788	Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. Annals of Thoracic Surgery, 2003, 76, 909-914.	0.7	31
789	The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Annals of Thoracic Surgery, 2003, 76, 1001-1008.	0.7	117
790	Menopausal effects on presentation, treatment, and survival of women with non–small cell lung cancer. Annals of Thoracic Surgery, 2003, 76, 1789-1795.	0.7	64
791	Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach. Annals of Thoracic Surgery, 2003, 76, 1802-1809.	0.7	37
792	Understanding disparities in outcomes in cardiovascular medicine and thoracic oncology in African-American patients. Annals of Thoracic Surgery, 2003, 76, S1346-S1347.	0.7	2
793	Lung cancer in african americans. Annals of Thoracic Surgery, 2003, 76, S1363-S1366.	0.7	9
794	Activation of PPAR \hat{I}^3 increases PTEN expression in pancreatic cancer cells. Biochemical and Biophysical Research Communications, 2003, 301, 50-53.	1.0	93
795	Androgen-independent prostate cancer DU145 cells suppress androgen-dependent growth of prostate stromal cells through production of inhibitory factors for androgen responsiveness. Biochemical and Biophysical Research Communications, 2003, 306, 629-636.	1.0	10
796	Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstetrics and Gynecology, 2003, 102, 594-599.	1.2	129
797	Novel mechanisms of sublethal oxidant toxicity: induction of premature senescence in human fibroblasts confers tumor promoter activity. Experimental Cell Research, 2003, 290, 38-48.	1.2	51
798	Phase II trial of anastrozole in women with asymptomatic m $\tilde{A}\frac{1}{4}$ llerian cancer. Gynecologic Oncology, 2003, 91, 596-602.	0.6	66
799	Use of a colonoscope instead of a sigmoidoscope to screen asymptomatic adults for colorectal cancer. Gastrointestinal Endoscopy, 2003, 58, 720-724.	0.5	12
800	Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatment. Cancer Letters, 2003, 189, 59-68.	3.2	21
801	Epigenetic gene silencing in cancer initiation and progression. Cancer Letters, 2003, 190, 125-133.	3.2	167
802	Cyclooxygenase-2 and prostate carcinogenesis. Cancer Letters, 2003, 191, 125-135.	3.2	222
803	Modern management of locally advanced cervical carcinoma. Cancer Treatment Reviews, 2003, 29, 389-399.	3.4	80
804	The development and validation of a comorbidity index for prostate cancer among Black men. Journal of Clinical Epidemiology, 2003, 56, 1064-1075.	2.4	24

#	Article	IF	CITATIONS
805	Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 327-333.	0.8	86
806	Late morbidity after treatment of breast cancer in relation to daily activities and quality of life: a systematic review. European Journal of Surgical Oncology, 2003, 29, 229-238.	0.5	210
807	Delay in diagnosis of soft tissue sarcomas. European Journal of Surgical Oncology, 2003, 29, 440-445.	0.5	78
808	Screening for breast cancer with MRI. Seminars in Ultrasound, CT and MRI, 2003, 24, 45-54.	0.7	22
809	Effects of Misattribution in Assigning Cause of Death on Prostate Cancer Mortality Rates. Annals of Epidemiology, 2003, 13, 450-454.	0.9	34
810	Early prostate cancer: is there a need for new treatment options?. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 105-116.	0.8	8
811	Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the department of defense (DOD) Center for Prostate Disease Research (CPDR) national database. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 447-455.	0.8	22
812	Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncology, The, 2003, 4, 397-406.	5.1	268
813	Diagnosis of Prostate Cancerâ€"The Clinical Use of Prostate Specific Antigen. EAU Update Series, 2003, 1, 3-8.	0.5	9
814	Section I: Epidemiological review. Seminars in Thoracic and Cardiovascular Surgery, 2003, 15, 158-166.	0.4	14
815	Section III: Endoscopic and other staging techniques. Seminars in Thoracic and Cardiovascular Surgery, 2003, 15, 180-186.	0.4	8
816	Section IV: Selective use of neoadjuvant therapy. Seminars in Thoracic and Cardiovascular Surgery, 2003, 15, 187-196.	0.4	2
817	Delaying Radical Cystectomy for Muscle Invasive Bladder Cancer Results in Worse Pathological Stage. Journal of Urology, 2003, 170, 1085-1087.	0.2	169
818	Phase II Trial of Irinotecan in Patients With Metastatic Epithelial Ovarian Cancer or Peritoneal Cancer. Journal of Clinical Oncology, 2003, 21, 291-297.	0.8	95
819	Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-ÂB activation through inhibition of IÂBÂ kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis, 2003, 24, 1269-1279.	1.3	277
820	MOLECULARPATHOGENESIS OFPANCREATICCANCER. Annual Review of Genomics and Human Genetics, 2003, 4, 237-256.	2.5	129
822	Cyclooxygenase-2 Inhibitor NS398 Enhances Antitumor Effect of Irradiation on Hormone Refractory Human Prostate Carcinoma Cells. Journal of Urology, 2003, 170, 2036-2039.	0.2	28
823	Concepts and Controversies in Cancer Screening. American Journal of Cancer, 2003, 2, 395-402.	0.4	4

#	Article	IF	CITATIONS
824	HER2-Positive Breast Cancer. American Journal of Cancer, 2003, 2, 169-179.	0.4	6
825	Metastatic Prostate Cancer. American Journal of Cancer, 2003, 2, 87-94.	0.4	0
826	Results of a Men??s Urological Health Screening Program at Lockheed Martin Aeronautical Systems. Disease Management and Health Outcomes, 2003, 11, 181-189.	0.3	1
827	Developments in the Systemic Therapy of Pancreatic Cancer. Cancer Investigation, 2003, 21, 73-86.	0.6	30
828	The Androgen Receptor: Structure, Mutations, and Antiandrogens. Cancer Investigation, 2003, 21, 400-417.	0.6	28
829	Phase II Trial of 96-Hour Paclitaxel in Previously Treated Patients with Advanced Esophageal Cancer. Cancer Investigation, 2003, 21, 512-516.	0.6	22
830	Breast Cancer Management. Pharmacoeconomics, 2003, 21, 383-396.	1.7	99
831	Hepatocellular Carcinoma: Are We Making Progress?. Cancer Investigation, 2003, 21, 418-428.	0.6	53
832	Tea Beverage in Chemoprevention of Prostate Cancer: A Mini-Review. Nutrition and Cancer, 2003, 47, 13-23.	0.9	83
833	New techniques for early detection of lung cancer. European Respiratory Journal, 2003, 21, 57S-66s.	3.1	69
834	New paradigms in adjuvant systemic therapy of breast cancer Endocrine-Related Cancer, 2003, 10, 75-89.	1.6	3
835	Use of Adjuvant Chemotherapy and Radiation Therapy for Colorectal Cancer in a Population-Based Cohort. Journal of Clinical Oncology, 2003, 21, 1293-1300.	0.8	289
836	Management of Highâ€Risk Populations with Locally Advanced Prostate Cancer. Oncologist, 2003, 8, 259-269.	1.9	34
837	Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma. Oncologist, 2003, 8, 451-458.	1.9	69
838	Monitoring In Situ Dosimetry and Protoporphyrin IX Fluorescence Photobleaching in the Normal Rat Esophagus During 5-Aminolevulinic Acid Photodynamic Therapy¶. Photochemistry and Photobiology, 2003, 78, 271.	1.3	62
839	Diarrhea or colorectal cancer: Can bacterial toxins serve as a treatment for colon cancer?. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3018-3020.	3.3	17
840	Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma. Journal of Clinical Oncology, 2003, 21, 1035-1043.	0.8	188
841	Quantitative GSTP1 Methylation and the Detection of Prostate Adenocarcinoma in Sextant Biopsies. Journal of the National Cancer Institute, 2003, 95, 1634-1637.	3.0	110

#	Article	IF	CITATIONS
842	Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial. Journal of Clinical Oncology, 2003, 21, 679-689.	0.8	360
843	Phase I Study of Paclitaxel and Topotecan for the Firstâ€Line Treatment of Extensiveâ€Stage Small Cell Lung Cancer. Oncologist, 2003, 8, 76-82.	1.9	15
844	Meta-Analysis of Prostate-Specific Antigen and Digital Rectal Examination as Screening Tests for Prostate Carcinoma. Journal of the American Board of Family Medicine, 2003, 16, 95-101.	0.8	198
845	Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices. Journal of Clinical Oncology, 2003, 21, 4524-4531.	0.8	416
846	Dispositional Optimism Predicts Survival Status 1 Year After Diagnosis in Head and Neck Cancer Patients. Journal of Clinical Oncology, 2003, 21, 543-548.	0.8	138
847	Detection of cancer-specific markers amid massive mass spectral data. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14666-14671.	3.3	166
848	A Double-Blind, Placebo-Controlled, Randomized Trial of Oral Sodium Clodronate for Metastatic Prostate Cancer (MRC PR05 Trial). Journal of the National Cancer Institute, 2003, 95, 1300-1311.	3.0	215
849	Colon Cancer: Prevalence, Screening, Gene Expression and Mutation, and Risk Factors and Assessment. Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews, 2003, 21, 65-131.	2.9	40
850	Miliary Tuberculosis Following Intravesical BCG Treatment. UroOncology, 2003, 3, 131-136.	0.1	0
851	Steroid Hormone Regulation and Prognostic Value of the Human Kallikrein Gene 14 in Ovarian Cancer. American Journal of Clinical Pathology, 2003, 119, 346-355.	0.4	62
852	Colorectal Cancer Screening. JAMA - Journal of the American Medical Association, 2003, 289, 1288.	3.8	376
853	Gastric cancer: epidemiology, pathology and treatment. Annals of Oncology, 2003, 14, ii31-ii36.	0.6	307
854	Role of Surgeon Volume in Radical Prostatectomy Outcomes. Journal of Clinical Oncology, 2003, 21, 401-405.	0.8	320
855	Epidemiology, treatment and chemoprevention in colorectal cancer. Annals of Oncology, 2003, 14, ii3-ii5.	0.6	60
856	Multicenter Phase II Trial of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). Japanese Journal of Clinical Oncology, 2003, 33, 371-376.	0.6	24
857	Identification of 9 Genes Differentially Expressed in Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology, 2003, 129, 754.	1.5	92
858	Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. Annals of Oncology, 2003, 14, ii25-ii29.	0.6	32
859	Current treatments and future perspectives in colorectal and gastric cancer. Annals of Oncology, 2003, 14, ii49-ii55.	0.6	40

#	Article	IF	CITATIONS
860	Computer-assisted detection of mammographic masses: A template matching scheme based on mutual information. Medical Physics, 2003, 30, 2123-2130.	1.6	130
861	Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer. New England Journal of Medicine, 2003, 349, 859-866.	13.9	2,286
862	Effects of Tomato Sauce Consumption on Apoptotic Cell Death in Prostate Benign Hyperplasia and Carcinoma. Nutrition and Cancer, 2003, 47, 40-47.	0.9	107
863	Colorectal Cancer Screening with CT Colonography, Colonoscopy, and Double-Contrast Barium Enema Examination: Prospective Assessment of Patient Perceptions and Preferences. Radiology, 2003, 227, 378-384.	3.6	285
864	A Phase II Study of Modified deGramont 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Treated Patients with Metastatic Colorectal Cancer. Cancer Investigation, 2003, 21, 505-511.	0.6	6
865	Screening for colorectal cancer on the front line. American Journal of Gastroenterology, 2003, 98, 915-923.	0.2	45
866	Recombinant vaccinia virus expressing IL-2 generates effective anti-tumor responses in an orthotopic murine model of head and neck carcinoma. Molecular Therapy, 2003, 8, 238-248.	3.7	17
867	Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12343-12348.	3.3	254
868	Determinants of colorectal cancer screening in women undergoing mammography. American Journal of Gastroenterology, 2003, 98, 1875-1880.	0.2	55
869	Primary Screening With Colonoscopy for Colorectal Cancer: A Targeted Algorithm?. American Journal of Gastroenterology, 2003, 98, 2587-2589.	0.2	4
870	Oral melphalan as a treatment for platinum-resistant ovarian cancer. British Journal of Cancer, 2003, 88, 1828-1830.	2.9	12
871	Colorectal Cancer Screening and Familial Risk: A Survey of Internal Medicine Residents' Knowledge and Practice Patterns. American Journal of Gastroenterology, 2003, 98, 1410-1416.	0.2	61
872	Temporal Trends (1973–1997) in Survival of Patients With Esophageal Adenocarcinoma in The United States: A Glimmer of Hope?. American Journal of Gastroenterology, 2003, 98, 1627-1633.	0.2	197
873	Fibronectin Protects Prostate Cancer Cells from Tumor Necrosis Factor-α-induced Apoptosis via the AKT/Survivin Pathway. Journal of Biological Chemistry, 2003, 278, 50402-50411.	1.6	133
874	Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer?. Journal of Clinical Oncology, 2003, 21, 959-962.	0.8	62
875	Prognostic Significance of Reverse Transcriptase Polymerase Chain Reaction for Prostate-Specific Antigen in Metastatic Prostate Cancer: A Nested Study Within CALGB 9583. Journal of Clinical Oncology, 2003, 21, 490-495.	0.8	54
876	A subset of familial colorectal neoplasia kindreds linked to chromosome 9q22.2-31.2. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12961-12965.	3.3	103
877	Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome. Journal of Clinical Oncology, 2003, 21, 1912-1921.	0.8	294

#	Article	IF	Citations
878	Gene Expression Patterns in Ovarian Carcinomas. Molecular Biology of the Cell, 2003, 14, 4376-4386.	0.9	302
879	Psychosocial Issues Associated with Genetic Testing for Breast and Ovarian Cancer Risk: An Integrative Review. Cancer Investigation, 2003, 21, 588-623.	0.6	71
880	Use of NSAIDs for the Chemoprevention of Colorectal Cancer. Annals of Pharmacotherapy, 2003, 37, 1664-1674.	0.9	62
881	Reducing the Agonist Activity of Antiandrogens by a Dominant-negative Androgen Receptor Coregulator ARA70 in Prostate Cancer Cells. Journal of Biological Chemistry, 2003, 278, 19619-19626.	1.6	39
882	Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1250-1255.	3.3	70
883	Asian Ethnicity–Related Differences in Gastric Cancer Presentation and Outcome Among Patients Treated at a Canadian Cancer Center. Journal of Clinical Oncology, 2003, 21, 2070-2076.	0.8	124
884	Dual Mechanisms for Lysophosphatidic Acid Stimulation of Human Ovarian Carcinoma Cells. Journal of the National Cancer Institute, 2003, 95, 733-740.	3.0	62
885	Genetics of Prostate Cancer. Clinical Medicine and Research, 2003, 1, 21-28.	0.4	8
886	Radical Prostatectomy for Prostate Cancer Patients with Prostate-specific Antigen >20 ng/ml. Japanese Journal of Clinical Oncology, 2003, 33, 574-579.	0.6	7
887	Randomized Phase III Trial of Standard Timed Doxorubicin Plus Cisplatin Versus Circadian Timed Doxorubicin Plus Cisplatin in Stage III and IV or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2003, 21, 3808-3813.	0.8	106
888	Temporarily Deferred Therapy (watchful waiting) for Men Younger Than 70 Years and With Low-Risk Localized Prostate Cancer in the Prostate-Specific Antigen Era. Journal of Clinical Oncology, 2003, 21, 4001-4008.	0.8	78
889	Radical Prostatectomy: The Retropubic Antegrade Approach. , 2003, , 301-309.		O
890	Validity and reliability of the Parental Sun Protection Scales. Health Education Research, 2003, 18, 58-73.	1.0	16
891	Emerging drugs for non-small cell lung cancer. Expert Opinion on Emerging Drugs, 2003, 8, 179-192.	1.0	13
892	Differences in physician referral practices and attitudes regarding hereditary breast cancer by clinical practice location. Genetics in Medicine, 2003, 5, 364-369.	1.1	38
893	Assessment of the Scope and Quality of Clinical Practice Guidelines in Lung Cancer*. Chest, 2003, 123, 7S-20S.	0.4	66
894	Gadobenate Dimeglumine-Enhanced MRI of the Breast:Analysis of Dose Response and Comparison with Gadopentetate Dimeglumine. American Journal of Roentgenology, 2003, 181, 663-676.	1.0	68
895	Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973–1997. Journal of Neurosurgery, 2003, 99, 458-466.	0.9	76

#	Article	IF	CITATIONS
896	The APC Tumor Suppressor Pathway. , 2003, 222, 021-040.		3
897	Is It a New Pattern of Pulmonary Aspergillosis?. American Journal of Roentgenology, 2003, 180, 539-540.	1.0	2
898	Imaging in the Diagnosis, Staging, and Follow-Up of Cancer of the Urinary Bladder. American Journal of Roentgenology, 2003, 180, 1045-1054.	1.0	114
899	Ocular Melanoma. Archives of Dermatology, 2003, 139, 1067.	1.7	85
900	Diagnosis and treatment of prostate cancers in renal-transplant recipients. Transplantation, 2003, 75, 237-239.	0.5	67
901	Does Continuous-Infusion Interleukin-2 Increase Survival in Metastatic Melanoma?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 141-145.	0.6	6
902	Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Current Opinion in Oncology, 2003, 15, 23-35.	1.1	77
903	Melanoma Chemoprevention: A Role for Statins or Fibrates?. American Journal of Therapeutics, 2003, 10, 203-210.	0.5	42
904	Preoperative Therapy with Concurrent Paclitaxel/Carboplatin/Infusional 5-FU and Radiation Therapy in Locoregional Esophageal Cancer. Cancer Journal (Sudbury, Mass), 2003, 9, 251-260.	1.0	97
905	Bisphosphonate therapy in the oncology setting. Expert Opinion on Emerging Drugs, 2003, 8, 469-488.	1.0	38
906	Risk of Malignancy in Unilocular Ovarian Cystic Tumors Less Than 10 Centimeters in Diameter. Obstetrics and Gynecology, 2003, 102, 594-599.	1.2	90
907	8q24 Amplification in Transitional Cell Carcinoma of Bladder. Applied Immunohistochemistry and Molecular Morphology, 2003, 11, 33-36.	0.6	7
908	Defining the Pathologic Diagnosis of Metaplasia, Atrophy, Dysplasia, and Gastric Adenocarcinoma. Journal of Clinical Gastroenterology, 2003, 36, S37-S43.	1.1	42
909	Potential Utility of Uroplakin III, Thrombomodulin, High Molecular Weight Cytokeratin, and Cytokeratin 20 in Noninvasive, Invasive, and Metastatic Urothelial (Transitional Cell) Carcinomas. American Journal of Surgical Pathology, 2003, 27, 1-10.	2.1	191
910	Gemcitabine and Cisplatin Is a Highly Effective Combination Chemotherapy in Patients With Advanced Cancer of the Gallbladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 174-177.	0.6	69
911	Breast cancer screening: controversies and future directions. Current Opinion in Obstetrics and Gynecology, 2003, 15, 1-8.	0.9	35
912	Immunotherapy of lymphoma: update and review of the literature. Current Opinion in Oncology, 2003, 15, 363-370.	1.1	4
913	Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment. Melanoma Research, 2003, 13, 201-203.	0.6	22

#	Article	IF	Citations
914	Chemotherapy-induced Secondary Malignancies. Journal of Infusion Nursing, 2003, 26, 353-361.	1.2	41
915	Molecular Differentiation of High- and Moderate-Grade Human Prostate Cancer by cDNA Microarray Analysis. Diagnostic Molecular Pathology, 2003, 12, 63-70.	2.1	47
916	Computed tomography colonography in routine clinical practice. European Journal of Gastroenterology and Hepatology, 2003, 15, 1323-1331.	0.8	6
917	Gastrin peptides: pathophysiologic role in gastrointestinal carcinogenesis. Current Opinion in Endocrinology, Diabetes and Obesity, 2003, 10, 39-49.	0.6	4
918	Sinonasal Tract and Nasopharyngeal Melanomas: A Clinicopathologic Study of 115 Cases With a Proposed Staging System. American Journal of Surgical Pathology, 2003, 27, 594-611.	2.1	309
919	The Importance of Mammography Screening in Elderly Women. Nurse Practitioner, 2003, 28, 50-53.	0.2	0
920	Impact of Immediate Reconstruction on the Local Recurrence of Breast Cancer After Mastectomy. Annals of Plastic Surgery, 2003, 50, 333-338.	0.5	57
921	Stereoscopic representation of the breast from two mammographic view with external markers. , 2003, 5029, 368.		0
922	Neoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 312-316.	0.6	5
923	A Phase II Study of the Dolastatin 15 Analogue LU 103793 in the Treatment of Advanced Non–Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 336-337.	0.6	37
924	Chemoradiotherapy in the Treatment of Regional Pancreatic Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 543-549.	0.6	23
925	Title is missing!. Applied Immunohistochemistry & Molecular Morphology, 2003, 11, 33-36.	2.0	3
926	Extracorporeal organotripsy for renal tumours. Current Opinion in Urology, 2003, 13, 221-225.	0.9	5
927	Quality of Life in Rectal Cancer Patients. Annals of Surgery, 2003, 238, 203-213.	2.1	348
928	Prevention of Lung Cancer*. Chest, 2003, 123, 50S-59S.	0.4	36
929	Ultraviolet Radiation in Alpine Skiing. Archives of Dermatology, 2003, 139, 60.	1.7	56
930	Screening programmes for the early detection and prevention of oral cancer., 2003,, CD004150.		21
931	Taxol Inhibits Melanoma Metastases Through Apoptosis Induction, Angiogenesis Inhibition, and Restoration of E-Cadherin and nm23 Expression. Journal of Pharmacological Sciences, 2003, 93, 197-203.	1.1	16

#	Article	IF	CITATIONS
932	Treatment of Limited-Stage Small Cell Lung Cancer. , 2003, , 186-206.		0
933	Breast And Gynecologic Health-Screening Behaviors Among 191 Women With Spinal Cord Injuries. Journal of Spinal Cord Medicine, 2003, 26, 145-149.	0.7	5
934	Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood, 2003, 101, 2340-2348.	0.6	103
935	The Solitary Pulmonary Nodule*. Chest, 2003, 123, 89S-96S.	0.4	300
936	Molecular Targets for Green Tea in Prostate Cancer Prevention. Journal of Nutrition, 2003, 133, 2417S-2424S.	1.3	218
937	Kidney cancer. , 2003, , 217-222.		0
939	Does Continuous-Infusion Interleukin-2 Increase Survival in Metastatic Melanoma?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 141-145.	0.6	4
940	Molecular Diagnostics. Hematology American Society of Hematology Education Program, 2003, 2003, 279-293.	0.9	19
942	Kidney Cancer., 0,, 333-345.		4
943	High-grade Prostatic Intraepithelial Neoplasia. , 2003, , 35-43.		0
944	Collaborative Colorectal Cancer Screening: A Successful Quality Improvement Initiative. Baylor University Medical Center Proceedings, 2003, 16, 341-344.	0.2	7
945	Predictors of Older Korean Americans' Participation in Colorectal Cancer Screening. Journal of Cancer Education, 2003, 18, 37-42.	0.6	43
946	The Delta Project: Increasing Breast Cancer Screening Among Rural Minority and Older Women by Targeting Rural Healthcare Providers. Oncology Nursing Forum, 2003, 30, 669-677.	0.5	32
947	Colon Cancer and Other Gastrointestinal Malignancies. , 2003, , 417-440.		1
948	Molecular Markers of Oral Premalignant Lesion Risk. , 2003, , 245-III.		1
949	Biology of Lung Cancer With Implications for New Therapies. Oncology Nursing Forum, 2003, 30, 273-280.	0.5	3
950	Adding concurrent low dose continuous infusion of cisplatin to radiotherapy in locally advanced cervical carcinoma: a prospective randomized pilot study. British Journal of Radiology, 2004, 77, 581-587.	1.0	13
951	Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-line Treatment in Patients with Advanced Gastric Cancer. Journal of Korean Medical Science, 2004, 19, 369.	1.1	15

#	Article	IF	CITATIONS
952	Treatment Options in Hormone-refractory Metastatic Prostate Carcinoma. Tumori, 2004, 90, 535-546.	0.6	34
953	Measuring quality of life in prostate cancer: progress and challenges. , 2004, , 126-159.		3
954	Hepatic Arterial Infusion Chemotherapy in Gastric Cancer: A Report of Four Cases and Analysis of the Literature. Tumori, 2004, 90, 428-434.	0.6	8
955	The Plasma Cell Dyscrasias. , 2004, 121, 113-144.		1
956	Oral Cancer Knowledge and Practices of Dentists along the Texas-Mexico Border. Journal of Cancer Education, 2004, 19, 6-11.	0.6	22
957	Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane. Journal of Korean Medical Science, 2004, 19, 547.	1.1	40
958	Improvement in Radiologists' Characterization of Malignant and Benign Breast Masses on Serial Mammograms with Computer-aided Diagnosis: An ROC Study. Radiology, 2004, 233, 255-265.	3.6	93
959	Discrimination of Human Lung Neoplasm from Normal Lung by Two Target Genes. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 516-519.	2.5	38
960	Volumetric Assessment of Pulmonary Nodules with ECG-Gated MDCT. American Journal of Roentgenology, 2004, 183, 1217-1223.	1.0	38
961	Can Computer-aided Detection with Double Reading of Screening Mammograms Help Decrease the False-Negative Rate? Initial Experience. Radiology, 2004, 232, 578-584.	3.6	125
962	Can we individualise chemotherapy for colorectal cancer?. Annals of Oncology, 2004, 15, 996-999.	0.6	5
963	Colorectal Cancer Screening: Why Aren't We Doing Better?. Clinics in Colon and Rectal Surgery, 2004, 17, 5-6.	0.5	1
964	Apigenin Induces Apoptosis through Proteasomal Degradation of HER2/neu in HER2/neu-overexpressing Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt-dependent Pathway. Journal of Biological Chemistry, 2004, 279, 4479-4489.	1.6	206
965	Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10143-10148.	3.3	554
966	Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Annals of Oncology, 2004, 15, 613-617.	0.6	198
967	An overview of the status of imaging screening technology for breast cancer. Annals of Oncology, 2004, 15, i18-i26.	0.6	58
968	Cyclin A as a Predictive Factor for Chemotherapy Response in Advanced Head and Neck Cancer. Clinical Cancer Research, 2004, 10, 8486-8492.	3.2	28
969	Cyclooxygenase (COX)-2 Inhibitor Celecoxib Abrogates Activation of Cigarette Smoke-Induced Nuclear Factor (NF)-ÎB by Suppressing Activation of I-ÎB α Kinase in Human Non-Small Cell Lung Carcinoma. Cancer Research, 2004, 64, 5004-5012.	0.4	119

#	Article	IF	CITATIONS
970	RasGTPase-activating protein is a target of caspases in spontaneous apoptosis of lung carcinoma cells and in response to etoposide. Carcinogenesis, 2004, 25, 909-921.	1.3	9
971	Lack of Microvessels in Well-Differentiated Regions of Human Head and Neck Squamous Cell Carcinoma A253 Associated with Functional Magnetic Resonance Imaging Detectable Hypoxia, Limited Drug Delivery, and Resistance to Irinotecan Therapy. Clinical Cancer Research, 2004, 10, 8005-8017.	3.2	47
972	Effect of Pregnancy on Survival in Women With Cutaneous Malignant Melanoma. Journal of Clinical Oncology, 2004, 22, 4369-4375.	0.8	164
973	Overexpression of the Nuclear Receptor Coactivator AlB1 (SRC-3) during Progression of Pancreatic Adenocarcinoma. Clinical Cancer Research, 2004, 10, 6134-6142.	3.2	106
974	Early Detection and Prognosis of Ovarian Cancer Using Serum YKL-40. Journal of Clinical Oncology, 2004, 22, 3330-3339.	0.8	124
975	Impairments, disabilities and health related quality of life after treatment for breast cancer: a follow-up study 2.7 years after surgery. Disability and Rehabilitation, 2004, 26, 78-84.	0.9	184
976	trans-3,4,5′-Trihydroxystibene Inhibits Hypoxia-Inducible Factor 1α and Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells. Clinical Cancer Research, 2004, 10, 5253-5263.	3.2	172
977	The Stable Nitroxide Tempol Facilitates Salivary Gland Protection during Head and Neck Irradiation in a Mouse Model. Clinical Cancer Research, 2004, 10, 1807-1812.	3.2	74
978	Increased Insulin-Like Growth Factor I Receptor Expression and Signaling Are Components of Androgen-Independent Progression in a Lineage-Derived Prostate Cancer Progression Model. Cancer Research, 2004, 64, 8620-8629.	0.4	148
979	Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Annals of Oncology, 2004, 15, 743-750.	0.6	82
980	Selective Activation of Ceruloplasmin Promoter in Ovarian Tumors. Cancer Research, 2004, 64, 1788-1793.	0.4	32
982	Docetaxel Versus Docetaxel Plus Cisplatin As Front-Line Treatment of Patients With Advanced Non—Small-Cell Lung Cancer: A Randomized, Multicenter Phase III Trial. Journal of Clinical Oncology, 2004, 22, 2602-2609.	0.8	124
983	Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2004, 96, 1133-1141.	3.0	367
984	Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate. Journal of Clinical Oncology, 2004, 22, 3776-3783.	0.8	537
985	Proinvasive Properties of Ovarian Cancer Ascites-Derived Membrane Vesicles. Cancer Research, 2004, 64, 7045-7049.	0.4	228
986	Differential Methylation Status of Tumor-Associated Genes in Head and Neck Squamous Carcinoma. Clinical Cancer Research, 2004, 10, 3825-3830.	3.2	140
987	Expression Level of Valosin-Containing Protein (p97) Is Associated with Prognosis of Esophageal Carcinoma. Clinical Cancer Research, 2004, 10, 5558-5565.	3.2	59
988	A Prospective Study of Folate Intake and the Risk of Pancreatic Cancer in Men and Women. American Journal of Epidemiology, 2004, 160, 248-258.	1.6	63

#	Article	IF	CITATIONS
989	Weekly Irinotecan in Patients with Metastatic Gastric Cancer Failing Cisplatin-based Chemotherapy. Japanese Journal of Clinical Oncology, 2004, 34, 8-13.	0.6	68
990	Cancer Trial Enrollment After State-Mandated Reimbursement. Journal of the National Cancer Institute, 2004, 96, 1063-1069.	3.0	39
991	Transcriptional activation of the human prostatic acid phosphatase gene by NF-ÂB via a novel hexanucleotide-binding site. Nucleic Acids Research, 2004, 32, 3566-3580.	6.5	18
992	Colon cancer: genomics and apoptotic events. Biological Chemistry, 2004, 385, 449-64.	1.2	83
993	Detection of Promoter Hypermethylation of Multiple Genes in the Tumor and Bronchoalveolar Lavage of Patients with Lung Cancer. Clinical Cancer Research, 2004, 10, 2284-2288.	3.2	163
994	Folate Is Associated with the Natural History of High-Risk Human Papillomaviruses. Cancer Research, 2004, 64, 8788-8793.	0.4	74
995	Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology, 2004, 15, 478-483.	0.6	129
996	Treatment of Carcinogenesis., 2004,, 607-673.		1
997	km23: A Novel TGFβ Signaling Target Altered in Ovarian Cancer. , 2004, 119, 315-327.		7
998	Progress in Head and Neck Cancer Immunotherapy: Can Tolerance and Immune Suppression Be Reversed?. Orl, 2004, 66, 332-340.	0.6	29
999	c-kit Expression in Adenocarcinomas of the Lung. Tumor Biology, 2004, 25, 235-242.	0.8	31
1000	Chemokine Receptors 6 and 7 Identify a Metastatic Expression Pattern in Squamous Cell Carcinoma of the Head and Neck., 2004, 62, 121-133.		30
1001	Chemoprevention of Gastric Cancer: Role of COX-2 Inhibitors and Other Agents. Digestive Diseases, 2004, 22, 320-326.	0.8	19
1002	Prophylactic mastectomy for the prevention of breast cancer. , 2004, , CD002748.		94
1003	Value of p16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients with Resectable Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 6119-6125.	3.2	84
1004	Casein Kinase II Alpha Subunit and C1-Inhibitor Are Independent Predictors of Outcome in Patients with Squamous Cell Carcinoma of the Lung. Clinical Cancer Research, 2004, 10, 5792-5803.	3.2	103
1005	Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis, 2004, 26, 271-279.	1.3	128
1006	Down Regulation of High in Normal-1 (HIN-1) is a Frequent Event in Stage I Non-Small Cell Lung Cancer and Correlates with Poor Clinical Outcome. Clinical Cancer Research, 2004, 10, 1338-1343.	3.2	27

#	ARTICLE	IF	CITATIONS
1007	Is hypoglycaemia a marker for increased long-term mortality risk in patients with coronary artery disease? An 8-year follow-up. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 135-143.	3.1	34
1008	The role of bisphosphonates in breast and prostate cancers Endocrine-Related Cancer, 2004, 11, 207-224.	1.6	109
1009	Loss of RhoB Expression in Human Lung Cancer Progression. Clinical Cancer Research, 2004, 10, 2742-2750.	3.2	158
1010	Expression Pattern of Chemokine Receptor 6 (CCR6) and CCR7 in Squamous Cell Carcinoma of the Head and Neck Identifies a Novel Metastatic Phenotype. Cancer Research, 2004, 64, 1861-1866.	0.4	149
1011	Connective Tissue Growth Factor and Its Role in Lung Adenocarcinoma Invasion and Metastasis. Journal of the National Cancer Institute, 2004, 96, 364-75.	3.0	155
1012	Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. British Journal of Cancer, 2004, 91, 129-140.	2.9	110
1013	p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. British Journal of Cancer, 2004, 90, 206-215.	2.9	164
1014	Multiple Management Modalities in Esophageal Cancer: Epidemiology, Presentation and Progression, Workâ€up, and Surgical Approaches. Oncologist, 2004, 9, 137-146.	1.9	58
1015	Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2004, 22, 3218-3229.	0.8	51
1016	Study of Hormone Refractory Prostate Cancer: Hospital Care and Palliative Care Resource Use at a VA Medical Center. Cancer Investigation, 2004, 22, 849-857.	0.6	19
1017	DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. Journal of Clinical Pathology, 2004, 57, 1057-1062.	1.0	85
1018	Kallikrein 4 is a Predominantly Nuclear Protein and Is Overexpressed in Prostate Cancer. Cancer Research, 2004, 64, 2365-2370.	0.4	101
1019	CT Colonography and Colonoscopy: Assessment of Patient Preference in a 5-week Follow-up Study. Radiology, 2004, 233, 328-337.	3.6	149
1020	A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Annals of Oncology, 2004, 15, 955-959.	0.6	212
1021	Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-Â gene in rat colon tumors. Carcinogenesis, 2004, 25, 1917-1923.	1.3	39
1022	Recent Advances in Melanoma Biology. Oncologist, 2004, 9, 182-187.	1.9	59
1023	Sex differences in survival in non-small cell lung cancer patients 1974–1998. Acta Oncológica, 2004, 43, 57-64.	0.8	51
1024	Devastating complications after brachytherapy in the treatment of prostate adenocarcinoma. BJU International, 2004, 93, 31-35.	1.3	94

#	Article	IF	CITATIONS
1025	Comparison of clinical and pathological features in African-American and Caucasian patients with localized prostate cancer. BJU International, 2004, 93, 1207-1210.	1.3	20
1026	The association between patient age and prostate cancer stage and grade at diagnosis. BJU International, 2004, 94, 303-306.	1.3	24
1027	Agreement Between Scales in the Measurement of Breast Cancer Risk Perceptions. Risk Analysis, 2004, 24, 665-673.	1.5	71
1028	The anti-tumor immune responses induced by a fusion protein of ovarian carcinoma anti-idiotypic antibody 6B11ScFv and murine GM-CSF in BALB/c mice. International Journal of Gynecological Cancer, 2004, 14, 234-241.	1.2	12
1029	Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor. International Journal of Gynecological Cancer, 2004, 14, 82-88.	1.2	40
1030	Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene, 2004, 23, 2385-2400.	2.6	235
1031	Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene, 2004, 23, 2996-3004.	2.6	96
1032	The epidemiology of non-Hodgkin's lymphoma. Oncogene, 2004, 23, 6524-6534.	2.6	349
1033	Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene, 2004, 23, 8171-8183.	2.6	75
1034	BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene, 2004, 23, 9326-9335.	2.6	95
1035	Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy. British Journal of Cancer, 2004, 90, 55-59.	2.9	47
1036	Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). British Journal of Cancer, 2004, 90, 82-86.	2.9	52
1037	Predicting biomarkers for ovarian cancer using gene-expression microarrays. British Journal of Cancer, 2004, 90, 686-692.	2.9	176
1038	A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. British Journal of Cancer, 2004, 90, 1516-1520.	2.9	126
1039	Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. British Journal of Cancer, 2004, 91, 1032-1037.	2.9	25
1040	High-grade prostatic intraepithelial neoplasia. Modern Pathology, 2004, 17, 360-379.	2.9	219
1041	Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer. Modern Pathology, 2004, 17, 440-448.	2.9	42
1042	Determining variables for repeat prostate biopsy. Prostate Cancer and Prostatic Diseases, 2004, 7, 93-98.	2.0	15

#	Article	IF	Citations
1043	Implications of Prognostic Factors and Risk Groups in the Management of Differentiated Thyroid Cancer. Laryngoscope, 2004, 114, 393-402.	1.1	177
1044	Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis and Orthotopic Liver Transplantation. American Journal of Transplantation, 2004, 4, 686-693.	2.6	186
1045	Use of proteomic patterns to screen for gastrointestinal malignancies. Surgery, 2004, 135, 243-247.	1.0	29
1046	Cancer in the elderly: pancreatic cancer. Surgical Oncology, 2004, 13, 201-210.	0.8	41
1047	Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells. Journal of Thoracic and Cardiovascular Surgery, 2004, 127, 92-98.	0.4	34
1048	Neoplasms of the liver and the bile ducts. Seminars in Roentgenology, 2004, 39, 412-427.	0.2	11
1049	Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium. Oral Oncology, 2004, 40, 1040-1047.	0.8	42
1050	Thyroid lobectomy: Operative anatomy, technique, and morbidity. Operative Techniques in Otolaryngology - Head and Neck Surgery, 2004, 15, 210-219.	0.1	6
1051	Clinical update: Novel targets in multiple myeloma. Seminars in Oncology, 2004, 31, 27-32.	0.8	16
1052	Selective dose escalation of chemoradiotherapy for esophageal cancer: Role of treatment intensification. Seminars in Oncology, 2004, 31, 13-19.	0.8	36
1053	Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study. Gynecologic Oncology, 2004, 92, 293-299.	0.6	20
1054	Long-term survival in an ovarian cancer patient with brain metastases. Gynecologic Oncology, 2004, 92, 978-980.	0.6	21
1055	Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecologic Oncology, 2004, 92, 965-969.	0.6	101
1056	Transcriptional activation of H- and N-ras oncogenes in human cervical cancer. Gynecologic Oncology, 2004, 92, 941-948.	0.6	32
1057	A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Gynecologic Oncology, 2004, 92, 957-964.	0.6	52
1058	Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Gynecologic Oncology, 2004, 92, 896-904.	0.6	24
1059	Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-Î ³ expression. Gynecologic Oncology, 2004, 93, 149-154.	0.6	47
1060	Cost-effectiveness analysis of the treatment for intermediate risk endometrial cancer: postoperative brachytherapy vs. observation1. Gynecologic Oncology, 2004, 93, 632-636.	0.6	29

#	Article	IF	CITATIONS
1061	Value of intraoperative imprint cytology of sentinel nodes in patients with cervical cancer. Gynecologic Oncology, 2004, 94, 175-180.	0.6	46
1062	Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel–Platinum?. Gynecologic Oncology, 2004, 94, 409-415.	0.6	17
1063	Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer. Gynecologic Oncology, 2004, 94, 719-724.	0.6	19
1064	A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. Gynecologic Oncology, 2004, 95, 114-119.	0.6	10
1065	Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecologic Oncology, 2004, 95, 686-690.	0.6	55
1066	Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. BMC Cancer, 2004, 4, 93.	1.1	34
1067	Positron emission tomography and colorectal carcinoma: an update 11No competing interests declared Journal of the American College of Surgeons, 2004, 198, 645-652.	0.2	6
1068	Office-Based cryoablation of breast fibroadenomas: 12-month followup1 1Funding for this study was provided by Sanarus Medical, Inc Journal of the American College of Surgeons, 2004, 198, 914-923.	0.2	50
1069	Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clinical Nutrition, 2004, 23, 239-247.	2.3	163
1070	Quality of Life Following Treatment for Early Prostate Cancer: Does Low Dose Rate (LDR) Brachytherapy Offer a Better Outcome? A Review. European Urology, 2004, 45, 134-141.	0.9	42
1071	Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. Cancer Genetics and Cytogenetics, 2004, 154, 27-35.	1.0	148
1072	Feasibility of laparoscopic debulking with electrosurgical loop excision procedure and argon beam coagulator at recurrence in patients with previous laparotomy debulking. American Journal of Obstetrics and Gynecology, 2004, 190, 1394-1397.	0.7	41
1073	The epigenetics of ovarian cancer drug resistance and resensitization. American Journal of Obstetrics and Gynecology, 2004, 191, 1552-1572.	0.7	156
1074	Altered Expression and Activation of the Nerve Growth Factor Receptors TrkA and p75 Provide the First Evidence of Tumor Progression to Effusion in Breast Carcinoma. Breast Cancer Research and Treatment, 2004, 83, 119-128.	1.1	78
1075	Expression and Initial Promoter Characterization of PCAN1 in Retinal Tissue and Prostate Cell Lines. Medical Oncology, 2004, 21, 145-154.	1.2	4
1076	Laparoscopic Sentinel Node Procedure Using a Combination of Patent Blue and Radiocolloid in Women With Endometrial Cancer. Annals of Surgical Oncology, 2004, 11, 344-349.	0.7	69
1077	Expression Level of Valosin-Containing Protein (p97) Is Correlated With Progression and Prognosis of Non-Small-Cell Lung Carcinoma. Annals of Surgical Oncology, 2004, 11, 697-704.	0.7	58
1078	Modulation of AP-1 by Natural Chemopreventive Compounds in Human Colon HT-29 Cancer Cell Line. Pharmaceutical Research, 2004, 21, 649-660.	1.7	81

#	Article	IF	CITATIONS
1079	A coupled column generation, mixed integer approach to optimal planning of intensity modulated radiation therapy for cancer. Mathematical Programming, 2004, 101, 319.	1.6	50
1080	Risk Factors Associated With Requiring a Stoma for the Management of Anal Cancer. Diseases of the Colon and Rectum, 2004, 47, 843-846.	0.7	9
1081	Irradiation of the inguinal lymph nodes in patients of differing body habitus: A comparison of techniques and resulting normal tissue complication probabilities. Medical Dosimetry, 2004, 29, 217-222.	0.4	4
1082	Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma. International Urology and Nephrology, 2004, 36, 417-423.	0.6	20
1083	Correlation of endorectal coil magnetic resonance imaging of the prostate with pathologic stage. World Journal of Urology, 2004, 22, 289-292.	1.2	11
1084	Magnetic resonance colonography: A promising new technique. Current Gastroenterology Reports, 2004, 6, 389-394.	1.1	3
1085	The role of positron emission tomographic imaging in breast cancer. Current Oncology Reports, 2004, 6, 62-68.	1.8	20
1086	Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors. Prostate, 2004, 60, 168-174.	1.2	75
1087	Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. Prostate, 2004, 60, 141-152.	1.2	50
1088	CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate, 2004, 61, 228-235.	1.2	84
1089	Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics, 2004, 4, 3975-3988.	1.3	89
1090	Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate. European Journal of Immunology, 2004, 34, 1091-1101.	1.6	23
1091	Cancer of the oral cavity: a comparison between institutions in a developing and a developed nation. Head and Neck, 2004, 26, 31-38.	0.9	59
1092	High frequency of HPV16-associated head and neck squamous cell carcinoma in the Puerto Rican population. Head and Neck, 2004, 26, 778-784.	0.9	34
1093	Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines. Genes Chromosomes and Cancer, 2004, 39, 171-184.	1.5	49
1094	Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy. Cancer, 2004, 100, 892-899.	2.0	261
1095	The natural history of breast carcinoma in the elderly. Cancer, 2004, 100, 1807-1813.	2.0	82
1096	Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression. Cancer, 2004, 100, 2367-2375.	2.0	38

#	Article	IF	CITATIONS
1097	Flow cytometric enrichment for respiratory epithelial cells in sputum. Cytometry, 2004, 60A, 1-7.	1.8	10
1098	Cervical biopsy-based comparison of a new liquid-based thin-layer preparation with conventional Pap smears. Diagnostic Cytopathology, 2004, 30, 220-226.	0.5	13
1099	Ductal lavage and its histopathologic basis: A cautionary tale. Diagnostic Cytopathology, 2004, 30, 166-171.	0.5	13
1100	Bcl-xL inhibits p53- but not apoptin-induced apoptosis in head and neck squamous cell carcinoma cell line. International Journal of Cancer, 2004, 109, 38-42.	2.3	34
1101	NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. International Journal of Cancer, 2004, 109, 499-506.	2.3	93
1102	Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-?B signaling. International Journal of Cancer, 2004, 111, 679-692.	2.3	256
1103	Global gene expression profiles of human head and neck squamous carcinoma cell lines. International Journal of Cancer, 2004, 112, 249-258.	2.3	77
1104	Prostate carcinoma: Opportunities for translational research. Journal of Cellular Biochemistry, 2004, 91, 433-442.	1.2	5
1105	Fingerprinting the diseased prostate: Associations between BPH and prostate cancer. Journal of Cellular Biochemistry, 2004, 91, 161-169.	1.2	31
1106	Surgical treatment of hepatocellular carcinoma: Similar long-term results despite geographic variations. Liver Transplantation, 2004, 10, S74-S80.	1.3	35
1107	The prognostic significance of margin width for extremity and trunk sarcoma. Journal of Surgical Oncology, 2004, 85, 68-76.	0.8	151
1108	Radioguided sentinel lymph node biopsy in patients with malignant cutaneous melanoma: The nuclear medicine contribution. Journal of Surgical Oncology, 2004, 85, 141-151.	0.8	55
1109	New fields of application of the sentinel lymph node biopsy in the pathologic staging of solid neoplasms: Review of literature and surgical perspectives. Journal of Surgical Oncology, 2004, 85, 171-179.	0.8	24
1110	Intraoperative imprint cytology of sentinel nodes in breast cancer. Journal of Surgical Oncology, 2004, 86, 128-133.	0.8	35
1111	Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magnetic Resonance in Medicine, 2004, 52, 80-88.	1.9	108
1112	Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer. Molecular Carcinogenesis, 2004, 39, 79-84.	1.3	22
1113	5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. Journal of Gene Medicine, 2004, 6, 514-525.	1.4	34
1114	Mechanical properties, density and quantitative CT scan data of trabecular bone with and without metastases. Journal of Biomechanics, 2004, 37, 523-530.	0.9	130

#	Article	IF	CITATIONS
1115	Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leukemia Research, 2004, 28, 429-442.	0.4	51
1116	Update on screening for prostate cancer with prostate-specific antigen. Critical Reviews in Oncology/Hematology, 2004, 50, 71-78.	2.0	52
1117	Predictive factors for response to chemotherapy in colorectal cancer patients. Critical Reviews in Oncology/Hematology, 2004, 52, 45-60.	2.0	12
1118	Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4919-4923.	1.0	17
1119	Enhancement of Radiation Cytotoxicity by UCN-01 in Non-small Cell Lung Carcinoma Cells. Radiation Research, 2004, 162, 623-634.	0.7	14
1120	Active Smoking, Household Passive Smoking, and Breast Cancer: Evidence From the California Teachers Study. Journal of the National Cancer Institute, 2004, 96, 29-37.	3.0	175
1121	Gene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes' B Colon Cancer. Journal of Clinical Oncology, 2004, 22, 1564-1571.	0.8	411
1122	Class Discovery Analysis of the Lung Cancer Gene Expression Data. DNA and Cell Biology, 2004, 23, 715-721.	0.9	6
1123	Health Economic Evaluation of Non-Melanoma Skin Cancer and Actinic Keratosis. Pharmacoeconomics, 2004, 22, 83-94.	1.7	32
1124	Comprehensive Proteomic Analysis of Human Pancreatic Juice. Journal of Proteome Research, 2004, 3, 1042-1055.	1.8	194
1125	Prognostic Significance of p16 Protein Levels in Oropharyngeal Squamous Cell Cancer. Clinical Cancer Research, 2004, 10, 5684-5691.	3.2	133
1126	Preventive Health Care in the Elderly Population: A Guide for Practicing Physicians. Mayo Clinic Proceedings, 2004, 79, 416-427.	1.4	9
1127	ANALYSIS OF ANDROGEN REGULATED HOMEOBOX GENE NKX3.1 DURING PROSTATE CARCINOGENESIS. Journal of Urology, 2004, 172, 1134-1139.	0.2	40
1128	Larynx squamous cell carcinoma: concepts and future directions. Surgical Oncology Clinics of North America, 2004, 13, 99-112.	0.6	13
1129	Watchful Waiting and Factors Predictive of Secondary Treatment of Localized Prostate Cancer. Journal of Urology, 2004, 171, 1111-1116.	0.2	27
1130	A NOVEL INTRAVESICAL THERAPY FOR SUPERFICIAL BLADDER CANCER IN AN ORTHOTOPIC MODEL: ONCOLYTIC REOVIRUS THERAPY. Journal of Urology, 2004, 172, 2018-2022.	0.2	34
1131	High-Resolution Genomic and Expression Profiling Reveals 105 Putative Amplification Target Genes in Pancreatic Cancer. Neoplasia, 2004, 6, 432-439.	2.3	104
1132	Increased Expression of the EZH2 Polycomb Group Gene in BMI-1-Positive Neoplastic Cells during Bronchial Carcinogenesis. Neoplasia, 2004, 6, 736-743.	2.3	106

#	Article	IF	CITATIONS
1133	Future of capsule endoscopy. Gastrointestinal Endoscopy Clinics of North America, 2004, 14, 219-227.	0.6	36
1135	Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology, 2004, 127, 422-427.	0.6	69
1136	Introduction: The burden of hepatocellular carcinoma. Gastroenterology, 2004, 127, S1-S4.	0.6	56
1137	Hepatocellular carcinoma: Summary and recommendations. Gastroenterology, 2004, 127, S319-S323.	0.6	45
1138	What have we learned and where are we going in the treatment of colorectal and gastric cancer?. European Journal of Cancer, Supplement, 2004, 2, 59-62.	2.2	0
1139	Correlates of Active and Passive Smoking in the California Teachers Study Cohort. Journal of Women's Health, 2004, 13, 778-790.	1.5	16
1140	Photodynamic therapy for peripheral lung cancer. Lung Cancer, 2004, 43, 77-82.	0.9	77
1141	Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin. Lung Cancer, 2004, 45, 227-236.	0.9	18
1142	Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study. Lung Cancer, 2004, 46, 197-204.	0.9	43
1143	Laparoscopic Sentinel Node Procedure for Cervical Cancer: Impact of Neoadjuvant Chemoradiotherapy. Annals of Surgical Oncology, 2004, 11, 445-452.	0.7	22
1144	Exercise and Prostate Cancer. Sports Medicine, 2004, 34, 363-369.	3.1	61
1145	Thoracic manifestations of common nonpulmonary malignancies of women. Clinics in Chest Medicine, 2004, 25, 379-390.	0.8	14
1146	Evolución del carcinoma broncopulmonar en el norte de la provincia de Castellón, 1993–2002. Archivos De Bronconeumologia, 2004, 40, 553-557.	0.4	14
1147	MDCT in Pancreatic Adenocarcinoma: /b> Prediction of Vascular Invasion and Resectability Using a Multiphasic Technique with Curved Planar Reformations. American Journal of Roentgenology, 2004, 182, 419-425.	1.0	239
1148	Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity. Mayo Clinic Proceedings, 2004, 79, 875-882.	1.4	120
1149	Screening for breast cancer with MRI. Magnetic Resonance Imaging Clinics of North America, 2004, 12, 593-601.	0.6	0
1150	Surgical margins for resection of primary cutaneous melanoma. Clinics in Dermatology, 2004, 22, 228-233.	0.8	23
1151	A new screening system for proliferation-independent anti-cancer agents. Cancer Letters, 2004, 210, 119-124.	3.2	11

#	Article	IF	Citations
1152	Effect of LY293111 in combination with gemcitabine in colonic cancer. Cancer Letters, 2004, 210, 41-46.	3.2	32
1153	Down-regulation of KAI1/CD82 protein expression in oral cancer correlates with reduced disease free survival and overall patient survival. Cancer Letters, 2004, 213, 91-98.	3.2	31
1154	DNA hypomethylation induced by non-genotoxic carcinogens in mouse and rat colon. Cancer Letters, 2004, 212, 145-151.	3.2	39
1155	Follicular-cell derived thyroid cancer in children. European Journal of Cancer, 2004, 40, 1655-1659.	1.3	14
1156	Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2004, 113, S7-S11.	0.5	114
1157	Multidetector row CT of the pancreas. European Journal of Radiology, 2004, 52, 18-30.	1.2	34
1158	Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochemical and Biophysical Research Communications, 2004, 322, 263-270.	1.0	214
1159	Action of solamargine on TNFs and cisplatin-resistant human lung cancer cells. Biochemical and Biophysical Research Communications, 2004, 322, 751-758.	1.0	66
1160	SU5416 inhibited VEGF and HIF- $1\hat{l}\pm$ expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochemical and Biophysical Research Communications, 2004, 324, 471-480.	1.0	59
1161	Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide. Experimental Cell Research, 2004, 298, 83-95.	1.2	25
1162	Adherence with colorectal cancer screening guidelines: a review. Preventive Medicine, 2004, 38, 536-550.	1.6	237
1163	Detection of apoptotic cells in whole saliva of patients with oral premalignant and malignant lesions: A preliminary study. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2004, 97, 465-470.	1.6	31
1164	Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program. Urology, 2004, 63, 337-341.	0.5	15
1165	Benefit of radical cystectomy in the elderly patient with significant co-morbidities. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 178-181.	0.8	64
1166	Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth. Molecular and Cellular Endocrinology, 2004, 214, 175-187.	1.6	13
1167	Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. Journal of Steroid Biochemistry and Molecular Biology, 2004, 92, 131-141.	1.2	101
1168	Sex steroid hormone metabolism and prostate cancer. Journal of Steroid Biochemistry and Molecular Biology, 2004, 92, 281-286.	1.2	77
1169	Barrett's esophagus: management of high-grade dysplasia and cancer. Journal of Surgical Research, 2004, 117, 44-51.	0.8	14

#	Article	IF	CITATIONS
1170	Prediction of lymph node metastasis by analysis of gene expression profiles in non-small cell lung cancer1. Journal of Surgical Research, 2004, 122, 61-69.	0.8	29
1171	Cryoablation treatment of benign breast lesions with 12-month follow-up. American Journal of Surgery, 2004, 188, 340-348.	0.9	49
1172	Analgesic therapy and the prevention of bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 11-15.	0.8	7
1173	Gender, racial and age differences in bladder cancer incidence and mortality. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 86-92.	0.8	147
1174	Prognostic and Predictive Factors in Earlyâ€Stage Breast Cancer. Oncologist, 2004, 9, 606-616.	1.9	476
1175	Tissue Disposition of 5â€oâ€Carboranyluracil—A Novel Agent for the Boron Neutron Capture Therapy of Prostate Cancer. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 291-306.	0.4	18
1176	Nursing roles in cancer prevention position statements. Seminars in Oncology Nursing, 2004, 20, 111-120.	0.7	7
1177	Prospective evaluation of screening colonoscopy: who is being screened?. Gastrointestinal Endoscopy, 2004, 60, 921-926.	0.5	22
1178	Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiotherapy and Oncology, 2004, 72, 231-241.	0.3	54
1179	Oral Preneoplasia and Chemoprevention of Squamous Cell Carcinoma of the Head and Neck. , 2003, 114, 61-83.		0
1180	Underutilization of Digital Rectal Examination When Screening for Prostate Cancer. Archives of Internal Medicine, 2004, 164, 313.	4.3	20
1181	Growth Repression in Diethylstilbestrol/Dimethylbenz[a]anthracene–Induced Rat Mammary Gland Tumor Using Hecate-CGβ Conjugate. Experimental Biology and Medicine, 2004, 229, 335-344.	1.1	11
1182	Radiotherapy for prostate cancer and sexual functioning. British Journal of Hospital Medicine, 2004, 65, 605-608.	0.3	4
1183	The Influence of Intravesical Therapy on Progression of Superficial Transitional Cell Carcinoma of the Bladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 522-528.	0.6	49
1184	Mode of Spread in the Early Phase of Lymphatic Metastasis in Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2004, 240, 993-1001.	2.1	37
1185	Performance evaluation of an information-theoretic CAD scheme for the detection of mammographic architectural distortion., 2004, , .		8
1186	Understanding the Factors Underlying Disparities in Cancer Screening Rates Using the Peters-Belson Approach. Medical Care, 2004, 42, 789-800.	1.1	66
1187	Prognostic Significance of Cyclooxygenase-2 in Oropharyngeal Squamous Cell Carcinoma. Clinical Cancer Research, 2004, 10, 1678-1684.	3.2	46

#	Article	IF	CITATIONS
1188	Gliomas following organ transplantation: analysis of the contents of a tumor registry. Journal of Neurosurgery, 2004, 101, 932-934.	0.9	8
1189	Paclitaxel and Carboplatin as Second-Line Therapy in Women With Platinum-Sensitive Ovarian Carcinoma Treated With Platinum and Paclitaxel as First-Line Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 46-50.	0.6	4
1190	\hat{I}^3 -Catenin Expression Is Reduced or Absent in a Subset of Human Non-small Cell Lung Cancers, and Its Re-expression Inhibits Cell Growth. Chest, 2004, 125, 122S-123S.	0.4	7
1191	Epidemiology, Staging, and Screening of Head and Neck Cancer. , 2003, 114, 15-60.		79
1192	New modalities in detection of recurrent ovarian cancer. Current Opinion in Obstetrics and Gynecology, 2004, 16, 5-9.	0.9	25
1193	Exploring Social Cognitive Theory Constructs for Promoting Exercise Among Breast Cancer Patients. Cancer Nursing, 2004, 27, 462???473.	0.7	82
1194	Advances in the Surgical Management of Liver Malignancies. Cancer Journal (Sudbury, Mass), 2004, 10, 74-87.	1.0	19
1195	The Generation and Anti-Myeloma Activity of a Chimeric Anti-CD54 Antibody, cUV3. Journal of Immunotherapy, 2004, 27, 419-424.	1.2	10
1196	Determinants of Functional Recovery in Older Adults Surgically Treated for Cancer. Cancer Nursing, 2004, 27, 10-16.	0.7	28
1197	Nonselective Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Gastrointestinal Bleeding: Relative and Absolute Risk Estimates From Recent Epidemiologic Studies. American Journal of Therapeutics, 2004, 11, 17-25.	0.5	47
1198	Barriers to colorectal cancer screening in a low income, urban population: a descriptive study. Health Education, 2004, 104, 68-76.	0.4	5
1200	Hypofractionated Proton Beam Radiotherapy for Stage I Lung Cancer. Chest, 2004, 126, 1198-1203.	0.4	182
1201	NAFLD, NASH and Orthotopic Liver Transplantation. , 0, , 208-217.		1
1202	Lymphatic Mapping and Sentinel Lymphadenectomy for Primary and Metastatic Pulmonary Malignant Neoplasms. Archives of Surgery, 2004, 139, 870.	2.3	43
1203	Relationship Between a History of Antecedent Cancer and the Probability of Malignancy for a Solitary Pulmonary Nodule. Chest, 2004, 125, 2175-2181.	0.4	95
1204	High Recurrence Rates of Basal Cell Carcinoma After Mohs Surgery in Patients With Chronic Lymphocytic Leukemia. Archives of Dermatology, 2004, 140, 985-8.	1.7	66
1205	Color and Power Doppler Sonography in the Diagnosis of Prostate Cancer. Journal of Ultrasound in Medicine, 2004, 23, 623-630.	0.8	30
1206	Dynamic Contrast-Enhanced MRI of Prostate Cancer. , 2005, , 191-213.		2

#	Article	IF	CITATIONS
1207	What Role for Contrast-Enhanced Ultrasound in Prostate Cancer Examination?., 2005,, 51-63.		0
1208	Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection. Archives of Surgery, 2005, 140, 1172.	2.3	30
1209	Health aspects of radiation exposure on a simulated mission to Mars. Radioactivity in the Environment, 2005, 7, 894-901.	0.2	2
1210	Fine-Needle Aspiration Biopsy of Pancreatic Adenocarcinoma. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, , 397-406.	0.0	0
1211	3 Role of Immunohistochemical Expression of p53 and Vascular Endothelial Growth Factor in Gastric Carcinoma. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, 4, 109-115.	0.0	0
1212	ANLN Plays a Critical Role in Human Lung Carcinogenesis through the Activation of RHOA and by Involvement in the Phosphoinositide 3-Kinase/AKT Pathway. Cancer Research, 2005, 65, 11314-11325.	0.4	163
1213	Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anti-Cancer Drugs, 2005, 16, 1045-1051.	0.7	12
1214	A Bayesian Network to Assist Mammography Interpretation. , 2005, , 695-720.		4
1215	Dietary Genistein Improves Survival and Reduces Expression of Osteopontin in the Prostate of Transgenic Mice with Prostatic Adenocarcinoma (TRAMP). Journal of Nutrition, 2005, 135, 989-995.	1.3	56
1216	A Population-Based Analysis of Temporal Trends in the Incidence of Squamous Anal Canal Cancer in Relation to the HIV Epidemic. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 451-455.	0.9	147
1217	Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer*. Current Opinion in Urology, 2005, 15, 163-166.	0.9	28
1218	Papillary Phenotype Confers Improved Survival After Resection of Hilar Cholangiocarcinoma. Annals of Surgery, 2005, 241, 703-714.	2.1	172
1219	Does interstitial lung disease predispose to lung cancer?. Current Opinion in Pulmonary Medicine, 2005, 11, 431-437.	1.2	132
1220	Oropharyngeal Cancer. Topics in Clinical Nutrition, 2005, 20, 229-242.	0.2	12
1221	Developmental Life Stage and Couples?? Experiences With Prostate Cancer. Cancer Nursing, 2005, 28, 85???98.	0.7	53
1222	The Health of Older-Adult, Long-term Cancer Survivors. Cancer Nursing, 2005, 28, 415-424.	0.7	103
1223	Potential Markers of Tongue Tumor Progression Selected by cDNA Micro Array. International Journal of Immunopathology and Pharmacology, 2005, 18, 513-524.	1.0	62
1224	Growth Suppressing Effect of Garlic Compound Diallyl Disulfide on Prostate Cancer Cell Line (PC-3) in Vitro. Biological and Pharmaceutical Bulletin, 2005, 28, 740-743.	0.6	28

#	Article	IF	CITATIONS
1225	Occupation, hobbies, and acute leukemia in adults. Leukemia Research, 2005, 29, 1117-1130.	0.4	21
1226	Epidermoid anal cancer: A review of a population-based series of 308 consecutive patients treated according to prospective protocols. International Journal of Radiation Oncology Biology Physics, 2005, 61, 92-102.	0.4	53
1227	Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence. International Journal of Radiation Oncology Biology Physics, 2005, 61, 450-455.	0.4	67
1228	Prostate Cancer Screening in Australasia. Clinical Oncology, 2005, 17, 231-233.	0.6	5
1229	Endoscopic Ultrasound for Thoracic Malignancy: A Review. Current Problems in Diagnostic Radiology, 2005, 34, 106-115.	0.6	13
1230	Ensemble strategies for a medical diagnostic decision support system: A breast cancer diagnosis application. European Journal of Operational Research, 2005, 162, 532-551.	3.5	91
1231	Use of a Patient Navigator to Increase Colorectal Cancer Screening in an Urban Neighborhood Health Clinic. Journal of Urban Health, 2005, 82, 216-224.	1.8	202
1232	Human Leukocyte Antigen (HLA) Class I Defects in Head and Neck Cancer: Molecular Mechanisms and Clinical Significance. Immunologic Research, 2005, 33, 113-134.	1.3	104
1233	3D proton MR spectroscopic imaging of prostate cancer using a standard spine coil at 1.5 i $\frac{1}{2}$ T in clinical routine: a feasibility study. European Radiology, 2005, 15, 653-660.	2.3	21
1234	Targeting of therapeutic agents to bone to treat metastatic cancer. Advanced Drug Delivery Reviews, 2005, 57, 995-1010.	6.6	57
1235	Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: An autopsy study. American Journal of Obstetrics and Gynecology, 2005, 192, 48-54.	0.7	74
1236	Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. International Journal of Gynecological Cancer, 2005, 15, 618-623.	1.2	53
1237	Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. International Journal of Gynecological Cancer, 2005, 15, 836-843.	1.2	14
1238	Establishment and characterization of a human ovarian sarcomatoid carcinoma cell line BUPH:OVSC. International Journal of Gynecological Cancer, 2005, 15, 856-865.	1.2	3
1239	Reproductive preservation for treatment of stage IA endometrial cancer in a young woman: hysteroscopic resection. International Journal of Gynecological Cancer, 2005, 15, 974-978.	1.2	65
1240	Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. International Journal of Gynecological Cancer, 2005, 15, 217-223.	1.2	51
1241	Villoglandular adenocarcinoma of the cervix recurrent in an episiotomy scar: a case report in a 32-year-old female. International Journal of Gynecological Cancer, 2005, 15, 366-371.	1.2	50
1242	Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU International, 2005, 95, 1086-1090.	1.3	84

#	Article	IF	Citations
1243	Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU International, 2005, 96, 1280-1285.	1.3	67
1244	Risk of colorectal adenomas in a multiethnic Asian patient population: Race does not matter. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 51-55.	1.4	9
1245	COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology, 2005, 46, 561-568.	1.6	52
1246	StAR and progesterone producing enzymes (3beta-hydroxysteroid dehydrogenase and cholesterol) Tj ETQq1 1 0.7 and real-time PCR studies. Cancer Science, 2005, 96, 232-239.	784314 rg 1.7	BT /Overloc 15
1247	Possible antitumor activity of 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line. Cancer Science, 2005, 96, 295-302.	1.7	17
1248	Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. European Journal of Cancer Care, 2005, 14, 151-154.	0.7	15
1249	Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). British Journal of Cancer, 2005, 93, 185-189.	2.9	92
1250	Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. British Journal of Cancer, 2005, 93, 29-34.	2.9	28
1251	Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. British Journal of Cancer, 2005, 93, 647-651.	2.9	47
1252	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. British Journal of Cancer, 2005, 93, 1334-1340.	2.9	73
1253	Colon cancer secreted protein-2 (CCSP-2), a novel candidate serological marker of colon neoplasia. Oncogene, 2005, 24, 724-731.	2.6	21
1254	Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene, 2005, 24, 5897-5904.	2.6	90
1255	Molecular Prognosticators and Genomic Instability in Papillary Thyroid Cancer. Laryngoscope, 2005, 115, 1479-1485.	1.1	5
1256	Antivascular Therapy of Oral Tongue Squamous Cell Carcinoma with PTK787. Laryngoscope, 2005, 115, 2249-2255.	1.1	19
1257	Notch2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Laboratory Investigation, 2005, 85, 1003-1012.	1.7	76
1258	Securin is overexpressed in breast cancer. Modern Pathology, 2005, 18, 985-990.	2.9	43
1259	Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Modern Pathology, 2005, 18, 1232-1242.	2.9	310
1260	Clinical features of hepatic metastasis in patients with ovarian cancer. International Journal of Gynecological Cancer, 2005, 15, 26-31.	1.2	19

#	Article	IF	Citations
1261	Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genetics and Cytogenetics, 2005, 162, 10-20.	1.0	81
1262	Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cancer Genetics and Cytogenetics, 2005, 163, 144-150.	1.0	27
1263	Community perceptions of suspicious pigmented skin lesions: are they accurate when compared to general practitioners?. Cancer Detection and Prevention, 2005, 29, 267-275.	2.1	5
1264	The role of folates in squamous cell carcinoma of the head and neck. Cancer Detection and Prevention, 2005, 29, 46-53.	2.1	36
1265	Screening mammography in Minnesota cancer patients. Cancer Detection and Prevention, 2005, 29, 116-123.	2.1	2
1266	Using Tree Analysis Pattern and SELDI-TOF-MS to Discriminate Transitional Cell Carcinoma of the Bladder Cancer from Noncancer Patients. European Urology, 2005, 47, 456-462.	0.9	63
1267	Adjuvant and Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: Literature Review. European Urology, 2005, 48, 60-68.	0.9	59
1268	Does the Tertiary Gleason Pattern Influence the PSA Progression-Free Interval after Retropubic Radical Prostatectomy for Organ-Confined Prostate Cancer?. European Urology, 2005, 48, 572-576.	0.9	47
1269	Developing an Appropriate Staging System for Esophageal Carcinoma. Journal of the American College of Surgeons, 2005, 201, 884-890.	0.2	45
1270	Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2005, 1730, 96-102.	2.4	12
1271	The management of secondary osteoporosis. Best Practice and Research in Clinical Rheumatology, 2005, 19, 1021-1037.	1.4	30
1272	Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines. Breast, 2005, 14, 304-309.	0.9	16
1273	The imaging manifestations of lung cancer. Seminars in Roentgenology, 2005, 40, 98-108.	0.2	7
1274	Current Status of Prostate Screening. Apollo Medicine, 2005, 2, 234-238.	0.0	0
1275	Expression and prognostic value of tuberous sclerosis complex 2 gene product tuberin in human pancreatic cancer. Surgery, 2005, 138, 450-455.	1.0	17
1276	Genetic portrait of mild and severe lingual dysplasia. Oral Oncology, 2005, 41, 365-374.	0.8	19
1277	Antiviral activity of Cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Oral Oncology, 2005, 41, 423-428.	0.8	32
1278	Expression of G-protein inwardly rectifying potassium channels (GIRKs) in lung cancer cell lines. BMC Cancer, 2005, 5, 104.	1.1	42

#	Article	IF	CITATIONS
1279	Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer. Gynecologic Oncology, 2005, 96, 241-244.	0.6	26
1280	Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecologic Oncology, 2005, 97, 436-441.	0.6	133
1281	Quality of life in long-term cervical cancer survivors. Gynecologic Oncology, 2005, 97, 310-317.	0.6	207
1282	Gamma-knife radiosurgery for the treatment of ovarian cancer metastatic to the brain. Gynecologic Oncology, 2005, 97, 858-861.	0.6	22
1283	A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. Gynecologic Oncology, 2005, 99, 183-188.	0.6	29
1284	Genetic and epigenetic aspects of bladder cancer. Journal of Cellular Biochemistry, 2005, 95, 24-33.	1.2	19
1285	High-resolution array comparative genomic hybridization of chromosome arm 8q: Evaluation of genetic progression markers for prostate cancer. Genes Chromosomes and Cancer, 2005, 44, 438-449.	1.5	85
1286	Centrosome abnormalities in ovarian cancer. International Journal of Cancer, 2005, 113, 746-751.	2.3	46
1287	Genotype phenotype correlations in Israeli colorectal cancer patients. International Journal of Cancer, 2005, 114, 58-73.	2.3	37
1288	Detection of epithelial ovarian cancer using $1H$ -NMR-based metabonomics. International Journal of Cancer, 2005, 113 , 782 - 788 .	2.3	322
1289	Gene expression profiling identifies IL-13 receptor ?2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin. International Journal of Cancer, 2005, 114, 870-878.	2.3	29
1290	Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer, 2005, 103, 402-408.	2.0	182
1291	Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer, 2005, 103, 2042-2052.	2.0	31
1292	Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin. Cancer, 2005, 104, 740-746.	2.0	42
1293	Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. British Journal of Surgery, 2005, 92, 615-623.	0.1	196
1294	HCV-hepatocellular carcinoma: New findings and hope for effective treatment. Microscopy Research and Technique, 2005, 68, 130-148.	1.2	13
1295	Identification of differentially expressed genes in oral squamous cell carcinoma. Molecular Carcinogenesis, 2005, 42, 97-108.	1.3	91
1296	Multimodal and three-dimensional imaging of prostate cancer. Computerized Medical Imaging and Graphics, 2005, 29, 477-486.	3.5	18

#	Article	IF	CITATIONS
1297	Investigation on Semecarpus Lehyam?a Siddha medicine for breast cancer. Planta, 2005, 220, 910-918.	1.6	37
1298	A "Snapshot" of an ovarian cancer clinical practice: Evidence for viewing the malignancy as a "chronic disease". Current Oncology Reports, 2005, 7, 393-394.	1.8	1
1299	Functional imaging in head and neck cancer. Current Oncology Reports, 2005, 7, 137-144.	1.8	10
1300	The Prognostic Importance of E-cadherin and p53 Gene Expression in Transitional Bladder Carcinoma Patients. International Urology and Nephrology, 2005, 37, 485-492.	0.6	9
1301	Barriers and Facilitators of Colon Cancer Screening Among Patients At Faith-Based Neighborhood Health Centers. Journal of Community Health, 2005, 30, 55-74.	1.9	25
1302	Predictors for patterns of brain relapse and overall survival in patients with non-small cell lung cancer. Journal of Neuro-Oncology, 2005, 73, 153-161.	1.4	13
1303	Polymorphisms of the DNA Mismatch Repair Gene HMSH2 in Breast Cancer Occurence and Progression. Breast Cancer Research and Treatment, 2005, 94, 199-204.	1.1	25
1304	Colorectal cancer screening behavior and health insurance status (United States). Cancer Causes and Control, 2005, 16, 735-742.	0.8	59
1305	A New Model for Lymphatic Metastasis: Development of a Variant of the MDA-MB-468 Human Breast Cancer Cell Line that Aggressively Metastasizes to Lymph Nodes. Clinical and Experimental Metastasis, 2005, 22, 351-361.	1.7	50
1306	Formulation and Evaluation of Aerosolized Celecoxib for the Treatment of Lung Cancer. Pharmaceutical Research, 2005, 22, 427-439.	1.7	22
1307	Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate, 2005, 62, 299-306.	1.2	57
1308	Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Prostate, 2005, 62, 322-338.	1.2	21
1309	Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate, 2005, 63, 29-43.	1.2	142
1310	Evidence for downregulation of calcium signaling proteins in advanced mouse adenocarcinoma. Prostate, 2005, 64, 128-138.	1.2	10
1311	Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics, 2005, 5, 4589-4596.	1.3	263
1312	<i>Helicobacter pylori</i> infection, glandular atrophy and intestinal metaplasia in superficial gastritis, gastric erosion, erosive gastritis, gastric ulcer and early gastric cancer. World Journal of Gastroenterology, 2005, 11, 791.	1.4	109
1313	Testicular lumps. Imaging, 2005, 17, 101-112.	0.0	0
1314	Treatment of Lung Cancer Using Clinically Relevant Oral Doses of the Cyclooxygenase-2 Inhibitor Rofecoxib. Annals of Surgery, 2005, 241, 168-178.	2.1	25

#	Article	IF	CITATIONS
1315	A Case and Review of Bowel Perforation Secondary to Metastatic Lung Cancer. American Surgeon, 2005, 71, 110-116.	0.4	94
1316	Evaluation of Screening Strategies for Improving Oral Cancer Mortality: A Cochrane Systematic Review. Journal of Dental Education, 2005, 69, 255-265.	0.7	84
1319	Screening for Prostate Cancer. , 2005, , 31-40.		0
1320	Melanoma genetics and the development of rational therapeutics. Journal of Clinical Investigation, 2005, 115, 813-824.	3.9	152
1322	Expectant management: an option for localized prostate cancer. Prostate Cancer and Prostatic Diseases, 2005, 8, 311-315.	2.0	6
1323	Resistance to the Tubulin-Binding Agents in Renal Cell Carcinoma: No Mutations in the Class I \hat{I}^2 -Tubulin Gene but Changes in Tubulin Isotype Protein Expression. Clinical Cancer Research, 2005, 11, 3439-3445.	3.2	23
1324	Single-agent Gemcitabine in the Treatment of Advanced Biliary Tract Cancers: a Phase II Study. Japanese Journal of Clinical Oncology, 2005, 35, 68-73.	0.6	64
1325	Autofluorescence bronchoscopy with white light bronchoscopy compared with white light bronchoscopy alone for the detection of precancerous lesions: a European randomised controlled multicentre trial. Thorax, 2005, 60, 496-503.	2.7	184
1326	Influence of beliefs about cervical cancer etiology on pap smear use among Latina immigrants. Ethnicity and Health, 2005, 10, 3-18.	1.5	97
1327	Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies. Clinical Cancer Research, 2005, 11, 1629-1638.	3.2	21
1328	Plakophilin 3 Oncogene as Prognostic Marker and Therapeutic Target for Lung Cancer. Cancer Research, 2005, 65, 7102-7110.	0.4	110
1329	Role of Mononuclear Cells and Inflammatory Cytokines in Pancreatic Cancer-Related Cachexia. Clinical Cancer Research, 2005, 11, 5802-5808.	3.2	135
1330	Overexpression of Soluble TRAIL Induces Apoptosis in Human Lung Adenocarcinoma and Inhibits Growth of Tumor Xenografts in Nude Mice. Cancer Research, 2005, 65, 1687-1692.	0.4	116
1331	Identifying Good Prognosis Group of Breast Cancer Patients with 1–3 Positive Axillary Nodes for Adjuvant Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) Chemotherapy. Japanese Journal of Clinical Oncology, 2005, 35, 514-519.	0.6	8
1332	Chemopreventive Effects of Deguelin, a Novel Akt Inhibitor, on Tobacco-Induced Lung Tumorigenesis. Journal of the National Cancer Institute, 2005, 97, 1695-1699.	3.0	145
1333	A Novel Human tRNA-Dihydrouridine Synthase Involved in Pulmonary Carcinogenesis. Cancer Research, 2005, 65, 5638-5646.	0.4	113
1334	Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Molecular Cancer Therapeutics, 2005, 4, 1505-1514.	1.9	133
1335	Targeted for Destruction: The Molecular Basis for Development of Novel Therapeutic Strategies in Renal Cell Cancer. Journal of Clinical Oncology, 2005, 23, 410-412.	0.8	7

#	Article	IF	CITATIONS
1336	Imaging of the Patient with Non–Small Cell Lung Cancer. Radiology, 2005, 237, 803-818.	3.6	47
1337	Proteomic Profiling of Pancreatic Cancer for Biomarker Discovery. Molecular and Cellular Proteomics, 2005, 4, 523-533.	2.5	128
1338	Vascular Endothelial Growth Factor Contributes to Prostate Cancer–Mediated Osteoblastic Activity. Cancer Research, 2005, 65, 10921-10929.	0.4	91
1339	Five Loci, SLT1 to SLT5, Controlling the Susceptibility to Spontaneously Occurring Lung Cancer in Mice. Cancer Research, 2005, 65, 8158-8165.	0.4	9
1340	Oxygen-enhanced MR Imaging: Correlation with Postsurgical Lung Function in Patients with Lung Cancer. Radiology, 2005, 236, 704-711.	3.6	71
1341	Differential Effects of Gonadotropin-Releasing Hormone (GnRH)-I and GnRH-II on Prostate Cancer Cell Signaling and Death. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4287-4298.	1.8	28
1342	Pharmacokinetics, Biodistribution, and Radioimmunotherapy with Monoclonal Antibody 776.1 in a Murine Model of Human Ovarian Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 589-602.	0.7	8
1343	WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15611-15616.	3.3	128
1344	Three-Dimensional CT Virtual Endoscopy in the Detection of Simulated Tumors in a Novel Phantom Bladder and Ureter Model. Journal of Endourology, 2005, 19, 188-192.	1.1	11
1345	Selecting Differentially Expressed Proteomic Markers from Mass Spectrometry Data. , 2005, 2005, 4775-8.		0
1346	Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial. Journal of Clinical Oncology, 2005, 23, 2332-2338.	0.8	297
1347	Targeted therapy for epithelial ovarian cancer. Expert Opinion on Therapeutic Targets, 2005, 9, 501-513.	1.5	6
1348	Loss of New Chemokine CXCL14 in Tumor Tissue Is Associated with Low Infiltration by Dendritic Cells (DC), while Restoration of Human CXCL14 Expression in Tumor Cells Causes Attraction of DC Both In Vitro and In Vivo. Journal of Immunology, 2005, 174, 5490-5498.	0.4	198
1349	Sodium Stibogluconate Interacts with IL-2 in Anti-Renca Tumor Action via a T Cell-Dependent Mechanism in Connection with Induction of Tumor-Infiltrating Macrophages. Journal of Immunology, 2005, 175, 7003-7008.	0.4	19
1350	Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture. Carcinogenesis, 2005, 26, 951-957.	1.3	30
1351	The αvβ6 integrin as a novel molecular target for colorectal cancer. Future Oncology, 2005, 1, 821-828.	1.1	22
1352	Status of Surgical Margins and Prognosis in Adult Soft Tissue Sarcomas of the Extremities: A Series of Patients Treated at a Single Institution. Journal of Clinical Oncology, 2005, 23, 96-104.	0.8	248
1353	Loss of RUNX3 Expression Significantly Affects the Clinical Outcome of Gastric Cancer Patients and Its Restoration Causes Drastic Suppression of Tumor Growth and Metastasis. Cancer Research, 2005, 65, 4809-4816.	0.4	92

#	Article	IF	CITATIONS
1354	5-Lipoxygenase, a Marker for Early Pancreatic Intraepithelial Neoplastic Lesions. Cancer Research, 2005, 65, 6011-6016.	0.4	77
1355	Gallbladder Cancer, a Different Disease that Needs Individual Trials. Journal of Clinical Oncology, 2005, 23, 7753-7754.	0.8	21
1356	Histologic Evaluation of Bronchial Squamous Lesions: Any Role in Lung Cancer Risk Assessment?. Clinical Cancer Research, 2005, 11, 1358-1360.	3.2	13
1357	Molecular Pathology of Non-Small-Cell Lung Cancer. Respiration, 2005, 72, 313-330.	1.2	51
1358	Molecular Profiling of Tumor Progression in Head and Neck Cancer. JAMA Otolaryngology, 2005, 131, 10.	1.5	79
1359	Therapy Tolerance in Selected Patients With Androgen-Independent Prostate Cancer Following Strontium-89 Combined With Chemotherapy. Journal of Clinical Oncology, 2005, 23, 7904-7910.	0.8	63
1360	2-(18F)-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Detects Clinical Relevant Adenomas of the Colon: A Prospective Study. Journal of Clinical Oncology, 2005, 23, 3713-3717.	0.8	92
1361	Expression Profile of Cancer-Testis Genes in 121 Human Colorectal Cancer Tissue and Adjacent Normal Tissue. Clinical Cancer Research, 2005, 11, 1809-1814.	3.2	85
1362	Comparative Effects of Bicalutamide (Casodex) versus Orchidectomy on Bone Mineral Density, Bone Remodelling, and Bone Biomechanics in Healthy Rats. Urologia Internationalis, 2005, 74, 301-307.	0.6	6
1363	Adjuvant 5-FU-Based Chemoradiotherapy for Patients Undergoing R-1/R-2 Resections for Pancreatic Cancer. Digestive Surgery, 2005, 22, 321-328.	0.6	26
1364	The links between axin and carcinogenesis. Journal of Clinical Pathology, 2005, 58, 225-236.	1.0	203
1365	Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma. Clinical Cancer Research, 2005, 11, 4818-4826.	3.2	73
1366	Follicular Cell-Derived Thyroid Cancer in Children. Hormone Research in Paediatrics, 2005, 63, 145-151.	0.8	31
1367	Sentinel node biopsy is reliable in early-stage cervical cancer but not in locally advanced disease. Annals of Oncology, 2005, 16, 1237-1242.	0.6	37
1368	Apigenin inhibits VEGF and HIFâ€1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB Journal, 2005, 19, 342-353.	0.2	285
1369	The Role of Whole-Body Bone Scanning and Clinical Factors in Detecting Bone Metastases in Patients With Non-small Cell Lung Cancer. Chest, 2005, 127, 449-454.	0.4	36
1370	Continuous Infusion of Oxaliplatin plus Chronomodulated Capecitabine in 5-Fluorouracil- and Irinotecan-Resistant Advanced Colorectal Cancer Patients. Oncology, 2005, 69, 27-34.	0.9	24
1371	Photodynamic Therapy for Cervical Intraepithelial Neoplasia. Oncology, 2005, 69, 110-116.	0.9	61

#	Article	IF	CITATIONS
1372	Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis. Experimental Cell Research, 2005, 304, 244-255.	1.2	55
1373	Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients. Journal of Clinical Oncology, 2005, 23, 5007-5018.	0.8	367
1374	The HGF Receptor c-Met Is Overexpressed in Esophageal Adenocarcinoma. Neoplasia, 2005, 7, 75-84.	2.3	54
1375	Bioinformatics in Otolaryngology. Otolaryngologic Clinics of North America, 2005, 38, 321-332.	0.5	1
1377	C-REACTIVE PROTEIN: A BIOMARKER OF SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH SUBCUTANEOUS INTERLEUKIN-2 BASED IMMUNOTHERAPY. Journal of Urology, 2005, 173, 52-55.	0.2	101
1378	Neoadjuvant and Adjuvant Therapy for Extremity Soft Tissue Sarcomas. Hematology/Oncology Clinics of North America, 2005, 19, 489-500.	0.9	17
1379	Squamous cell carcinoma of the oropharynx and hypopharynx. Otolaryngologic Clinics of North America, 2005, 38, 59-74.	0.5	42
1380	Diagnostic radiology: Major weapon in patient care or weapon of mass destruction?. Journal of the American College of Radiology, 2005, 2, 301-303.	0.9	4
1381	Variability in Flexible Sigmoidoscopy Performance Among Examiners in a Screening Trial. Clinical Gastroenterology and Hepatology, 2005, 3, 792.e1-792.e.	2.4	37
1382	Percutaneous Ablation of Renal Malignancies. Journal of Vascular and Interventional Radiology, 2005, 16, P210-P212.	0.2	0
1383	The characteristics of disseminated tumor cells in pancreatic cancer: A black box needs to be explored. Pancreatology, 2005, 5, 316-324.	0.5	19
1384	4-YEAR PROSTATE SPECIFIC ANTIGEN PROGRESSION AND DIAGNOSIS OF PROSTATE CANCER IN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER, SECTION ROTTERDAM. Journal of Urology, 2005, 174, 489-494.	0.2	47
1385	Dutasteride: a novel dual inhibitor of $5\hat{l}_{\pm}$ -reductase for benign prostatic hyperplasia. Expert Opinion on Pharmacotherapy, 2005, 6, 311-317.	0.9	21
1386	System for Live Virtual-Endoscopic Guidance of Bronchoscopy., 0, , .		9
1387	Mortality Risk From Squamous Cell Skin Cancer. Journal of Clinical Oncology, 2005, 23, 759-765.	0.8	384
1388	Therapeutic potential of Kupffer cells in prevention of liver metastases outgrowth. Immunobiology, 2005, 210, 259-265.	0.8	31
1389	Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. Journal of the American Academy of Dermatology, 2005, 53, 1067-1071.	0.6	131
1390	Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge. Journal of Clinical Neuroscience, 2005, 12, 1-5.	0.8	38

#	Article	IF	CITATIONS
1391	Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. Journal of Steroid Biochemistry and Molecular Biology, 2005, 94, 111-121.	1.2	49
1392	Enzymes as modulators in malignant transformation. Journal of Steroid Biochemistry and Molecular Biology, 2005, 93, 277-283.	1.2	63
1393	Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells, Molecules, and Diseases, 2005, 34, 197-200.	0.6	88
1394	Association of CK19 mRNA detection of occult cancer cells in mediastinal lymph nodes in non-small cell lung carcinoma and high risk of early recurrence. European Journal of Cancer, 2005, 41, 306-312.	1.3	35
1395	Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): A natural disease model provides insights into viral carcinogenesis. European Journal of Cancer, 2005, 41, 807-815.	1.3	88
1396	Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone – finally an effective chemotherapy. European Journal of Cancer, 2005, 41, 502-507.	1.3	22
1397	Dynamic optical breast imaging: A new technique to visualise breast vessels: Comparison with breast MRI and preliminary results. European Journal of Radiology, 2005, 54, 72-79.	1.2	21
1398	Inhibition of osteopontin expression and function in oral cancer cell lines by antisense oligonucleotides. Cancer Letters, 2005, 217, 87-95.	3.2	25
1399	Polysaccharides isolated from Phellinus gilvus inhibit melanoma growth in mice. Cancer Letters, 2005, 218, 43-52.	3.2	51
1400	Experimental model of pulmonary metastasis treatment with IFNî±. Cancer Letters, 2005, 225, 75-83.	3.2	12
1401	Diallyl sulfide inhibits diethylstilbesterol-induced DNA adducts in the breast of female ACI rats. Food and Chemical Toxicology, 2005, 43, 1323-1331.	1.8	16
1402	Analysis of Orthologous Gene Expression between Human Pulmonary Adenocarcinoma and a Carcinogen-Induced Murine Model. American Journal of Pathology, 2005, 167, 1763-1775.	1.9	269
1403	Factors associated with colon cancer screening: the role of patient factors and physician counseling. Preventive Medicine, 2005, 41, 23-29.	1.6	279
1404	An intervention for parents to promote preschool children's sun protection: Effects of Sun Protection is Fun!. Preventive Medicine, 2005, 41, 357-366.	1.6	25
1405	FDG-PET in the detection of early pancreatic cancer in a BOP hamster model. Nuclear Medicine and Biology, 2005, 32, 445-450.	0.3	8
1406	Targeted Intra-Arterial Chemoradiation for Advanced Tonsil Cancer. Otolaryngology - Head and Neck Surgery, 2005, 133, 882-887.	1.1	4
1407	Integrin-Mediated Resistance to Chemotherapy-Induced Apoptosis in Cancer Cells., 2005,, 323-333.		0
1408	Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Molecular Cancer, 2005, 4, 26.	7.9	25

#	ARTICLE	IF	CITATIONS
1409	Increased Expression of Valosin-Containing Protein (p97) Is Correlated With Disease Recurrence in Follicular Thyroid Cancer. Annals of Surgical Oncology, 2005, 12, 925-934.	0.7	44
1410	Gene expression signatures for colorectal cancer microsatellite status and HNPCC. British Journal of Cancer, 2005, 92, 2240-2248.	2.9	70
1411	CT screening for lung cancer. Seminars in Roentgenology, 2005, 40, 193-196.	0.2	5
1412	Expression of the p16INK4a gene product, methylation of the p16INK4a promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer, 2005, 48, 299-306.	0.9	56
1413	Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. Lung Cancer, 2005, 49, 145-154.	0.9	110
1414	LY293111 Improves Efficacy of Gemcitabine Therapy on Pancreatic Cancer in a Fluorescent Orthotopic Model in Athymic Mice. Neoplasia, 2005, 7, 417-425.	2.3	44
1415	Radiofrequency Ablation for Tumor-Related Massive Hematuria. Journal of Vascular and Interventional Radiology, 2005, 16, 417-421.	0.2	24
1416	Radiofrequency Ablation of Renal Cell Carcinoma: Part 1, Indications, Results, and Role in Patient Management over a 6-Year Period and Ablation of 100 Tumors. American Journal of Roentgenology, 2005, 185, 64-71.	1.0	561
1417	Docetaxel in the treatment of breast cancer: current experience and future prospects. Expert Review of Anticancer Therapy, 2005, 5, 613-633.	1.1	11
1418	Management Strategies for Partially Platinum-Sensitive Ovarian Cancer. American Journal of Cancer, 2006, 5, 341-354.	0.4	5
1419	Inhibition of c-Met as a Therapeutic Strategy for Esophageal Adenocarcinoma. Neoplasia, 2006, 8, 949-955.	2.3	31
1420	Palliation and Supportive Care in Radiation Medicine. Hematology/Oncology Clinics of North America, 2006, 20, 187-211.	0.9	16
1421	Impact of FDG-PET/MRI Image Fusion on the Detection of Pancreatic Cancer. Pancreatology, 2006, 6, 512-519.	0.5	46
1422	Gaucher disease and multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1365-1368.	0.6	35
1423	Meta-Analysis and Meta-Review of Thyroid Cancer Gene Expression Profiling Studies Identifies Important Diagnostic Biomarkers. Journal of Clinical Oncology, 2006, 24, 5043-5051.	0.8	279
1425	Prostate Cancer Prevention and Finasteride. Journal of Urology, 2006, 176, 2010-2013.	0.2	18
1426	Neuro-Fuzzy Modeling: An Accurate and Interpretable Method for Predicting Bladder Cancer Progression. Journal of Urology, 2006, 175, 474-479.	0.2	32
1427	Computerized Tomography Guided Percutaneous Renal Cryoablation With the Patient Under Conscious Sedation: Initial Clinical Experience. Journal of Urology, 2006, 175, 447-453.	0.2	141

#	Article	IF	CITATIONS
1428	Validation of hysteroscopic view in cases of endometrial hyperplasia and cancer in patients with abnormal uterine bleeding. Journal of Minimally Invasive Gynecology, 2006, 13, 409-412.	0.3	41
1429	Ad-IRF-1 Induces Apoptosis in Esophageal Adenocarcinoma. Neoplasia, 2006, 8, 31-37.	2.3	9
1430	Colonoscopy Issues Related to Women. Gastrointestinal Endoscopy Clinics of North America, 2006, 16, 153-163.	0.6	15
1431	Discharge Practice Patterns Following Cystectomy for Bladder Cancer: Evidence for the Shifting of the Burden of Care. Journal of Urology, 2006, 176, 2612-2618.	0.2	42
1432	Age Stratified Functional Outcomes After Laparoscopic Radical Prostatectomy. Journal of Urology, 2006, 176, 2448-2452.	0.2	51
1433	Prognostic factors in prostate cancer. Diagnostic Pathology, 2006, 1, 4.	0.9	77
1434	Diffuse Large B-Cell NHL. , 2006, 131, 121-140.		6
1435	BL22 and lymphoid malignancies. Best Practice and Research in Clinical Haematology, 2006, 19, 685-699.	0.7	16
1436	Craniofacial Tissue Engineering by Stem Cells. Journal of Dental Research, 2006, 85, 966-979.	2.5	308
1437	Serum Androgen Levels in Black, Hispanic, and White Men. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4326-4334.	1.8	117
1438	Understanding and Interpreting MRI of the Genitourinary Tract. Urologic Clinics of North America, 2006, 33, 301-317.	0.8	11
1439	Abdominal positron-emission tomography lesions with increased standardized uptake values correlate with intraoperative findings. American Journal of Surgery, 2006, 191, 39-44.	0.9	3
1440	Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm. American Journal of Surgery, 2006, 191, 593-597.	0.9	26
1442	Fertility preservation in female cancer patients: current developments and future directions. Fertility and Sterility, 2006, 85, 1-11.	0.5	174
1443	The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 1217-1225.	1.1	73
1444	Analysis of a novel human gene, LOC92912, over-expressed in hypopharyngeal tumours. Biochemical and Biophysical Research Communications, 2006, 339, 422-429.	1.0	15
1445	External Qi of Yan Xin Qigong differentially regulates the Akt and extracellular signal-regulated kinase pathways and is cytotoxic to cancer cells but not to normal cells. International Journal of Biochemistry and Cell Biology, 2006, 38, 2102-2113.	1.2	35
1446	Differential metastasis-associated gene analysis of prostate carcinoma cells derived from primary tumor and spontaneous lymphatic metastasis in nude mice with orthotopic implantation of PC-3M cells. Cancer Letters, 2006, 233, 79-88.	3.2	18

#	Article	IF	Citations
1447	Overexpression and diffuse expression pattern of IQGAP1 at invasion fronts are independent prognostic parameters in ovarian carcinomas. Cancer Letters, 2006, 243, 120-127.	3.2	62
1448	Expression profiling and individualisation of treatment for ovarian cancer. Current Opinion in Pharmacology, 2006, 6, 345-349.	1.7	18
1449	Novel therapeutic agents in ovarian cancer. European Journal of Surgical Oncology, 2006, 32, 875-886.	0.5	53
1450	Effect of selenium-enriched malt on hepatocarcinogenesis, paraneoplastic syndrome and the hormones regulating blood glucose in rats treated by diethylnitrosamine. Life Sciences, 2006, 78, 2315-2321.	2.0	16
1451	Control of cell proliferation by steroids: The role of 17HSDs. Molecular and Cellular Endocrinology, 2006, 248, 141-148.	1.6	49
1452	Correlation between reduction of syndecan-1 expression and clinico-pathological parameters in squamous cell carcinoma of tongue. International Journal of Oral and Maxillofacial Surgery, 2006, 35, 252-257.	0.7	14
1453	Erectile dysfunction andÂradiation therapy forÂprostate cancer. Sexologies, 2006, 15, 116-120.	0.5	5
1454	Noninvasive monitoring of colonic carcinogenesis: feasibility of [18F]FDG-PET in the azoxymethane model. Nuclear Medicine and Biology, 2006, 33, 245-248.	0.3	20
1455	Expression of p16INK4A, p53, and Rb proteins are independent from the presence of human papillomavirus genes in oral squamous cell carcinoma. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2006, 102, 344-352.	1.6	65
1456	Prognostic factors in lymph node-positive prostate cancer. Urology, 2006, 67, 1016-1021.	0.5	41
1457	Cardiovascular effects of androgen depletion and replacement therapy. Urology, 2006, 67, 1126-1132.	0.5	8
1458	Nucleic acid-based marker approaches to urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 510-527.	0.8	17
1459	Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World Journal of Gastroenterology, 2006, 12, 3911.	1.4	47
1460	Comorbidities and the Risk of Late-Stage Prostate Cancer. Scientific World Journal, The, 2006, 6, 2460-2470.	0.8	12
1461	The Pathological Features of Ovarian Neoplasia. , 0, , 20-46.		1
1462	Screening for Lung Cancer., 0,, 46-56.		0
1463	Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood, 2006, 107, 1315-1324.	0.6	77
1464	Small Bowel Perforation Secondary to Metastatic Lung Cancer: A Case Report with Literature Review. Visceral Medicine, 2006, 22, 92-94.	0.5	2

#	Article	IF	CITATIONS
1466	Genetic Analysis of Oral Squamous Cell Carcinoma by cDNA Microarrays Focused Apoptotic Pathway. International Journal of Immunopathology and Pharmacology, 2006, 19, 675-682.	1.0	19
1467	Caution Note on the Use of the Internal Mammary Artery in Breast Reconstruction. Plastic and Reconstructive Surgery, 2006, 117, 1653-1654.	0.7	24
1468	Taxane Therapy for Early Stage Breast Cancer. Women's Health, 2006, 2, 99-114.	0.7	2
1469	Selective Neck Dissection for Node-Positive Necks in Patients With Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology, 2006, 132, 79.	1.5	23
1470	Challenges of Recruitment of Breast Cancer Survivors to a Randomized Clinical Trial for Osteoporosis Prevention. Cancer Nursing, 2006, 29, 21-31.	0.7	36
1471	Change in Need for Psychosocial Support for Women with Early Stage Breast Cancer. Journal of Psychosocial Oncology, 2005, 23, 65-77.	0.6	22
1472	Phase I Study of Pegylated Liposomal Doxorubicin in Combination With Ifosfamide in Pretreated Ovarian Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 399-404.	0.6	5
1473	Preoperative FDG-PET for Axillary Metastases in Patients With Breast Cancer. Archives of Surgery, 2006, 141, 783.	2.3	39
1474	The current status of positron-emission tomography scanning in the evaluation and follow-up of patients with head and neck cancer. Current Opinion in Otolaryngology and Head and Neck Surgery, 2006, 14, 73-81.	0.8	16
1475	Cost-Effectiveness of Preventive Strategies for Women with a <i>BRCA1</i> or a <i>BRCA2</i> Mutation. Annals of Internal Medicine, 2006, 144, 397.	2.0	144
1476	Combined Treatment of Ionizing Radiation With Genistein on Cervical Cancer HeLa Cells. Journal of Pharmacological Sciences, 2006, 102, 129-135.	1.1	30
1477	Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided High Dose Rate brachytherapy boost. Radiation Oncology, 2006, 1, 28.	1.2	9
1478	Coping among older-adult, long-term cancer survivors. Psycho-Oncology, 2006, 15, 143-159.	1.0	109
1479	Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate, 2006, 66, 1311-1318.	1.2	225
1480	Quantitative proteomic profiling of pancreatic cancer juice. Proteomics, 2006, 6, 3871-3879.	1.3	118
1481	The prognostic impact of the time interval to recurrence for the mortality in recurrent colorectal cancer. Colorectal Disease, 2006, 8, 696-703.	0.7	35
1482	Endoglin (CD105) expression in human renal cell carcinoma. BJU International, 2006, 97, 706-710.	1.3	49
1483	Intercellular Communication and Human Prostate Carcinogenesis. Annals of the New York Academy of Sciences, 2002, 963, 156-168.	1.8	23

#	Article	IF	CITATIONS
1484	High Recurrence Rates of Squamous Cell Carcinoma after Mohs' Surgery in Patients with Chronic Lymphocytic Leukemia. Dermatologic Surgery, 2005, 31, 38-42.	0.4	45
1485	Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer. International Journal of Gynecological Cancer, 2006, 16, 507-514.	1.2	9
1486	Time course and outcome of central recurrence after radiation therapy for carcinoma of the cervix. International Journal of Gynecological Cancer, 2006, 16, 1106-1111.	1.2	28
1487	Clinicopathologic study of the putative precursor lesions of epithelial ovarian cancer in low-risk women. International Journal of Gynecological Cancer, 2006, 16, 501-506.	1.2	14
1488	A rare case of choroidal metastasis presented after conservative management of endometrial cancer. International Journal of Gynecological Cancer, 2006, 16, 2044-2048.	1,2	33
1489	Black-white differences in risk perceptions of breast cancer survival and screening mammography benefit. Journal of General Internal Medicine, 2006, 21, 371-377.	1.3	28
1490	Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. Journal of Oral Pathology and Medicine, 2007, 36, 30-34.	1.4	27
1491	Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Science, 2006, 97, 1366-1373.	1.7	85
1492	Candidate lung tumor susceptibility genes identified through whole-genome association analyses in inbred mice. Nature Genetics, 2006, 38, 888-895.	9.4	75
1493	Identification of serum biomarkers for colon cancer by proteomic analysis. British Journal of Cancer, 2006, 94, 1898-1905.	2.9	198
1494	Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Modern Pathology, 2006, 19, 1339-1343.	2.9	61
1495	Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Modern Pathology, 2006, 19, 1631-1637.	2.9	116
1496	Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplantation, 2006, 37, 731-737.	1.3	100
1497	Transcriptional targeting of adenovirus vectors with the squamous cell carcinoma-specific antigen-2 promoter for selective apoptosis induction in lung cancer. Cancer Gene Therapy, 2006, 13, 856-863.	2.2	10
1498	Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene, 2006, 25, 1984-1988.	2.6	88
1499	Labeling tumor cells with fluorescent nanocrystal–aptamer bioconjugates. Biosensors and Bioelectronics, 2006, 21, 1859-1866.	5.3	146
1500	Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer. Bioorganic and Medicinal Chemistry, 2006, 14, 6525-6538.	1.4	29
1501	The inherited genetics of pancreatic cancer and prospects for secondary screening. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 253-283.	1.0	43

#	Article	IF	CITATIONS
1502	Quantitative PSA mRNA determination in blood: A biochemical tool for scoring localized prostate cancer. Clinical Biochemistry, 2006, 39, 333-338.	0.8	9
1503	EF5 binding and clinical outcome in human soft tissue sarcomas. International Journal of Radiation Oncology Biology Physics, 2006, 64, 922-927.	0.4	55
1504	Molecular signatures associated with clinical outcome in patients with high-risk head-and-neck squamous cell carcinoma treated by surgery and radiation. International Journal of Radiation Oncology Biology Physics, 2006, 64, 670-677.	0.4	36
1505	Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: A pilot study. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1008-1013.	0.4	30
1506	Prognostic Effect of Re-Excision in Adult Soft Tissue Sarcoma of the Extremity. Annals of Surgical Oncology, 2006, 13, 110-117.	0.7	141
1507	Hemithyroidectomy: The Optimal Initial Surgical Approach for Individuals Undergoing Surgery for a Cytological Diagnosis of Follicular Neoplasm. Annals of Surgical Oncology, 2006, 13, 425-432.	0.7	32
1508	Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. American Journal of Obstetrics and Gynecology, 2006, 195, 979-986.	0.7	60
1509	The Relationship of Religiosity and Spirituality to Quality of Life Among Cancer Patients. Journal of Clinical Psychology in Medical Settings, 2006, 13, 29-35.	0.8	41
1510	Design of tele-educational system for interpreting dental tumor images. Journal of Medical Systems, 2006, 30, 351-362.	2.2	0
1511	Predictors of use of health care services among elderly lung cancer patients: the first year after diagnosis. Supportive Care in Cancer, 2006, 14, 243-250.	1.0	23
1512	Colorectal cancer in a population with endemic Schistosoma mansoni: is this an at-risk population?. International Journal of Colorectal Disease, 2006, 22, 175-181.	1.0	48
1513	The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2006, 132, 399-407.	1.2	70
1514	Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). Journal of Cancer Research and Clinical	1.2	175
1515	Oncology, 2006, 132, 205-212. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer, 2006, 9, 129-135.	2.7	28
1516	The promoter hypermethylation of DAPK gene and p16 gene in sera from Chinese non-small cell lung cancer patients. Chinese-German Journal of Clinical Oncology, 2006, 5, 184-188.	0.1	2
1517	Deregulation of the p16-cyclin D1/cyclin-dependent kinase 4–retinoblastoma pathway involved in the rat bladder carcinogenesis induced by terephthalic acid-calculi. Urological Research, 2006, 34, 321-328.	1.5	7
1518	Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?. Cancer Immunology, Immunotherapy, 2006, 55, 891-899.	2.0	82
1519	Immunohistochemical Detection of Apoptotic Proteins, p53/Bax and JNK/FasL Cascade, in the Lung of Rats Exposed to Cigarette Smoke. Archives of Toxicology, 2006, 80, 328-336.	1.9	39

#	Article	IF	CITATIONS
1520	Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magnetic Resonance Imaging, 2006, 24, 541-548.	1.0	65
1521	An automatic system to discriminate malignant from benign massive lesions on mammograms. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2006, 569, 596-600.	0.7	15
1523	Regulation of the p14ARF-Mdm2-p53 pathway: An overview in breast cancer. Experimental and Molecular Pathology, 2006, 81, 115-122.	0.9	79
1524	Abraxane in the treatment of ovarian cancer: The absence of hypersensitivity reactions. Gynecologic Oncology, 2006, 100, 437-438.	0.6	77
1525	Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecologic Oncology, 2006, 101, 12-17.	0.6	73
1526	Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts. Gynecologic Oncology, 2006, 102, 462-467.	0.6	11
1527	Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience. Gynecologic Oncology, 2006, 102, 285-291.	0.6	123
1528	Ovarian cancer metastatic to the breast. Gynecologic Oncology, 2006, 102, 386-390.	0.6	17
1529	Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecologic Oncology, 2006, 103, 145-150.	0.6	31
1530	Primary care patients' understanding of colorectal cancer screening. Cancer Detection and Prevention, 2006, 30, 67-74.	2.1	32
1531	Real-time detection of mesothelin in pancreatic cancer cell line supernatant using an acoustic wave immunosensor. Cancer Detection and Prevention, 2006, 30, 180-187.	2.1	31
1532	Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cellular Signalling, 2006, 18, 2262-2271.	1.7	193
1533	Photodynamic therapy down-regulates the invasion promoting factors in human oral cancer. Archives of Oral Biology, 2006, 51, 1104-1111.	0.8	37
1534	Molecular Biology of Colorectal Cancer: New Targets. Seminars in Oncology, 2006, 33, 14-23.	0.8	13
1535	The Angiogenic Switch Molecule, Secreted FGF-Binding Protein, an Indicator of Early Stages of Pancreatic and Colorectal Adenocarcinoma. Seminars in Oncology, 2006, 33, 50-56.	0.8	172
1536	Identification of molecular targets for immunotherapy of patients with head and neck squamous cell carcinoma. Oral Oncology, 2006, 42, 306-316.	0.8	32
1537	Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC Cancer, 2006, 6, 134.	1.1	34
1538	Microarray-based identification and RT-PCR test screening for epithelial-specific mRNAs in peripheral blood of patients with colon cancer. BMC Cancer, 2006, 6, 250.	1.1	23

#	Article	IF	Citations
1539	Prognostic Value of Apoptosis-Associated Speck-like Protein Containing a CARD Gene Promoter Methylation in Resectable Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2006, 8, 62-65.	1,1	15
1540	Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathology International, 2006, 56, 62-70.	0.6	86
1541	A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer, 2006, 106, 1339-1346.	2.0	100
1542	Genetic alterations in urothelial bladder carcinoma. Cancer, 2006, 106, 1205-1216.	2.0	72
1543	Lysophosphatidic acid acyltransferase- \hat{l}^2 (LPAAT- \hat{l}^2) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival. Cancer, 2006, 107, 1511-1519.	2.0	38
1544	Acute myeloid leukemia: Epidemiology and etiology. Cancer, 2006, 107, 2099-2107.	2.0	500
1545	In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. International Journal of Cancer, 2006, 118, 2337-2343.	2.3	108
1546	In vivoimaging of tumor response to therapy using a dual-modality imaging strategy. International Journal of Cancer, 2006, 118, 2796-2802.	2.3	117
1547	4-HPR modulates gene expression in ovarian cells. International Journal of Cancer, 2006, 119, 1005-1013.	2.3	6
1548	ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. International Journal of Cancer, 2006, 119, 269-274.	2.3	54
1549	Expression profiling correlates with treatment response in women with advanced serous epithelial ovarian cancer. International Journal of Cancer, 2006, 119, 875-883.	2.3	24
1550	Fluorescence staining of human ovarian cancer tissue following application of 5-aminolevulinic acid: Fluorescence microscopy studies. Lasers in Surgery and Medicine, 2006, 38, 549-554.	1.1	28
1551	Genistein affects androgen-responsive genes through both androgen- and estrogen-induced signaling pathways. Molecular Carcinogenesis, 2006, 45, 18-25.	1.3	25
1552	DNA Image Cytometry Is a Useful Adjunct Tool in the Prediction of Disease Outcome in Patients with Stage II and Stage III Colorectal Cancer. Oncology, 2006, 70, 427-437.	0.9	5
1553	Hypnosis to Manage Anxiety and Pain Associated with Colonoscopy for Colorectal Cancer Screening:Case Studies and Possible Benefits. International Journal of Clinical and Experimental Hypnosis, 2006, 54, 416-431.	1.1	45
1554	The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer. Cancer Research, 2006, 66, 9408-9419.	0.4	113
1555	Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas. Carcinogenesis, 2006, 27, 2497-2510.	1.3	37
1556	Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93. Journal of Clinical Oncology, 2006, 24, 337-344.	0.8	328

#	Article	IF	CITATIONS
1557	Identification of kaempferol as an inhibitor of cigarette smoke-induced activation of the aryl hydrocarbon receptor and cell transformation. Carcinogenesis, 2006, 28, 639-647.	1.3	51
1558	Treatment Issues in Clear Cell Carcinoma of the Ovary: A Different Entity?. Oncologist, 2006, 11, 1089-1094.	1.9	84
1559	Posttraumatic Stress and Related Impairment in Survivors of Childhood Cancer in Early Adulthood Compared to Healthy Peers. Journal of Pediatric Psychology, 2006, 31, 356-366.	1.1	118
1560	Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. Journal of Medical Genetics, 2006, 44, 166-172.	1.5	47
1561	Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly. Journal of Clinical Oncology, 2006, 24, 2368-2375.	0.8	150
1562	PC Cell–Derived Growth Factor Confers Resistance to Dexamethasone and Promotes Tumorigenesis in Human Multiple Myeloma. Clinical Cancer Research, 2006, 12, 49-56.	3.2	37
1563	p53 Transgenic Mice Are Highly Susceptible to 4-Nitroquinoline-1-Oxide-Induced Oral Cancer. Molecular Cancer Research, 2006, 4, 401-410.	1.5	27
1564	Development of engineered antibodies specific for the $M\tilde{A}^{1/4}$ llerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Molecular Cancer Therapeutics, 2006, 5, 2096-2105.	1.9	24
1565	Preclinical Pharmacology of a Nonsteroidal Ligand for Androgen Receptor-Mediated Imaging of Prostate Cancer. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 402-408.	1.3	8
1566	Expression of a Fibroblast Growth Factor–Binding Protein during the Development of Adenocarcinoma of the Pancreas and Colon. Cancer Research, 2006, 66, 1191-1198.	0.4	42
1567	Brain Metastases from Epithelial Ovarian Cancer: A Review of the Literature. Oncologist, 2006, 11, 252-260.	1.9	66
1568	Prognostic Significance of p53 and Ki-67 Antigen Expression in Surgically Treated Non–Small Cell Lung Cancer. American Journal of Clinical Pathology, 2006, 125, 425-431.	0.4	22
1569	Family History, Perceived Risk, and Prostate Cancer Screening among African American Men. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2167-2173.	1.1	74
1570	Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions. Journal of Clinical Pathology, 2006, 59, 1171-1174.	1.0	15
1571	A Multiplex Tissue Immunoblotting Assay for Proteomic Profiling: A Pilot Study of the Normal to Tumor Transition of Esophageal Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1403-1408.	1.1	38
1572	The Epidemiology of Basal Cell and Squamous Cell Carcinoma. , 2006, , 1-9.		6
1573	Activation of CDCA1-KNTC2, Members of Centromere Protein Complex, Involved in Pulmonary Carcinogenesis. Cancer Research, 2006, 66, 10339-10348.	0.4	127
1574	Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis. Clinical Cancer Research, 2006, 12, 1897-1905.	3.2	85

#	Article	IF	CITATIONS
1575	Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4+ T Cells. Clinical Cancer Research, 2006, 12, 398-404.	3.2	32
1576	Quantitation of Promoter Methylation of Multiple Genes in Urine DNA and Bladder Cancer Detection. Journal of the National Cancer Institute, 2006, 98, 996-1004.	3.0	237
1577	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 2006, 17, 1120-1127.	0.6	93
1578	Real-time Image-Based Guidance Method for Lung-Cancer Assessment. , 0, , .		11
1579	Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3914-3919.	3.3	94
1580	Altered Expression of \hat{l}^2 -catenin, E-cadherin, Cycloxygenase-2, and p53 Protein by Ovine Intestinal Adenocarcinoma Cells. Veterinary Pathology, 2006, 43, 613-621.	0.8	8
1581	Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15540-15545.	3.3	179
1582	Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments. Journal of the National Cancer Institute, 2006, 98, 1655-1663.	3.0	159
1583	RNASEL Gene Polymorphisms and the Risk of Prostate Cancer: a Meta-analysis. Clinical Cancer Research, 2006, 12, 5713-5719.	3.2	58
1584	Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial. British Journal of Cancer, 2006, 94, 74-78.	2.9	6
1585	Noncardia Gastric Adenocarcinoma Remains an Important and Deadly Cancer in the United States: Secular Trends in Incidence and Survival. American Journal of Gastroenterology, 2006, 101, 2485-2492.	0.2	63
1586	Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach. Molecular and Cellular Proteomics, 2006, 5, 157-171.	2.5	421
1587	Prostate cancer incidence varies among males from different Y-chromosome lineages. Prostate Cancer and Prostatic Diseases, 2006, 9, 303-309.	2.0	21
1588	Comparison of Aminolevulinic Acid– and Hexylester Aminolevulinate–Induced Protoporphyrin IX Fluorescence for the Detection of Ovarian Cancer in a Rat Model. Photomedicine and Laser Surgery, 2007, 25, 304-311.	2.1	16
1589	Combined modalities approach for localized adult extremity soft-tissue sarcoma. Expert Review of Anticancer Therapy, 2007, 7, 1135-1144.	1.1	11
1590	Coculture with Prostate Cancer Cells Alters Endoglin Expression and Attenuates Transforming Growth Factor-Î ² Signaling in Reactive Bone Marrow Stromal Cells. Molecular Cancer Research, 2007, 5, 585-603.	1.5	32
1591	Oxytocin and the Human Prostate in Health and Disease. International Review of Cytology, 2007, 263, 253-286.	6.2	10
1592	Characterization of a Putative Ovarian Oncogene, Elongation Factor 1α, Isolated by Panning a Synthetic Phage Display Single-Chain Variable Fragment Library with Cultured Human Ovarian Cancer Cells. Clinical Cancer Research, 2007, 13, 5889-5896.	3.2	19

#	Article	IF	Citations
1593	Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non†small cell lung carcinoma. Molecular Cancer Therapeutics, 2007, 6, 1683-1691.	1.9	249
1594	Identification of Human Aldehyde Dehydrogenase 1 Family Member A1 as a Novel CD8+ T-Cell–Defined Tumor Antigen in Squamous Cell Carcinoma of the Head and Neck. Cancer Research, 2007, 67, 10538-10545.	0.4	135
1595	Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer. Acta Oncológica, 2007, 46, 324-329.	0.8	3
1596	Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Molecular Cancer Therapeutics, 2007, 6, 542-551.	1.9	86
1597	Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Molecular Cancer Therapeutics, 2007, 6, 1765-1773.	1.9	52
1598	Frequency and prognostic significance of HPV DNA in sentinel lymph nodes of patients with cervical cancer. Annals of Oncology, 2007, 18, 1513-1517.	0.6	24
1599	Prospective study on bright lumen magnetic resonance colonography in comparison with conventional colonoscopy. British Journal of Radiology, 2007, 80, 235-241.	1.0	24
1600	Bronchial Intraepithelial Neoplasia/Early Central Airways Lung Cancer. Chest, 2007, 132, 221S-233S.	0.4	100
1601	EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2007, 2, 423-429.	0.5	84
1602	Postoperative Lung Function in Lung Cancer Patients: Comparative Analysis of Predictive Capability of MRI, CT, and SPECT. American Journal of Roentgenology, 2007, 189, 400-408.	1.0	82
1603	Covered self-expandable metal stents in pancreatic malignancy regardless of resectability: a new concept validated by a decision analysis. Endoscopy, 2007, 39, 319-324.	1.0	73
1604	Prevention of Irradiation-induced Salivary Hypofunction by Microvessel Protection in Mouse Salivary Glands. Molecular Therapy, 2007, 15, 2101-2106.	3.7	95
1605	Breast Cancer Prevention with Older Women: A Gender-Focused Intervention Study. Health Care for Women International, 2007, 28, 872-887.	0.6	8
1606	Acute Inpatient Palliative Medicine in a Cancer Center: Clinical Problems and Medical Interventions—A Prospective Study. American Journal of Hospice and Palliative Medicine, 2007, 24, 20-28.	0.8	50
1607	Phosphorylation and Activation of Cell Division Cycle Associated 8 by Aurora Kinase B Plays a Significant Role in Human Lung Carcinogenesis. Cancer Research, 2007, 67, 4113-4122.	0.4	110
1608	LOXL1 and LOXL4 Are Epigenetically Silenced and Can Inhibit Ras/Extracellular Signal-Regulated Kinase Signaling Pathway in Human Bladder Cancer. Cancer Research, 2007, 67, 4123-4129.	0.4	102
1609	Increased Expression of Insulin-like Growth Factor-II Messenger RNA–Binding Protein 1 Is Associated with Tumor Progression in Patients with Lung Cancer. Clinical Cancer Research, 2007, 13, 434-442.	3.2	98
1610	Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgraduate Medical Journal, 2007, 83, 338-343.	0.9	47

#	Article	IF	CITATIONS
1611	High-grade lesion: what does it tell us?. Thorax, 2007, 62, 2-3.	2.7	4
1612	Differential Radiation Protection of Salivary Glands versus Tumor by Tempol with Accompanying Tissue Assessment of Tempol by Magnetic Resonance Imaging. Clinical Cancer Research, 2007, 13, 4928-4933.	3.2	105
1613	Primary Prevention of Breast Cancer by Hormone-Induced Differentiation., 2007, 174, 111-130.		39
1614	Monocyte Chemotactic Protein-1 Mediates Prostate Cancer–Induced Bone Resorption. Cancer Research, 2007, 67, 3646-3653.	0.4	154
1615	Activation of KIF4A as a Prognostic Biomarker and Therapeutic Target for Lung Cancer. Clinical Cancer Research, 2007, 13, 6624-6631.	3.2	126
1616	Galanin Is Up-Regulated in Colon Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2373-2378.	1.1	35
1617	Heat Shock Protein 70 Increases Tumorigenicity and Inhibits Apoptosis in Pancreatic Adenocarcinoma. Cancer Research, 2007, 67, 616-625.	0.4	219
1618	Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients. Clinical Cancer Research, 2007, 13, 3617-3622.	3.2	156
1619	Retrospective Evaluation of Sequential Outpatient Chemotherapy for Advanced Gastric Cancer. Chemotherapy, 2007, 53, 226-232.	0.8	5
1620	Prostate Cancer with Supraclavicular Lymphadenopathy and Bulky Abdominal Tumor. Internal Medicine, 2007, 46, 1135-1138.	0.3	6
1621	Prostate cancer: the new evidence base for diagnosis and treatment. Pathology, 2007, 39, 537-544.	0.3	14
1622	Lung Cancer with Isolated Skip Metastasis to an Abdominal Lymph Node. Oncology Research and Treatment, 2007, 30, 375-377.	0.8	3
1623	Health Belief Model Variables as Predictors of Progression in Stage of Mammography Adoption. American Journal of Health Promotion, 2007, 21, 255-261.	0.9	51
1624	Prostate Cancer Epigenetics: A Review on Gene Regulation. Gene Regulation and Systems Biology, 2007, 1, GRSB.S398.	2.3	11
1625	Tumor Necrosis Has no Prognostic Value in Neoadjuvant Chemotherapy for Soft Tissue Sarcoma. Clinical Orthopaedics and Related Research, 2007, 455, 219-224.	0.7	40
1626	Comparison of Pancreas Juice Proteins from Cancer Versus Pancreatitis Using Quantitative Proteomic Analysis. Pancreas, 2007, 34, 70-79.	0.5	93
1627	Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anti-Cancer Drugs, 2007, 18, 477-485.	0.7	75
1628	Trastuzumab not for ductal carcinoma in situ?. Anti-Cancer Drugs, 2007, 18, 1231-1235.	0.7	0

#	Article	IF	CITATIONS
1630	The Effects of Cancer-Related Pain and Fatigue on Functioning of Older Adult, Long-term Cancer Survivors. Cancer Nursing, 2007, 30, 421-433.	0.7	72
1631	Synthesis and Cytotoxic Activity of Novel Pyrazoline Derivatives against Human Lung Tumor Cell Line (A549). Journal of the Chinese Chemical Society, 2007, 54, 81-86.	0.8	10
1632	Prostate-Specific Antigen/Prostatic Acid Phosphatase Ratio Is Significant Prognostic Factor in Patients with Stage IV Prostate Cancer. Urology, 2007, 70, 702-705.	0.5	19
1633	Colon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4. Cell Stem Cell, 2007, 1, 389-402.	5 . 2	968
1634	Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. European Journal of Cancer, 2007, 43, 415-432.	1.3	170
1635	S100A2–S100P expression profile and diagnosis of non-small cell lung carcinoma: Impairment by advanced tumour stages and neoadjuvant chemotherapy. European Journal of Cancer, 2007, 43, 1935-1943.	1.3	50
1636	Influence of detector collimation and beam pitch for identification and image quality of ground-glass attenuation and nodules on 16- and 64-detector row CT systems: Experimental study using chest phantom. European Journal of Radiology, 2007, 64, 406-413.	1.2	7
1637	Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 21-29.	1.4	27
1638	Development of time-resolved immunofluorometric assays for CA 72-4 and application in sera of patients with gastric tumors. Clinica Chimica Acta, 2007, 380, 106-111.	0.5	18
1640	The cancer incidence temporality index: An index to show temporal changes in the age of onset of overall and specific cancer (England and Wales, 1971–1999). Biomedicine and Pharmacotherapy, 2007, 61, 623-630.	2.5	6
1641	Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Letters, 2007, 247, 56-71.	3.2	87
1642	Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis. International Journal of Oral and Maxillofacial Surgery, 2007, 36, 159-164.	0.7	37
1643	The risk of malignancy index in discrimination of adnexal masses. International Journal of Gynecology and Obstetrics, 2007, 96, 186-191.	1.0	48
1644	Human papillomavirus subtype 16 is common in Pakistani women with cervical carcinoma. International Journal of Infectious Diseases, 2007, 11, 313-317.	1.5	51
1646	MicroRNA Signatures in Human Ovarian Cancer. Cancer Research, 2007, 67, 8699-8707.	0.4	1,356
1647	Ultrasound Evaluation of Testicular Neoplasms. Ultrasound Clinics, 2007, 2, 27-44.	0.2	11
1648	Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 2007, 25, 2811-2818.	0.8	371
1649	Invasive Ability of Human Renal Cell Carcinoma Cell Line Caki-2 Is Accelerated by Gamma-Aminobutyric Acid, via Sustained Activation of ERK1/2 Inducible Matrix Metalloproteinases. Cancer Investigation, 2007, 25, 574-583.	0.6	28

#	Article	IF	Citations
1650	Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma. Journal of Proteome Research, 2007, 6, 4025-4031.	1.8	88
1651	α-Chaconine-reduced Metastasis Involves a PI3K/Akt Signaling Pathway with Downregulation of NF-κB in Human Lung Adenocarcinoma A549 cells. Journal of Agricultural and Food Chemistry, 2007, 55, 11035-11043.	2.4	68
1652	S100A8 Is Identified as a Biomarker of HPV18-Infected Oral Squamous Cell Carcinomas by Suppression Subtraction Hybridization, Clinical Proteomics Analysis, and Immunohistochemistry Staining. Journal of Proteome Research, 2007, 6, 2143-2151.	1.8	52
1653	Comparison of Contrast Enhanced Color Doppler Targeted Biopsy to Conventional Systematic Biopsy: Impact on Gleason Score. Journal of Urology, 2007, 178, 464-468.	0.2	122
1654	Coregistered Ventilation and Perfusion SPECT Using Krypton-81m and Tc-99mâ°'Labeled Macroaggregated Albumin With Multislice CT. Academic Radiology, 2007, 14, 830-838.	1.3	49
1655	CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: An independent prognostic factor. Lung Cancer, 2007, 56, 105-114.	0.9	56
1656	Colorectal Cancer. Mayo Clinic Proceedings, 2007, 82, 114-129.	1.4	55
1657	Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer, 2007, 58, 131-138.	0.9	106
1658	Gain of Chromosome 8q: A Potential Prognostic Marker in Resectable Adenocarcinoma of the Pancreas?. Annals of Surgical Oncology, 2007, 14, 1327-1335.	0.7	15
1660	Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. Journal of Translational Medicine, 2007, 5, 51.	1.8	28
1661	Are bone scintigraphy examinations requested in oncologic patients according to established indications?. Revista Española De Medicina Nuclear, 2007, 26, 286-293.	0.3	1
1662	Carcinogenicity of Agricultural Pesticides in Adults and Children. Journal of Agromedicine, 2007, 12, 39-56.	0.9	25
1663	Immuno-gene Therapy for Metastatic Prostate Cancer. , 2008, , 337-353.		0
1664	Expression of Cyr61, CTGF, and WISP-1 Correlates with Clinical Features of Lung Cancer. PLoS ONE, 2007, 2, e534.	1.1	122
1665	Chemopreventive Effects of Sarcotriol on Ultraviolet B-induced Skin Tumor Development in SKH-1 Hairless Mice. Marine Drugs, 2007, 5, 197-207.	2.2	11
1667	High frequency of p 16 promoter methylation in non-small cell lung carcinomas from Chile. Biological Research, 2007, 40, .	1.5	14
1668	Acquisition of Apoptotic Resistance in Cadmium-Transformed Human Prostate Epithelial Cells: Bcl-2 Overexpression Blocks the Activation of JNK Signal Transduction Pathway. Environmental Health Perspectives, 2007, 115, 1094-1100.	2.8	43
1669	Non-Hodgkin's lymphoma in childhood: clinical and epidemiological characteristics and survival analysis at a single center in Northeast Brazil. Jornal De Pediatria, 2007, 83, 547-554.	0.9	19

#	Article	IF	CITATIONS
1670	Cigarette Smoking and Risk of Lung Cancer in Korean Men: The Seoul Male Cancer Cohort Study. Journal of Korean Medical Science, 2007, 22, 508.	1.1	20
1672	The Changing Age Distribution of Prostate Cancer in Canada. Canadian Journal of Public Health, 2007, 98, 60-64.	1.1	13
1673	Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional 1H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of $4\hat{a}\in 10$ ng/ml. NMR in Biomedicine, 2007, 20, 11-20.	1.6	50
1674	Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone. NMR in Biomedicine, 2007, 20, 505-511.	1.6	62
1675	Urinary biomarkers of tea polyphenols and risk of colorectal cancer in the Shanghai Cohort Study. International Journal of Cancer, 2007, 120, 1344-1350.	2.3	89
1676	Fluorescence in situ hybridization for detecting genomic alterations of cyclin D1 and p16 in oral squamous cell carcinomas. Cancer, 2007, 110, 2230-2239.	2.0	23
1677	HMGA2 overexpression in non-small cell lung cancer. Molecular Carcinogenesis, 2007, 46, 503-511.	1.3	151
1678	Long term administration of granulocyte-macrophage colony stimulating factor decreases development of 1-2 dimethylhydrazine-induced colon cancer in rats. Journal of Surgical Oncology, 2007, 95, 12-21.	0.8	1
1679	Characterization of mammographic masses using a gradient-based segmentation algorithm and a neural classifier. Computers in Biology and Medicine, 2007, 37, 1479-1491.	3.9	73
1680	Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Critical Reviews in Oncology/Hematology, 2007, 61, 243-254.	2.0	23
1681	Tumor lysis syndrome in elderly. Critical Reviews in Oncology/Hematology, 2007, 64, 31-42.	2.0	25
1682	Computer-based system for the virtual-endoscopic guidance of bronchoscopy. Computer Vision and Image Understanding, 2007, 108, 171-187.	3.0	81
1683	Phantom breast sensations and phantom breast pain: A 2-year prospective study and a methodological analysis of literature. European Journal of Pain, 2007, 11, 99-99.	1.4	67
1684	Postoperative Radiotherapy for Maxillary Sinus Cancer: Long-Term Outcomes and Toxicities of Treatment. International Journal of Radiation Oncology Biology Physics, 2007, 68, 719-730.	0.4	86
1686	Effects of active form of EGFR on disease-free survival in ovarian cancer women. Reports of Practical Oncology and Radiotherapy, 2007, 12, 225-229.	0.3	0
1687	Oncogenic role of JC virus in lung cancer. Journal of Pathology, 2007, 212, 306-315.	2.1	60
1688	A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors. Prostate, 2007, 67, 829-839.	1.2	8
1689	Comparative proteomic analysis of human pancreatic juice: Methodological study. Proteomics, 2007, 7, 1345-1355.	1.3	50

#	Article	IF	CITATIONS
1690	Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene, 2007, 26, 4969-4978.	2.6	102
1691	Predictors of Prolonged Length of Stay After Major Elective Head and Neck Surgery. Laryngoscope, 2007, 117, 1756-1763.	1.1	58
1692	Class III $\hat{l}^2 \hat{a} \in \text{tubulin}$, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology, 2007, 51, 539-546.	1.6	72
1693	An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Therapy, 2007, 14, 480-487.	2.2	24
1694	Clinicians' attitudes to prostate cancer peer-support groups. BJU International, 2007, 99, 68-71.	1.3	36
1695	Diagnostic performance of threeâ€dimensional ultrasound extended imaging at scrotal mass lesions. International Journal of Urology, 2007, 14, 1025-1033.	0.5	8
1696	Simvastatin inactivates ?1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Science, 2007, 98, 890-899.	1.7	50
1697	Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. Cancer Science, 2007, 98, 1902-1913.	1.7	49
1698	The Value of the Van Nuys Prognostic Index in Ductal Carcinoma In Situ of the Breast: A Retrospective Analysis. Breast Journal, 2007, 13, 359-367.	0.4	25
1699	A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. International Journal of Gynecological Cancer, 2007, 17, 771-776.	1.2	101
1700	Sentinel lymph node in endometrial cancer. International Journal of Gynecological Cancer, 2007, 17, 1113-1117.	1,2	62
1701	Predictors of Colorectal Screening in Rural Colorado: Testing to Prevent Colon Cancer in the High Plains Research Network. Journal of Rural Health, 2007, 23, 238-245.	1.6	45
1702	Relationship between XRCC1 polymorphisms and susceptibility to prostate cancer in men from Han, Southern China. Asian Journal of Andrology, 2007, 9, 331-338.	0.8	31
1703	Improving Survival for Patients with Breast Cancer Compared with Intramural and Extramural Benchmarks. Clinical Breast Cancer, 2007, 7, 480-485.	1.1	3
1704	Evolving Nonendocrine Therapeutic Options for Metastatic Breast Cancer: How Adjuvant Chemotherapy Influences Treatment. Clinical Breast Cancer, 2007, 7, 841-849.	1.1	13
1705	A Second Transient Prostate-Specific Antigen Elevation After External-Beam Radiation Therapy and Fractionated Magnetic Resonance Imaging–Guided High-Dose Rate Brachytherapy Boost. Clinical Genitourinary Cancer, 2007, 5, 406-408.	0.9	O
1706	Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-κB-dependent pathway in human lung cancer cells. Biochemical Pharmacology, 2007, 74, 1702-1712.	2.0	74
1707	Methylenetetrahydrofolate reductase and methionine synthase polymorphisms and risk of bladder cancer in a Tunisian population. Cancer Genetics and Cytogenetics, 2007, 176, 48-53.	1.0	30

#	Article	IF	CITATIONS
1708	Short-term nutritional implications of total gastrectomy for malignancy, and the impact of parenteral nutritional support. Clinical Nutrition, 2007, 26, 718-727.	2.3	41
1709	A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. European Journal of Pharmacology, 2007, 564, 26-36.	1.7	116
1710	Feasibility of ovarian preservation in patients with early stage endometrial carcinoma. Gynecologic Oncology, 2007, 104, 52-57.	0.6	86
1711	Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?. Gynecologic Oncology, 2007, 104, 212-216.	0.6	44
1712	Contribution of the sentinel node procedure to tailoring the radicality of hysterectomy for cervical cancer. Gynecologic Oncology, 2007, 106, 251-256.	0.6	27
1713	Sentinel lymph node detection in early stage uterine cervix carcinoma: A systematic review. Gynecologic Oncology, 2007, 106, 604-613.	0.6	150
1714	Promoter polymorphisms of DNMT3B and the risk of head and neck squamous cell carcinoma in Taiwan: A case–control study. Oral Oncology, 2007, 43, 345-351.	0.8	37
1715	Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral Oncology, 2007, 43, 1021-1025.	0.8	26
1716	Factors predicting poor survival after resection of stage IA non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2007, 134, 850-856.	0.4	83
1717	Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer patients. Journal of Zhejiang University: Science B, 2007, 8, 638-646.	1.3	7
1718	Actual role of radiofrequency ablation of liver metastases. European Radiology, 2007, 17, 2062-2070.	2.3	97
1719	Expression Level of Hepatoma-Derived Growth Factor Correlates with Tumor Recurrence of Esophageal Carcinoma. Annals of Surgical Oncology, 2007, 14, 2141-2149.	0.7	57
1720	Laparoscopic Sentinel Node Biopsy in Cervical Cancer Using a Combined Detection: 5–Years Experience. Annals of Surgical Oncology, 2007, 14, 2392-2399.	0.7	26
1721	Monitoring In Situ Dosimetry and Protoporphyrin IX Fluorescence Photobleaching in the Normal Rat Esophagus During 5-Aminolevulinic Acid Photodynamic Therapy ¶. Photochemistry and Photobiology, 2007, 78, 271-277.	1.3	3
1722	HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathology and Oncology Research, 2007, 13, 180-185.	0.9	32
1723	College students' knowledge of risk and screening recommendations for breast, cervical, and testicular cancers. Journal of Cancer Education, 2007, 22, 86-90.	0.6	14
1724	Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 658-666.	3.3	101
1725	Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine. Cancer Immunology, Immunotherapy, 2007, 56, 1275-1283.	2.0	16

#	Article	IF	CITATIONS
1726	Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Cancer Chemotherapy and Pharmacology, 2007, 59, 613-620.	1.1	23
1727	Video Capsule Endoscopy to Diagnose Metastatic Melanoma. Digestive Diseases and Sciences, 2007, 52, 1036-1037.	1.1	0
1728	Improved survival in BRCA2 carriers with ovarian cancer. Familial Cancer, 2007, 6, 113-119.	0.9	60
1729	A multigenic approach to predict breast cancer risk. Breast Cancer Research and Treatment, 2007, 104, 159-164.	1.1	31
1730	Consumption of different types of meat and the risk of renal cancer: meta-analysis of case–control studies. Cancer Causes and Control, 2007, 18, 125-133.	0.8	67
1731	Quelques éléments particuliers concernant l'épidémiologie des sarcomes. Oncologie, 2007, 9, 84-87	.0.2	3
1732	Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. Journal of Gastroenterology, 2007, 42, 389-394.	2.3	67
1733	Importance of polymorphisms in NF-κB1 and NF-κBIα genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. Journal of Cancer Research and Clinical Oncology, 2007, 133, 859-866.	1.2	49
1735	Malignant phenotype of PC3 cell line was inhibited by siRNA targeting PAR gene. Journal of Huazhong University of Science and Technology [Medical Sciences], 2007, 27, 440-443.	1.0	1
1736	Preemptive Total Gastrectomy for Hereditary Gastric Cancer. Journal of Gastrointestinal Surgery, 2007, 11, 314-317.	0.9	9
1737	Effects of small interfering RNAs targeting MAPK1 on gene expression profile in HeLa cells as revealed by microarray analysis. Cell Biology International, 2008, 32, 1081-1090.	1.4	10
1738	Interest in breast cancer chemoprevention among older women. Breast Cancer Research and Treatment, 2008, 108, 435-453.	1.1	16
1739	Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients. Clinical and Experimental Metastasis, 2008, 25, 887-892.	1.7	28
1740	Performance of integrated FDG–PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG–PET/non-contrast-enhanced CT and enhanced CT. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1439-1448.	3.3	105
1741	RFA of renal cell carcinoma in a solitary kidney. Abdominal Imaging, 2008, 33, 230-236.	2.0	16
1742	Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by Bifidobacterium adolescentis SPM0212. Archives of Pharmacal Research, 2008, 31, 468-473.	2.7	118
1743	Clinical outcome following radical hysterectomy and pelvic lymphadenectomy for early-stage cervical cancer. Chinese-German Journal of Clinical Oncology, 2008, 7, 723-727.	0.1	1
1744	Modelling the Recurrence of Bladder Cancer. Acta Applicandae Mathematicae, 2008, 104, 91-105.	0.5	2

#	Article	IF	CITATIONS
1745	Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma. Bulletin of Experimental Biology and Medicine, 2008, 145, 535-538.	0.3	10
1746	Importance of postpolypectomy surveillance and postpolypectomy compliance to follow-up screening—review of literature. International Journal of Colorectal Disease, 2008, 23, 453-459.	1.0	35
1747	Mucinous colorectal adenocarcinoma: influence of mucin expression (Muc1, 2 and 5) on clinico-pathological features and prognosis. International Journal of Colorectal Disease, 2008, 23, 757-765.	1.0	42
1748	Pancreatic cancer: a generalized diseaseâ€"prognostic impact of cancer cell dissemination. Langenbeck's Archives of Surgery, 2008, 393, 911-917.	0.8	7
1749	The value of BAL fluid LDH level in differentiating benign from malignant solitary pulmonary nodules. Journal of Cancer Research and Clinical Oncology, 2008, 134, 489-493.	1.2	17
1750	Targeted disruption of the galectin-3 gene results in decreased susceptibility to NNK-induced lung tumorigenesis: an oligonucleotide microarray study. Journal of Cancer Research and Clinical Oncology, 2008, 134, 777-788.	1.2	28
1751	Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries. BMC Medical Genomics, 2008, 1, 56.	0.7	52
1752	Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tcaâ€8113 cell lines by shikonin was partly through the inactivation of NFâ€∢i>κ⟨/i>B pathway. Phytotherapy Research, 2008, 22, 407-415.	2.8	79
1753	<i>Brucea javanica</i> fruit induces cytotoxicity and apoptosis in pancreatic adenocarcinoma cell lines. Phytotherapy Research, 2008, 22, 477-486.	2.8	56
1754	Osteoblastsâ€derived BMPâ€2 enhances the motility of prostate cancer cells via activation of integrins. Prostate, 2008, 68, 1341-1353.	1.2	57
1755	Osteoblastsâ€derived TGFâ€Î²1 enhance motility and integrin upregulation through Akt, ERK, and NFâ€ÎºBâ€dependent pathway in human breast cancer cells. Molecular Carcinogenesis, 2008, 47, 526-537.	1.3	29
1756	Longâ€term outcomes in extremity soft tissue sarcoma after a pathologically negative reâ€resection and without radiotherapy. Cancer, 2008, 112, 2774-2779.	2.0	35
1757	Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis. Cancer, 2008, 114, 275-283.	2.0	40
1758	A review of the clinical relevance of mismatchâ€repair deficiency in ovarian cancer. Cancer, 2008, 113, 733-742.	2.0	96
1759	A new prostate cancer therapeutic approach: Combination of androgen ablation with COXâ€⊋ inhibitor. International Journal of Cancer, 2008, 123, 195-201.	2.3	34
1760	Modeling the recurrence–progression process in bladder carcinoma. Computers and Mathematics With Applications, 2008, 56, 619-630.	1.4	7
1761	Intrarectal Amifostine During External Beam Radiation Therapy for Prostate Cancer Produces Significant Improvements in Quality of Life Measured by EPIC Score. International Journal of Radiation Oncology Biology Physics, 2008, 70, 90-95.	0.4	51
1762	Limits of Day-Before Lymphoscintigraphy to Localize Sentinel Nodes in Women with Cervical Cancer. Annals of Surgical Oncology, 2008, 15, 2173-2179.	0.7	14

#	Article	IF	CITATIONS
1763	Anniversary Paper: Past and current issues, and trends in brachytherapy physics. Medical Physics, 2008, 35, 4708-4723.	1.6	62
1764	Controlling recurrent papillary thyroid carcinoma in the neck by ultrasonography-guided percutaneous ethanol injection. European Radiology, 2008, 18, 835-842.	2.3	67
1765	Expression of the cell-cell adhesion molecule \hat{l}^2 -catenin in colorectal carcinomas and their metastases. Apmis, 2008, 116, 1-9.	0.9	15
1766	Elevated thymosin β15 expression is associated with progression and metastasis of nonâ€small cell lung cancer. Apmis, 2008, 116, 484-490.	0.9	8
1767	Vitamin D Receptor, UVR, and Skin Cancer: A Potential Protective Mechanism. Journal of Investigative Dermatology, 2008, 128, 2357-2361.	0.3	44
1768	LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. International Journal of Gynecological Cancer, 2008, 18, 711-717.	1.2	135
1769	Initial clinical experience with realâ€time transrectal ultrasonographyâ€magnetic resonance imaging fusionâ€guided prostate biopsy. BJU International, 2008, 101, 841-845.	1.3	166
1770	Information needs and preferences of low and high literacy consumers for decisions about colorectal cancer screening: utilizing a linguistic model. Health Expectations, 2008, 11, 123-136.	1.1	75
1771	Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary?. Gynecologic Oncology, 2008, 111, 523-526.	0.6	40
1772	Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. Gynecologic Oncology, 2008, 110, 360-364.	0.6	33
1773	Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics, 2008, 9, 99.	1.2	93
1774	RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells. Oral Oncology, 2008, 44, 1172-1180.	0.8	33
1775	Umbelliprenin from Ferula szowitsiana inhibits the growth of human M4Beu metastatic pigmented malignant melanoma cells through cell-cycle arrest in G1 and induction of caspase-dependent apoptosis. Phytomedicine, 2008, 15, 103-111.	2.3	90
1776	Sentinel lymph node biopsy in gynaecological cancers: The importance of micrometastases in cervical cancer. Surgical Oncology, 2008, 17, 227-235.	0.8	47
1777	Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma. Expert Opinion on Medical Diagnostics, 2008, 2, 151-159.	1.6	0
1778	pH-Responsive Nanoparticles for Cancer Drug Delivery. Methods in Molecular Biology, 2008, 437, 183-216.	0.4	61
1779	Inhibition of Cell Growth and VEGF Expression in Ovarian Cancer Cells by Flavonoids. Nutrition and Cancer, 2008, 60, 800-809.	0.9	196
1780	Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. Journal of Experimental and Clinical Cancer Research, 2008, 27, 62.	3.5	62

#	Article	IF	CITATIONS
1783	Potential of Magnetic Resonance Spectroscopic Imaging in Predicting Absence of Prostate Cancer in Men With Serum Prostate-Specific Antigen Between 4 and 10 ng/mL: A Follow-up Study. Urology, 2008, 72, 859-863.	0.5	57
1784	Biopsy of the small renal mass: Time to shift the clinical paradigm?. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 337-338.	0.8	3
1785	The Role of Infectious Agents in the Etiology of Ocular Adnexal Neoplasia. Survey of Ophthalmology, 2008, 53, 312-331.	1.7	113
1786	Incidence and risk factors for low trauma fractures in men with prostate cancer. Bone, 2008, 43, 556-560.	1.4	27
1787	Kaempferol-7-O-Î ² -d-glucoside (KG) isolated from Smilax china L. rhizome induces G2/M phase arrest and apoptosis on HeLa cells in a p53-independent manner. Cancer Letters, 2008, 264, 229-240.	3.2	90
1788	Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis. Cancer Letters, 2008, 271, 105-116.	3.2	62
1789	Expression profiling of angiogenic genes for the characterisation of colorectal carcinoma. European Journal of Cancer, 2008, 44, 1761-1769.	1.3	5
1790	Successful treatment of small cell lung cancer during pregnancy. Lung Cancer, 2008, 61, 129-130.	0.9	26
1791	Sarcoma Epidemiology and Etiology: Potential Environmental and Genetic Factors. Surgical Clinics of North America, 2008, 88, 451-481.	0.5	138
1792	Expression and Clinical Significance of CacyBP/SIP in Pancreatic Cancer. Pancreatology, 2008, 8, 470-477.	0.5	21
1796	Reducing the Risk of Distant Metastases: A Better End Point in Adjuvant Aromatase Inhibitor Breast Cancer Trials?. Cancer Investigation, 2008, 26, 481-490.	0.6	10
1797	Development of Novobiocin Analogues That Manifest Anti-proliferative Activity against Several Cancer Cell Lines. Journal of Organic Chemistry, 2008, 73, 2130-2137.	1.7	121
1798	Gaseous Nitrogen Oxide Promotes Human Lung Cancer Cell Line A549 Migration, Invasion, and Metastasis via iNOS-Mediated MMP-2 Production. Toxicological Sciences, 2008, 106, 364-375.	1.4	30
1799	Activation of Placenta-Specific Transcription Factor (i>Distal-less (i>Homeobox 5 Predicts Clinical Outcome in Primary Lung Cancer Patients. Clinical Cancer Research, 2008, 14, 2363-2370.	3.2	48
1800	Institutional and Comprehensive Review of Laryngeal Leukoplakia. Annals of Otology, Rhinology and Laryngology, 2008, 117, 74-79.	0.6	134
1801	Lower Osteopontin Plasma Levels Are Associated With Superior Outcomes in Advanced Non–Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: SWOG Study S0003. Journal of Clinical Oncology, 2008, 26, 4771-4776.	0.8	96
1802	Gender differences in colorectal cancer incidence, mortality, hospitalizations and surgical procedures in Canada. Journal of Public Health, 2008, 30, 194-201.	1.0	56
1803	Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis, 2008, 29, 35-43.	1.3	116

#	Article	IF	CITATIONS
1804	Integrated Analysis of Copy Number Alterations and Loss of Heterozygosity in Human Pancreatic Cancer Using a High-Resolution, Single Nucleotide Polymorphism Array. Oncology, 2008, 75, 102-112.	0.9	13
1805	Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status. British Journal of Cancer, 2008, 98, 956-964.	2.9	65
1806	State-of-the-art: prostate LDR brachytherapy. Prostate Cancer and Prostatic Diseases, 2008, 11, 237-240.	2.0	13
1807	Overexpression of OLC1, Cigarette Smoke, and Human Lung Tumorigenesis. Journal of the National Cancer Institute, 2008, 100, 1592-1605.	3.0	22
1808	A Fiber-Modified Mesothelin Promoter–Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer. Clinical Cancer Research, 2008, 14, 3582-3588.	3.2	28
1809	Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference. Clinical Cancer Research, 2008, 14, 6387-6395.	3.2	64
1810	Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission. Clinical Cancer Research, 2008, 14, 2740-2748.	3.2	98
1811	Analysis of chloroethane toxicity and carcinogenicity including a comparison with bromoethane. Toxicology and Industrial Health, 2008, 24, 655-675.	0.6	6
1812	Leupaxin, a Novel Coactivator of the Androgen Receptor, Is Expressed in Prostate Cancer and Plays a Role in Adhesion and Invasion of Prostate Carcinoma Cells. Molecular Endocrinology, 2008, 22, 1606-1621.	3.7	37
1813	The Inguinal Canal: Anatomy and Imaging Features of Common and Uncommon Masses. Radiographics, 2008, 28, 819-835.	1.4	102
1814	Telomerase Transcriptional Targeting of Inducible Bax/TRAIL Gene Therapy Improves Gemcitabine Treatment of Pancreatic Cancer. Molecular Therapy, 2008, 16, 252-260.	3.7	18
1815	Diagnostic and Prognostic MicroRNAs in Stage II Colon Cancer. Cancer Research, 2008, 68, 6416-6424.	0.4	459
1816	153Sm: its use in multiple myeloma and report of a clinical experience. Expert Opinion on Investigational Drugs, 2008, 17, 1379-1387.	1.9	15
1817	Methionine and Vitamin B6 Intake and Risk of Pancreatic Cancer: A Prospective Study of Swedish Women and Men. Yearbook of Gastroenterology, 2008, 2008, 57.	0.1	14
1818	Developmental potential of oocytes fertilized by conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) after cryopreservation and mesometrial autotransplantation of rabbit ovarian tissue. Animal, 2008, 2, 1371-1376.	1.3	2
1819	Development and preliminary results of an in vivo Raman probe for early lung cancer detection. Proceedings of SPIE, 2008, , .	0.8	1
1820	Cancer Diagnostics Using 1H-NMR-Based Metabonomics. Ernst Schering Research Foundation Workshop, 2008, , 205-226.	0.7	4
1821	An Exploration of Urban and Rural Differences in Lung Cancer Survival Among Medicare Beneficiaries. American Journal of Public Health, 2008, 98, 1280-1287.	1.5	102

#	Article	IF	CITATIONS
1822	Biosensor Techniques Used for Determination of Telomerase Activity in Cancer Cells. Sensors, 2008, 8, 347-369.	2.1	13
1824	Detection of Bladder Tumors With 3-Dimensional Sonography and Virtual Sonographic Cystoscopy. Journal of Ultrasound in Medicine, 2008, 27, 45-53.	0.8	43
1825	Intracellular uptake and intraspheroidal distribution of hypericin and hydrophilic analogues using E-cadherin transfected T-24 human bladder cancer cells. Proceedings of SPIE, 2008, , .	0.8	0
1826	Prognostic Significance of Growth Factors and the Urokinase-Type Plasminogen Activator System in Pancreatic Ductal Adenocarcinoma. Pancreas, 2008, 36, 160-167.	0.5	51
1828	Predictive factors of years of potential life lost by colorectal cancer. European Journal of Gastroenterology and Hepatology, 2008, 20, 766-772.	0.8	4
1829	A Randomized, Controlled, Double-Blind Trial of Patient-Controlled Sedation with Propofol/Remifentanil Versus Midazolam/Fentanyl for Colonoscopy. Anesthesia and Analgesia, 2008, 106, 434-439.	1.1	88
1830	Significant Down-Regulation of the Plasminogen Activator Inhibitor 1 mRNA in Pancreatic Cancer. Pancreas, 2008, 36, 173-177.	0.5	12
1831	Benzo (a) pyrene induced tumorigenesity of human immortalized oral epithelial cells: transcription profiling. Chinese Medical Journal, 2008, 121, 1882-1890.	0.9	8
1832	Introduction: epidemiology, pathology and clinical presentation., 0,, 1-18.		0
1833	A Recurrence of Ovarian Carcinoma Presenting as Only Axillary Lymphatic Metastasis: A Case Report. Journal of Breast Cancer, 2008, 11, 102.	0.8	1
1834	Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer: Comparative Analysis between 1st-line and 2nd-line Docetaxel. Yonsei Medical Journal, 2008, 49, 775.	0.9	9
1835	Efficiency Analysis of Competing Tests for Finding Differentially Expressed Genes in Lung Adenocarcinoma. Cancer Informatics, 2008, 6, CIN.S791.	0.9	26
1836	Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) in Breast Cancer. Magnetic Resonance Insights, 2008, 2, MRI.S991.	2.5	1
1837	Endoscopic Ultrasound-Guided Intratumoural Therapy for Pancreatic Cancer. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 405-410.	1.8	31
1838	Visualizing Head and Neck Tumors in Vivo Using Near-Infrared Fluorescent Transferrin Conjugate. Molecular Imaging, 2008, 7, 7290.2008.0006.	0.7	31
1839	Fertility preservation in patients with early epithelial ovarian cancer. Journal of Gynecologic Oncology, 2009, 20, 44.	1.0	48
1840	Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. International Journal of Biological Markers, 2009, 24, 258-264.	0.7	12
1841	Suppression of Akt1 expression by small interference RNA inhibits SGC7901 cell growth in vitro and in vivo. Oncology Reports, 2009, 22, 1305-13.	1.2	1

#	Article	IF	CITATIONS
1842	Epithelial Neoplasms of the Stomach. , 2009, , 563-579.		7
1843	Can We Use Single Nucleotide Polymorphism and Runt Domain Transcription Factor 3 Methylation as Tumor Markers for Bladder Cancer?. Korean Journal of Urology, 2009, 50, 311.	1.2	1
1844	Clinical manifestations in patients with ovarian clear cell carcinoma with or without co-existing endometriosis. Gynecological Endocrinology, 2009, 25, 435-440.	0.7	17
1845	Diagnosis and management of thyroid carcinoma: a focus on serum thyroglobulin. Expert Review of Endocrinology and Metabolism, 2009, 4, 25-43.	1.2	44
1846	The Oncopathic Potency of <i>Clostridium perfringens</i> Is Independent of Its α-Toxin Gene. Human Gene Therapy, 2009, 20, 751-758.	1.4	3
1847	microRNA-451 Regulates Macrophage Migration Inhibitory Factor Production and Proliferation of Gastrointestinal Cancer Cells. Clinical Cancer Research, 2009, 15, 2281-2290.	3.2	328
1848	Something New Under the Sun: Lutein's Role in Skin Health. American Journal of Lifestyle Medicine, 2009, 3, 349-352.	0.8	2
1849	Lymphangiogenesis in Esophageal AdenocarcinomasLymphatic Vessel Density as Prognostic Marker in Esophageal Adenocarcinoma. American Journal of Clinical Pathology, 2009, 131, 92-98.	0.4	40
1850	Mandibular Metastasis of a Signet Ring Cell Carcinoma of the Breast in a Patient who Underwent Bilateral Mastectomy more than 25 Years Earlier. Breast Care, 2009, 4, 3-3.	0.8	5
1851	Biomarker Discovery: Validation and Decision-Making in Product Development. Sexually Transmitted Diseases, 2009, 36, S76-S80.	0.8	8
1852	Significance of Bowel Wall Thickening on Computed Tomography Scan: Higher Risk of Pathology Among African Americans Compared to Hispanics. Journal of the National Medical Association, 2009, 101, 345-348.	0.6	4
1853	Serum Osteopontin Levels are Highly Prognostic for Survival in Advanced Non-small Cell Lung Cancer: Results from JMTO LC 0004. Journal of Thoracic Oncology, 2009, 4, 1104-1110.	0.5	50
1854	Benign and Malignant Tumors of the Gallbladder and Extrahepatic Biliary Tract., 2009,, 845-875.		23
1855	The Role of the Calcium-Sensing Receptor in the Development and Progression of Cancer. Endocrine Reviews, 2009, 30, 178-195.	8.9	116
1856	Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial. Clinical Cancer Research, 2009, 15, 5258-5266.	3.2	46
1857	Benefit of Whole Pelvic Radiotherapy Combined with Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer. Journal of Biomedicine and Biotechnology, 2009, 2009, 1-8.	3.0	22
1859	Metastatic non-small-cell lung cancer and the use of gemcitabine during pregnancy. Journal of Perinatology, 2009, 29, 63-65.	0.9	35
1860	Serum Insulin-like Growth Factor-I and Mammary Tumor Development in <i>Ad libitum</i> –Fed, Chronic Calorie–Restricted, and Intermittent Calorie–Restricted MMTV-TGF-α Mice. Cancer Prevention Research, 2009, 2, 712-719.	0.7	38

#	Article	IF	CITATIONS
1861	A Gonadotropin-Releasing Hormone-II Antagonist Induces Autophagy of Prostate Cancer Cells. Cancer Research, 2009, 69, 923-931.	0.4	46
1862	Noninvasive Multiparametric Imaging of Metastasis-Permissive Microenvironments in a Human Prostate Cancer Xenograft. Cancer Research, 2009, 69, 8822-8829.	0.4	39
1863	Smoking and atherosclerotic cardiovascular disease: Part I: Atherosclerotic disease process. Biomarkers in Medicine, 2009, 3, 411-428.	0.6	17
1864	Sentinel lymph node examination for cancer of the uterine cervix. Journal of Clinical Pathology, 2009, 62, 1062-5.	1.0	15
1865	Kaempferol Inhibits Angiogenesis and VEGF Expression Through Both HIF Dependent and Independent Pathways in Human Ovarian Cancer Cells. Nutrition and Cancer, 2009, 61, 554-563.	0.9	174
1866	<i>In vitro</i> cytotoxic effects of <i>Senecio stabianus</i> Lacaita (Asteraceae) on human cancer cell lines. Natural Product Research, 2009, 23, 1707-1718.	1.0	46
1867	Sulforaphane enhances caspase-dependent apoptosis through inhibition of cyclooxygenase-2 expression in human oral squamous carcinoma cells and nude mouse xenograft model. Oral Oncology, 2009, 45, 654-660.	0.8	19
1868	Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. Journal of Controlled Release, 2009, 140, 277-283.	4.8	114
1869	Increased cytoplasmic S100A6 expression is associated with pulmonary adenocarcinoma progression. Pathology International, 2009, 59, 623-630.	0.6	20
1870	Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression. BMC Cancer, 2009, 9, 25.	1.1	29
1871	Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer, 2009, 9, 61.	1.1	87
1872	Design and methods for a cluster randomized trial of the Sunless Study: A skin cancer prevention intervention promoting sunless tanning among beach visitors. BMC Public Health, 2009, 9, 50.	1.2	17
1873	Extracellular calcium promotes the migration of breast cancer cells through the activation of the calcium sensing receptor. Experimental Cell Research, 2009, 315, 2072-2080.	1.2	94
1874	Stage IV ovarian cancer: Disease site-specific rationale for postoperative treatment. Gynecologic Oncology, 2009, 112, 22-27.	0.6	36
1875	The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecologic Oncology, 2009, 112, 28-34.	0.6	62
1876	Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: A meta-analysis of randomized clinical trials. Clinical Therapeutics, 2009, 31, 962-979.	1.1	47
1877	CCL5 increases lung cancer migration via PI3K, Akt and NF-κB pathways. Biochemical Pharmacology, 2009, 77, 794-803.	2.0	155
1878	In vitro enhancement effect of humic acid on the progression of lung cancer cells. Chemico-Biological Interactions, 2009, 181, 463-471.	1.7	10

#	Article	IF	CITATIONS
1879	Reduction of TIP30 correlates with poor prognosis of gastric cancer patients and its restoration drastically inhibits tumor growth and metastasis. International Journal of Cancer, 2009, 124, 713-721.	2.3	35
1880	PAMAM Dendrimers Mediate siRNA Delivery to Target Hsp27 and Produce Potent Antiproliferative Effects on Prostate Cancer Cells. ChemMedChem, 2009, 4, 1302-1310.	1.6	116
1881	Late rectal complications after prostate brachytherapy for localized prostate cancer. Cancer, 2009, 115, 1827-1839.	2.0	80
1882	Conjunctival sac fluid contains elevated levels of soluble TRAIL: Implications for the antiâ€ŧumoral surveillance of the anterior surface of the eye. Journal of Cellular Physiology, 2009, 218, 199-204.	2.0	11
1883	Distinct genomic aberrations associated with <i>ERG</i> rearranged prostate cancer. Genes Chromosomes and Cancer, 2009, 48, 366-380.	1.5	86
1884	Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy. Journal of Cancer Research and Clinical Oncology, 2009, 135, 551-557.	1.2	15
1885	Minimally invasive surgery for colorectal cancer: quality of life, body image, cosmesis, and functional results. Surgical Endoscopy and Other Interventional Techniques, 2009, 23, 577-582.	1.3	37
1886	Cell death in the skin. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 549-569.	2.2	115
1887	The effect of symptom duration in epithelial ovarian cancer on prognostic factors. Archives of Gynecology and Obstetrics, 2009, 279, 797-801.	0.8	9
1888	Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model. Clinical and Experimental Metastasis, 2009, 26, 981-992.	1.7	28
1889	Indication for Postoperative Adjuvant Therapy in Biliary Carcinoma Based on Analysis of Recurrence and Survival After Surgical Resection. Digestive Diseases and Sciences, 2009, 54, 1360-1364.	1.1	22
1890	Patient Preference and Acceptance with Sodium Phosphate Tablet Preparation for Colonoscopy. Digestive Diseases and Sciences, 2009, 54, 1555-1559.	1.1	6
1891	Elevated expression of L-selectin ligand in lymph node-derived human prostate cancer cells correlates with increased tumorigenicity. Glycoconjugate Journal, 2009, 26, 75-81.	1.4	10
1892	New therapeutics targeting colon cancer stem cells. Current Colorectal Cancer Reports, 2009, 5, 209-216.	1.0	44
1893	Investigational agents in the management of non-small cell lung cancer. Current Oncology Reports, 2009, 11, 275-284.	1.8	5
1894	Papillary thyroid carcinoma presenting with upper respiratory tract obstruction and pulmonary metastases. World Journal of Pediatrics, 2009, 5, 229-231.	0.8	6
1895	Biochemical characterization of breast tumors by in vivo and in vitro magnetic resonance spectroscopy (MRS). Biophysical Reviews, 2009, 1, 21-26.	1.5	3
1896	Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response. Abdominal Imaging, 2009, 34, 593-609.	2.0	37

#	Article	IF	CITATIONS
1897	Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunology, Immunotherapy, 2009, 58, 449-459.	2.0	347
1898	Reexcision of Soft Tissue Sarcoma: Sufficient Local Control but Increased Rate of Metastasis. World Journal of Surgery, 2009, 33, 2599-2605.	0.8	39
1899	Deep depletion of abundant serum proteins reveals lowâ€abundant proteins as potential biomarkers for human ovarian cancer. Proteomics - Clinical Applications, 2009, 3, 853-861.	0.8	49
1900	Induction of the interleukin 6/ signal transducer and activator of transcription pathway in the lungs of mice sub-chronically exposed to mainstream tobacco smoke. BMC Medical Genomics, 2009, 2, 56.	0.7	27
1901	Knockdown of câ€FLIP _L enhanced AD5â€10 antiâ€death receptor 5 monoclonal antibodyâ€induced apoptosis in human lung cancer cells. Cancer Science, 2009, 100, 940-947.	1.7	9
1902	Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Therapy, 2009, 16, 227-236.	2.2	38
1903	Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Reviews Cancer, 2009, 9, 167-181.	12.8	452
1904	The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras. Oncogene, 2009, 28, 1393-1399.	2.6	44
1905	Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression. Oncogene, 2009, 28, 3971-3982.	2.6	15
1906	High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. British Journal of Cancer, 2009, 100, 1144-1153.	2.9	128
1907	Promoter hypermethylation of mismatch repair genes, <i>hMLH1</i> and <i>hMSH2</i> in oral squamous cell carcinoma. Oral Diseases, 2009, 15, 206-213.	1.5	56
1908	The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. Apmis, 2009, 117, 162-175.	0.9	51
1909	Comparison of carcinoembryonic antigen prognostic value in serum and tumour tissue of patients with colorectal cancer. Colorectal Disease, 2009, 11, 276-281.	0.7	31
1910	Screening for cervical cancer among Israeli lesbian women. International Nursing Review, 2009, 56, 433-441.	1.5	28
1911	Prognostic Significance of Oncogenic Markers in Ductal Carcinoma In Situ of the Breast: A Clinicopathologic Study. Breast Journal, 2009, 15, 120-132.	0.4	41
1912	Lymphovascular space involvement in early stage wellâ€differentiated endometrial cancer is associated with increased mortality. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 991-994.	1.1	46
1913	Early prediction of lung cancer based on the combination of trace element analysis in urine and an Adaboost algorithm. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 746-752.	1.4	44
1914	A Markov model for analyzing the evolution of bladder carcinoma. Mathematical and Computer Modelling, 2009, 50, 726-732.	2.0	5

#	Article	IF	CITATIONS
1915	Symptom occurrence and associated clinical factors in nursing home residents with cancer. Research in Nursing and Health, 2009, 32, 453-464.	0.8	22
1916	Strong Impact of Micrometastatic Tumor Cell Load in Patients with Esophageal Carcinoma. Annals of Surgical Oncology, 2009, 16, 454-462.	0.7	56
1917	Pathological Diagnosis and Cytoreduction of Cardiophrenic Lymph Node and Pleural Metastasis in Ovarian Cancer Patients Using Video-Assisted Thoracic Surgery. Annals of Surgical Oncology, 2009, 16, 1990-1996.	0.7	52
1918	Myricetin Suppresses Invasion and Migration of Human Lung Adenocarcinoma A549 Cells: Possible Mediation by Blocking the ERK Signaling Pathway. Journal of Agricultural and Food Chemistry, 2009, 57, 3490-3499.	2.4	82
1919	The Promoter Hypermethylation of DAPK Gene and p16 Gene in Non-Small Cell Lung Cancer Patients. , 2009, , .		1
1920	¹⁸ F, ⁶⁴ Cu, and ⁶⁸ Ga Labeled RGD-Bombesin Heterodimeric Peptides for PET Imaging of Breast Cancer. Bioconjugate Chemistry, 2009, 20, 1016-1025.	1.8	131
1921	Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. European Journal of Cancer, 2009, 45, 2324-2332.	1.3	97
1922	α-Tomatine inactivates PI3K/Akt and ERK signaling pathways in human lung adenocarcinoma A549 cells: Effect on metastasis. Food and Chemical Toxicology, 2009, 47, 1985-1995.	1.8	67
1923	1H NMR-based metabonomic and pattern recognition analysis for detection of oral squamous cell carcinoma. Clinica Chimica Acta, 2009, 401, 8-13.	0.5	66
1925	Incidental Prostate Cancer Detected by Cystoprostatectomy in Korean Men. Urology, 2009, 73, 153-157.	0.5	14
1926	Nuclear Matrix Protein 22 as Adjunct to Urine Cytology and Cystoscopy in Follow-up of Superficial TCC of Urinary Bladder. Urology, 2009, 73, 592-596.	0.5	33
1927	Peripheral or Axial Bone Density Measurements to Identify Osteoporosis in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy?. Urology, 2009, 73, 1347-1351.	0.5	7
1928	Gamma tubulin: A promising indicator of recurrence in squamous cell carcinoma of the larynx. Otolaryngology - Head and Neck Surgery, 2009, 140, 498-504.	1.1	9
1929	Hepatocellular cancer care: Cost is important but only one factor of disease burden. Journal of Hepatology, 2009, 50, 10-12.	1.8	12
1930	Reproductive Factors and Risk of Pancreatic Cancer in Women: A Review of the Literature. Annals of Epidemiology, 2009, 19, 103-111.	0.9	35
1931	Transforming growth factor- \hat{l}^21 increases cell migration and \hat{l}^21 integrin up-regulation in human lung cancer cells. Lung Cancer, 2009, 64, 13-21.	0.9	56
1932	Osteopontin increases lung cancer cells migration via activation of the $\hat{l}\pm\nu\hat{l}^23$ integrin/FAK/Akt and NF- \hat{l}^2 B-dependent pathway. Lung Cancer, 2009, 64, 263-270.	0.9	105
1933	Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer. Lung Cancer, 2009, 66, 58-63.	0.9	40

#	ARTICLE	IF	CITATIONS
1934	Combined Analysis of Smoking, TP53, and FGFR3 Mutations in Tunisian Patients with Invasive and Superficial High-Grade Bladder Tumors. Cancer Investigation, 2009, 27, 998-1007.	0.6	12
1935	Therapeutic Human Papillomavirus Vaccination. Public Health Genomics, 2009, 12, 331-342.	0.6	20
1936	The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. Journal of Experimental and Clinical Cancer Research, 2009, 28, 97.	3.5	21
1937	Surgical Approaches and Short-Term Surgical Outcomes for Patients with Morbid Obesity and Endometrial Cancer. Journal of Gynecologic Surgery, 2009, 25, 41-48.	0.0	2
1938	Implication of preoperative cervical cytology in endometrial carcinoma. Basic and Applied Pathology, 2009, 2, 30-34.	0.2	3
1939	Epigenetic biomarkers in urothelial bladder cancer. Expert Review of Molecular Diagnostics, 2009, 9, 259-269.	1.5	34
1940	Surgical Management of Melanoma. Hematology/Oncology Clinics of North America, 2009, 23, 565-581.	0.9	19
1941	Genetic alterations in precancerous pancreatic lesions and their clinical implications. Gastroenterologie Clinique Et Biologique, 2009, 33, 1028-1035.	0.9	11
1942	Do Young Patients with Colorectal Cancer Have a Poorer Prognosis than Old Patients?. Journal of Surgical Research, 2009, , .	0.8	0
1944	Les altérations génétiques dans les lésions précancéreuses pancréatiques et leurs implications en clinique. Gastroenterologie Clinique Et Biologique, 2009, 33, e1-e9.	0.9	1
1945	Transperitoneal Laparoscopic Prostatectomy Does Not Increase Small Bowel Within the Target Volume for Postoperative Radiotherapy. Journal of Urology, 2009, 182, 2280-2284.	0.2	4
1946	Laparoscopic Versus Open Proctectomy for Rectal Cancer. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2009, 19, 118-122.	0.4	13
1947	UV radiation, vitamin D and epidermal carcinogenesis. Expert Review of Dermatology, 2009, 4, 557-566.	0.3	0
1948	Initial Diagnosis of Mediastinal Lymph Node Metastases From Prostate Cancer by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration. Journal of Bronchology and Interventional Pulmonology, 2009, 16, 59-60.	0.8	3
1950	Extra-abdominal Metastases From Epithelial Ovarian Carcinoma. International Journal of Gynecological Cancer, 2009, 19, 611-614.	1.2	37
1951	Pattern of care and survival in older women with breast cancer in India. Journal of Radiotherapy in Practice, 2010, 9, 237-245.	0.2	3
1952	Vascular Endothelial Growth Factor Receptor 2-Specific Microbubbles for Molecular Ultrasound Detection of Prostate Cancer in a Rat Model. Investigative Radiology, 2010, 45, 675-684.	3.5	35
1953	Chronomodulated chemotherapy versus conventional chemotherapy for Advanced and /or Metastatic Colorectal Cancer. The Cochrane Library, 0, , .	1.5	О

#	Article	IF	CITATIONS
1954	Similarities and differences between smoking-related gene expression in nasal and bronchial epithelium. Physiological Genomics, 2010, 41, 1-8.	1.0	107
1956	TGF- \hat{l}^21 Reverses Inhibition of COX-2 With NS398 and Increases Invasion in Prostate Cancer Cells. American Journal of the Medical Sciences, 2010, 339, 425-432.	0.4	6
1957	Assessment of tissue redox status using metabolic responsive contrast agents and magnetic resonance imaging. Journal of Pharmacy and Pharmacology, 2010, 60, 1049-1060.	1.2	78
1958	Imaging ovarian cancer and peritoneal metastasesâ€"current and emerging techniques. Nature Reviews Clinical Oncology, 2010, 7, 381-393.	12.5	108
1959	Evaluación de la expresión de la subunidad p22 phox de la NADPH oxidasa (NOX) en cáncer de próstata e hiperplasia prostática benigna: estudio comparativo. Actas Urológicas Españolas, 2010, 34, 340-345.	0.3	1
1960	Diagnosis of bladder cancer: contrast-enhanced ultrasound. Abdominal Imaging, 2010, 35, 494-503.	2.0	32
1961	Radiofrequency Ablation of Liver Metastases—Software-Assisted Evaluation of the Ablation Zone in MDCT: Tumor-Free Follow-Up Versus Local Recurrent Disease. CardioVascular and Interventional Radiology, 2010, 33, 297-306.	0.9	17
1963	Vitamin D and the skin. Journal of Bone and Mineral Metabolism, 2010, 28, 117-130.	1.3	72
1964	Place du ganglion sentinelle dans le cancer du col de l'utérus en 2009. Oncologie, 2010, 12, 45-48.	0.2	2
1965	Web-based Training Method for Interpretation of Dental Images. Journal of Digital Imaging, 2010, 23, 493-500.	1.6	4
1966	Application of Boosting Classification and Regression to Modeling the Relationships Between Trace Elements and Diseases. Biological Trace Element Research, 2010, 134, 146-159.	1.9	7
1967	α-Mangostin Suppresses Phorbol 12-myristate 13-acetate-Induced MMP-2/MMP-9 Expressions via αvβ3 Integrin/FAK/ERK and NF-κB Signaling Pathway in Human Lung Adenocarcinoma A549 Cells. Cell Biochemistry and Biophysics, 2010, 58, 31-44.	0.9	89
1968	Downregulation of ABI1 expression affects the progression and prognosis of human gastric carcinoma. Medical Oncology, 2010, 27, 632-639.	1.2	43
1969	Establishment and characterization of androgen-independent human prostate cancer cell lines, PcBra1, PcBra2, and PcBra3. In Vitro Cellular and Developmental Biology - Animal, 2010, 46, 123-130.	0.7	0
1970	Plumbagin inhibits TPA-induced MMP-2 and u-PA expressions by reducing binding activities of NF-κB and AP-1 via ERK signaling pathway in A549 human lung cancer cells. Molecular and Cellular Biochemistry, 2010, 335, 181-193.	1.4	71
1971	Overexpression of Kif2a promotes the progression and metastasis of squamous cell carcinoma of the oral tongue. Oral Oncology, 2010, 46, 65-69.	0.8	45
1972	STAMP alters the growth of transformed and ovarian cancer cells. BMC Cancer, 2010, 10, 128.	1.1	6
1973	Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells. BMC Cancer, 2010, 10, 391.	1.1	30

#	ARTICLE	IF	CITATIONS
1974	Trends in the incidence and survival of multiple myeloma in South East England 1985-2004. BMC Cancer, 2010, 10, 74.	1.1	20
1975	Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients. World Journal of Surgical Oncology, 2010, 8, 30.	0.8	11
1976	Female breast cancer mortality clusters within racial groups in the United States. Health and Place, 2010, 16, 209-218.	1.5	30
1977	Molecular characterization of commonly used cell lines for bone tumor research: A transâ€European EuroBoNet effort. Genes Chromosomes and Cancer, 2010, 49, 40-51.	1.5	141
1978	Addressing cancer health disparities using a global biopsychosocial approach. Cancer, 2010, 116, 264-269.	2.0	13
1979	The impact of reâ€excision of inadequately resected soft tissue sarcomas on surgical therapy, results, and prognosis: A single institution experience with 682 patients. Journal of Surgical Oncology, 2010, 102, 626-633.	0.8	31
1980	Pre-resuscitation factors associated with mortality in 49,130 cases of in-hospital cardiac arrest: A report from the National Registry for Cardiopulmonary Resuscitation. Resuscitation, 2010, 81, 302-311.	1.3	161
1981	Mouse models for unraveling the importance of diet in colon cancer prevention. Journal of Nutritional Biochemistry, 2010, 21, 77-88.	1.9	60
1982	Age–period–cohort analysis of colorectal cancer in East Anglia, 1971–2005. Cancer Epidemiology, 2010, 34, 232-237.	0.8	6
1983	Polymorphisms of glutathione-S-transferase M1 and T1 and prostate cancer risk in a Tunisian population. Cancer Epidemiology, 2010, 34, 598-603.	0.8	25
1984	Identification of racial disparities in breast cancer mortality: does scale matter?. International Journal of Health Geographics, 2010, 9, 35.	1.2	25
1985	Molecular characterization of the Gγâ€globinâ€₹ag transgenic mouse model of hormone refractory prostate cancer: Comparison to human prostate cancer. Prostate, 2010, 70, 630-645.	1.2	9
1986	Chemoprevention of skin cancer by the flavonoid fraction of <i>Saraca asoka</i> . Phytotherapy Research, 2010, 24, 666-672.	2.8	25
1987	ILâ€1β induces expression of matrix metalloproteinaseâ€9 and cell migration via a câ€Srcâ€dependent, growth factor receptor transactivation in A549 cells. British Journal of Pharmacology, 2010, 160, 1595-1610.	2.7	74
1988	Strong cytotoxic effect of the bradykinin antagonist BKM \hat{a} \in 570 in ovarian cancer cells \hat{a} \in " analysis of the molecular mechanisms of its antiproliferative action. FEBS Journal, 2010, 277, 5146-5160.	2.2	25
1989	Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 66-73.	0.7	6
1990	Plasma concentrations of VCAMâ€l and PAlâ€l: A predictive biomarker for postâ€operative recurrence in colorectal cancer. Cancer Science, 2010, 101, 1886-1890.	1.7	38
1991	Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx. Laryngoscope, 2010, 113, 1944-1948.	1.1	59

#	Article	IF	Citations
1992	Acacetin Inhibits TPAâ€Induced MMPâ€2 and uâ€PA Expressions of Human Lung Cancer Cells Through Inactivating JNK Signaling Pathway and Reducing Binding Activities of NFâ€PB and APâ€1. Journal of Food Science, 2010, 75, H30-8.	1.5	37
1993	Gene Expression Analysis for Tumor Profiling. , 2010, , 225-241.		0
1994	NSAIDs: Old Drugs Reveal New Anticancer Targets. Pharmaceuticals, 2010, 3, 1652-1667.	1.7	48
1995	Cigarette Smoke Alters Tissue Inhibitor of Metalloproteinase 1 and Matrix Metalloproteinase 9 Levels in the Basolateral Secretions of Human Asthmatic Bronchial Epithelium In Vitro. Journal of Investigative Medicine, 2010, 58, 725-729.	0.7	18
1996	Targeted Therapies in Epithelial Ovarian Cancers. Cancers, 2010, 2, 88-113.	1.7	12
1997	Expression of p53, p16 and Ki67 proteins in ductal adenocarcinoma of the pancreatic head and their relation with survival and cell differentiation. Einstein (Sao Paulo, Brazil), 2010, 8, 444-448.	0.3	0
1998	Evaluation of the heme oxygenase-1 expression in esophagitis and esophageal cancer induced by different reflux experimental models and diethylnitrosamine. Acta Cirurgica Brasileira, 2010, 25, 304-310.	0.3	8
1999	The Histopathology of Skeletal Metastases. , 2010, , 243-250.		4
2000	Outcome of Colonic Surgery in Elderly Patients with Colon Cancer. Journal of Oncology, 2010, 2010, 1-5.	0.6	84
2001	Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. Annals of Oncology, 2010, 21, 2201-2205.	0.6	41
2002	Confirmation of Linkage to and Localization of Familial Colon Cancer Risk Haplotype on Chromosome 9q22. Cancer Research, 2010, 70, 5409-5418.	0.4	42
2003	Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer. Therapeutic Advances in Medical Oncology, 2010, 2, 319-329.	1.4	45
2004	Topographical Sensitivity and Specificity of Endorectal Coil Magnetic Resonance Imaging for Prostate Cancer Detection. Urologia Internationalis, 2010, 84, 388-394.	0.6	17
2005	MicroRNA Expression Profiling of Oral Carcinoma Identifies New Markers of Tumor Progression. International Journal of Immunopathology and Pharmacology, 2010, 23, 1229-1234.	1.0	218
2006	The Role of Phytonutrients in Skin Health. Nutrients, 2010, 2, 903-928.	1.7	85
2007	The Synergistic Effect of Recombinant Human Endostatin (YH-16) Combined with Oxaliplatin on Human Colorectal Carcinoma. Journal of International Medical Research, 2010, 38, 111-126.	0.4	8
2009	MUC1 immunotherapy. Immunotherapy, 2010, 2, 305-327.	1.0	120
2010	Influence of Sex Hormones on Cancer Progression. Journal of Clinical Oncology, 2010, 28, 4038-4044.	0.8	171

#	Article	IF	CITATIONS
2011	T Cell-Tumor Interaction Directs the Development of Immunotherapies in Head and Neck Cancer. Clinical and Developmental Immunology, 2010, 2010, 1-14.	3.3	33
2012	Prospective efficacy of molecular preoperative diagnostics of papillary thyroid carcinoma. Acta Medica Lituanica, 2010, 17, 35-39.	0.2	0
2013	Human papillomavirus prevalence in invasive cervical carcinomas in Bulgaria. Journal of Clinical Pathology, 2010, 63, 1121-1123.	1.0	5
2014	A Quest for Initiating Cells of Head and Neck Cancer and Their Treatment. Cancers, 2010, 2, 1528-1554.	1.7	3
2015	Caring for cancer patients on non-specialist wards. British Journal of Nursing, 2010, 19, 761-767.	0.3	41
2016	Upper Gastrointestinal Cancer Predisposition Syndromes. Hematology/Oncology Clinics of North America, 2010, 24, 815-835.	0.9	12
2017	Dysphagia as a Cause of Chest Pain: An Otolaryngologist's View. Medical Clinics of North America, 2010, 94, 243-257.	1.1	0
2018	Ablation of Liver Metastases: Current Status. Journal of Vascular and Interventional Radiology, 2010, 21, S214-S222.	0.2	30
2019	Prostate-specific Antigen Testing and Prostate Cancer Screening. Primary Care - Clinics in Office Practice, 2010, 37, 441-459.	0.7	11
2020	Interferon-gamma in Brain Tumor Immunotherapy. Neurosurgery Clinics of North America, 2010, 21, 77-86.	0.8	36
2021	The Differences between Male and Female Breast Cancer. , 2010, , 459-472.		5
2022	Positron emission tomography for the detection of colorectal adenomas. Digestive and Liver Disease, 2010, 42, 185-190.	0.4	16
2024	EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy. Gastrointestinal Endoscopy, 2010, 71, 513-518.	0.5	148
2025	Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer, 2010, 67, 170-176.	0.9	301
2026	Restoration of Oral and Craniofacial Defects by Stem Cells and Bioengineering Approaches. , 2010, , 359-370.		0
2027	Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells. Molecular Cancer, 2010, 9, 47.	7.9	60
2028	Evaluation of the expression of p22 phox subunit of NADPH oxidase (NOX) in prostate cancer and benign prostatic hyperplasia: A comparative study. Actas Urológicas Españolas (English Edition), 2010, 34, 340-345.	0.2	0
2029	Inhibition of Breast Cancer Cell Growth and Invasiveness by Dual Silencing of HER-2 and VEGF. Molecular Pharmaceutics, 2010, 7, 543-556.	2.3	42

#	Article	IF	CITATIONS
2030	Prophylactic mastectomy for the prevention of breast cancer. The Cochrane Library, 2010, , CD002748.	1.5	229
2031	MicroRNAs, ultraconserved genes and colorectal cancers. International Journal of Biochemistry and Cell Biology, 2010, 42, 1291-1297.	1.2	46
2032	Dihydroartemisinin inactivates NF-κB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Letters, 2010, 293, 99-108.	3.2	149
2033	Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer. Cancer Treatment Reviews, 2010, 36, 8-15.	3.4	2
2034	Renal cell carcinoma in patients with a solitary kidney after nephrectomy treated with radiofrequency ablation: Mid term results. European Journal of Radiology, 2010, 73, 652-656.	1.2	46
2035	Fertility-sparing surgery in young women with invasive epithelial ovarian cancer. European Journal of Surgical Oncology, 2010, 36, 404-408.	0.5	68
2036	Opium consumption and risk of bladder cancer: A case-control analysis. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 610-616.	0.8	39
2037	Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with thoracic esophageal squamous cell carcinoma: A report of 1077 cases. Radiotherapy and Oncology, 2010, 95, 229-233.	0.3	72
2038	Role of PET/CT in Ovarian Cancer. American Journal of Roentgenology, 2010, 194, W464-W470.	1.0	63
2039	A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nature Communications, 2011, 2, 600.	5.8	67
2040	Socioeconomic Factors and Diagnosis of Uveal Melanoma in the Mid-Southern United States. Current Eye Research, 2011, 36, 824-830.	0.7	10
2041	Diagnosis of Early Stage Ovarian Cancer by ¹ H NMR Metabonomics of Serum Explored by Use of a Microflow NMR Probe. Journal of Proteome Research, 2011, 10, 1765-1771.	1.8	70
2042	Optical Observation of Lung Cancer With Attenuated Total Reflectance–Fourier Transform Infrared Microscope (ATR-FTIR) and Confocal Raman Microscope. Spectroscopy Letters, 2011, 44, 312-317.	0.5	8
2043	Diseases of the testis and epididymis. , 2011, , 593-620.		4
2044	Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. British Journal of Cancer, 2011, 105, 1288-1294.	2.9	62
2045	Classification histologique des cancers broncho-pulmonaires non à petites cellules. Revue Des Maladies Respiratoires Actualites, 2011, 3, 295-301.	0.0	1
2046	An Evidence-based Perspective of Herbal Remedies for Cancer Patients. Evidence-based Anticancer Complementary and Alternative Medicine, 2011, , 409-432.	0.1	0
2047	Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients. Lung Cancer, 2011, 74, 124-131.	0.9	57

#	Article	IF	CITATIONS
2048	Molecular Targeted Therapy in Ovarian Cancer. Drugs, 2011, 71, 947-967.	4.9	14
2049	Comparison of three malignancy risk indices and CA-125 in the preoperative evaluation of patients with pelvic masses. BMC Research Notes, 2011, 4, 206.	0.6	16
2050	Orthotopic Models of Esophageal Carcinoma and Their Use in Drug Discovery. Current Protocols in Pharmacology, 2011, 54, Unit14.20.	4.0	5
2051	Cancer in Long-Term Care. Clinics in Geriatric Medicine, 2011, 27, 301-327.	1.0	2
2052	Orai1/CRACM1 overexpression suppresses cell proliferation via attenuation of the store-operated calcium influx-mediated signalling pathway in A549 lung cancer cells. Biochimica Et Biophysica Acta - General Subjects, 2011, 1810, 1278-1284.	1.1	52
2053	A potential role of ruxolitinib in leukemia. Expert Opinion on Investigational Drugs, 2011, 20, 1159-1166.	1.9	13
2054	Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994. International Journal of Gynecology and Obstetrics, 2011, 114, 133-136.	1.0	20
2055	Korean Scutellaria baicalensis water extract inhibits cell cycle G1/S transition by suppressing cyclin D1 expression and matrix-metalloproteinase-2 activity in human lung cancer cells. Journal of Ethnopharmacology, 2011, 133, 634-641.	2.0	59
2056	Synthesis and Biological Evaluation of (6- and 7-Phenyl) Coumarin Derivatives as Selective Nonsteroidal Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1. Journal of Medicinal Chemistry, 2011, 54, 248-261.	2.9	61
2057	Do Young Patients with Colorectal Cancer Have a Poorer Prognosis than Old Patients?. Journal of Surgical Research, 2011, 167, 231-236.	0.8	31
2058	Biochemical observations in rats fed with cycads, Nigerian-like and western-like folic acid supplemented diets. African Journal of Biotechnology, 2011, 10, 8101-8106.	0.3	1
2059	HÃBITOS ALIMENTARIOS Y RIESGO DE CANCER DE PIEL NO MELANOMA. Revista Chilena De Nutricion, 2011, 38, 15-21.	0.1	O
2060	Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma. Sao Paulo Medical Journal, 2011, 129, 371-379.	0.4	4
2061	WT1/EGR1-mediated control of STIM1 expression and function in cancer cells. Frontiers in Bioscience - Landmark, 2011, 16, 2402.	3.0	21
2062	Smoking and polymorphisms in folate metabolizing genes and their effects on the histological stage and grade for bladder tumors. Bulletin Du Cancer, 2011, 98, E1-E10.	0.6	8
2063	Current Perspectives on Immunomodulation of NK Cells in Melanoma. , 0, , .		1
2064	Determinants of Altered Life Perspectives Among Older-Adult Long-term Cancer Survivors. Cancer Nursing, 2011, 34, 209-218.	0.7	14
2065	Genome-Wide De Novo Methylation in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2011, 21, 269-279.	1.2	16

#	Article	IF	CITATIONS
2066	Role of ultrasound in the diagnosis of testicular lesions. Imaging in Medicine, 2011, 3, 587-595.	0.0	4
2067	Detection of lung cancer with blood microRNA-21 expression levels in Chinese population. Oncology Letters, 2011, 2, 991-994.	0.8	35
2068	Renal mass sampling: An enlightened perspective. International Journal of Urology, 2011, 18, 5-19.	0.5	47
2069	Functional variant (â^'1304T>G) in the <i>MKK4</i> promoter is associated with decreased risk of acute myeloid leukemia in a southern Chinese population. Cancer Science, 2011, 102, 1462-1468.	1.7	13
2070	Biopsychosocial Assessment Criteria for Functional Chronic Visceral Pain: A Pilot Review of Concept and Practice. Pain Medicine, 2011, 12, 552-564.	0.9	5
2071	Andrographolide down-regulates hypoxia-inducible factor- $\hat{\Pi}_{\pm}$ in human non-small cell lung cancer A549 cells. Toxicology and Applied Pharmacology, 2011, 250, 336-345.	1.3	57
2072	Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 841-849.	1.7	88
2073	Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary. Gynecologic Oncology, 2011, 122, 334-338.	0.6	34
2074	Predictive value of pathological and immunohistochemical parameters for axillary lymph node metastasis in breast carcinoma. Diagnostic Pathology, 2011, 6, 18.	0.9	26
2075	The association of Streptococcus bovis/gallolyticus with colorectal tumors: The nature and the underlying mechanisms of its etiological role. Journal of Experimental and Clinical Cancer Research, 2011, 30, 11.	3.5	249
2076	Increased expression of Toll-like receptor-9 has close relation with tumour cell proliferation in oral squamous cell carcinoma. Archives of Oral Biology, 2011, 56, 877-884.	0.8	29
2077	Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2011, 91, 1668-1673.	0.7	67
2078	Cudratricusxanthone G inhibits human colorectal carcinoma cell invasion by MMP-2 down-regulation through suppressing activator protein-1 activity. Biochemical Pharmacology, 2011, 81, 1192-1200.	2.0	16
2079	Clinical outcomes of fertility-sparing treatments in young patients with epithelial ovarian carcinoma. Journal of Zhejiang University: Science B, 2011, 12, 787-795.	1.3	21
2080	Complications of Esophageal Surgery: Role of Imaging in Diagnosis and Treatments. Current Problems in Diagnostic Radiology, 2011, 40, 15-28.	0.6	10
2081	A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Investigational New Drugs, 2011, 29, 1045-1049.	1.2	75
2082	Estimating treatment effects on healthcare costs under exogeneity: is there a â€~magic bullet'?. Health Services and Outcomes Research Methodology, 2011, 11, 1-26.	0.8	26
2083	Solitary pulmonary nodules: consequences for patient quality of life. Quality of Life Research, 2011, 20, 101-109.	1.5	21

#	Article	IF	Citations
2084	PKCα take part in CCR7/NF-κB autocrine signaling loop in CCR7-positive squamous cell carcinoma of head and neck. Molecular and Cellular Biochemistry, 2011, 357, 181-187.	1.4	20
2085	Expression of EMSY gene in sporadic ovarian cancer. Molecular Biology Reports, 2011, 38, 359-363.	1.0	9
2086	Quantitative analysis of TEM-8 and CEA tumor markers indicating free tumor cells in the peripheral blood of colorectal cancer patients. International Journal of Colorectal Disease, 2011, 26, 1265-1270.	1.0	24
2087	The use of MRI for selecting patients with endometrial cancer and significant co-morbidities for vaginal hysterectomy. Archives of Gynecology and Obstetrics, 2011, 283, 1097-1101.	0.8	9
2088	XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 502-510.	2.2	28
2089	Usefulness of percutaneous biopsy in diagnosing benign renal masses that mimic malignancy. Abdominal Imaging, 2011, 36, 91-101.	2.0	23
2090	Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology, 2011, 67, 519-525.	1.1	9
2091	A stochastic approach to risk management for prostate cancer patients on active surveillance. Journal of Theoretical Biology, 2011, 284, 61-70.	0.8	2
2092	Classification Models for Detection of Lung Cancer Based on Nine Element Distribution of Urine Samples. Biological Trace Element Research, 2011, 142, 18-28.	1.9	12
2093	α-Tomatine Suppresses Invasion and Migration of Human Non-Small Cell Lung Cancer NCI-H460 Cells Through Inactivating FAK/PI3K/Akt Signaling Pathway and Reducing Binding Activity of NF-κB. Cell Biochemistry and Biophysics, 2011, 60, 297-310.	0.9	59
2094	Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549. Medical Oncology, 2011, 28, 565-571.	1.2	38
2095	Incidence of colorectal cancer in Kashmir valley, India. Indian Journal of Gastroenterology, 2011, 30, 7-11.	0.7	33
2096	High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. Journal of Translational Medicine, 2011, 9, 31.	1.8	44
2097	Modeling microRNA-mRNA Interactions Using PLS Regression in Human Colon Cancer. BMC Medical Genomics, 2011, 4, 44.	0.7	45
2098	Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients. Journal of Surgical Oncology, 2011, 103, 518-530.	0.8	36
2099	Tobacco carcinogen mediated upâ€regulation of APâ€1 dependent proâ€angiogenic cytokines in head and neck carcinogenesis. Molecular Carcinogenesis, 2011, 50, 668-679.	1.3	30
2100	RANKL increases migration of human lung cancer cells through intercellular adhesion moleculeâ€1 upâ€regulation. Journal of Cellular Biochemistry, 2011, 112, 933-941.	1.2	68
2102	Synthetic Antitumor Vaccines Containing MUC1 Glycopeptides with Two Immunodominant Domains—Induction of a Strong Immune Response against Breast Tumor Tissues. Angewandte Chemie - International Edition, 2011, 50, 9977-9981.	7.2	90

#	ARTICLE	IF	Citations
2103	Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Nonâ€"Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer, 2011, 12, 138-141.	1.1	15
2104	17,20-Lyase inhibitors. Part 4: Design, synthesis and structure–activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 1751-1770.	1.4	14
2105	Estimation of premature mortality from oral cancer in Japan, 1995 and 2005. Cancer Epidemiology, 2011, 35, 342-344.	0.8	10
2106	Over-expression of Gadd45a enhances radiotherapy efficacy in human Tca8113 cell line. Acta Pharmacologica Sinica, 2011, 32, 253-258.	2.8	12
2107	Efficacy of Ultrasound-Guided Percutaneous Ethanol Injection Treatment in Patients with a Limited Number of Metastatic Cervical Lymph Nodes from Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2750-2755.	1.8	121
2108	Locoregional Control of Metastatic Well-Differentiated Thyroid Cancer by Ultrasound-Guided Radiofrequency Ablation. American Journal of Roentgenology, 2011, 197, W331-W336.	1.0	132
2109	Comparison of different phosphorus-containing ligands complexing 68Ga for PET-imaging of bone metabolism. Radiochimica Acta, 2011, 99, 43-51.	0.5	35
2110	Introduction: Epidemiology, Risk Factors, Pathology, and Natural History of Head and Neck Neoplasms. Medical Radiology, 2011, , 1-17.	0.0	O
2111	Epithelial-Mesenchymal Transition (EMT) Protein Expression in a Cohort of Stage II Colorectal Cancer Patients With Characterized Tumor Budding and Mismatch Repair Protein Status. International Journal of Surgical Pathology, 2011, 19, 751-760.	0.4	59
2112	Breast Cancer Screening and Problem Solving Using Mammography, Ultrasound, and Magnetic Resonance Imaging. Ultrasound Quarterly, 2011, 27, 23-47.	0.3	36
2113	Detection of Bladder Cancer Recurrence with Real-Time Three-Dimensional Ultrasonography-Based Virtual Cystoscopy. Journal of International Medical Research, 2011, 39, 2264-2272.	0.4	7
2114	Coordinated Cancer Germline Antigen Promoter and Global DNA Hypomethylation in Ovarian Cancer: Association with the <i>BORIS/CTCF</i> Expression Ratio and Advanced Stage. Clinical Cancer Research, 2011, 17, 2170-2180.	3.2	85
2115	Evaluation of Diffusion-Weighted Magnetic Resonance Imaging and Contrast-Enhanced Harmonic Ultrasonography in Detection and Location of Prostate Transition-Zone Cancer. Journal of International Medical Research, 2011, 39, 256-266.	0.4	5
2116	Increased Expression of MicroRNA-21 and Its Association with Chemotherapeutic Response in Human Colorectal Cancer. Journal of International Medical Research, 2011, 39, 2288-2295.	0.4	33
2117	Outcomes of Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma. Journal of Skin Cancer, 2011, 2011, 1-6.	0.5	23
2118	Thyroid Carcinoma in Children and Adolescentsâ€"Systematic Review of the Literature. Journal of Thyroid Research, 2011, 2011, 1-7.	0.5	63
2119	Long-term results of adjuvant radiotherapy in stage I endometrial cancer. Turk Onkoloji Dergisi, 2011, 26, 2-11.	0.0	0
2120	Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells. American Journal of Physiology - Renal Physiology, 2011, 301, G347-G355.	1.6	28

#	Article	IF	CITATIONS
2121	Metastatic Ovarian and Primary Peritoneal Cancer: Assessing Chemotherapy Response with Diffusion-weighted MR Imagingâ€"Value of Histogram Analysis of Apparent Diffusion Coefficients. Radiology, 2011, 261, 182-192.	3.6	211
2122	Detection of <i>HOXA9</i> gene methylation in tumor tissues and induced sputum samples from primary lung cancer patients. Clinical Chemistry and Laboratory Medicine, 2011, 49, 699-704.	1.4	49
2123	Screening for Prostate Cancer by Digital Rectal Examination and PSA Determination in Senegal. ISRN Oncology, 2011, 2011, 1-4.	2.1	9
2124	Endoscopic Palliation for Pancreatic Cancer. Cancers, 2011, 3, 1947-1956.	1.7	6
2125	Overexpression of Hedgehog Signaling Is Associated with Epidermal Tumor Formation in Vitamin D Receptor–Null Mice. Journal of Investigative Dermatology, 2011, 131, 2289-2297.	0.3	91
2126	Lung Cancer and Interstitial Lung Diseases: A Systematic Review. Pulmonary Medicine, 2012, 2012, 1-11.	0.5	73
2127	Preoperative FDG-PET/CT Is an Important Tool in the Management of Patients with Thick (T4) Melanoma. Dermatology Research and Practice, 2012, 2012, 1-6.	0.3	10
2128	Aberrant Methylation in Promoters of <i>GSTP1</i> , <i>p16</i> , <i>p14</i> , and <irassf1a< i=""> Genes in Smokers of North India. ISRN Pulmonology, 2012, 2012, 1-6.</irassf1a<>	0.3	5
2129	Posttraumatic stress disorders in long-term Egyptian survivors after childhood cancer. Middle East Current Psychiatry, 2012, 19, 40-47.	0.5	0
2130	Comparative immunopathological study of cyclooxygenase-2, p53, and vascular endothelial growth factor in normal, premalignant, and malignant oral mucosa. Egyptian Journal of Oral & Maxillofacial Surgery, 2012, 3, 70-77.	0.0	0
2131	The effect of MELatOnin on Depression, anxietY, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: protocol for a randomised, placebo-controlled, double-blinded trial. BMJ Open, 2012, 2, e000647.	0.8	37
2132	The role of lycopene and its derivatives in the regulation of transcription systems: implications for cancer prevention. American Journal of Clinical Nutrition, 2012, 96, 1173S-1178S.	2.2	58
2133	Evaluating the association between endometrial cancer and polycystic ovary syndrome. Human Reproduction, 2012, 27, 1327-1331.	0.4	189
2134	Effects to exposure of tobacco smoke and alcohol on the tongue and pharynx of rats. Inhalation Toxicology, 2012, 24, 153-160.	0.8	9
2135	Chemoprevention of Two-Stage Skin Cancer In vivo by <i>Saraca asoca</i> . Integrative Cancer Therapies, 2012, 11, 279-286.	0.8	21
2136	KHC-4 Anti-Cancer Effects on Human PC3 Prostate Cancer Cell Line. The American Journal of Chinese Medicine, 2012, 40, 1063-1071.	1.5	12
2137	LMX1A as a Prognostic Marker in Ovarian Mucinous Cystadenocarcinoma. American Journal of Clinical Pathology, 2012, 137, 971-977.	0.4	6
2138	Screening for Familial Colorectal Cancer Risk amongst Colonoscopy Patients New to an Open-Access Endoscopy Center. ISRN Gastroenterology, 2012, 2012, 1-8.	1.5	1

#	Article	IF	CITATIONS
2139	Implication of DNA Methylation Profiling in Oral Epithelium for Lung Cancer Screening. ISRN Pulmonology, 2012, 2012, 1-6.	0.3	0
2140	A Case Report of Surgical Resections with Local and Systemic Chemotherapy for Three Recurrences of Colon Cancer Occurring Ten Years after Colectomy. Case Reports in Oncology, 2012, 5, 373-379.	0.3	2
2141	Chemokine receptor 7 via proline-rich tyrosine kinase-2 upregulates the chemotaxis and migration ability of squamous cell carcinoma of the head and neck. Oncology Reports, 2012, 28, 1659-1664.	1.2	14
2142	Clinical significance of GADD153 expression in stage I non-small cell lung cancer. Oncology Letters, 2012, 4, 408-412.	0.8	8
2143	Annexin A5 protein expression is associated with the histological differentiation of uterine cervical squamous cell carcinoma in patients with an increased serum concentration. Molecular Medicine Reports, 2012, 6, 1249-1254.	1.1	10
2144	Tongue Cancer and Epigenetic Factors: An in-vitro Study on 298 Micro-RNAS. European Journal of Inflammation, 2012, 10, 447-454.	0.2	0
2145	Evaluation of serum highâ€density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1635-1640.	1.4	49
2146	Tumor budding in colorectal carcinoma: time to take notice. Modern Pathology, 2012, 25, 1315-1325.	2.9	238
2147	Design, Synthesis, and Evaluation of pH-Dependent Hydrolyzable Emetine Analogues as Treatment for Prostate Cancer. Journal of Medicinal Chemistry, 2012, 55, 7450-7459.	2.9	28
2148	Differential proteomic analysis of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular proteins associated with bone metastasis. Journal of Proteome Research, 2012, 11, 2247-2260.	1.8	23
2149	The Role of FDG-PET/CT in Ovarian Cancer Patients with High Tumor Markers or Suspicious Lesion on Contrast-Enhanced CT in Evaluation of Recurrence and/or in Determination of Intraabdominal Metastases. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2012, 31, 3-8.	0.0	15
2150	The Role of FDG-PET/CT in Ovarian Cancer Patients with High Tumor Markers or Suspicious Lesion on Contrast-Enhanced CT in Evaluation of Recurrence and/or in Determination of Intraabdominal Metastases. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2012, 31, 3-8.	0.1	0
2152	Locoregional Recurrence after Mastectomy with Immediate Transverse Rectus Abdominis Myocutaneous (TRAM) Flap Reconstruction. Annals of Surgical Oncology, 2012, 19, 2679-2684.	0.7	27
2153	Molecular-targeted therapies for ovarian cancer: prospects for the future. International Journal of Clinical Oncology, 2012, 17, 424-429.	1.0	28
2154	Solitary metachronous gastric metastasis from pulmonary adenocarcinoma: Report of a case. International Journal of Surgery Case Reports, 2012, 3, 385-388.	0.2	21
2155	Tumor characteristics and recurrence patterns in triple negative breast cancer: A comparison between younger (<65) and elderly (⩾65) patients. European Journal of Cancer, 2012, 48, 2962-2968.	1.3	25
2156	L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial. Nutrition Journal, 2012, 11, 52.	1.5	93
2157	Osteoblast-secreted collagen upregulates paracrine Sonic hedgehog signaling by prostate cancer cells and enhances osteoblast differentiation. Molecular Cancer, 2012, 11, 30.	7.9	23

#	Article	IF	Citations
2158	CIAPIN1 nuclear accumulation predicts poor clinical outcome in epithelial ovarian cancer. World Journal of Surgical Oncology, 2012, 10, 112.	0.8	8
2159	Analysis of aberrant methylation on promoter sequences of tumor suppressor genes and total DNA in sputum samples: a promising tool for early detection of COPD and lung cancer in smokers. Diagnostic Pathology, 2012, 7, 87.	0.9	56
2160	The emerging role of T cell cytokines in non-small cell lung cancer. Cytokine and Growth Factor Reviews, 2012, 23, 315-322.	3.2	33
2161	Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy. Gastrointestinal Endoscopy, 2012, 76, 962-971.	0.5	95
2162	68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Nuclear Medicine and Biology, 2012, 39, 993-999.	0.3	71
2163	Association between polymorphisms of DNA repair gene ERCC5 and oral squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012, 114, 624-629.	0.2	21
2164	Critical study of resection margins in adult soft-tissue sarcoma surgery. Orthopaedics and Traumatology: Surgery and Research, 2012, 98, S9-S18.	0.9	39
2165	Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients. Lung Cancer, 2012, 75, 110-118.	0.9	7 3
2166	Angiolymphatic invasion exerts a strong impact on surgical outcomes for stage I lung adenocarcinoma, but not non-adenocarcinoma. Lung Cancer, 2012, 77, 394-400.	0.9	33
2167	Role of Peroxisome Proliferator Activated Receptor-Gamma in Bacillus Calmette-Guérin Bladder Cancer Therapy. Journal of Urology, 2012, 188, 2384-2390.	0.2	17
2168	Malignant and benign thyroid nodules after total body irradiation preceding hematopoietic cell transplantation during childhood. European Journal of Endocrinology, 2012, 167, 225-233.	1.9	29
2169	Cancer Stem Cells of the Head and Neck. Stem Cells and Cancer Stem Cells, 2012, , 275-286.	0.1	0
2170	CEUS in the differentiation between low and high-grade bladder carcinoma. Journal of Ultrasound, 2012, 15, 247-251.	0.7	21
2171	Tumor Multiplicity Is an Independent Prognostic Factor of Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin Immunotherapy. Ultrastructural Pathology, 2012, 36, 320-324.	0.4	18
2172	Protective actions of vitamin D in UVB induced skin cancer. Photochemical and Photobiological Sciences, 2012, 11, 1808-1816.	1.6	39
2173	Impact of DNA polymorphisms in key DNA base excision repair proteins on cancer risk. Human and Experimental Toxicology, 2012, 31, 981-1005.	1.1	106
2174	Role of Neoadjuvant Chemotherapy (NACT) Followed by Surgical Cytoreduction in Advanced Epithelial Ovarian Cancer. Journal of Obstetrics and Gynecology of India, 2012, 62, 541-545.	0.3	3
2175	Inflammatory Transcriptome Profiling of Human Monocytes Exposed Acutely to Cigarette Smoke. PLoS ONE, 2012, 7, e30120.	1.1	44

#	Article	IF	CITATIONS
2176	Zoledronic Acid as an Adjuvant Therapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2012, 7, e40783.	1.1	17
2177	Gynecologic. Medical Radiology, 2012, , 181-193.	0.0	0
2178	Recent Development and Trends in Molecular Imaging Probes for Prostate Cancer., 2012,,.		1
2179	Oncologists' use of patient educational materials about cancer and fertility preservation. Psycho-Oncology, 2012, 21, 1244-1249.	1.0	34
2180	Overexpression of CDC20 predicts poor prognosis in primary nonâ€small cell lung cancer patients. Journal of Surgical Oncology, 2012, 106, 423-430.	0.8	136
2181	EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head and Neck, 2012, 34, 681-686.	0.9	32
2182	Integrating multiple microarray datasets on oral squamous cell carcinoma to reveal dysregulated networks. Head and Neck, 2012, 34, 1789-1797.	0.9	8
2183	Disseminated tumor cells in pancreatic cancerâ€"an independent prognosticator of disease progression and survival. International Journal of Cancer, 2012, 131, E475-83.	2.3	30
2184	Surgical management of proximal bile duct cancers. Langenbeck's Archives of Surgery, 2012, 397, 869-879.	0.8	20
2185	Cancer of the bile ducts. , 2012, , 771-788.e4.		3
2185	Cancer of the bile ducts. , 2012, , 771-788.e4. Radiofrequency ablation of renal cell carcinoma in patients with a solitary kidney: a retrospective analysis of our experience. Radiologia Medica, 2012, 117, 606-615.	4.7	5
	Radiofrequency ablation of renal cell carcinoma in patients with a solitary kidney: a retrospective	4.7	
2186	Radiofrequency ablation of renal cell carcinoma in patients with a solitary kidney: a retrospective analysis of our experience. Radiologia Medica, 2012, 117, 606-615. Stadiazione preoperatoria locoregionale del carcinoma del colon-sigma: colonografia TC		5
2186 2187	Radiofrequency ablation of renal cell carcinoma in patients with a solitary kidney: a retrospective analysis of our experience. Radiologia Medica, 2012, 117, 606-615. Stadiazione preoperatoria locoregionale del carcinoma del colon-sigma: colonografia TC multidetettore con aria versus acqua. Radiologia Medica, 2012, 117, 254-267. Dietary Exposure Estimates of 14 Trace Elements in Xuanwei and Fuyuan, Two High Lung Cancer	4.7	5 24
2186 2187 2188	Radiofrequency ablation of renal cell carcinoma in patients with a solitary kidney: a retrospective analysis of our experience. Radiologia Medica, 2012, 117, 606-615. Stadiazione preoperatoria locoregionale del carcinoma del colon-sigma: colonografia TC multidetettore con aria versus acqua. Radiologia Medica, 2012, 117, 254-267. Dietary Exposure Estimates of 14 Trace Elements in Xuanwei and Fuyuan, Two High Lung Cancer Incidence Areas in China. Biological Trace Element Research, 2012, 146, 287-292.	4.7 1.9	5 24 25
2186 2187 2188 2189	Radiofrequency ablation of renal cell carcinoma in patients with a solitary kidney: a retrospective analysis of our experience. Radiologia Medica, 2012, 117, 606-615. Stadiazione preoperatoria locoregionale del carcinoma del colon-sigma: colonografia TC multidetettore con aria versus acqua. Radiologia Medica, 2012, 117, 254-267. Dietary Exposure Estimates of 14 Trace Elements in Xuanwei and Fuyuan, Two High Lung Cancer Incidence Areas in China. Biological Trace Element Research, 2012, 146, 287-292. Elements in Lung Tissues of Patients from a High Lung Cancer Incidence Area of China. Biological Trace Element Research, 2012, 148, 7-10. A Review of the Current Profile of Gastric Cancer Presentation in the University College Hospital Ibadan, a Tertiary Health Care Institution in the Tropics. Journal of Gastrointestinal Cancer, 2012, 43,	4.7 1.9	5 24 25 9
2186 2187 2188 2189 2190	Radiofrequency ablation of renal cell carcinoma in patients with a solitary kidney: a retrospective analysis of our experience. Radiologia Medica, 2012, 117, 606-615. Stadiazione preoperatoria locoregionale del carcinoma del colon-sigma: colonografia TC multidetettore con aria versus acqua. Radiologia Medica, 2012, 117, 254-267. Dietary Exposure Estimates of 14 Trace Elements in Xuanwei and Fuyuan, Two High Lung Cancer Incidence Areas in China. Biological Trace Element Research, 2012, 146, 287-292. Elements in Lung Tissues of Patients from a High Lung Cancer Incidence Area of China. Biological Trace Element Research, 2012, 148, 7-10. A Review of the Current Profile of Gastric Cancer Presentation in the University College Hospital Ibadan, a Tertiary Health Care Institution in the Tropics. Journal of Gastrointestinal Cancer, 2012, 43, 177-180. What is the impact of cervical invasion on lymph node metastasis in patients with stage IIIC	4.7 1.9 1.9	5 24 25 9

#	Article	IF	CITATIONS
2194	Stem cells in squamous head and neck cancer. Critical Reviews in Oncology/Hematology, 2012, 81, 224-240.	2.0	55
2195	Cytologic features and diagnostic accuracy of analysis of effusions for detection of ovarian carcinoma in dogs. Veterinary Clinical Pathology, 2012, 41, n/a-n/a.	0.3	17
2196	Electron beam radiotherapy for tongue cancer using an intra-oral cone. Oral Oncology, 2012, 48, 463-468.	0.8	1
2197	¿Está aumentando el cáncer cutáneo en nuestro paÃs?. Piel, 2012, 27, 295-299.	0.0	2
2198	Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma. Gynecologic Oncology, 2012, 126, 118-123.	0.6	29
2199	A review of the epidemiology of oral and pharyngeal carcinoma: update. Head & Neck Oncology, 2012, 4, 1.	2.3	103
2200	Adenocarcinomas of the Esophagogastric Junction Are More Likely to Respond to Preoperative Chemotherapy than Distal Gastric Cancer. Annals of Surgical Oncology, 2012, 19, 2108-2118.	0.7	65
2201	Immunotherapy for metastatic melanoma. Journal of Cellular Biochemistry, 2012, 113, 725-734.	1.2	14
2202	Vitamin D and the skin: Physiology and pathophysiology. Reviews in Endocrine and Metabolic Disorders, 2012, 13, 3-19.	2.6	162
2203	Transforming growth factor- \hat{l}^21 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways. Molecular Biology Reports, 2012, 39, 3549-3556.	1.0	118
2204	Surgical approaches to gastric cancer. Journal of Surgical Oncology, 2013, 107, 250-258.	0.8	20
2205	Association between MTHFR Ala222Val (rs1801133) polymorphism and bladder cancer susceptibility: a systematic review and meta-analysis. Tumor Biology, 2013, 34, 2565-2572.	0.8	3
2206	NBS1 rs1805794G>C polymorphism is associated with decreased risk of acute myeloid leukemia in a Chinese population. Molecular Biology Reports, 2013, 40, 3749-3756.	1.0	15
2207	Smoking-Related Cancer Epidemiology. , 2013, , 107-136.		1
2208	Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis. BMC Cancer, 2013, 13, 303.	1,1	45
2209	Minimally invasive surgery for colorectal cancer: quality of life and satisfaction with care in elderly patients. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 2911-2920.	1.3	29
2210	Telomerase as a potential marker for inflammation and cancer detection in bronchial washing: A prospective study. Clinical Biochemistry, 2013, 46, 1701-1704.	0.8	4
2211	Gastroprotective Effects of Bioactive Foods. , 2013, , 465-483.		2

#	Article	IF	Citations
2212	miR-137 suppresses cell growth in ovarian cancer by targeting AEG-1. Biochemical and Biophysical Research Communications, 2013, 441, 357-363.	1.0	59
2213	Optimal predictive value of preoperative serum carcinoembryonic antigen for surgical outcomes in stage I nonâ€small cell lung cancer: Differences according to histology and smoking status. Journal of Surgical Oncology, 2013, 107, 619-624.	0.8	13
2214	Late recurrence of stage la ovarian mucinous cystadenocarcinoma in teenage patients. Journal of Pediatric Surgery Case Reports, 2013, 1, 174-176.	0.1	0
2215	Mechanism of arctigenin-mediated specific cytotoxicity against human lung adenocarcinoma cell lines. Phytomedicine, 2013, 21, 39-46.	2.3	34
2216	Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. Medical Oncology, 2013, 30, 681.	1.2	48
2217	Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer. Biomarkers, 2013, 18, 679-686.	0.9	66
2218	Contrast-Enhanced Ultrasonography of the Testes. Ultrasound Clinics, 2013, 8, 509-523.	0.2	12
2219	Evaluation of lung flute in sputum samples for molecular analysis of lung cancer. Clinical and Translational Medicine, 2013, 2, 15.	1.7	48
2220	Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer, 2013, 13, 349.	1.1	98
2221	Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase. Molecular Cancer, 2013, 12, 54.	7.9	31
2222	In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour models. Nuclear Medicine and Biology, 2013, 40, 823-830.	0.3	38
2223	Zoledronate for Metastatic Bone Disease and Pain: A Meta-Analysis of Randomized Clinical Trials. Pain Medicine, 2013, 14, 257-264.	0.9	18
2224	Downregulation of G3BPs inhibits the growth, migration and invasion of human lung carcinoma H1299 cells by suppressing the Src/FAK-associated signaling pathway. Cancer Gene Therapy, 2013, 20, 622-629.	2.2	28
2225	Extracellular matrix protein fibronectin induces matrix metalloproteinases in human prostate adenocarcinoma cells PC-3. Cell Communication and Adhesion, 2013, 20, 105-114.	1.0	21
2226	Targeted radio-nuclide therapy of skeletal metastases. Cancer Treatment Reviews, 2013, 39, 18-26.	3.4	50
2227	Role of CT virtual colonoscopy versus conventional colonoscopy in the evaluation of colonic polyps. Egyptian Journal of Radiology and Nuclear Medicine, 2013, 44, 425-432.	0.3	0
2228	Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines. Translational Research, 2013, 161, 447-468.	2.2	19
2229	Association between polymorphisms in the promoter region of miR-143/145 and risk of colorectal cancer. Human Immunology, 2013, 74, 993-997.	1.2	58

#	Article	IF	CITATIONS
2230	Tumor Ablation. Ultrasound Clinics, 2013, 8, 171-183.	0.2	1
2231	Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma. Cancer Letters, 2013, 338, 47-56.	3.2	108
2232	Endoplasmic reticulum ribosome-binding protein 1 (RRBP1) overexpression is frequently found in lung cancer patients and alleviates intracellular stress-induced apoptosis through the enhancement of GRP78. Oncogene, 2013, 32, 4921-4931.	2.6	70
2233	Prognostic significance of CD151 overexpression in non-small cell lung cancer. Lung Cancer, 2013, 81, 109-116.	0.9	25
2234	Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies. Translational Research, 2013, 162, 77-92.	2.2	48
2235	Expression of the FUT2 gene and CD44 marker in patients with oral lesions. Inmunologia (Barcelona,) Tj ETQq $1\ 1$	0.784314	rgBT /Overl
2236	Ovarian cancer: lon channel and aquaporin expression as novel targets of clinical potential. European Journal of Cancer, 2013, 49, 2331-2344.	1.3	60
2237	Carbon nanotubes enhance the internalization of drugs by cancer cells and decrease their chemoresistance to cytostatics. Nanotechnology, 2013, 24, 045102.	1.3	28
2238	Effects of simvastatin and rosuvastatin on <scp>RAS</scp> protein, matrix metalloproteinases and NFâ€PB in lung cancer and in normal pulmonary tissues. Cell Proliferation, 2013, 46, 172-182.	2.4	35
2239	Inhibition of CK2 enhances UV-triggered apoptotic cell death in lung cancer cell lines. Oncology Reports, 2013, 30, 377-384.	1.2	17
2240	microRNA detection in feces, sputum, pleural effusion and urine: Novel tools for cancer screening (Review). Oncology Reports, 2013, 30, 535-544.	1.2	41
2241	Photodynamic Agents with Anti-metastatic Activities. ACS Chemical Biology, 2013, 8, 1737-1746.	1.6	28
2242	Maslinic acid inhibits the metastatic capacity of DU145 human prostate cancer cells: possible mediation via hypoxia-inducible factor- $1\hat{l}_{\pm}$ signalling. British Journal of Nutrition, 2013, 109, 210-222.	1.2	38
2243	MicroRNAâ€182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas. Journal of Cellular Biochemistry, 2013, 114, 1464-1473.	1.2	113
2244	Molecular Mechanisms of Castrate Resistant Prostate Cancer. , 2013, , 43-64.		1
2245	The effects of low-dose splenic irradiation and radiotherapy on immune system of patients with locally advanced non-small cell lung cancer. Chinese-German Journal of Clinical Oncology, 2013, 12, 51-55.	0.1	3
2246	Construction of the human miRNA-451 expression vector and its expression in gastric carcinoma cell line SGC-7901. Chinese-German Journal of Clinical Oncology, 2013, 12, 379-384.	0.1	0
2247	Characterizing the psychological distress response before and after a cancer diagnosis. Journal of Behavioral Medicine, 2013, 36, 591-600.	1.1	28

#	Article	IF	CITATIONS
2248	Multiplexed cytokine profiling of serum for detection of colorectal cancer. Future Oncology, 2013, 9, 1017-1027.	1.1	30
2249	The Protective Role of Vitamin D Signaling in Non-Melanoma Skin Cancer. Cancers, 2013, 5, 1426-1438.	1.7	17
2250	Inhibitory Effect of Baicalin and Baicalein on Ovarian Cancer Cells. International Journal of Molecular Sciences, 2013, 14, 6012-6025.	1.8	89
2251	Endoscopic Ultrasound–Guided Pancreatic Fiducial Placement. Pancreas, 2013, 42, 692-695.	0.5	39
2252	Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120–180. Anti-Cancer Drugs, 2013, 24, 945-957.	0.7	14
2253	Testing to Prevent Colon Cancer: Results From a Rural Community Intervention. Annals of Family Medicine, 2013, 11, 500-507.	0.9	20
2254	The Expression of Activin Receptor–Like Kinase 1 among Patients with Head and Neck Cancer. Otolaryngology - Head and Neck Surgery, 2013, 148, 965-973.	1.1	10
2255	Proteomic analysis of bladder cancer by iTRAQ after <i>Bifidobacterium infantis</i> HSV-TK/GCV suicide gene treatment. Biological Chemistry, 2013, 394, 1333-1342.	1.2	15
2256	Sulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/ \hat{l}^2 -Catenin Signaling. Molecular Cancer Therapeutics, 2013, 12, 1848-1859.	1.9	113
2257	The role of 1.5 <scp>T</scp> esla magnetic resonance imaging in staging prostate cancer. ANZ Journal of Surgery, 2013, 83, 234-238.	0.3	17
2258	Cultivated Sea Lettuce is a Multiorgan Protector from Oxidative and Inflammatory Stress by Enhancing the Endogenous Antioxidant Defense System. Cancer Prevention Research, 2013, 6, 989-999.	0.7	17
2259	Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells. Cell Death and Disease, 2013, 4, e512-e512.	2.7	19
2260	Paediatric thyroid cancer: the Scottish experience. Scottish Medical Journal, 2013, 58, 34-40.	0.7	1
2261	Risk for Psychosocial Problems in Pediatric Cancer: Impact of Socioeconomics. Children's Health Care, 2013, 42, 231-247.	0.5	21
2262	Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis?: A Clinicopathologic Study of 176 Patients with Pathological Stage IA Lung Adenocarcinoma Based on the IASLC/ATS/ERS Classification. Journal of Thoracic Oncology, 2013, 8, 1196-1202.	0.5	108
2263	The In ovo CAM-assay as a Xenograft Model for Sarcoma. Journal of Visualized Experiments, 2013, , e50522.	0.2	43
2264	The Role of Cryosurgery of the Prostate for Nonsurgical Candidates. Journal of the Society of Laparoendoscopic Surgeons, 2013, 17, 423-428.	0.5	29
2265	Awareness of Oral Cancer in a Northwestern Nigerian State: Assessing the Knowledge, Opinion, and Practice of Traditional Healers and Herbalists. Journal of Oral Oncology, 2013, 2013, 1-7.	0.0	7

#	Article	IF	CITATIONS
2266	Expression of ABCG2 Associated with Tumor Response in Metastatic Colorectal Cancer Patients Receiving First-line FOLFOX Therapy – Preliminary Evidence. International Journal of Biological Markers, 2013, 28, 182-186.	0.7	10
2267	Evaluation of Alpha 1-Antitrypsin and the Levels of mRNA Expression of Matrix Metalloproteinase 7, Urokinase Type Plasminogen Activator Receptor and COX-2 for the Diagnosis of Colorectal Cancer. PLoS ONE, 2013, 8, e51810.	1.1	23
2268	miRNA-27b Targets Vascular Endothelial Growth Factor C to Inhibit Tumor Progression and Angiogenesis in Colorectal Cancer. PLoS ONE, 2013, 8, e60687.	1.1	156
2269	p38α Negatively Regulates Survival and Malignant Selection of Transformed Bronchioalveolar Stem Cells. PLoS ONE, 2013, 8, e78911.	1.1	8
2270	Human Calmodulin-Like Protein CALML3: A Novel Marker for Normal Oral Squamous Mucosa That Is Downregulated in Malignant Transformation. International Journal of Dentistry, 2013, 2013, 1-8.	0.5	8
2271	Amino-Functionalized Silica Nanoparticles: In Vitro Evaluation for Targeted Delivery and Therapy of Pancreatic Cancer. Journal of Nanotechnology, 2013, 2013, 1-8.	1.5	28
2272	Comparison of Nasal Epithelial Smoking-Induced Gene Expression on Affymetrix Exon 1.0 and Gene 1.0 ST Arrays. Scientific World Journal, The, 2013, 2013, 1-7.	0.8	3
2273	Activation of uPAR Is Required for Cigarette Smoke Extract-Induced Epithelialâ€Mesenchymal Transition in Lung Epithelial Cells. Oncology Research, 2014, 21, 295-305.	0.6	10
2274	CCR7 Regulates Cell Migration and Invasion through JAK2/STAT3 in Metastatic Squamous Cell Carcinoma of the Head and Neck. BioMed Research International, 2014, 2014, 1-11.	0.9	30
2275	Synthesis and Cytotoxic Activity Evaluation of Novel Arylpiperazine Derivatives on Human Prostate Cancer Cell Lines. Molecules, 2014, 19, 12048-12064.	1.7	20
2276	Clinicopathologic features of epithelial ovarian carcinoma in younger vs. older patients: analysis in Japanese women. Journal of Gynecologic Oncology, 2014, 25, 118.	1.0	20
2277	Colorectal cancer mortality in Poland – analysis of regional variation. Archives of Medical Science, 2014, 1, 63-67.	0.4	4
2278	Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 & Camp; It; I & Camp; I	0.1	35
2280	Impact of a complex nutraceutical supplement on primary tumour formation and metastasis in Trp53+/ \hat{a} €" cancer-prone mice. Mutagenesis, 2014, 29, 177-187.	1.0	3
2281	Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data. Cancer Genetics, 2014, 207, 474-488.	0.2	76
2282	Metastasis-associated gene 1 promotes invasion and migration potential of laryngeal squamous cell carcinoma cells. Oncology Letters, 2014, 7, 399-404.	0.8	10
2283	The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases. Disease Markers, 2014, 2014, 1-10.	0.6	27
2284	Chemopreventive potential of Apium leptophyllum (Pers.) against DMBA induced skin carcinogenesis model by modulatory influence on. Indian Journal of Pharmacology, 2014, 46, 531.	0.4	12

#	Article	IF	CITATIONS
2285	Iminoflavones Combat 1,2-Dimethyl Hydrazine-Induced Aberrant Crypt Foci Development in Colon Cancer. BioMed Research International, 2014, 2014, 1-7.	0.9	5
2286	Roles of F-box proteins in human digestive system tumors (Review). International Journal of Oncology, 2014, 45, 2199-2207.	1.4	12
2287	Long Non-Coding RNA LSINCT5 Predicts Negative Prognosis and Exhibits Oncogenic Activity in Gastric Cancer. Medicine (United States), 2014, 93, e303.	0.4	51
2288	Cancer identified incidentally in the prostate following radical cystoprostatectomy: an Australian study. ANZ Journal of Surgery, 2014, 84, 473-476.	0.3	4
2289	Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor. British Journal of Cancer, 2014, 110, 2965-2974.	2.9	63
2290	Influence of histopathologic factors on pattern of metastasis in squamous cell carcinoma of the head and neck. Laryngoscope, 2014, 124, E160-6.	1.1	16
2291	The impact of lymph vascular space invasion on recurrence and survival in patients with early stage endometrial cancer. European Journal of Cancer Care, 2014, 23, 380-384.	0.7	15
2292	A Method for Reproduction of Metastases in the Liver. Bulletin of Experimental Biology and Medicine, 2014, 157, 773-775.	0.3	11
2293	ABCG2-Meditated Multidrug Resistance and Tumor-Initiating Capacity of Side Population Cells from Colon Cancer. Oncology Research and Treatment, 2014, 37, 666-672.	0.8	38
2294	Free-B-Ring flavonoids as potential lead compounds for colon cancer therapy. Molecular and Clinical Oncology, 2014, 2, 581-585.	0.4	16
2295	Validation of the Risk of Malignancy Index in primary evaluation of ovarian masses. Middle East Fertility Society Journal, 2014, 19, 324-328.	0.5	3
2296	The Use of Pharmacogenomics for Selection of Therapy in Non-Small-Cell Lung Cancer. Clinical Medicine Insights: Oncology, 2014, 8, CMO.S18369.	0.6	3
2297	Cell-Specific Aptamers for Nano-medical Applications. Nucleic Acids and Molecular Biology, 2014, , 261-283.	0.2	0
2298	Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model. Biomedicine and Pharmacotherapy, 2014, 68, 65-69.	2.5	5
2299	Overexpression of chemerin was associated with tumor angiogenesis and poor clinical outcome in squamous cell carcinoma of the oral tongue. Clinical Oral Investigations, 2014, 18, 997-1004.	1.4	56
2300	Manganese Superoxide Dismutase Is a Promising Target for Enhancing Chemosensitivity of Basal-Like Breast Carcinoma. Antioxidants and Redox Signaling, 2014, 20, 2326-2346.	2.5	35
2301	Metastasis of ovarian cancer is mediated by kallikrein related peptidases. Clinical and Experimental Metastasis, 2014, 31, 135-147.	1.7	47
2302	Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 145-150.	1.2	93

#	Article	IF	CITATIONS
2303	STMN-1 Gene: A Predictor of Survival in Stage IIA Esophageal Squamous Cell Carcinoma After Ivor-Lewis Esophagectomy?. Annals of Surgical Oncology, 2014, 21, 315-321.	0.7	21
2304	Lack of association of microvessel density with prognosis of renal cell carcinoma: evidence from meta-analysis. Tumor Biology, 2014, 35, 2769-2776.	0.8	5
2305	Effect of chemotherapy on quality of life in patients with non-small cell lung cancer. Supportive Care in Cancer, 2014, 22, 1417-1428.	1.0	33
2306	Aberrant expression of DPPA2 and HIWI genes in colorectal cancer and their impacts on poor prognosis. Tumor Biology, 2014, 35, 5299-5305.	0.8	22
2307	Epidemiological study on the relationship between the environmental pollution and lung cancer in high lung cancer incidence areas, China. Environmental Earth Sciences, 2014, 71, 4761-4766.	1.3	0
2308	Epidemiology and Risk Factors of Biliary Tract and Primary Liver Tumors. Surgical Oncology Clinics of North America, 2014, 23, 171-188.	0.6	39
2309	Scanning Electron Microscopy of the Tongue, Pharynx, and Larynx of Rats Exposed to Cigarette Smoke. Journal of Voice, 2014, 28, 287-290.	0.6	11
2310	Transitional cell and clear cell renal carcinoma: differentiation of distinct histological types with multiphase CT. Acta Radiologica, 2014, 55, 1112-1119.	0.5	17
2311	Which imaging technique should we use in the follow up of gynaecological cancer?. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2014, 28, 769-791.	1.4	22
2312	Stathmin overexpression identifies high risk for lymphatic metastatic recurrence in <i>p</i> <scp>N</scp> ₀ esophageal squamous cell carcinoma patients. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 944-950.	1.4	17
2313	BRCA1 promoter hypermethylation and protein expression in ovarian carcinomaâ€"an Indian study. Tumor Biology, 2014, 35, 4277-4284.	0.8	14
2314	Head and Neck Cutaneous Squamous Cell Carcinoma Requiring Parotidectomy: Prognostic Indicators and Treatment Selection. Otolaryngology - Head and Neck Surgery, 2014, 150, 610-617.	1.1	32
2315	MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG. Cancer Letters, 2014, 353, 201-210.	3.2	67
2316	Neferine, an alkaloid from lotus seed embryo, inhibits human lung cancer cell growth by MAPK activation and cell cycle arrest. BioFactors, 2014, 40, 121-131.	2.6	94
2317	<scp>MiRNA /scp> expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. IUBMB Life, 2014, 66, 371-377.</scp>	1.5	60
2318	Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib. Medical Oncology, 2014, 31, 203.	1.2	8
2319	Early channel transurethral resection of the prostate for patients with urinary retention after brachytherapy. Journal of Zhejiang University: Science B, 2014, 15, 756-760.	1.3	1
2320	Thermal ablation techniques: a curative treatment of bone metastases in selected patients?. European Radiology, 2014, 24, 1971-1980.	2.3	107

#	Article	IF	CITATIONS
2321	Diet modulation is an effective complementary agent in preventing and treating breast cancer lung metastasis. Clinical and Experimental Metastasis, 2014, 31, 625-638.	1.7	4
2322	The inhibitory effects of a new cobalt-based polyoxometalate on the growth of human cancer cells. Dalton Transactions, 2014, 43, 6070.	1.6	51
2323	Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A. Tumor Biology, 2014, 35, 6373-6381.	0.8	35
2324	Beclin1 inhibits proliferation, migration and invasion in tongue squamous cell carcinoma cell lines. Oral Oncology, 2014, 50, 983-990.	0.8	43
2326	Acinar Cell Carcinoma of Exocrine Pancreas in Two Horses. Journal of Comparative Pathology, 2014, 150, 388-392.	0.1	5
2327	The increased risk of adverse outcomes in bilateral deep inferior epigastric artery perforator flap breast reconstruction compared to unilateral reconstruction: A systematic review and meta-analysis. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2014, 67, 143-156.	0.5	52
2328	Identification of ENO1 As a Potential Sputum Biomarker for Early-Stage Lung Cancer by Shotgun Proteomics. Clinical Lung Cancer, 2014, 15, 372-378.e1.	1.1	46
2329	AAGL Practice Report: Morcellation During Uterine Tissue Extraction. Journal of Minimally Invasive Gynecology, 2014, 21, 517-530.	0.3	122
2330	Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer. Acta Biomaterialia, 2014, 10, 142-150.	4.1	40
2331	Quality of Life After Laparoscopic Colectomy for Cancer. Journal of the Society of Laparoendoscopic Surgeons, 2014, 18, 225-235.	0.5	11
2332	Cholesterol induces autophagic and apoptotic death in gastric carcinoma cells. International Journal of Oncology, 2014, 44, 805-811.	1.4	25
2333	The selective cytotoxicity elicited by phytochemical extract from Senecio graveolens (Asteraceae) on breast cancer cells is enhanced by hypoxia. International Journal of Oncology, 2014, 44, 1357-1364.	1.4	20
2335	John Henryism, Depression, and Perceived Social Support in Black Women. Journal of Black Psychology, The, 2014, 40, 115-137.	1.0	73
2336	Complications after surgery for colorectal cancer affect quality of life and surgeon–patient relationship. Colorectal Disease, 2014, 16, O407-19.	0.7	43
2337	CCR7 regulates cell migration and invasion through MAPKs in metastatic squamous cell carcinoma of head and neck. International Journal of Oncology, 2014, 45, 2502-2510.	1.4	46
2338	Silencing Kif2a induces apoptosis in squamous cell carcinoma of the oral tongue through inhibition of the Pl3K/Akt signaling pathway. Molecular Medicine Reports, 2014, 9, 273-278.	1.1	39
2339	Quercetin induces the apoptosis of human ovarian carcinoma cells by upregulating the expression of microRNA-145. Molecular Medicine Reports, 2015, 12, 3127-3131.	1.1	53
2340	Upregulation of SOX9 promotes cell proliferation, migration and invasion in lung adenocarcinoma. Oncology Letters, 2015, 10, 990-994.	0.8	29

#	Article	IF	CITATIONS
2341	Isolation and phenotypic characterization of cancer stem-like side population cells in colon cancer. Molecular Medicine Reports, 2015, 12, 3531-3536.	1.1	10
2342	Chemopreventive effects of Strobilanthes crispus leaf extract on azoxymethane-induced aberrant crypt foci in rat colon. Scientific Reports, 2015, 5, 13312.	1.6	21
2343	Tripartite motif-containing 29 as a novel biomarker in non-small cell lung cancer. Oncology Letters, 2015, 10, 2283-2288.	0.8	34
2344	Evaluation of chemopreventive potential of Strobilanthes crispus against colon cancer formation in vitro and in vivo. BMC Complementary and Alternative Medicine, 2015, 15, 419.	3.7	23
2345	Enzymeâ€Instructed Intracellular Molecular Selfâ€Assembly to Boost Activity of Cisplatin against Drugâ€Resistant Ovarian Cancer Cells. Angewandte Chemie - International Edition, 2015, 54, 13307-13311.	7.2	158
2346	Neamine is preferential as an anti-prostate cancer reagent by inhibiting cell proliferation and angiogenesis, with lower toxicity than cis-platinum. Oncology Letters, 2015, 10, 137-142.	0.8	6
2347	Sexual, marital, and general life functioning in couples coping with colorectal cancer: a dyadic study across time. Psycho-Oncology, 2015, 24, 1181-1188.	1.0	22
2348	Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer. Medicine (United States), 2015, 94, e1489.	0.4	34
2349	Serum Levels of Trace Elements in Patients with Testicular Cancers. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 1101-1107.	0.7	19
2350	Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers. PLoS ONE, 2015, 10, e0143178.	1.1	14
2351	Combination of axitinib and dasatinib for anti-cancer activities in two prostate cancer cell lines. Bangladesh Journal of Pharmacology, 2015, 11, 130.	0.1	1
2352	Prostatic adenocarcinoma presenting as isolated inguinal lymphadenopathy. BMJ Case Reports, 2015, 2015, bcr2015210825.	0.2	1
2353	Winter Polycyclic Aromatic Hydrocarbon-Bound Particulate Matter from Peri-urban North China Promotes Lung Cancer Cell Metastasis. Environmental Science & Environmental Science & 2015, 49, 14484-14493.	4.6	89
2354	Locoregional control of recurrent papillary thyroid carcinoma by ultrasound-guided percutaneous microwave ablation: A prospective study. International Journal of Hyperthermia, 2015, 31, 403-408.	1.1	47
2355	Low DICER1 expression is associated with attenuated neutrophil differentiation and autophagy of NB4 APL cells. Journal of Leukocyte Biology, 2015, 98, 357-363.	1.5	8
2356	Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer. Clinical Cancer Research, 2015, 21, 5151-5163.	3.2	15
2357	Diagnosic system for predicting bladder cancer recurrence using association rules. , 2015, , .		2
2358	miR-375 inhibits cell growth and correlates with clinical outcomes in tongue squamous cell carcinoma. Oncology Reports, 2015, 33, 2061-2071.	1.2	21

#	Article	IF	CITATIONS
2359	The flavonoid nobiletin inhibits tumor growth and angiogenesis of ovarian cancers via the Akt pathway. International Journal of Oncology, 2015, 46, 2629-2638.	1.4	71
2360	The role of Pyk2 in the CCR7-mediated regulation of metastasis and viability in squamous cell carcinoma of the head and neck cells in vivo and in vitro. Oncology Reports, 2015, 34, 3280-3287.	1.2	10
2361	Prognostic factors for reoperation of recurrent retroperitoneal sarcoma: The role of clinicopathological factors other than histologic grade. Journal of Surgical Oncology, 2015, 111, 165-172.	0.8	21
2362	The association of GSTM1 and GSTT1 polymorphisms with squamous cell carcinoma of cervix in Pakistan. Tumor Biology, 2015, 36, 5195-5199.	0.8	10
2363	Global identification of genes targeted by DNMT3b for epigenetic silencing in lung cancer. Oncogene, 2015, 34, 621-630.	2.6	37
2364	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut, 2015, 64, 1721-1731.	6.1	197
2365	Antioxidant activity of ethanolic extract of Tinospora cordifolia on N-nitrosodiethylamine (diethylnitrosamine) induced liver cancer in male Wister albino rats. Journal of Pharmacy and Bioallied Sciences, 2015, 7, 40.	0.2	22
2366	RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients–a short report. Cellular Oncology (Dordrecht), 2015, 38, 319-325.	2.1	10
2367	The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study. International Journal of Surgery, 2015, 19, 91-94.	1.1	23
2368	p53 regulates cytoskeleton remodeling to suppress tumor progression. Cellular and Molecular Life Sciences, 2015, 72, 4077-4094.	2.4	33
2369	Rho Guanine Nucleotide Exchange Factor 5 Increases Lung Cancer Cell Tumorigenesis via MMP-2 and Cyclin D1 Upregulation. Molecular Cancer Therapeutics, 2015, 14, 1671-1679.	1.9	11
2370	Clinicopathological features and outcome of gastric metastases from primary lung cancer: A case report and systematic review. Oncology Letters, 2015, 9, 1373-1379.	0.8	15
2371	MicroRNA-134 regulates lung cancer cell H69 growth and apoptosis by targeting WWOX gene and suppressing the ERK1/2 signaling pathway. Biochemical and Biophysical Research Communications, 2015, 464, 748-754.	1.0	22
2372	Dual-phase F-18 FDG PET–CT in staging and lymphoscintigraphy for detection of sentinel lymph nodes in oral cavity cancers. Clinical Imaging, 2015, 39, 781-786.	0.8	3
2373	FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function. Gastroenterology, 2015, 149, 1006-1016.e9.	0.6	90
2374	Life expectancy and expected years of life lost to oral cancer in Taiwan: A nation-wide analysis of 22,024 cases followed for 10 years. Oral Oncology, 2015, 51, 349-354.	0.8	32
2375	Malignancy rate of 10,731 uteri morcellated during laparoscopic supracervical hysterectomy (LASH). Archives of Gynecology and Obstetrics, 2015, 292, 665-672.	0.8	101
2376	Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer and Metastasis Reviews, 2015, 34, 19-40.	2.7	76

#	Article	IF	Citations
2377	Gly322Asp and Asn127Ser single nucleotide polymorphisms (SNPs) of hMSH2 mismatch repair gene and the risk of triple-negative breast cancer in Polish women. Familial Cancer, 2015, 14, 81-88.	0.9	7
2378	Diffusion-weighted imaging and dynamic contrast-enhanced MRI in assessing response and recurrent disease in gynaecological malignancies. Cancer Imaging, 2015, 15, 3.	1.2	54
2379	Histopathology of skeletal metastases. , 2015, , 461-470.		0
2380	Block Copolymer Nanostructures and Their Applications: A Review. Polymer-Plastics Technology and Engineering, 2015, 54, 1077-1095.	1.9	19
2381	Quality Appraisal of Clinical Practice Guidelines on Pancreatic Cancer. Medicine (United States), 2015, 94, e635.	0.4	9
2382	Vitamin D receptor, a tumor suppressor in skin. Canadian Journal of Physiology and Pharmacology, 2015, 93, 349-354.	0.7	32
2383	A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality. Cancer Causes and Control, 2015, 26, 1521-1550.	0.8	76
2384	Characteristics and Limitations of FDG PET/CT for Imaging of Squamous Cell Carcinoma of the Head and Neck: A Comprehensive Review of Anatomy, Metastatic Pathways, and Image Findings. American Journal of Roentgenology, 2015, 205, W519-W531.	1.0	43
2385	MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer. Gynecologic Oncology, 2015, 139, 513-519.	0.6	40
2386	Colonic Stenting as a Successful Bridge to Surgery in a Centenarian with Obstructing Colonic Carcinoma. Journal of the American Geriatrics Society, 2015, 63, 618-620.	1.3	0
2388	NOX1 to NOX2 switch deactivates AMPK and induces invasive phenotype in colon cancer cells through overexpression of MMP-7. Molecular Cancer, 2015, 14, 123.	7.9	58
2389	Incidence of lung cancer in patients with systemic sclerosis treated with extracorporeal photopheresis. Photodermatology Photoimmunology and Photomedicine, 2015, 31, 175-183.	0.7	7
2390	Trends in survival of multiple myeloma: A thirty-year population-based study in a single institution. Cancer Epidemiology, 2015, 39, 693-699.	0.8	24
2391	Impaired T-bet-pSTAT1 \hat{l}_{\pm} and perforin-mediated immune responses in the tumoral region of lung adenocarcinoma. British Journal of Cancer, 2015, 113, 902-913.	2.9	15
2392	SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation. Digestive Diseases and Sciences, 2015, 60, 3304-3317.	1.1	17
2393	Global DNA Methylation Profiling Technologies and the Ovarian Cancer Methylome. Methods in Molecular Biology, 2015, 1238, 653-675.	0.4	22
2394	MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase. Tumor Biology, 2015, 36, 1313-1321.	0.8	66
2395	Oral Health Awareness of Onclogy Nurses at Charllotte Maxeke Johannesburg Hospital. Journal of Oral Hygiene & Health, 2016, 04, .	0.2	1

#	Article	IF	CITATIONS
2396	Role of surgery for colorectal cancer in the elderly. World Journal of Gastrointestinal Surgery, 2016, 8, 606.	0.8	46
2397	Primary Neuroendocrine Tumors of the Ureter: A Short Review. Archives of Pathology and Laboratory Medicine, 2016, 140, 714-717.	1.2	17
2398	Mitotic arrest induced in human DU145 prostate cancer cells in response to KHC-4 treatment. Environmental Toxicology, 2016, 31, 1879-1887.	2.1	2
2399	Acetylshikonin inhibits growth of oral squamous cell carcinoma by inducing apoptosis. Archives of Oral Biology, 2016, 70, 149-157.	0.8	25
2400	Establishment and characterization of a human papillomavirus type 16–positive tonsillar carcinoma xenograft in BALB/c nude mice. Head and Neck, 2016, 38, 417-425.	0.9	16
2401	Comparison of differentiated thyroid cancer in children and adolescents (â‰ 2 OÂyears) with young adults. Clinical Endocrinology, 2016, 84, 571-577.	1.2	39
2402	Image guided surgery in the management of head and neck cancer. Oral Oncology, 2016, 57, 32-39.	0.8	22
2403	Design, synthesis and biological evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines. Chinese Chemical Letters, 2016, 27, 277-282.	4.8	8
2404	Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients. Lung Cancer, 2016, 92, 53-61.	0.9	86
2405	Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade. Pancreatology, 2016, 16, 423-433.	0.5	95
2406	A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice. Molecular Cancer Therapeutics, 2016, 15, 1163-1176.	1.9	19
2407	Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines. Oncology Letters, 2016, 12, 2065-2070.	0.8	23
2408	Prostate cancer markers: An update. Biomedical Reports, 2016, 4, 263-268.	0.9	43
2409	Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature. Oncology, 2016, 91, 211-216.	0.9	10
2410	ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells. Tumor Biology, 2016, 37, 12889-12896.	0.8	48
2411	RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer. International Journal of Cancer, 2016, 138, 217-228.	2.3	37
2412	Noninvasive Failure Load Prediction of Vertebrae with Simulated Lytic Defects and Biomaterial Augmentation. Tissue Engineering - Part C: Methods, 2016, 22, 717-724.	1.1	11
2413	Biosynthesized Vitis vinifera seed gold nanoparticles induce apoptotic cell death in A431Âskin cancer cells. RSC Advances, 2016, 6, 82205-82218.	1.7	41

#	Article	IF	CITATIONS
2414	Plasma long non-coding RNA MALAT1 is associated with distant metastasis in patients with epithelial ovarian cancer. Oncology Letters, 2016, 12, 1361-1366.	0.8	48
2415	Ikaros expression sensitizes leukemic cells to the chemotherapeutic drug doxorubicin. Oncology Letters, 2016, 12, 1178-1182.	0.8	0
2416	miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nature Communications, 2016, 7, 11406.	5.8	245
2417	Regulation of ADSC Osteoinductive Potential Using Notch Pathway Inhibition and Gene Rescue: A Potential On/Off Switch for Clinical Applications in Bone Formation and Reconstructive Efforts. Plastic and Reconstructive Surgery, 2016, 138, 642e-652e.	0.7	22
2418	Immunohistochemistry markers in diagnosing high-grade serous carcinoma of ovary with breast metastasis: a rare case report. Southern African Journal of Gynaecological Oncology, 2016, 8, 34-36.	0.3	0
2419	Prostate cancer - evidence of exercise and nutrition trial (PrEvENT): study protocol for a randomised controlled feasibility trial. Trials, 2016, 17, 123.	0.7	14
2420	Systematic review of pre-operative exercise in colorectal cancer patients. Techniques in Coloproctology, 2016, 20, 81-89.	0.8	67
2421	Trends in registered medical marijuana participation across 13 US states and District of Columbia. Drug and Alcohol Dependence, 2016, 159, 72-79.	1.6	99
2423	Social inequalities in oral cancer literacy in an adult population in a multicultural deprived area of the UK. Journal of Public Health, 2016, 38, 474-482.	1.0	9
2424	Phosphorylation of BMK1 induces prostatic carcinoma cell proliferation by promoting entry into the S phase of the cell cycle. Oncology Letters, 2016, 11, 99-104.	0.8	5
2425	Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 310-314.	1.0	12
2427	Correlated and Coupled Trajectories of Cancer-Related Worries and Depressive Symptoms among Long-Term Cancer Survivors. Behavioral Medicine, 2016, 42, 82-92.	1.0	10
2428	Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator. Gene Therapy, 2016, 23, 38-49.	2.3	17
2429	Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status. European Archives of Oto-Rhino-Laryngology, 2016, 273, 2157-2169.	0.8	33
2430	Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?. Journal of Cancer Research and Clinical Oncology, 2016, 142, 201-212.	1.2	13
2431	HDAC10 as a potential therapeutic target in ovarian cancer. Gynecologic Oncology, 2017, 144, 613-620.	0.6	39
2432	Complications in DIEP Flap Breast Reconstruction After Mastectomy for Breast Cancer: A Prospective Cohort Study Comparing Unilateral Versus Bilateral Reconstructions. Annals of Surgical Oncology, 2017, 24, 1465-1474.	0.7	39
2433	Increased tumor-infiltrating plasmacytoid dendritic cells predicts poor prognosis in oral squamous cell carcinoma. Archives of Oral Biology, 2017, 78, 129-134.	0.8	36

#	ARTICLE	IF	CITATIONS
2434	Synthesis of hetero annulated isoxazolo-, pyrido- and pyrimido carbazoles: Screened for inÂvitro antitumor activity and structure activity relationships, a novel 2-amino-4-(3'-bromo-4'-methoxyphenyl)-8-chloro-11 H -pyrimido[4,5- a]carbazole as an antitumor agent. European Journal of Medicinal Chemistry, 2017, 128, 319-331.	2.6	18
2435	<i>In Vitro</i> Mouse and Human Serum Stability of a Heterobivalent Dual-Target Probe That Has Strong Affinity to Gastrin-Releasing Peptide and Neuropeptide Y1 Receptors on Tumor Cells. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 24-32.	0.7	14
2436	Jak3 is involved in CCR7-dependent migration and invasion in metastatic squamous cell carcinoma of the head and neck. Oncology Letters, 2017, 13, 3191-3197.	0.8	11
2438	Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*. American Journal of Hematology, 2017, 92, 866-871.	2.0	17
2439	Regulation of cytotoxicity and apoptosis-associated pathways contributes to the enhancement of efficacy of cisplatin by baicalein adjuvant in human A549 lung cancer cells. Oncology Letters, 2017, 13, 2799-2804.	0.8	19
2440	High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma. Medicine (United States), 2017, 96, e6472.	0.4	31
2441	microRNA-664 enhances proliferation, migration and invasion of lung cancer cells. Experimental and Therapeutic Medicine, 2017, 13, 3555-3562.	0.8	17
2442	Deprivación andrógenica en cáncer de próstata y riesgo de fractura a largo plazo. Actas Urológicas Españolas, 2017, 41, 491-496.	0.3	6
2443	Comorbidity profiles among women with postcoital bleeding: a nationwide health insurance database. Archives of Gynecology and Obstetrics, 2017, 295, 935-941.	0.8	10
2444	miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1. International Journal of Oncology, 2017, 50, 1383-1391.	1.4	17
2445	Synthesis, docking, cytotoxicity, and LTA 4 H inhibitory activity of new gingerol derivatives as potential colorectal cancer therapy. Bioorganic and Medicinal Chemistry, 2017, 25, 1277-1285.	1.4	40
2446	Androgen deprivation in prostate cancer and the long-term risk of fracture. Actas Urológicas Españolas (English Edition), 2017, 41, 491-496.	0.2	0
2447	Inhibition of protein kinase CK2 sensitizes non-small cell lung cancer cells to cisplatin via upregulation of PML. Molecular and Cellular Biochemistry, 2017, 436, 87-97.	1.4	18
2448	Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin. Oncology Letters, 2017, 14, 5819-5824.	0.8	6
2449	Nuclear \hat{l}^2 -catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer. Pathology Research and Practice, 2017, 213, 915-921.	1.0	11
2450	Mental Illness Is Not Associated with Adherence to Colorectal Cancer Screening: Results from the California Health Interview Survey. Digestive Diseases and Sciences, 2017, 62, 224-234.	1.1	6
2451	Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer. European Archives of Oto-Rhino-Laryngology, 2017, 274, 3497-3501.	0.8	29
2452	Structure and Function of a Prostate Cancer Dissemination–Permissive Extracellular Matrix. Clinical Cancer Research, 2017, 23, 2245-2254.	3.2	53

#	Article	IF	CITATIONS
2453	A New Vertebral Body Replacement Strategy Using Expandable Polymeric Cages. Tissue Engineering - Part A, 2017, 23, 223-232.	1.6	12
2454	Synthesis and antimicrobial activity of novel quinoline derivatives bearing pyrazoline and pyridine analogues. Medicinal Chemistry Research, 2017, 26, 109-119.	1.1	63
2455	Ecology of the Metastatic Process. , 2017, , 153-165.		8
2456	Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing. Oncotarget, 2017, 8, 18166-18176.	0.8	19
2457	Changing Trends in oral cancer – a global scenario. Journal of College of Medical Sciences-Nepal, 2017, 6, 613-619.	0.2	167
2458	MDL-12330A potentiates TRAIL-induced apoptosis in gastric cancer cells through CHOP-mediated DR5 upregulation. Korean Journal of Physiology and Pharmacology, 2017, 21, 397.	0.6	5
2459	Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing. Oncotarget, 2017, 8, 59113-59122.	0.8	52
2460	Kelussia odoratissima Mozaff. activates intrinsic pathway of apoptosis in breast cancer cells associated with S phase cell cycle arrest via involvement of p21/p27 in vitro and in vivo. Drug Design, Development and Therapy, 2017, Volume11, 337-350.	2.0	10
2461	ANTITUMOR EFFECTS OF CHRYSANTHEMIN IN PC-3 HUMAN PROSTATE CANCER CELLS ARE MEDIATED VIA APOPTOSIS INDUCTION, CASPASE SIGNALLING PATHWAY AND LOSS OF MITOCHONDRIAL MEMBRANE POTENTIAL Tropical Journal of Obstetrics and Gynaecology, 2017, 14, 54-61.	0.3	13
2462	LET spectra behind high-density titanium and stainless steel hip implants irradiated with a therapeutic proton beam. Radiation Measurements, 2018, 110, 7-13.	0.7	3
2463	Synthesis and biological evaluation of estrone 3- O -ether derivatives containing the piperazine moiety. Steroids, 2018, 134, 101-109.	0.8	12
2464	Intraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices. Expert Opinion on Drug Delivery, 2018, 15, 481-494.	2.4	24
2465	Risk of second malignancies among survivors of pediatric thyroid cancer. International Journal of Clinical Oncology, 2018, 23, 625-633.	1.0	11
2466	Formulation and optimization of topotecan nanoparticles: In vitro characterization, cytotoxicity, cellular uptake and pharmacokinetic outcomes. Journal of Photochemistry and Photobiology B: Biology, 2018, 183, 222-232.	1.7	49
2467	Deciphering the biochemical and molecular mechanism underlying the in vitro and in vivo chemotherapeutic efficacy of ruthenium quercetin complex in colon cancer. Molecular Carcinogenesis, 2018, 57, 700-721.	1.3	26
2468	MiR-1275 promotes cell migration, invasion and proliferation in squamous cell carcinoma of head and neck via up-regulating IGF- $1R$ and CCR7. Gene, 2018 , 646 , 1 -7.	1.0	39
2469	Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85. Archives of Gynecology and Obstetrics, 2018, 297, 699-707.	0.8	24
2470	What predicts emotional response in men awaiting prostate biopsy?. BMC Urology, 2018, 18, 27.	0.6	12

#	ARTICLE	IF	CITATIONS
2471	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ: British Medical Journal, 2018, 360, j5757.	2.4	153
2472	Synthesis, biological evaluation and SAR of naftopidil-based arylpiperazine derivatives. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1534-1539.	1.0	9
2473	Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. Journal of Drug Delivery Science and Technology, 2018, 45, 334-345.	1.4	35
2474	A rare case of advanced lung cancer presenting as a symptomatic gastric tumor. Molecular and Clinical Oncology, 2018, 8, 595-599.	0.4	8
2475	miRNAs and ovarian cancer: An overview. Journal of Cellular Physiology, 2018, 233, 3846-3854.	2.0	150
2476	Cytology and high risk <scp>HPV</scp> testing in cervical cancer screening program: Outcome of 3â€year followâ€up in an academic institute. Diagnostic Cytopathology, 2018, 46, 22-27.	0.5	6
2477	Risk-Reducing Mastectomy and Breast Reconstruction. Clinics in Plastic Surgery, 2018, 45, 129-136.	0.7	7
2478	Molecular Diagnosis and Targeted Therapy for Gastric Cancer. Current Human Cell Research and Applications, 2018, , 63-80.	0.1	0
2479	Prevalence of Brain Metastases. , 2018, , 3-8.		0
2480	Communication Network Structures and Content of Men with Prostate Cancer: Models for Explaining Health-Related Quality of Life. Health Communication, 2018, 33, 601-610.	1.8	3
2481	NMR-based metabolomics to select a surgical method for treating papillary thyroid carcinoma. Clinics, 2018, 73, e333.	0.6	3
2482	Great Role in Gynecological Cancer Prophylaxis of a Unique Health Check-Up Institute, Ningen Dock in Japan (Review). , 0, , .		0
2483	Ovarian Cancer Overview: Molecular Biology and Its Potential Clinical Application. , 0, , .		1
2484	Incidence and Mortality Patterns of Acute Myeloid Leukemia in Belgrade, Serbia (1999–2013). Medicina (Lithuania), 2018, 54, 5.	0.8	8
2485	hsa_circ_0061140 Knockdown Reverses FOXM1-Mediated Cell Growth and Metastasis in Ovarian Cancer through miR-370 Sponge Activity. Molecular Therapy - Nucleic Acids, 2018, 13, 55-63.	2.3	86
2486	MRI-based automated detection of implanted low dose rate (LDR) brachytherapy seeds using quantitative susceptibility mapping (QSM) and unsupervised machine learning (ML). Radiotherapy and Oncology, 2018, 129, 540-547.	0.3	24
2487	Prolonged Versus Short-Duration Use of Nasogastric Tubes in Patients with Head and Neck Cancer During Radiotherapy Alone or Combined Chemoradiotherapy. Nutrition and Cancer, 2018, 70, 1069-1074.	0.9	0
2488	PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?. BMC Cancer, 2018, 18, 945.	1.1	19

#	Article	IF	CITATIONS
2489	Targeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma. Tumor Biology, 2018, 40, 101042831880018.	0.8	40
2490	Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer. Cancer Immunology, Immunotherapy, 2018, 67, 1753-1765.	2.0	26
2491	MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway. Biomedicine and Pharmacotherapy, 2018, 104, 763-770.	2.5	65
2492	Blood‑based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer‑risk stratification. Oncology Letters, 2018, 16, 1357-1365.	0.8	20
2493	Functional Analyses of RUNX3 and CaMKIINα in Ovarian Cancer Cell Lines Reveal Tumor-Suppressive Functions for CaMKIINα and Dichotomous Roles for RUNX3 Transcript Variants. International Journal of Molecular Sciences, 2018, 19, 253.	1.8	8
2494	Renal Cancer., 2018,, 445-446.		0
2496	Silencing Livin improved the sensitivity of colon cancer cells to 5-fluorouracil by regulating crosstalk between apoptosis and autophagy. Oncology Letters, 2018, 15, 7707-7715.	0.8	6
2497	Exercise prehabilitation in elective intra-cavity surgery: A role within the ERAS pathway? A narrative review. International Journal of Surgery, 2018, 56, 328-333.	1.1	23
2498	FBP1 promotes ovarian cancer development through the acceleration of cell cycle transition and metastasis. Oncology Letters, 2018 , 16 , 1682 - 1688 .	0.8	11
2499	Chemopreventive and Anticancer Effects of Plumbagin: Novel Mechanism(s) via Modulation of Cellular Redox., 2018,, 325-341.		6
2500	Culture supernatants of oral cancer cells induce impaired IFN-α production of pDCs partly through the down-regulation of TLR-9 expression. Archives of Oral Biology, 2018, 93, 141-148.	0.8	13
2501	Systemic cervical cytology training and quality control programs can improve the interpretation of Papanicolaou tests. Journal of the American Society of Cytopathology, 2019, 8, 27-33.	0.2	5
2502	Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and cytotoxicity. Saudi Pharmaceutical Journal, 2019, 27, 49-55.	1.2	19
2503	An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Scientific Reports, 2019, 9, 12070.	1.6	58
2504	Fertility-Sparing surgery for young women with ovarian endometrioid carcinoma: a multicenteric comparative study using inverse probability of treatment weighting. European Journal of Obstetrics and Gynecology and Reproductive Biology: X, 2019, 4, 100071.	0.6	5
2505	Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin. Molecular Medicine Reports, 2019, 20, 2258-2266.	1.1	19
2506	Blockage of HOTAIR Reduced Cell Proliferation in Human Ovarian Cancer Cells Through Upregulation of AKT2. Indian Journal of Gynecologic Oncology, 2019, 17, 1.	0.1	2
2507	Clinico-pathological features of colon cancer patients undergoing emergency surgery: a comparison between elderly and non-elderly patients. Open Medicine (Poland), 2019, 14, 726-734.	0.6	9

#	Article	IF	CITATIONS
2508	circPIP5K1A serves as a competitive endogenous RNA contributing to ovarian cancer progression via regulation of miRâ€661/IGFBP5 signaling. Journal of Cellular Biochemistry, 2019, 120, 19406-19414.	1.2	39
2509	Anti-Tumor Potential of a 5-HT3 Receptor Antagonist as a Novel Autophagy Inducer in Lung Cancer: A Retrospective Clinical Study with In Vitro Confirmation. Journal of Clinical Medicine, 2019, 8, 1380.	1.0	6
2510	Clinical and Pathological Characteristics and Outcomes of Clear Cell Carcinoma of Ovary: A Tertiary Cancer Centre Data. Indian Journal of Gynecologic Oncology, 2019, 17, 1.	0.1	0
2511	Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays. Molecular Medicine Reports, 2019, 20, 593-603.	1.1	19
2512	Comparison and applicability of molecular classifications for gastric cancer. Cancer Treatment Reviews, 2019, 77, 29-34.	3.4	65
2513	A 17 years retrospective study on multiple metal stents for complex malignant hilar biliary strictures: Survival, stents patency and outcomes of re-interventions for occluded metal stents. Digestive and Liver Disease, 2019, 51, 1287-1293.	0.4	9
2514	Aggressive papillary thyroid carcinoma in a child with type 2 congenital generalized lipodystrophy. Archives of Endocrinology and Metabolism, 2019, 63, 79-83.	0.3	2
2515	Mathematical modeling of the dynamics of the bladder cancer and the immune response applied to a patient: Evolution and shortâ€ŧerm prediction. Mathematical Methods in the Applied Sciences, 2019, 42, 5746-5757.	1.2	2
2516	Optimized Production and Biological Evaluation of 68Ga-PDTMP as a New Agent for PET Bone Scanning. Journal of Medical Imaging and Radiation Sciences, 2019, 50, 142-148.	0.2	3
2517	Co-expression of XIAP and CIAP1 Play Synergistic Effect on Patient's Prognosis in Head and Neck Cancer. Pathology and Oncology Research, 2019, 25, 1111-1116.	0.9	6
2518	Cost-effectiveness analysis of the oral cancer screening program in Taiwan. Oral Oncology, 2019, 89, 59-65.	0.8	24
2519	ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance. Clinical Science, 2019, 133, 83-99.	1.8	51
2520	UNC-45A Is a Novel Microtubule-Associated Protein and Regulator of Paclitaxel Sensitivity in Ovarian Cancer Cells. Molecular Cancer Research, 2019, 17, 370-383.	1.5	21
2521	Inhibition of ATP citrate lyase (ACLY) protects airway epithelia from PM2.5-induced epithelial-mesenchymal transition. Ecotoxicology and Environmental Safety, 2019, 167, 309-316.	2.9	25
2522	Neoplasms of the Prostate., 2020,, 415-525.e42.		3
2523	Utility of Ultrasound for Evaluating Masses in the Pediatric Population. Advances in Clinical Radiology, 2020, 2, 235-245.	0.1	0
2524	Development of a stereoscopic CT metal artifact management algorithm using gantry angle tilts for head and neck patients. Journal of Applied Clinical Medical Physics, 2020, 21, 120-130.	0.8	9
2525	The PLCE1 rs2274223 variant is associated with the risk of laryngeal squamous cell carcinoma. International Journal of Medical Sciences, 2020, 17, 2826-2830.	1.1	2

#	Article	IF	Citations
2526	Serum Exosomal miR-941 as a promising Oncogenic Biomarker for Laryngeal Squamous Cell Carcinoma. Journal of Cancer, 2020, 11, 5329-5344.	1.2	28
2527	Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene. Journal of Cellular and Molecular Medicine, 2020, 24, 11177-11187.	1.6	20
2528	Pharmacology, toxicity and pharmacokinetics of acetylshikonin: a review. Pharmaceutical Biology, 2020, 58, 950-958.	1.3	23
2529	Genotype of Null Polymorphisms in Genes GSTM1, GSTT1, CYP1A1, and CYP1A1*2A (rs4646903) Tj ETQq1 1 0.78412, 2478.	4314 rgBT 1.7	/Overlock 8
2530	Oncological and Reproductive Outcomes of Fertility-sparing Surgery in Women with Early-stage Epithelial Ovarian Carcinoma: A Multicenter Retrospective Study. Current Medical Science, 2020, 40, 745-752.	0.7	5
2531	Metabolism of prostate cancer by magnetic resonance spectroscopy (MRS). Biophysical Reviews, 2020, 12, 1163-1173.	1.5	20
2532	Epoxyazadiradione exhibit activities in head and neck squamous cell carcinoma by targeting multiple pathways. Apoptosis: an International Journal on Programmed Cell Death, 2020, 25, 763-782.	2.2	11
2533	Wide resection of soft tissue sarcomas after unplanned primary procedures. Medicine (United States), 2020, 99, e19067.	0.4	5
2534	A lower cut-off for lymph node harvest predicts for poorer overall survival after rectal surgery post neoadjuvant chemoradiotherapy. World Journal of Surgical Oncology, 2020, 18, 58.	0.8	6
2535	A review of stereotactic body radiotherapy for the spine. Physical and Engineering Sciences in Medicine, 2020, 43, 799-824.	1.3	5
2536	Studies on the invitro anticancer activity of mangostin and acetylated mangostin against MCF-7 cell lines. Chemical Data Collections, 2020, 28, 100476.	1.1	2
2537	Association of promoter methylation of RASSF1A and KRAS mutations in non-small cell lung carcinoma in Kashmiri population (India). Heliyon, 2020, 6, e03488.	1.4	2
2538	Outcomes for Vertebrectomy for Malignancy and Correlation to the Spine Instability Neoplastic Score (SINS): a 10-Year Single-Center Perspective. World Neurosurgery, 2020, 138, e151-e159.	0.7	1
2539	New aspects of vitamin D metabolism and action — addressing the skin as source and target. Nature Reviews Endocrinology, 2020, 16, 234-252.	4.3	181
2540	<p>Overexpression of Progerin Results in Impaired Proliferation and Invasion of Non-Small Cell Lung Cancer Cells</p> . OncoTargets and Therapy, 2020, Volume 13, 2629-2642.	1.0	7
2541	Biochemical and molecular aspects of 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis: a review. Toxicology Research, 2020, 9, 2-18.	0.9	39
2542	Expression and clinical implication of cyclooxygenase-2 and E-cadherin in oral squamous cell carcinomas. Cancer Biology and Therapy, 2020, 21, 667-674.	1.5	17
2543	Weekly radiotherapy in elderly breast cancer patients: a comparison between two hypofractionation schedules. Clinical and Translational Oncology, 2021, 23, 372-377.	1,2	O

#	ARTICLE	IF	CITATIONS
2544	Papillary Thyroid Carcinoma in Children: Clinicopathological Profile and Outcomes of Management. World Journal of Surgery, 2021, 45, 496-506.	0.8	8
2545	miRNA for the assessment of lymph node metastasis in patients with oral squamous cell carcinoma: Systematic review and metanalysis. Journal of Oral Pathology and Medicine, 2021, 50, 345-352.	1.4	6
2546	Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. Cancer Immunology, Immunotherapy, 2021, 70, 1189-1202.	2.0	7
2547	Pediatric Head and Neck Neoplasms. , 2021, , 364-381.		0
2548	CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients. Clinical Epigenetics, 2021, 13, 15.	1.8	10
2549	Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. Cancers, 2021, 13, 1298.	1.7	24
2550	Identification of key regulators associated with colon cancer prognosis and pathogenesis. Journal of Cell Communication and Signaling, 2022, 16, 115-127.	1.8	12
2551	Clinical and ultrasonographic features of choroidal metastases based on primary cancer site: Long-term experience in a single center. PLoS ONE, 2021, 16, e0249210.	1.1	6
2552	Adneksiyal Kitlelerde Preoperatif Tanı ile Postoperatif Histopatolojik Tanıların Retrospektif Karşılaştırılması. İstanbul Gelişim Ĝniversitesi Sağlık Bilimleri Dergisi, 2021, , 30-41.	0.0	0
2553	LncRNA NEAT1 contributes to the acquisition of a tumor like-phenotype induced by PM 2.5 in lung bronchial epithelial cells via HIF- $1\hat{l}\pm$ activation. Environmental Science and Pollution Research, 2021, 28, 43382-43393.	2.7	17
2554	Activation of COL11A1 by PRRX1 promotes tumor progression and radioresistance in ovarian cancer. International Journal of Radiation Biology, 2021, 97, 958-967.	1.0	4
2555	Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies. Cancers, 2021, 13, 2607.	1.7	26
2556	To Enhance or Not to Enhance? The Role of Contrast Medium 18F-FDG PET/CT in Recurrent Ovarian Carcinomas. Medicina (Lithuania), 2021, 57, 561.	0.8	2
2558	Norcantharidin triggers apoptotic cell death in non-small cell lung cancer via a mitophagy-mediated autophagy pathway. Annals of Translational Medicine, 2021, 9, 971-971.	0.7	8
2559	First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. Cancer Reports, 2021, 4, e1419.	0.6	4
2560	Pancreatic cancer: A review of epidemiology, trend, and risk factors. World Journal of Gastroenterology, 2021, 27, 4298-4321.	1.4	180
2561	Treatment of tumour tissue with radioâ€frequency hyperthermia (using antibody arrying) Tj ETQq0 0 0 rgBT /C	Overlock 10	0 Jf 50 102 T
2562	Impact of Inequities on Delay in Breast Cancer Management in Women Undergoing Second Opinions. Journal of Surgical Research, 2021, 268, 445-451.	0.8	3

#	Article	IF	CITATIONS
2563	The histopathology of skeletal metastases. , 2022, , 771-782.		0
2564	Head-to-head comparison between 18F-FDG PET/low-dose CT and 18F-FDG PET/contrast-enhanced CT in relapsing ovarian carcinoma: a systematic review and meta-analysis. Clinical and Translational Imaging, 2021, 9, 73-81.	1.1	3
2565	Somatic mutations in oral squamous cell carcinomas in 98 Japanese patients and their clinical implications. Cancer Treatment and Research Communications, 2021, 29, 100456.	0.7	3
2566	Detection, Isolation and Study of Disseminated Prostate Cancer Cells in the Peripheral Blood and Bone Marrow. , 2003, , 87-116.		2
2568	Legislative Proposals for Reversing the Cancer Epidemic and Controlling Run-Away Industrial Technologies. Environmental Science and Technology Library, 2004, , 149-170.	0.1	2
2569	Quality of Life in Long-Term Cancer Survivors. , 2007, , 43-65.		16
2570	Radioguided Surgery of Solitary Pulmonary Nodules. , 2008, , 262-268.		6
2571	Urinary Bladder. , 2010, , 497-505.		22
2572	Urinary Bladder. , 2010, , 569-577.		1
2573	Clinical Aspects of Bone Metastases in Prostate Cancer. Cancer Treatment and Research, 2004, 118, 23-46.	0.2	18
2574	Early Detection of Ovarian Cancer: Promise and Reality. Cancer Treatment and Research, 2002, 107, 61-97.	0.2	115
2576	Small Intestine., 2002,, 107-112.		2
2577	Urinary Bladder. , 2002, , 335-340.		10
2578	Selecting the Right Targets for Cancer Therapy. , 2004, , 3-49.		1
2579	Strategies for Chemoprevention in Pancreatic Cancer., 2005, , 489-499.		1
2580	Racial Differences in Prostate Cancer Mortality. , 2007, , 355-376.		1
2581	The Vitamin D Receptor as Tumor Suppressor in Skin. Advances in Experimental Medicine and Biology, 2020, 1268, 285-306.	0.8	47
2582	Prostate Cancer Screening., 2007, 175, 65-81.		19

#	Article	IF	CITATIONS
2583	Acute Myeloid Leukemia: Epidemiology and Etiology. , 2008, , 47-56.		10
2584	Pathology of Lung Cancer., 2004, , 39-55.		1
2585	The New Paradigm in Breast Cancer Prevention. , 2004, , 379-438.		2
2586	Assay-Assisted Treatment Selection for Women with Breast or Ovarian Cancer. Recent Results in Cancer Research, 2003, 161, 126-145.	1.8	14
2587	Chemoprevention of Lung Cancer: New Directions. Recent Results in Cancer Research, 2003, 163, 172-181.	1.8	1
2588	Key Issues in Lung Cancer Chemoprevention Trials of New Agents. Recent Results in Cancer Research, 2003, 163, 182-195.	1.8	6
2589	Problems with Prostate-Specific Antigen Screening: A Critical Review. Recent Results in Cancer Research, 2003, 163, 226-231.	1.8	5
2591	Cancer of the Prostate. , 2002, , 575-602.		1
2592	Neoplasms of the prostate., 2008,, 442-579.		9
2593	Cancer of the Rectum. , 2008, , 1535-1556.		2
2594	Molecular Biology and Molecular Genetics of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer., 2004, , 385-398.		1
2595	Nutrition and Breast Cancer. , 2001, , 337-355.		2
2596	Cancer of the Prostate: Incidence in the USA. , 2003, , 115-119.		2
2597	Intrahepatic and Extrahepatic Biliary Cancer. , 2007, , 782-826.		4
2598	Diseases of the Anorectum. , 2010, , 2257-2274.e3.		5
2600	Treatment of small cell lung cancer. Critical Reviews in Oncology/Hematology, 2004, 52, 117-126.	2.0	29
2601	Improving knowledge of the prostate cancer screening dilemma among African American men: an academic-community partnership in Washington, DC. Public Health Reports, 2001, 116, 590-598.	1.3	41
2602	Molecular predictors of prognosis and responseto therapy in colorectal cancer. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 791-801.	0.5	7

#	Article	IF	CITATIONS
2604	Circular RNA S-7 promotes ovarian cancer EMT via sponging miR-641 to up-regulate ZEB1 and $\langle i \rangle$ MDM2 $\langle i \rangle$. Bioscience Reports, 2020, 40, .	1.1	22
2606	Brachytherapy of Prostate Cancer and Sexual Dysfunction. UroOncology, 2003, 2, 107-112.	0.1	4
2607	Oral Health. , 2005, , 304-328.		9
2608	MOLECULAR GENETIC PROFILING OF GLEASON GRADE 4/5 PROSTATE CANCERS COMPARED TO BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 2001, , 2171-2177.	0.2	8
2609	ROLE OF EARLY ADJUVANT HORMONAL THERAPY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Journal of Urology, 2001, , 2208-2215.	0.2	7
2610	INCREASING INCIDENCE OF ALL STAGES OF KIDNEY CANCER IN THE LAST 2 DECADES IN THE UNITED STATES:. Journal of Urology, 2002, , 57-60.	0.2	16
2611	SUPERFICIAL BLADDER CARCINOMA TREATED WITH BACILLUS CALMETTE-GUERIN:. Journal of Urology, 2002, 494-501.	0.2	3
2612	PERCENT PROSTATE NEEDLE BIOPSY TISSUE WITH CANCER IS MORE PREDICTIVE OF BIOCHEMICAL FAILURE OR ADVERSE PATHOLOGY AFTER RADICAL PROSTATECTOMY THAN PROSTATE SPECIFIC ANTIGEN OR GLEASON SCORE. Journal of Urology, 2002, 167, 516-520.	0.2	32
2613	Comparison of [18F]Fluorocholine and [18F]Fluorodeoxyglucose for Positron Emission Tomography of Androgen Dependent and Androgen Independent Prostate Cancer. Journal of Urology, 2002, , 273-280.	0.2	6
2614	Targeted Screening For Prostate Cancer In High Risk Families:. Journal of Urology, 2002, , 483-487.	0.2	2
2615	Results of the 5 Region Prostate Biopsy Method:. Journal of Urology, 2002, , 500-503.	0.2	4
2616	The Role Of Caveolin-1 In Androgen Insensitive Prostate Cancer. Journal of Urology, 2002, , 1589-1596.	0.2	4
2617	An Interval Longer than 12 Weeks Between the Diagnosis of Muscle Invasion and Cystectomy is Associated with Worse Outcome in Bladder Carcinoma. Journal of Urology, 2003, , 110-115.	0.2	6
2618	How to Diagnose Malignant Melanoma. Nurse Practitioner, 2002, 27, 26-27.	0.2	3
2619	Significance of the Depth of Tumor Invasion and Lymph Node Metastasis in Superficially Invasive (T1) Esophageal Adenocarcinoma. American Journal of Surgical Pathology, 2005, 29, 1079-1085.	2.1	205
2620	Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. Anti-Cancer Drugs, 2015, 26, 682-686.	0.7	3
2621	Intraoperative Near-infrared Fluorescence (NIR) Imaging With Indocyanine Green (ICG) Can Identify Bone and Soft Tissue Sarcomas Which May Provide Guidance for Oncological Resection. Annals of Surgery, 2021, 273, e63-e68.	2.1	28
2623	Squamous cell carcinoma of external auditory canal lacking epidermal growth factor receptor protein overexpression, in an elderly Omani with oculocutaneous albinism treated with palliative radiotherapy. BMJ Case Reports, 2014, 2014, bcr2013203226-bcr2013203226.	0.2	2

#	Article	IF	CITATIONS
2624	Breast Cancer. Clinical Cancer Research, 2004, 10, 380s-384s.	3.2	77
2625	Robotics in Colonoscopy. American Journal of Robotic Surgery, 2014, 1, 48-54.	0.2	7
2626	Gene expression profiling predicts clinical outcome of prostate cancer. Journal of Clinical Investigation, 2004, 113, 913-923.	3.9	405
2627	Risk Factors and Health Promotion in Families of Patients With Breast Cancer. Clinical Journal of Oncology Nursing, 2002, 6, 83-87.	0.3	4
2628	Risk Factors for Ovarian Cancer: Lesbian and Heterosexual Women. Oncology Nursing Forum, 2002, 29, E1-E7.	0.5	59
2629	Prognostic Significance of Molecular Genetic Aberrations on Chromosome Segment 11p15.5 in Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2002, 20, 1353-1360.	0.8	42
2631	Colorectal Cancer Screening Practices among Attendees at a Cancer Screening Clinic. Journal of Cancer Education, 2003, 18, 30-36.	0.6	4
2632	Strategies for Increasing Physicians', Nurses', and Mammography Technicians' Participation in Research. Journal of Cancer Education, 2003, 18, 78-80.	0.6	3
2633	Barriers to Colorectal Cancer Screening: An Educational Diagnosis. Journal of Cancer Education, 2004, 19, 170-173.	0.6	31
2634	A Prospective Study of 2-[18F] Fluoro-2-Deoxy-D-Glucose/Positron Emission Tomography Scan, 99mTc-Labeled Arcitumomab (CEA-Scan), and Blind Second-Look Laparotomy for Detecting Colon Cancer Recurrence in Patients With Increasing Carcinoembryonic Antigen Levels., 2001, 8, 779.		3
2635	Frequency of Nonsentinel Lymph Node Metastasis in Melanoma. Annals of Surgical Oncology, 2002, 9, 137-141.	0.7	30
2636	Predictors of Locoregional Recurrence Among Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Therapy. Annals of Surgical Oncology, 2002, 9, 256-265.	0.7	5
2637	Surgical Treatment Variation in a Prospective, Randomized Trial of Chemoradiotherapy in Gastric Cancer: The Effect of Undertreatment. Annals of Surgical Oncology, 2002, 9, 278-286.	0.7	13
2638	Matrix metalloproteinases and their role in pancreatic cancer: A review of preclinical studies and clinical trials., 2002, 9, 668.		11
2639	3,6-diazabicyclo[3.3.1]heptanes Induces Apoptosis and Arrests Cell Cycle in Prostate Cancer Cells. Medical Science Monitor, 2020, 26, e920266.	0.5	1
2641	Cytoplasmic Staining of TTF-1 in the Differential Diagnosis of Hepatocellular Carcinoma vs Cholangiocarcinoma and Metastatic Carcinoma of the Liver. American Journal of Clinical Pathology, 2006, 125, 519-525.	0.4	28
2642	Mitochondrial DNA Haplogroup Analysis Reveals no Association between the Common Genetic Lineages and Prostate Cancer in the Korean Population. PLoS ONE, 2008, 3, e2211.	1.1	31
2643	Comparative Profiling of Primary Colorectal Carcinomas and Liver Metastases Identifies LEF1 as a Prognostic Biomarker. PLoS ONE, 2011, 6, e16636.	1.1	56

#	Article	IF	CITATIONS
2644	Targeting KSHV/HHV-8 Latency with COX-2 Selective Inhibitor Nimesulide: A Potential Chemotherapeutic Modality for Primary Effusion Lymphoma. PLoS ONE, 2011, 6, e24379.	1.1	38
2645	Interaction of Caveolin-1 with Ku70 Inhibits Bax-Mediated Apoptosis. PLoS ONE, 2012, 7, e39379.	1.1	24
2646	Counting Highly Cited Papers for University Research Assessment: Conceptual and Technical Issues. PLoS ONE, 2012, 7, e47210.	1.1	17
2647	Genetic Polymorphisms of GSTM1, GSTT1, and GSTP1 with Prostate Cancer Risk: A Meta-Analysis of 57 Studies. PLoS ONE, 2012, 7, e50587.	1.1	48
2648	Omega-3 Eicosapentaenoic Acid Decreases CD133 Colon Cancer Stem-Like Cell Marker Expression While Increasing Sensitivity to Chemotherapy. PLoS ONE, 2013, 8, e69760.	1.1	53
2649	RBP2 Induces Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e84735.	1.1	27
2650	Neutrophils Infiltration in the Tongue Squamous Cell Carcinoma and Its Correlation with CEACAM1 Expression on Tumor Cells. PLoS ONE, 2014, 9, e89991.	1.1	51
2651	Spatial Clustering of Breast Cancer: An Epidemiological Analysis of Iranian Women. Iranian Journal of Cancer Prevention, 2017, In Press, .	0.7	4
2652	Subdiaphragmatic vagotomy promotes tumor growth and reduces survival via TNFα in a murine pancreatic cancer model. Oncotarget, 2017, 8, 22501-22512.	0.8	63
2653	SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress. Oncotarget, 2017, 8, 16712-16727.	0.8	18
2654	Differentiation between high- and low-grade urothelial carcinomas using contrast enhanced ultrasound. Oncotarget, 2017, 8, 70883-70889.	0.8	13
2655	Molecular profiling identifies prognostic markers of stage IA lung adenocarcinoma. Oncotarget, 2017, 8, 74846-74855.	0.8	7
2656	MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget, 2015, 6, 26457-26471.	0.8	70
2657	GIT1 promotes lung cancer cell metastasis through modulating Rac1/Cdc42 activity and is associated with poor prognosis. Oncotarget, 2015, 6, 36278-36291.	0.8	39
2658	Newly recognized extratumoral features of colorectal cancer challenge the current tumor-node-metastasis staging system. Annals of Gastroenterology, 2018, 31, 525-534.	0.4	10
2659	The Tumor Suppressor Actions of the Vitamin D Receptor in Skin., 2014, 810, 282-302.		11
2660	Is it necessary to cure prostate cancer when it is possible? (Understanding the role of prostate infl) Tj ETQq0 0 0 0	rgBT /Over	lock 10 Tf 50
2661	DNA Repair Proteins as Therapeutic Targets in Ovarian Cancer. Current Protein and Peptide Science, 2019, 20, 316-323.	0.7	6

#	Article	IF	CITATIONS
2662	Searching for Cancer Information on the Internet: Analyzing Natural Language Search Queries. Journal of Medical Internet Research, 2003, 5, e31.	2.1	46
2663	Radiation Risk of Screening CT. American Journal of Roentgenology, 2003, 180, 540-541.	1.0	2
2664	Developments in therapeutic human papillomavirus vaccination. Acta Chirurgica Iugoslavica, 2009, 56, 29-37.	0.0	2
2665	Role of lymphangiogenesis in lung cancer Folia Histochemica Et Cytobiologica, 2010, 47, 333-42.	0.6	12
2666	Treatment of Reproductive Dysfunction in Males with Spinal Cord Injury and Other Neurologically Disabling Diseases., 2007,, 491-504.		4
2667	Implication of stem cells in the biology and therapy of head and neck cancer. GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery, 2011, 10, Doc01.	0.8	5
2668	Changing patterns of colorectal cancer in China over a period of 20 years. World Journal of Gastroenterology, 2005, 11, 4685.	1.4	103
2669	Correlation between the expressions of gastrin, somatostatin and cyclin and cyclin-depend kinase in colorectal cancer. World Journal of Gastroenterology, 2005, 11, 7211.	1.4	8
2670	Correlation between expression of gastrin, somatostatin and cell apoptosis regulation gene bcl-2/bax in large intestine carcinoma. World Journal of Gastroenterology, 2005, 11, 721.	1.4	18
2671	Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater. World Journal of Gastroenterology, 2006, 12, 437.	1.4	9
2672	Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy. World Journal of Gastroenterology, 2006, 12, 6515.	1.4	13
2673	Differences in characteristics of colorectal neoplasm between young and elderly Thais. World Journal of Gastroenterology, 2006, 12, 7684.	1.4	5
2674	Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases. World Journal of Gastroenterology, 2007, 13, 1569.	1.4	47
2675	Expression level of beta-catenin is associated with prognosis of esophageal carcinoma. World Journal of Gastroenterology, 2007, 13, 2622.	1.4	11
2676	Reduced microRNA 375 in colorectal cancer upregulates metadherin-mediated signaling. World Journal of Gastroenterology, 2019, 25, 6495-6507.	1.4	11
2677	The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World Journal of Gastroenterology, 2002, 8, 193.	1.4	161
2678	Feasibility and safety of fertility-sparing surgery in epithelial ovarian cancer with dense adhesion: a long-term result from a single institution. Journal of Gynecologic Oncology, 2020, 31, e85.	1.0	3
2679	Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience. Radiation Oncology Journal, 2013, 31, 25.	0.7	9

#	Article	IF	CITATIONS
2680	Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis. Korean Journal of Internal Medicine, 2008, 23, 116.	0.7	28
2681	Colonic Lipid Peroxidation, Nuclear Membrane ATPase and Stress Enzymes in Rats Fed a Nigerian-Like Diet and Cycas. Journal of Biological Sciences, 2007, 7, 526-531.	0.1	3
2682	Care of Patients After Esophagectomy. Critical Care Nurse, 2004, 24, 16-29.	0.5	14
2683	Induction of Apoptosis in Human DU145 Prostate Cancer Cells by KHC-4 Treatment. Chinese Journal of Physiology, 2014, 57, 99-104.	0.4	3
2684	Palliative surgical approach in advanced nonresponsive mucinous ovarian cancer: A rare case report. Indian Journal of Palliative Care, 2016, 22, 173.	1.0	1
2685	Immunity over inability: The spontaneous regression of cancer. Journal of Natural Science, Biology and Medicine, 2011, 2, 43.	1.0	119
2686	Role of endoscopic ultrasound in treatment of pancreatic cancer. Endoscopic Ultrasound, 2013, 2, 181.	0.6	18
2687	A clinicopathological study of oral potentially malignant disorders. Journal of Head & Neck Physicians and Surgeons, 2016, 4, 29.	0.2	13
2688	Characteristic changes of the ablation zone on contrast-enhanced computed tomography after radiofrequency ablation of hepatic metastases. Indian Journal of Radiology and Imaging, 2018, 28, 320-326.	0.3	4
2689	Impact of the New AJCC Staging System and Adjuvant Treatment in Rectal Cancer. Cancer Research and Treatment, 2004, 36, 121.	1.3	6
2690	Tumor Angiogenesis: Initiation and Targeting - Therapeutic Targeting of an FGF-Binding Protein, an Angiogenic Switch Molecule, and Indicator of Early Stages of Gastrointestinal Adenocarcinomas Cancer Research and Treatment, 2006, 38, 189.	1.3	19
2691	Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer. Cancer Research and Treatment, 2009, 41, 12.	1.3	29
2692	A Case of Metachronous Metastasis to the Breast from Non-Small Cell Lung Carcinoma. Cancer Research and Treatment, 2010, 42, 172.	1.3	11
2693	Impact of External Radiotherapy on Survival after Stage I ndometrial Cancer: Results from a Population-Based Study. Journal of Cancer Science & Therapy, 2011, 03, .	1.7	3
2694	Mechanisms of Chemoresistance in Human Ovarian Cancer at a Glance. Gynecology & Obstetrics (Sunnyvale, Calif), 2012, 02, .	0.1	10
2695	Tumor-Dependent and -Independent Serum/Plasma Biomarkers for Early Diagnosis of Lung Cancer. Translational Medicine (Sunnyvale, Calif), 2016, 06, .	0.4	5
2696	Evaluation of a public expense-covered gynecologic screening program in Japan 2005-2009. Open Journal of Obstetrics and Gynecology, 2011, 01, 21-24.	0.1	2
2697	Clinical Presentation of Ovarian Tumors. Open Journal of Obstetrics and Gynecology, 2016, 06, 205-209.	0.1	2

#	Article	IF	CITATIONS
2698	Lower Incidence of Positive Gynecological Cancers in Examinees of a Unique Health Check-Up Institute, Ningen Dock in Japan, 2011-2016. Open Journal of Obstetrics and Gynecology, 2017, 07, 545-551.	0.1	1
2699	The impact of pre-procedural waiting period and anxiety level on pain perception in patients undergoing transrectal ultrasound guided prostate biopsy. Diagnostic and Interventional Radiology, 2011, 18, 195-9.	0.7	26
2700	Colorectal cancer and its delayed diagnosis: have we improved in the past 25 years?. Revista Espanola De Enfermedades Digestivas, 2011, 103, 458-463.	0.1	17
2701	Fertility Preservation: A Case Series. International Journal of Infertility and Fetal Medicine, 2011, 2, 114-117.	0.0	1
2702	A case of metastatic prostate adenocarcinoma to an inguinal lymph node. Central European Journal of Urology, 2012, 65, 96-97.	0.2	11
2703	Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. International Journal of Biological Markers, 2009, 24, 258-264.	0.7	12
2704	Multiple myeloma: the disease and its treatment. International Journal of Basic and Clinical Pharmacology, 2013, 2, 103.	0.0	8
2705	Comparative study of GST polymorphism in relation to age in COPD and lung cancer. Tuberkuloz Ve Toraks, 2013, 61, 275-282.	0.2	7
2706	Reduced Expression of Syndecan-1 in Oral Cancer., 0, , .		2
2707	Conserved Genetic Findings in Metastatic Bladder Cancer. Archives of Pathology and Laboratory Medicine, 2001, 125, 1197-1199.	1.2	27
2708	Proteomic Approaches to Tumor Marker Discovery. Archives of Pathology and Laboratory Medicine, 2002, 126, 1518-1526.	1.2	203
2709	The Spectrum of Kit (CD117) Immunoreactivity in Lung and Pleural Tumors: A Study of 96 Cases Using a Single-Source Antibody With a Review of the Literature. Archives of Pathology and Laboratory Medicine, 2004, 128, 538-543.	1.2	60
2710	Neoplasia of Gallbladder and Biliary Epithelium. Archives of Pathology and Laboratory Medicine, 2010, 134, 1621-1627.	1.2	29
2711	Awareness and Knowledge of Oral Cancer among University Students in Malaysia. Asian Pacific Journal of Cancer Prevention, 2012, 13, 165-168.	0.5	28
2712	Screening for Colorectal Neoplasias with Fecal Occult Blood Tests: False-positive Impact of Non-Dietary Restriction. Asian Pacific Journal of Cancer Prevention, 2012, 13, 237-241.	0.5	5
2713	Pancreatic Cancer in Universiti Sains Malaysia Hospital: A Retrospective Review of Years 2001-2008. Asian Pacific Journal of Cancer Prevention, 2012, 13, 2857-2860.	0.5	4
2714	Calcium Sensing Receptor Modulation for Cancer Therapy. Asian Pacific Journal of Cancer Prevention, 2012, 13, 3561-3568.	0.5	12
2715	Sociodemographic Predictors of Recall and Recognition of Colorectal Cancer Symptoms and Anticipated Delay in Help-Seeking in a Multiethnic Asian Population. Asian Pacific Journal of Cancer Prevention, 2013, 14, 3799-3804.	0.5	23

#	ARTICLE	IF	CITATIONS
2716	Factors Predicting Microinvasion in Ductal Carcinoma in situ. Asian Pacific Journal of Cancer Prevention, 2014, 15, 55-60.	0.5	39
2717	Hepatic Resection is Safe for Metachronous Hepatic Metastases from Ovarian Cancer. Cancer Biology and Medicine, 2012, 9, 182-7.	1.4	19
2718	New approach of prediction of recurrence in thyroid cancer patients using machine learning. Medicine (United States), 2021, 100, e27493.	0.4	5
2719	MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer. Journal of Oncology, 2021, 2021, 1-25.	0.6	13
2720	Voided urine test to diagnose prostate cancer: Preliminary report. CytoJournal, 2021, 18, 26.	0.8	0
2721	Clinical Features of Primary and Metastatic Hepatic Malignancies. Cancer Treatment and Research, 2001, 109, 1-14.	0.2	O
2722	Screening and Surveillance., 2002,, 65-80.		0
2723	Estimation of Performance and Sequential Selection of Diagnostic Tests in Patients With Lung Lesions Suspicious for Cancer. Archives of Pathology and Laboratory Medicine, 2002, 126, 19-27.	1.2	9
2724	Surgery for Germ Cell Tumours: Current Status in the USA. , 2002, , 139-146.		0
2725	A family with familial prostate cancer in which the proband was a hemodialysis patient Nihon Toseki Igakkai Zasshi, 2002, 35, 197-202.	0.2	O
2726	Cancer of the Liver, Biliary Tree, and Pancreas. , 2002, , 478-505.		0
2727	Treatment of Stomatitis and Oropharyngeal Pain in the Oncology Patient. , 2002, , 385-400.		O
2728	ALLELIC LOSS ON CHROMOSOMES 8 AND 9 CORRELATES WITH CLINICAL OUTCOME IN LOCALLY ADVANCED CLEAR CELL CARCINOMA OF THE KIDNEY. Journal of Urology, 2002, , 1464-1468.	0.2	1
2732	<title>Registration of prostate brachytherapy seeds with prostate anatomy for improved patient dosimetry</title> ., 2002, , .		O
2734	Prostate Cancer Stage Shift has Eliminated the Gap in Disease-free Survival in Black and White American Men after Radical Prostatectomy. Journal of Urology, 2002, , 479-482.	0.2	0
2737	Breast and Prostate Cancer: a Comparison of Two Common Endocrinologic Malignancies. , 2003, , 159-166.		1
2738	L-Canavanine as a radiosensitization agent for human pancreatic cancer cells., 2003,, 37-43.		0
2739	Genitourinary Malignancies: Bladder/Penis/Urethral Cancers. , 2003, , 521-530.		O

#	Article	IF	CITATIONS
2740	Renal Cancer., 2003,, 513-520.		0
2741	Soft-Tissue Sarcomas., 2003,, 597-608.		1
2742	Prostate Cancer: Detection and Biopsy Strategies. , 2003, , 129-136.		1
2743	Does Radiation Therapy Really Work for Prostate Cancer?., 2003,, 377-386.		0
2744	Tumors of the Female Reproductive Organs. , 2003, , 887-894.		2
2745	Allogeneic Stem Cell Transplantation for Breast Cancer. , 2003, , 57-68.		0
2747	Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 565-584.	0.5	4
2748	Prostate., 2003,, 591-605.		1
2749	Uterine Cancer., 2003,, 531-543.		0
2750	Early Breast Cancer., 2003,, 331-342.		0
2751	The Decision-making Process for Prostate Cancer., 2003, , 231-252.		0
2753	Bone Sarcomas. , 2003, , 587-595.		0
2754	Cervical, Vulvar, and Vaginal Cancer., 2003,, 545-561.		0
2755	Classification, Epidemiology, and Etiology of Brain Tumors. , 2003, , 1006-1012.		0
2756	Selected Disorders of the Genitourinary System. , 2003, , 852-858.		0
2757	Cancer biotherapy: 2003 disease-related activity. , 2003, , 615-674.		0
2758	Neurologic Complications of Genitourinary Malignancies. , 2003, , 327-338.		1
2759	Prostate Cancer Treatment Outcomes between African Americans and Caucasians. , 2003, , 137-143.		0

#	Article	IF	CITATIONS
2760	Aerodigestive Tract Chemoprevention Trials and Prevention of Second Primary Tumors., 2003, , 271-285.		0
2761	Mechanisms and prevention of erectile dysfunction after radiotherapy for prostate cancer. , 2003, , 98-104.		0
2762	Prognostic tissue factors for prostate cancer: recent developments and pitfalls. , 2003, , 268-280.		0
2763	Cancer Management in Older Women. , 2004, , 1171-1185.		O
2764	Stomach, Adenomas and Carcinomas of the. , 2004, , 453-458.		0
2765	Lung Cancer and Tobacco: Historical Issues, Epidemiology, and Intervention. , 2004, , 77-90.		0
2766	Stomach, Adenomas and Carcinomas of the. , 2004, , 513-517.		0
2767	Retrospective Investigation of the Patients with Endometrial Cancer. Journal of the Japanese Association of Rural Medicine, 2004, 53, 103-109.	0.0	0
2768	Clinically Useful Biomarkers. , 2004, , 29-38.		0
2769	The Difference Between Male and Female Breast Cancer. , 2004, , 648-657.		0
2770	Novel Alternatives to Chemotherapy in Advanced Disease: Gene Transfer. , 2004, , 99-120.		0
2771	Prostate Cancer: Models for Developing Novel Therapeutic Approaches. Cancer Metastasis - Biology and Treatment, 2004, , 163-186.	0.1	0
2772	Vaccines for the Immunotherapy of Prostate Cancer. , 2004, , 451-464.		0
2773	Human Papillomavirus Infection in Men and Women: The Impact of Nutrition on Cervical Cancer., 2004,, 796-812.		0
2774	Screening and Early Detection for Genitourinary Cancer. , 2004, , 47-60.		0
2775	Medical Therapy for Endometrial Hyperplasia and Early Endometrial Cancer in Patients Desiring Future Childbearing., 2004,, 516-527.		0
2776	Anatomic Radical Prostatectomy in the Management of Localized Prostate Cancer., 2004,, 1-62.		0
2777	Current Perspectives in Gastric Adenocarcinoma. CRC Series in Modern Nutrition Science, 2004, , .	0.0	0

#	Article	IF	Citations
2779	Acute myeloid leukemia in children and adolescents. , 2004, , 617-632.		0
2780	The Role of Primary Surgery in Advanced Endometrial Cancer. , 2004, , 305-325.		O
2781	Laparoscopic Radical Nephrectomy. , 2005, , 821-843.		0
2782	Age scope of high-risk population for esophageal cancer in Ci county. World Journal of Gastroenterology, 2005, 11, 1818.	1.4	1
2783	Carcinoma of the Prostate—Diagnosis and Staging. , 2005, , 962-992.		0
2784	Tobacco Cessation for the Dental Team: A Practical Guide Part 1: Background & Dental Practice, 2005, 6, 158-166.	0.2	0
2786	Prevalence of Human Papilloma Virus with Intraepithelial Lesions and Cervical Cancer in Qatar. Qatar Medical Journal, 2005, 2005, .	0.2	0
2787	Functional Lipidomics., 2005, , 101-124.		1
2788	Fluorodeoxyglucose-PET in Breast Cancer. , 2006, , 89-103.		0
2790	Current State of the Treatment in Metastatic Breast Cancer. Journal of Breast Cancer, 2006, 9, 4.	0.8	0
2791	Large-Cell Lymphoma. , 2006, , 295-324.		0
2792	IMRT Lung., 2006,, 359-369.		0
2793	Importancia de los programas de prevenci $ ilde{A}^3$ n primaria y secundaria en el c $ ilde{A}_1$ ncer de piel. , 2006, , 85-91.		0
2794	Adjuvant Therapy of Breast Cancer. , 2006, , 153-219.		0
2795	Radical Prostatectomy and Other Pelvic Surgeries. , 2006, , 135-154.		3
2796	Health Beliefs of Nurses about Breast Self Examination. Journal of Medical Sciences (Faisalabad,) Tj ETQq1 1 0.78	4314 rgB ⁻ 0.0 rgB-	「/gverlock 1
2798	Intraoperative Diagnosis of Liver, Biliary, and Pancreatic Disease., 2007,, 362-372.		0
2799	Aspirin Induced Changes in Enzymes of Colonic Energy Metabolism and ATPases of Rats Exposed to Cycas and Fed a Nigerian-Like Diet. Journal of Medical Sciences (Faisalabad, Pakistan), 2007, 7, 1250-1258.	0.0	0

#	Article	IF	CITATIONS
2800	A Mathematical Model for Prediction of Recurrence in Bladder Cancer Patients. Mathematics in Industry, 2008, , 868-872.	0.1	0
2802	Imaging of Endometrioid Adenocarcinoma of the Uterus Metastatic to the Ciliary Body. Ophthalmic Surgery Lasers and Imaging Retina, 2008, 39, 246-249.	0.4	0
2804	Extremity Reconstruction. , 2008, , 190-214.		0
2808	Abdominal lymph node metastasis from prostatic adenocarcinoma in a patient with esophageal squamous cell carcinoma. Annals of Cancer Research and Therapy, 2009, 17, 29-31.	0.1	O
2809	Maligne Ovarialtumoren in der Schwangerschaft. , 2009, , 231-245.		0
2812	Biological therapy of melanoma. , 2009, , 633-644.		0
2813	Melanoma screening with serial whole body photographic change detection using Melanoscan $\hat{A}^{\text{@}}$ technology. Dermatology Online Journal, 2009, 15, .	0.2	6
2814	Thyroid Cancer: Identification of Gene Expression Markers for Diagnosis. , 2010, , 353-377.		0
2815	Papillary Thyroid Carcinoma: Use of HBME1 and CK19 as Diagnostic Markers. , 2010, , 379-385.		0
2816	Genetic Epidemiology of Mismatch Repair Deficiency in Ovarian Cancer. , 2010, , 367-398.		0
2817	Cancer of the Genitourinary Tract., 2010,, 233-277.		0
2818	Prospective efficacy of molecular preoperative diagnostics of papillary thyroid carcinoma. Acta Medica Lituanica, 2010, 17, 35-39.	0.2	O
2820	Breast Disorders and Breast Cancer Screening. , 2010, , 1206-1211.e1.		0
2822	Knowledge of Prostate Cancer Screening Among Native African Urban Population in Nigeria Nigerian Quarterly Journal of Hospital Medicine, 2010, 19, 145-7.	0.2	22
2823	The relationship between microscopic hematuria and bladder cancer: are currently available diagnostic methods reliable?. Turk Uroloji Dergisi, 2010, 36, 103-107.	0.4	0
2824	The Role of Tomato Lycopene in Cancer Prevention. , 2011, , 47-66.		2
2825	Mohs Micrographic Surgery., 2011,, 2354-2354.		6
2826	Expression Profiling of Mouse Models of Human Cancer: Model Categorization and Guidance for Preclinical Testing. , 2012, , 209-234.		O

#	Article	IF	Citations
2827	Pancreatic Cancer Genetics., 2012,, 51-79.		0
2828	Contrast Enhanced Ultrasound and Ultrasound-Guided Minimally Invasive Therapy for the Diagnosis and Treatment of Focal Thyroid Lesions., 2012,, 297-303.		O
2829	Screening and Early Detection for Genitourinary Cancer. , 2012, , 27-42.		0
2830	The skin and vitamin D. Human Health Handbooks, 2012, , 92-113.	0.1	0
2831	Neurocognitive Impairment (NI)., 2012,, 193-219.		0
2832	The Role of Fiducial Placement in the Treatment of Pancreatic Cancer: The Expanding Role of Endoscopic Ultrasound. Pancreatic Disorders & Therapy, 2012, 02, .	0.3	1
2833	Cerebellar metastasis from serous adenocarcinoma of the ovary mimicking pilocytic astrocytoma. Journal of Innovative Optical Health Sciences, 2012, 7, 141.	0.5	1
2834	Clinico-Pathological Correlation Of The Expression Of Cyclin D1 And Bcl-2 In Oral Squamous Cell Carcinomas -A Tissue Microarray Study. International Journal of Scientific Research (Ahmedabad,) Tj ETQq1 1 0.7	84 5.1 04 rgB	T (Overlock
2835	Utility of PET/CT in the staging and treatment of patients with Merkel Cell Carcinoma and Melanoma. Journal of Nuclear Medicine & Radiation Therapy, 2013, 04, .	0.2	O
2836	Impact of reconstruction methods and pathological factors on survival after pancreaticoduodenectomy. South Asian Journal of Cancer, 2013, 2, 160.	0.2	4
2837	Ocular and Adnexal Lymphoma: Epidemiological Aspects. Essentials in Ophthalmology, 2014, , 47-56.	0.0	1
2838	PET-CT of Gynecological Malignancies and Ovarian Cancer. , 2014, , 839-850.		0
2839	Imaging Technologies and Applications in Early Diagnosis and Prognosis for Breast Cancer. , 2014, , 371-391.		0
2840	An observational study to find out the frequency of Gall Bladder Cancer in patients of gall bladder disease. IOSR Journal of Dental and Medical Sciences, 2014, 13, 01-05.	0.0	O
2841	Clinical Profile and Management of Gall Bladder Cancer: Our Early Experience. Journal of Nobel Medical College, 2014, 3, 27-30.	0.1	0
2843	A 7-Years Retrospective Study of Gastrointestinal Cancers Incidence in the Western Iran. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, EC01-5.	0.8	2
2844	Parental Occupational Exposure and Risk of Acute Leukemia in Children: A Tunisian Population-Based Case-Control Study. International Journal of Clinical Medicine, 2016, 07, 193-203.	0.1	0
2845	RISK OF MALIGNANCY INDEX 2 IN PREOPERATIVE EVALUATION OF OVARIAN MASSES AND ITS CORRELATION WITH HISTOPATHOLOGY. Journal of Evolution of Medical and Dental Sciences, 2016, 5, 376-380.	0.1	O

#	Article	IF	CITATIONS
2846	Diagnosis System for Predicting Bladder Cancer Recurrence Using Association Rules and Decision Trees. Studies in Computational Intelligence, 2016, , 43-64.	0.7	0
2847	Prostate Cancer Screening. , 2016, , 173-185.		0
2848	The Impact of Lymphovascular Space Invasion on Recurrence and Survival in Iranian Patients With Early Stage Endometrial Cancer. World Journal of Oncology, 2016, 7, 70-74.	0.6	4
2849	Expression of the Gene Encoding Secretor Type Galactoside 2 <i>α</i> Fucosyltransferase (<i>FUT</i> 2) and CD44 Marker in Urogenital Tumors. Open Journal of Genetics, 2016, 06, 96-104.	0.1	O
2850	Not all gastric masses are gastric cancer. BMJ Case Reports, 2016, 2016, bcr2015213535.	0.2	5
2851	Intestinal Polyposis Syndromes and Hereditary Colorectal Cancer. , 2016, , 563-596.		0
2852	ORAL CANCER: CLINICOPATHOLOGICAL STUDY OF 5 YEARS AT A TERTIARY CARE CENTRE. Journal of Evidence Based Medicine and Healthcare, 2016, 3, 3613-3616.	0.0	0
2853	Patient-Reported Outcomes of Surgery of Non-Small Cell Lung Cancer: Evaluation Based on the Questionnaires of Anti-Aging Quality of Life and the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. Surgical Science, 2017, 08, 203-219.	0.1	2
2854	Malignancy rate of 10,731 uteri morcellated during laparoscopic supracervical hysterectomy. Russian Bulletin of Obstetrician-Gynecologist, 2017, 17, 38.	0.0	0
2855	Patient-Reported Outcomes of Chemotherapy Involving Non-Small Cell Lung Cancer: Evaluation by Questionnaires of Quality of Life Regarding Anti-Aging and Anti-Cancer Drugs. Advances in Lung Cancer (Irvine), 2017, 06, 13-35.	0.2	0
2858	STUDY OF GASTROINTESTINAL CANCERS IN A TERTIARY CARE HOSPITAL. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 5537-5542.	0.0	0
2859	Efficacy of reamberin in the correction of lipid peroxidation processes in the plasma of patients with ovarian cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2018, 7, 40.	0.0	8
2860	Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?. Turkish Journal of Haematology, 2018, 35, 271-276.	0.2	2
2861	Post-Mastectomy Phantom Breast Syndrome. , 2018, 3, 1-6.		5
2862	The comparison of pelvic mass score and risk of malignancy index-3 in discrimination of benign and malignant adnexal masses. Sisli Etfal Hastanesi Tip Bulteni, 2019, 54, 490-496.	0.1	1
2864	Clinical risk profile associated with ovarian cancer. Obstetrica Si Ginecologie, 2019, 1, 22.	0.0	0
2866	Epidemiology and Risk Factor of Lung Cancer in Morocco. Biosciences, Biotechnology Research Asia, 2019, 16, 55-59.	0.2	0
2867	Multiphoton and harmonic generation imaging methods enable direct visualization of drug nanoparticle carriers in conjunction with vasculature in fibrotic prostate tumor mouse model., 2019,		O

#	Article	IF	CITATIONS
2868	Gastrointestinal Cancers: Gastric Cancer. , 2019, , .		О
2869	Comparison of nodal irradiation dose using radiotherapy for patients with thoracic esophageal cancer. Oncology Letters, 2020, 19, 1042-1050.	0.8	2
2870	MicroRNA‑32 promotes ovarian cancer cell proliferation and motility by targeting SMG1. Oncology Letters, 2020, 20, 733-741.	0.8	10
2871	Evaluation of <i>E2F3</i> and <i>survivin</i> expression in peripheral blood as potential diagnostic markers of prostate cancer. Turkish Journal of Biochemistry, 2020, 45, 525-532.	0.3	1
2872	Bir diş hekimliği fakültesine başvuran hastalarda oral mukozal lezyonlar ve kanserlerle ilgili farkındalıği ve yaklaşımın değerlendirilmesi. Mersin Üniversitesi Sağlık Bilimleri Dergisi, 0, , .	i, 0.2	0
2873	Obstruksiyona neden olmuş kolorektal kanserli yaşlı hastalarda acil cerrahi sonuçları: Tek merkez deneyimi. Ankara Eğitim Ve Araştırma Hastanesi Tıp Dergisi, 0, , .	0.1	1
2878	Wavelet-based Feature Analysis for Classification of Breast Masses from Normal Dense Tissue. , 2006, , 722-729.		0
2879	Chemotherapy in Prostate Cancer. , 2005, , 83-94.		O
2881	Introduction: Epidemiology, Risk Factors, Pathology, and Natural History of Head and Neck Neoplasms. Medical Radiology, 2008, , 1-15.	0.0	0
2883	Chemoprevention of Upper Aerodigestive Tract Cancer. , 2005, , 371-382.		О
2884	Strategies in Skin Cancer Chemoprevention. , 2005, , 403-419.		0
2885	Intensity-Modulated Radiation Therapy in the Management of Head and Neck Cancer. , 2005, , 115-124.		1
2889	Isolated Limb Perfusion in Advanced Soft Tissue Sarcomas. , 2007, , 407-415.		1
2890	Proteomics of Human Pancreatic Juice. , 2007, , 377-397.		0
2891	Chemotherapy in Prostate Cancer. , 2007, , 50-74.		0
2892	Steroid Hormone Regulation and Prognostic Value of the Human Kallikrein Gene 14 in Ovarian Cancer. American Journal of Clinical Pathology, 2003, 119, 0-0.	0.4	О
2893	Thorax and Vasculature. , 2008, , 663-861.		O
2894	Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response. Abdominal Imaging, 2009, 34, 593.	2.0	1

#	Article	IF	CITATIONS
2895	Percutaneous Ablation of Liver Tumors. Medical Radiology, 2021, , 269-282.	0.0	0
2896	Pedodontist ve Pediatristlerin Çocuklardaki Ağız Kanserlerinin Erken Tanısındaki Farkındalıkları. Osmangazİ Journal of Medicine, 2020, 42, 58-64.	0.1	O
2897	Treatment of tumour tissue with radiofrequency hyperthermia (using antibody-carrying) Tj ETQq0 0 0 rgBT /Overl	ock 10 Tf	50 662 Td (n
2898	Ultrasound-Guided Percutaneous Ethanol Ablation for the Management of Recurrent Thyroid Cancer: Evaluation of Efficacy and Impact on Disease Course. International Journal of Thyroidology, 2020, 13, 128-141.	0.1	5
2899	Does PSA screening reduce prostate cancer mortality?. Cmaj, 2002, 166, 600-1.	0.9	2
2900	Palliative surgery for cancer pain. Western Journal of Medicine, 2002, 176, 107-10.	0.3	17
2901	Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma. Reviews in Urology, 2002, 4, 103-11.	0.9	5
2902	Biomarkers for early detection and optimized treatment for transitional cell carcinoma. Reviews in Urology, 2001, 3, 210-2.	0.9	O
2903	Prostate cancer screening practices and beliefs. Journal of General Internal Medicine, 2001, 16, 831-7.	1.3	27
2904	Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Reviews in Urology, 2005, 7, 203-10.	0.9	23
2905	Gene expression levels in different stages of progression in oral squamous cell carcinoma. Proceedings, 2002, , 415-9.	0.6	5
2906	Non-association between acrochordons and colonic polyps in a minority population. Journal of the National Medical Association, 2003, 95, 746-9.	0.6	3
2908	Cigarette smoke alters tissue inhibitor of metalloproteinase 1 and matrix metalloproteinase 9 levels in the basolateral secretions of human asthmatic bronchial epithelium in vitro. Journal of Investigative Medicine, 2010, 58, 725-9.	0.7	7
2909	Noncoding RNAs and Cancer. Avicenna Journal of Medical Biotechnology, 2009, 1, 55-70.	0.2	11
2910	Risk of malignancy index as an evaluation of preoperative pelvic mass. Caspian Journal of Internal Medicine, 2011, 2, 331-5.	0.1	3
2911	Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma. International Journal of Clinical and Experimental Pathology, 2014, 7, 2361-71.	0.5	6
2912	Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer. International Journal of Clinical and Experimental Medicine, 2014, 7, 1459-64.	1.3	0
2913	The vitamin D receptor: a tumor suppressor in skin. Discovery Medicine, 2011, 11, 7-17.	0.5	52

#	Article	IF	Citations
2914	\hat{l} -Cadinene inhibits the growth of ovarian cancer cells via caspase-dependent apoptosis and cell cycle arrest. International Journal of Clinical and Experimental Pathology, 2015, 8, 6046-56.	0.5	14
2915	Recurrence after hepatic resection in colorectal cancer liver metastasis -Review article Journal of Medicine and Life, 2015, 8 Spec Issue, 12-4.	0.4	22
2916	Effectiveness of Antegrade Access in Bladder Tumors With Inaccessible Urethra. Reviews in Urology, 2015, 17, 241-5.	0.9	0
2917	The role and expression of miR-100 and miR-203 profile as prognostic markers in epithelial ovarian cancer. American Journal of Translational Research (discontinued), 2016, 8, 2403-10.	0.0	11
2918	The role of serum osteoprotegerine in metastatic prostate cancer - a case control study. Hippokratia, 2016, 20, 133-138.	0.3	2
2919	Tobacco-use Cessation Counseling Service Usage. West Virginia Medical Journal, 2016, 112, 66-71.	0.1	0
2920	Female Fertility Preservation, Clinical and Experimental Options. Journal of Reproduction and Infertility, 2018, 19, 125-132.	1.0	5
2921	Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1‧TAT1 loop in lung adenocarcinoma. Cancer Science, 2022, 113, 205-220.	1.7	10
2922	Exploration of Potential miRNA Biomarkers and Prediction for Ovarian Cancer Using Artificial Intelligence. Frontiers in Genetics, 2021, 12, 724785.	1.1	10
2923	Neoadjuvant chemotherapy for bladder cancer. Journal of Cancer Research and Practice, 2020, 7, 149.	0.2	1
2924	Recent progress in optimizing radiotherapy in chemo-radiotherapy for stage III non-small cell lung cancer., 2002, 4, 9-22.		0
2925	Cervical cancer. The case of Mexico. , 2002, 4, 413-415.		0
2926	Thyroid Carcinoma in Children and Young Adults: Retrospective Review of 19 Cases. Acta Medica Portuguesa, 2013, 26, 578-582.	0.2	2
2927	GREEN SYNTHESIS OF GOLD NANOPARTICLES OF ISOLATED CITRUS BIOFLAVONOID FROM ORANGE: CHARACTERIZATION AND IN VITRO CYTOTOXICITY AGAINST COLON CANCER CELL LINES COLO 320DM AND HT29. Indian Drugs, 2020, 57, 61-69.	0.1	8
2929	To Lighten the Burden of Cure: Thyroid Disease in Long-Term Survivors After TBI Conditioning for Paediatric ALL. Frontiers in Pediatrics, 2021, 9, 798974.	0.9	3
2930	Point-of-care detection assay based on biomarker-imprinted polymer for different cancers: a state-of-the-art review. Polymer Bulletin, 2023, 80, 1-46.	1.7	6
2931	Variations in approaches to breast cancer screening among primary care physicians. Journal of Cancer Education, 2002, 17, 205-10.	0.6	12
2932	L-Canavanine as a radiosensitization agent for human pancreatic cancer cells. Molecular and Cellular Biochemistry, 2003, 244, 37-43.	1.4	5

#	Article	IF	CITATIONS
2933	The magnitude and predictors of cervical squamous intraepithelial lesions among women in Enugu, Nigeria: a cross-sectional study of women in a low-resource setting. Pan African Medical Journal, 2022, 41, 130.	0.3	0
2934	Oncologic outcomes of fertility-sparing surgery in early stage epithelial ovarian cancer: a population-based propensity score-matched analysis. Archives of Gynecology and Obstetrics, 2022, 306, 1679-1688.	0.8	3
2935	BAALC gene expression tells a serious patient outcome tale in NPM1-wild type/FLT3-ITD negative cytogenetically normal-acute myeloid leukemia in adults. Blood Cells, Molecules, and Diseases, 2022, 95, 102662.	0.6	1
2936	Survival of Women Previously Diagnosed of Melanoma with Subsequent Pregnancy: A Systematic Review and Meta-Analysis and a Single-Center Experience. Journal of Clinical Medicine, 2022, 11, 83.	1.0	0
2941	Genitourinary Cancer., 0,, 309-334.		0
2943	Anticancer potential of leaf and leaf-derived callus extracts of Aerva javanica against MCF-7 breast cancer cell line. Journal of Cancer Research and Therapeutics, 2018, 14, 321-327.	0.3	10
2944	Colorectal cancer screening by primary care physicians in Texas: a rural-urban comparison. Journal of Cancer Education, 2001, 16, 199-204.	0.6	15
2945	Impact of previous local treatment for prostate cancer on subsequent metastatic disease. Journal of Urology, 2002, 168, 1008-12.	0.2	54
2946	On the role of the islets of Langerhans in pancreatic cancer. Histology and Histopathology, 2004, 19, 999-1011.	0.5	34
2948	Cationic Nanoparticulate System for Codelivery of MicroRNA-424 and Podophyllotoxin as a Multimodal Anticancer Therapy. Molecular Pharmaceutics, 2022, 19, 2092-2104.	2.3	4
2949	Positron emission tomography imaging of lung and esophageal cancer., 0,, 9-17.		2
2950	New potential of the complex therapy of anogenital papilloma viral infection. Vestnik Dermatologii I Venerologii, 2011, 87, 79-84.	0.2	0
2951	Pediatric Head and Neck Malignancies. , 2015, , 272-292.e2.		0
2955	Lysophospholipids Are Potential Biomarkers of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1185-1191.	1.1	283
2956	Composite scoring system and optimal tumor budding cut-off number for estimating lymph node metastasis in submucosal colorectal cancer. BMC Cancer, 2022, 22, .	1.1	2
2957	FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3. Bioscience Reports, 2022, 42, .	1.1	3
2959	Use of phosphodiesterase-5 inhibitors and the incidence of melanoma. Cancer Epidemiology, 2022, 81, 102251.	0.8	2
2960	ETHICAL ISSUES CONFRONTING ONCOLOGY NURSES. Nursing Clinics of North America, 2001, 36, 827-841.	0.7	4

#	Article	IF	CITATIONS
2961	BARRIERS TO PALLIATIVE AND SUPPORTIVE CARE. Nursing Clinics of North America, 2001, 36, 843-853.	0.7	9
2963	Prostat biyopsi ve radikal prostatektomide Gleason skor konkordansının değerlendirilmesi. Cukurova Anestezi Ve Cerrahi Bilimler Dergisi, 2022, 5, 274-279.	0.1	0
2964	The Role of Some Selenoproteins in the Etiopathogenesis of Breast Cancer. İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi, 2022, , 381-390.	0.0	0
2965	Stoma versus anastomosis after sphincter-sparing rectal cancer resection; the impact on health-related quality of life. International Journal of Colorectal Disease, 2022, 37, 2197-2205.	1.0	5
2967	High-grade B-cell lymphoma. Medicinski Pregled, 2022, 75, 88-95.	0.1	0
2968	Synthesis, biological evaluation, and molecular docking of novel hydroxyzine derivatives as potential AR antagonists. Frontiers in Chemistry, 0, 10 , .	1.8	1
2969	Her2 Expression in Thyroid Tumors. American Surgeon, 2003, 69, 1100-1103.	0.4	10
2970	Can [F-18] fluorodeoxyglucose positron emission tomography replace sentinel lymph node biopsy for the detection of axillary metastases in patients with early-stage breast cancer?*. Turkish Journal of Medical Sciences, 0, , .	0.4	2
2971	A comparative mRNA- and miRNA transcriptomics reveals novel molecular signatures associated with metastatic prostate cancers. Frontiers in Genetics, 0, 13 , .	1.1	3
2972	A retrospective study on sperm cryopreservation in 1034 patients diagnosed with cancer in southern China. Asian Journal of Andrology, 2022, .	0.8	0
2973	Local Excision of Rectal Carcinoma. American Surgeon, 2001, 67, 774-779.	0.4	30
2974	Prognostic Factors Associated with Resectable Carcinoma of the Esophagus. American Surgeon, 2002, 68, 258-263.	0.4	31
2975	Preoperative Anemia in Colon Cancer: Assessment of Risk Factors. American Surgeon, 2002, 68, 582-587.	0.4	55
2976	Laparoscopic Gastrojejunostomy for Gastric Outlet Obstruction in Pancreatic Cancer. American Surgeon, 2004, 70, 910-913.	0.4	24
2977	Thermal Ablation of Liver Tumours: How the Scenario Has Changed in the Last Decade. European Medical Journal Hepatology, 0, , 88-94.	1.0	4
2978	Colorectal Cancer in Patients Younger than 40 Years of Age. American Surgeon, 2002, 68, 871-876.	0.4	19
2979	Análisis de osteopontina como factor pronóstico y predictivo en cáncer de pulmón de células no pequeñas localmente avanzado y avanzado tratados con quimioterapia con o sin radioterapia en General Pico, La Pampa. , 2018, 23, .		0
2980	Tamoxifen Delivery to Breast Cancer Cells (MCF-7) Via Hydroxyapatite Microspheres. Eurasian Journal of Biological and Chemical Sciences, 2022, 5, 111-118.	0.0	0

#	Article	IF	CITATIONS
2981	A 6-Year Retrospective Study of the Demographics of Glottic Keratosis in a Tertiary Care Voice Centre. Indian Journal of Otolaryngology and Head and Neck Surgery, 0, , .	0.3	0
2983	Intraoperative Evaluation of Soft Tissue Sarcoma Surgical Margins with Indocyanine Green Fluorescence Imaging. Cancers, 2023, 15, 582.	1.7	5
2984	Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line derived from a Chinese patient. Cancer Cell International, 2022, 22, .	1.8	2
2985	In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. , 2023, , 387-415.		O
2986	Novel insight on GRP/GRPR axis in diseases. Biomedicine and Pharmacotherapy, 2023, 161, 114497.	2.5	0
2987	Patient profile and treatment outcome of rectal cancer patients treated with multimodality therapy at a regional cancer center. Indian Journal of Cancer, 2004, 41, 120.	0.2	10
2988	Radioactive iodine therapy of juvenile differentiated thyroid carcinoma. Endocrinology&Metabolism International Journal, 2019, 7, 91-94.	0.1	0
2996	Systemic Onco-sphere: An Overview from the Host's Perspective. , 2023, , 391-418.		O